Maternal docosahexaenoic acid (DHA) supplementation and fetal DHA accretion by Montgomery, Colette
 
 
 
 
 
 
 
https://theses.gla.ac.uk/ 
 
 
 
 
Theses Digitisation: 
https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ 
This is a digitised version of the original print thesis. 
 
 
 
 
 
 
 
 
Copyright and moral rights for this work are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge 
 
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author 
 
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses 
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
Maternal Docosahexaenoic Acid (DHA) 
Supplementation and Fetal DHA Accretion
Colette Montgomery B.Sc. (Hons), SRD
A Thesis submitted in fulfilment of the Degree of 
Doctor of Philosophy
to
The Faculty of Medicine 
University of Glasgow
April 2001
from research conducted at the
University Department of Child Health 
Yorkhill Hospitals, Glasgow, U.K.
under the supervision of 
Professor Lawrence T. Weaver
© Colette Montgomery
ProQuest Number: 10646004
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uesL
ProQuest 10646004
Published by ProQuest LLO (2017). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLO.
ProQuest LLO.
789 East Eisenhower Parkway 
P.Q. Box 1346 
Ann Arbor, Ml 48106- 1346
(üLASGOW 1  
UNIVERSITY I L I B R A R Y :  I
Cof  ^2
DEDICATION
Dedicated to all the love and support 1 have received, 
and to the memory of Dad and Uncle Charlie.
ACKNOWLEDGEMENTS
I would like to thank Professor Lawrence Weaver for the opportunity to undertake this 
Ph.D. and for his continual support and encouragement throughout.
I gratefully acknowledge R.P. Scherer Ltd. for the donation of the supplements used, 
and thank Dr. Helene Cooper for her interest in the study. I thank Ms. Rachel Elsom 
for organising the randomization of the supplements, and for leading the many 
discussions on breast milk!
I thank Dr. Alan Cameron for acting as the consultant obstetrician for the study. The 
consultants, midwifes and clerical staff of the QMH ante-natal clinic were of great help 
during the enrolment of participants. Many thanks to all Labour Suite staff for their 
help with sample collection at the deliveries, and to the nursing staff of the post-natal 
wards. I am indebted to the mothers and babies for their partieipation and for making 
the FOMI study such a memorable experience.
Many people were of assistance during my time in the laboratory. My thanks to Dr. 
Tom Preston, my Adviser, and to Ms. Christine Slater for help and support with the 
laboratory analysis. I am grateful to Dr. Brian Speake for analysing the umbilical cord 
tissue samples and for his contribution to the study. Thanks also to Dr. Jim 
Farquharson and Dr. Cherry Jamieson for their advice, and to Mr. Martin McMillan for 
helping me in the laboratory. Dr. Christine Edwards and Mr. Sandy Fletcher are 
thanked for their advice on the finer points of tissue homogenization.
I acknowledge those involved in the continuation and evolution of this study in 
investigating infant visual development, including Dr. Naveed Sattar, Dr. Daphne 
McCulloch and Ms. Cari Malcolm. I am grateful to David Young for his advice on 
statistical analyses. I thanlc Ms. Jean Hyslop for her patience and assistance in the 
preparation of everything from the FOMI logo and leaflets/posters, to the diagrams and 
formatting of this thesis.
I also thanlc the many people in the Departments of Child Health and Human Nutrition 
who supported me tliroughout this time, especially Dr. John Reilly, Dr. Khalid Khan, 
Dr. Diane Jackson and Mrs. Myra Fergusson. Many thanks are due to Dr. Alison
Parrett and Ms. Emma-Jane “Bariatrie Surgery” Gault for their understanding and 
tolerance, and for allowing me to distract them from their work when gossip arose!
I wish to thank my brother Gerard who first encouraged me to “do science” when I 
wanted to “do law”, and whose own Ph.D. graduation day was such a poignant time 
for our family. I cannot express enough gratitude for our parents, who ensured we had 
every opportunity they themselves did not, and who loved and encouraged us 
throughout. For my Dad, whose courage and humour were inspirational, and for my 
Mum, whose love has been unfailing, I hope I have done my best.
AUTHOR’S DECLARATION
I declare that the work contained in this thesis is original. The recruitment of 
participants, the collection and analyses of samples, and the analysis and presentation 
of data were entirely undertaken by the author, unless otherwise stated. This thesis and 
the work contained herein was supervised by Professor Lawrence T. Weaver.
Colette Montgomery
SUPERVISOR’S DECLARATION
I declare that the work contained in this thesis was performed by the author and that 
during the period of study, the requirements for the Degree of Doctor of Philosophy 
have been fulfilled.
 ^   A # '  Iatîm
Professor Lawrence T. Weaver 
Samson Gemmell Chair of Child Health
LIST OF CONTENTS 
Dedication 
Acknowledgements 
Author’s Declaration 
List of Contents 
List of Tables 
List of Figures 
List of Publications 
List of Abbreviations 
Summary
Chapter 1:
1.1
1.2
Chapter 2:
2.1
2.2
2.3
2.4
2.5
2.6 
2.7
Fatty Acid Structure and Function
Definitions of Lipids
N-3 PUFA Intakes and Requirements
Introduction
Classification of Fish and Definition of Fish Oils 
Original Sources of n-3 PUFA Obtained From Fish Oils 
Current n-3 PUFA Intakes in the Human Diet 
Requirements for n-3 PUFA 
Achieving n-3 PUFA Recommendations 
Possible Adverse Effects of n-3 PUFA Intake
1
ii
iv
V
xvi
xxi
xxiii
xxiv
XXV
1.1.1 Introduction 1
1.1.2 Fatty Acids 1
1.1.2(a) Chain Length 2
1.1.2(b) Saturation 2
1.1.2(c) Nomenclature 3
1.1.2(d) Essentiality 10
1.1.2(e) Forms 10
1.1.3 Acylglycerols 10
1.1.3(a) Nature and Fatty Acid Composition 11
1.1.4 Phospholipids 12
1.1.4(a) Membrane Structure and Function 13
Functions of Lipids 14
1.2.1 Lipids in Energy and Metabolism 15
1.2.2 Lipids in Cell Membrane Struetures 15
18
18
19
21
22
25
26
2.8 Possible Implications of n-3 Intake for Duration and Outcome of
Pregnancy 27
Chapter 3: Fatty Acid Metabolism
3.1 Assimilation and Metabolism of Fat 30
3.1.1 Adult/Matemal F at Digestion and Absorption
3.1.1(a) Gastric Digestion 30
3.1.1(b) Intestinal Digestion 33
3.1.1(c) Jejunal Absorption 34
3.1.1(d) Plasma Cireulation 35
3.1.1(e) Peripheral Tissue Accretion 36
3.1.2 Infant F at Digestion and Absorption 3 8
3.1.2(a) Gastric Digestion 38
3.1.2(b) Intestinal Digestion 3 9
3.1.2(c) Jejunal Absorption and Plasma Circulation 40
3.1.2(d) Colonic Metabolism 40
3.1.3 F atty Acid S ynthesis 43
3.1.4 Triacylglycerol Synthesis 48
3.1.5 Fatty Acid Oxidation 51
3.2 Lipid Metabolism During Pregnancy and Fetal PUFA Supply
3.2.1 Introduction 57
3.2.2 Overview of Physiology 57
3.2.3 Maternal Adaptations and Metabolism 58
3.2.4 Plaeental Transport and Metabolism 58
3.2.5 Fetal Lipid Accretion 59
3.3 Postnatal Fat Accumulation
3.3.1 Introduction 62
3.3.2 Adipose Tissue 63
3.3.3 Brain Tissue 63
Chapter 4: Biomarkers of Fatty Acid Status
4.1 Introduction 65
4.2 Circulating Levels of Fatty Acids 65
4.3 Tissue Levels of Fatty Acids
4.3.1. Relation to Growth and Development 70
4.3.2. Relation to Storage and Potential Status 72
VI
4.4 Concluding Remarks 72
Chapter 5: Maternal and Fetal Fatty Acid Status
5.1 Maternal and Fetal Fatty Acid Status
5.1.1 Introduction 7 4
5.1.2 Maternal F atty Acid Status
5.1.2(a) Relative to Non-pregnant Female Status 74
5.1.2(b) Changes during Pregnancy and with Parturition
74
5.1.2(c) F actors Affecting Maternal Status
(i) Parity 76
(ii) Maternal Diet 77
(iii) Maternal Lifestyle/Habits 78
(iv) Gestation 78
(v) Health of Mother and Fetus 79
Fetal Fatty Acid Status 80
5.1.3(a) F actors Affecting F etal Status
(i) Parity 81
(ii) Maternal Diet 81
(iii) Genetics 82
(iv) Maternal Lifestyle/Habits 82
(v) Gestation 83
(vi) Health of Mother and Fetus 83
Relationship between Maternal and Fetal Blood Status
5.1.4(a) Comparison of Mother and Offspring 84
5.1.4(b) Correlation of F atty Aeid Status of Mother and
Offspring 85
5.1.5 Fatty Acid Status of Placental Tissue 85
5.1.6 Fatty Acid Status of Umbilical Cord Tissue 86
5.1.6(a) Factors Affecting Umbilical Vessel Status
(i) Maternal Status 87
(ii) Parity 87
(iii) Maternal Diet 87
(iv) Genetics 87
(v) Gestation 88
Vll
(vi) Singleton and Multiple Pregnaneies 88
(vii) Health o f  Mother and Fetus 8 8
5.2 Fatty Acid Status of Breast Milk
5.2.1 Introduction 89
5.2.2 Total Lipids 91
5.2.3 Fatty Acids
5.2.3(a) Within Triacylglycerols 92
5.2.3(b) Sources 93
5.2.3(c) Contributions 93
5.2.4 Factors Affecting Total Lipid and Fatty Acid Composition 
5.2.4(a) Suckling 94
5.2.4(b) Diurnal Rhythm 94
5.2.4(c) Stage of Lactation 95
5.2.4(d) Geography 96
5.2.4(e) Maternal Diet 97
5.2.4(f) Season 99
5.2.4(g) Socio-economic Status 100
5.2.4(h) Parity 100
5.2.4(i) Maternal Age 100
5.2.4(j) Length of Gestation 101
5.2.4(k) Maternal Health and Disease
(i) Insulin Dependent Diabetes Mellitus 101
(ii) Cystic Fibrosis 102
(iii) Type I Hyperlipoproteinemia 102
(iv) Hypobetalipoproteinemia 103
(v) Infection 103
(vi) Atopy 103
(vii) Exercise 103
5.3 Relationship between Infant PUFA Intake and Development 104
5.4 Perspective and Coneluding Remarks 105
Chapter 6: Study Design
6.1 Aims 107
6.2 Hypotheses 107
6.3 Study Design 107
VUl
6.4 Sample Size Calculation 108
6.5 Randomization 109
6.6 Supplements 109
6.7 Inclusion and Exclusion Criteria 112
6.8 Ethical Approval 112
6.9 Study Identification 113
6.10 Medical and Nursing Staff 113
6.11 Study Participation 113
6.12 Diet and Living Habits of Participants 114
6.13 Acknowledgement of Study Participants and Hospital Staff 115
Chapter 7: Study Participants
7.1 Enrolment 116
7.2 Withdrawals and Exclusions 116
7.3 Maternal Characteristics 117
7.4 Fish Intake, Alcohol and Smoking 118
7.5 Socio-economic Status 120
7.6 Compliance with Capsule Consumption 121
7.7 Delivery 121
7.8 Infant Characteristics 121
7.9 Infant Anthropometry 122
7.10 Blood, Tissue and Breast Milk Samples 123
Chapter 8: Materials and Methods
8.1 Methods of F atty Acid Analysis
8.1.1 Intro duction 125
8.1.2 Lipid Extraction 125
8.1.3 Derivatization 127
8.1.4 Gas Chromatography 128
8.2 Validation of Methods 134
8.2.1 Standards 134
8.2.2 Validation of Lipid Extraetion Procedure
8.2.2(a) Sample Concentrating by Drying under Nitrogen
136
8.2.2(b) Extraction Yield Test 136
8.2.3 Validation of FAME Derivatization Procedure 137
IX
8,2,4 Validation of GC-MS Analytical Procedures
8.2.4(a) Linearity Tests -  High and Low Concentration
Standard Curves 138
8.2.4(b) Analytical Precision for Measures of Peak Area
and Concentration 138
8.3 Collection, Initial Preparation and Storage of Samples
8.3.1 Blood Samples; Red Blood Cells and Plasma 142
8.3.2 Placental Tissue 142
8.3.3 Umbilical Cord Tissue 143
8.3.4 Breast Milk 144
8.3.5 Sample Analyses 144
8.4 Material and Methods
8.4.1 Samples analysed at Yorkhill
8.4.1(a) Reagents 144
8.4.1(b) Standards 145
8.4.1(c) ' Glassware 146
8.4.1(d) Extraction Procedure 146
(i) Red Blood Cells 146
(ii) Plasma 147
(iii) Placenta 148
(iv) Breast Milk 148
8.4.1 (e) Derivatization (Méthylation) Procedure 149
8.4.1(f) Gas Chromatography-Mass Spectrometry 149
8.4.2 Samples analysed at SAC, Ayr 150
8.4.3 Results 151
8.5 Statistical Methods
8.5.1 Biochemical Variables 154
8.5.2 Distribution of Data 155
8.5.3 Effeet of Variables on DHA 155
8.5.4 Analysis between Groups : Mann-Whitney Tests 155
8.5.5 Analysis within Groups (Paired Data) : Sign Tests 155
8.5.6 Statistics Programme 156
Chapter 9: Results of Supplementation Study
9.1 DHA and Other Variables
9.1.1 DHA and Parity 157
9.1.2 DHA and Interval Between Pregnancies 157
9.1.3 DHA and Frequency of Fish Consumption 158
9.1.4 DHA and Recent Fish Consumption 159
9.1.5 Concluding Remarks 160
9.2 Analyses Between Fish Oil and Placebo Groups
9.2.1 RBC Fatty Acids: % Total Fatty Acids (Relative Levels) 
9.2.1(a) Maternal RBC at 15 weeks gestation 161
9.2.1(b) Maternal RBC at 28 weeks gestation 162
9.2.1(c) Maternal RBC at Birth 163
9.2.1(d) Umbilical Cord RBC 163
9.2.2 RBC Fatty Acids: Concentration (Absolute Levels)
9.2.2(a) Maternal RBC at 15 weeks gestation 166
9.2.2(b) Maternal RBC at 28 weeks gestation 166
9.2.2(c) Maternal RBC at Birth 167
9.2.2(d) Umbilical Cord RBC 168
9.2.3 Plasma Fatty Acids: % Total Fatty Acids (Relative Levels) 
9.2.3(a) Maternal Plasma at 15 weeks gestation 169
9.2.3(b) Maternal Plasma at 28 weeks gestation 170
9.2.3(c) Maternal Plasma at Birth 171
9.2.3(d) Umbilical Cord Plasma 172
9.2.4 Plasma Fatty Acids: Concentration (Absolute Levels)
9.2.4(a) Maternal Plasma at 15 weeks gestation 175
9.2.4(b) Maternal Plasma at 28 weeks gestation 176
9.2.4(c) Maternal Plasma at Birth 177
9.2.4(d) Umbilical Cord Plasma 178
9.2.5 Placental Tissue Fatty Acids: % Total Fatty Acids (Relative 
Levels) 179
9.2.6 Placental Tissue Fatty Acids: Concentration (Absolute Levels)
180
9.2.7 Umbilical Cord Tissue Fatty Acids: % Total Fatty Acids 
(Relative Levels) 183
9.2.8 Breast Milk Fatty Acids: % Total Fatty Acids (Relative Levels)
185
XI
9.2.9 Breast Milk Fatty Acids: Concentration (Absolute Levels)
185
9.3 Analyses Within Groups: Longitudinal Change and the Relationship
between Maternal and Fetal Status
9.3.1 RBC Fatty Acids: % Total Fatty Acids (Relative Levels)
9.3.1(a) Fish Oil Group: Maternal RBC at 15 and 28
weeks gestation 188
9.3.1(b) Fish Oil Group: Maternal RBC at 28 weeks and
Birth 188
9.3.1(c) Fish Oil Group: Maternal RBC at Birth and Fetal
Umbilical Cord RBC 188
9.3.1(d) Placebo Group: Maternal RBC at 15 and 28
weeks gestation 191
9.3.1(e) Placebo Group: Maternal RBC at 28 weeks and
Birth 191
9.3.1(f) Placebo Group : Maternal RBC at Birth and Fetal
Umbilical Cord RBC 192
9.3.2 RBC Fatty Acids: Concentration (Absolute Levels)
9.3.2(a) Fish Oil Group: Maternal RBC at 15 and 28
weeks gestation 194
9.3.2(b) Fish Oil Group: Maternal RBC at 28 weeks and
Birth 194
9.3.2(c) Fish Oil Group: Maternal RBC at Birth and Fetal
Umbilical Cord RBC 194
9.3.2(d) Placebo Group: Maternal RBC at 15 and 28
weeks gestation 197
9.3.2(e) Placebo Group: Maternal RBC at 28 weeks and
Birth 197
9.3.2(f) Placebo Group: Maternal RBC at Birth and Fetal
Umbilical Cord RBC 197
9.3.3 Plasma Fatty Acids: % Total Fatty Acids (Relative Levels) 
9.3.3(a) Fish Oil Group: Maternal Plasma at 15 and 28
weeks gestation 200
Xll
9.3.3(b) Fish Oil Group: Maternal Plasma at 28 weeks
and Birth 200
9.3.3(c) Fish Oil Group: Maternal Plasma at Birth and
Fetal Umbilical Cord Plasma 200
9.3.3(d) Placebo Group: Maternal Plasma at 15 and 28
weeks gestation 203
9.3.3(e) Placebo Group: Maternal Plasma at 28 weeks and
Birth 203
9.3.3(f) Placebo Group: Maternal Plasma at Birth and
Fetal Umbilical Cord Plasma 204
9.3.4 Plasma Fatty Acids: Concentration (Absolute Levels)
9.3.4(a) Fish Oil Group: Maternal Plasma at 15 and 28
weeks gestation 206
9.3.4(b) Fish Oil Group: Maternal Plasma at 28 weeks
and Birth 206
9.3.4(c) Fish Oil Group: Maternal Plasma at Birth and
Fetal Umbilical Cord Plasma 206
9.3.4(d) Placebo Group: Maternal Plasma at 15 and 28
weeks gestation 209
9.3.4(e) Placebo Group: Maternal Plasma at 28 weeks and
Birth 209
9.3.4(f) Placebo Group: Maternal Plasma at Birth and
Fetal Umbilical Cord Plasma 209
9.4 Comparison of the Fatty Acid Patterns of Fish Oil and Placebo Groups
9.4.1 RBC Fatty Acids: % Total Fatty Acids (Relative Levels)
9.4.1(a) Maternal RBC at 15 and 28 weeks gestation
212
9.4.1 (b) Maternal RBC at 28 weeks and Birth 213
9.4.1(c) Maternal RBC at Birth and Fetal Umbilical Cord
RBC 214
9.4.2 RBC Fatty Acids: Concentration (Absolute Levels)
9.4.2(a) Maternal RBC at 15 and 28 weeks gestation
215
9.4.2(b) Maternal RBC at 28 weeks and Birth 215
X lll
9.4.2(c) Maternal RBC at Birth and Fetal Umbilical Cord 
RBC 216
9.4.3 Plasma Fatty Acids: % Total Fatty Acids (Relative Levels) 
9.4.3(a) Maternal Plasma at 15 and 28 weeks gestation
217
9.4.3(b) Maternal Plasma at 28 weeks and Birth 217
9.4.3(c) Maternal Plasma at Birth and Fetal Umbilical
Cord Plasma 218
9.4.4 Plasma Fatty Acids: Concentration (Absolute Levels)
9.4.4(a) Maternal Plasma at 15 and 28 weeks gestation
219
9.4.4(b) Maternal Plasma at 28 weeks and Birth 220
9.4.4(c) Maternal Plasma at Birth and Fetal Umbilical
Cord Plasma 221
9.4.5 Placental Tissue Fatty Acids: % Total Fatty Acids (Relative 
Levels) 222
9.4.6 Placental Tissue Fatty Acids: Concentration (Absolute Levels)
222
9.4.7 Umbilical Cord Tissue Fatty Acids: % Total Fatty Acids 
(Relative Levels) 222
9.4.8 Breast Milk Fatty Acids: % Total Fatty Acids (Relative Levels)
222
9.4.9 Breast Milk Fatty Acids: Concentration (Absolute Levels) 222 
Chapter 10: Discussion
10.1 Overview 223
10.2 DHA in Relation to Parity and Diet 224
10.3 Effect of Supplementation on Maternal and Fetal Status
10.3.1 Summary 225
10.3.2 RBC Fatty Acids: % Total Fatty Acids (Relative Levels) 226
10.3.3 RBC Fatty Acids: Concentration (Absolute Levels) 227
10.3.4 Plasma Fatty Acids: % Total Fatty Acids (Relative Levels) 228
10.3.5 Plasma Fatty Acids: Concentration (Absolute Levels) 229
10.3.6 Placental Tissue 229
10.3.7 Umbilical Cord Tissue 230
XIV
10.3.8 Breast Milk 230
10.4 Study Limitations and Future Studies
10.4.1 Adipose Tissue 231
10.4.2 Analysis of Total Lipids 233
10.5 Conclusion 234
Bibliography 237
Appendices
Appendix 1 Introductory Leaflet 284
Appendix 2 Consent Form 285
Appendix 3 Advice Leaflet  ^ 287
Appendix 4 Case Note Consent 288
Appendix 5 Questionnaire 289
XV
LIST OF TABLES
Table 1 Nomenclature of saturated fatty aeids.
Nomenclature of monounsaturated fatty acids. 
Nomenclature of polyunsaturated fatty acids. 
Selected species of fish and their n-3 PUFA content.
Table 2 
Table 3 
Table 4 
Table 5
Table 6
9
20
The contribution of food groups to daily intake of fat and fatty acids by 
adults. 21
Comparison of the recommended intakes of unsaturated fatty acids for 
healthy adults made by the COMA Report (1991) and the BNF Task Force 
(1992). 23
Table 7 BNF Task Foree recommended intakes of unsaturated fatty acids for
healthy adults. 23
Table 8 Fatty acid composition of human milk in U.K. 24
Table 9 Summary of BNF Task Force (1992) recommendations for PUFA intakes
in special groups. 25
Table 10 Classification and characteristics of lipases. 32
Table 11 Classifieation of bile acids and salts. 33
Table 12 Classification of lipoproteins. 36
Table 13 Desaturase enzymes. 44
Table 14 Assigmnent of fatty acids at 5n-positions of triacylglycerol molecules. 48
Table 15 Seleeted studies demonstrating relationship between dietary and circulating 
levels of fatty acids in neonates. 69
Table 16 Changes in breast milk with time postpartum. 89
Table 17 Nutrient composition of breast milk. 90
Table 18 Summary of study protocol. 108
Table 19 Composition of active supplement and placebo capsules, according to 
certification by the manufacturer and analysis by GC-MS. 112
XVI
Table 20 Time of antenatal sampling and delivery in days (weeks + days) after 
conception for all those enrolled who continued to take part in the study.
116
Table 21 Numbers and withdrawal rates in study sample and treatment groups. 116
Table 22 Obstetric history of whole study sample and both treatment groups. 117
Table 23 Expeeted and actual modes of delivery for the study participants. 117
Table 24 Heights and weights of study participants, as recorded by nursing staff at 
time of booking (approx. 10 weeks gestation). 118
Table 25 Frequency of weekly fish consumption, in the whole study sample and in 
the randomised treatment groups, during gestation and at time of delivery.
119
Table 26 Lifestyle characteristics of study participants. 119
Table 27 Numbers in study sample consuming supplements other than those given in 
study. 120
Table 28 Socio-economic status of study sample. 121
Table 29 Characteristics of infants. 122
Table 30 Infant anthropometry. 123
Table 31 Numbers of samples obtained at each time point from the whole study
sample and in each group. 124
Table 32 Relative fatty acid levels (% fatty acids) in various human tissues. 135
Table 33 Composition of non-esterifred fatty acid standard prepared in the 
laboratory (Standard H). 136
Table 34 Mean coefficient of variation (CV) for all sample types and standards for 
selected fatty acids measured as both peak area and concentration. 139
Table 35 Fatty acids measured in samples analysed at Yorldiill, compared to those
measured in umbilical cord tissue samples analysed at SAC, Ayr. 152
Table 36 Median values for DHA as a % TFA and its concentration (nmol/ml for 
RBC, plasma and breast milk, nmol/g for plaeental tissue) in samples from 
nulliparous and parous participants. 157
XVll
Table 37 Median values for DHA as a % TFA and its concentration (nmol/ml for
RBC, plasma and breast milk, nmol/g for placental tissue) in samples from
parous participants whose last previous pregnancy was 1 year or less, or 
more than 1 year, prior to the current pregnancy. 158
Table 38 Median values for DHA as a % TFA and its concentration (nmol/ml) in 
samples from participants whose consumption of fish was classified as (1) 
never or less than once per week, or (2) once or more per week, at 15 
weeks gestation, 159
Table 39 Median values for DHA as a % TFA and its concentration (nmol/ml) in 
samples from participants whose consumption of fish was classified as (1) 
never or less than once per week, or (2) once or more per week, at 28 
weeks gestation. 159
Table 40 Median values for DHA as a % TFA and its concentration (nmol/ml for
RBC, plasma and breast milk, nmol/g for placental tissue) in samples from
participants whose consumption of fish was classified as (1) never or less 
than once per week, or (2) once or more per week, at time of birth. 159
Table 41 Median values for DHA as a % TFA and its concentration (nmol/ml) in 
samples from participants who had consumed fish more than 24 hours 
prior to sampling, or 24 hours or less before sampling at 15 weeks 
gestation. 160
Table 42 Median values for DHA as a % TFA and its concentration (nmol/ml) in 
samples from participants who had consumed fish more than 24 hours 
prior to sampling, or 24 hours or less before sampling at 28 weeks 
gestation. 160
Table 43 Percentage total fatty acids in maternal RBC total lipids at 15 weeks 
gestation for both groups. 161
Table 44 Percentage total fatty acids in maternal RBC total lipids at 28 weeks 
gestation for both groups. 162
Table 45 Percentage total fatty acids in maternal RBC total lipids at birth for both
groups. 163
X V lll
Table 46 Percentage total fatty acids in umbilical cord RBC total lipids for both 
groups. 164
Table 47 Total fatty acid concentrations (nmol/ml) in maternal RBC total lipids at 
15 weeks gestation for both groups. 166
Table 48 Total fatty acid concentrations (nmol/ml) in maternal RBC total lipids at 
28 weeks gestation for both groups. 167
Table 49 Total fatty acid concentrations (nmol/ml) in maternal RBC total lipids at 
birth for both groups. 168
Table 50 Total fatty acid concentrations (nmol/ml) in umbilical cord RBC total
lipids for both groups. 169
Table 51 Percentage total fatty acids in maternal plasma total lipids at 15 weeks 
gestation for both groups. 170
Table 52 Percentage total fatty acids in maternal plasma total lipids at 28 weeks 
gestation for both groups. 171
Table 53 Percentage total fatty acids in maternal plasma total lipids at birth for both
groups. 172
Table 54 Percentage total fatty acids in umbilical cord plasma total lipids for both
groups. 173
Table 55 Total fatty acid concentrations (nmol/ml) in maternal plasma total lipids at 
15 weeks gestation for both groups. 176
Table 56 Total fatty acid concentrations (nmol/ml) in maternal plasma total lipids at 
28 weeks gestation for both groups. 177
Table 57 Total fatty acid concentrations (nmol/ml) in maternal plasma total lipids at 
birth for both groups. 178
Table 58 Total fatty aeid concentrations (nmol/ml) in umbilical cord plasma total
lipids for both groups. 179
Table 59 Percentage total fatty acids in placental tissue total lipids for both groups.
180
Table 60 Total fatty acid concentrations (nmol/g) in placental tissue total lipids for 
both groups. 181
XIX
Table 61 Percentage total fatty acids in umbilical cord tissue total lipids for both
groups. 183
Table 62 Percentage total fatty acids in breast milk total lipids for both groups.
185
Table 63 Total fatty acid concentrations (nmol/ml) in breast milk total lipids for both
groups. 186
Table 64 Summary of indices measured and the statistically significant (p<0.05) 
differences between groups. 226
XX
LIST OF FIGURES
Figure 1 Basic structure of a fatty acid. 1
Figure 2 Fatty acid isomers in (a) cis configuration, (b) trans configuration. 3
Figure 3 Fatty acid nomenclature. 5
Figure 4 Structure of glycerol. 11
Figure 5 Structure of a triacylglycerol. 12
Figure 6 Structure of a phospholipid. 13
Figure 7 Schematic representation of a phospholipid and a phospholipid bilayer.
14
Figure 8 Hydrolysis of a triacylglycerol by gastrointestinal lipases. 42
Figure 9 Elongation and desaturation of fatty acids. 47
Figure 10 Synthesis of a triacylglycerol molecule. 50
Figure 11 The “carnitine shuffle”. 53
Figure 12 P-oxidation of fatty acids prior to energy production via the TCA cycle.
56
Figure 13 Typical chromatogram of fatty acid methyl esters obtained by GC. 131
Figure 14 Analytical precision for C22:6n-3 based on peak area. 140
Figure 15 Analytical precision for C22:6n-3 based on concentration. 141
Figure 16 % DHA (median & quartiles) in RBC of both groups. 165
Figure 17 DHA concentration (median & quartiles) in RBC of both groups. 165
Figure 18 % DHA (median & quartiles) in plasma of both groups. 174
Figure 19 DHA concentration (median & quartiles) in plasma of both groups. 174
Figure 20 % DHA (median & quartiles) in placental tissue of both groups. 182
Figure 21 DHA concentration (median & quartiles) in placental tissue of both groups.
182
Figure 22 % DHA (median & quartiles) in umbilical cord tissue of both groups. 184
Figure 23 % DHA (median & quartiles) in breast milk of both groups. 187
XXI
Figure 24 DHA concentration (median & quartiles) in breast milk of both groups.
187
Figure 25 Longitudinal changes in % DHA in RBC of fish oil group. 190
Figure 26 Longitudinal changes in % DHA in RBC of placebo group. 193
Figure 27 Longitudinal ehanges in DHA concentration in RBC of fish oil group.
196
Figure 28 Longitudinal changes in DHA concentration in RBC of placebo group.
199
Figure 29 Longitudinal changes in % DHA in plasma of fish oil group. 202
Figure 30 Longitudinal ehanges in % DHA in plasma of placebo group. 205
Figure 31 Longitudinal changes in DHA concentration in plasma of fish oil group.
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Figure 32 Longitudinal changes in DHA concentration in plasma of placebo group.
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SUMMARY
Background
Docosahexaenoic acid (DHA) (C22;6n-3) is a polyunsaturated fatty acid that is an 
essential constituent of cell membranes, particularly of the nervous system where it is 
found in relatively high concentrations in the brain and retina. DHA is obtained by 
endogenous synthesis, dependent on an adequate dietary intake of its parent essential 
fatty acid a-linolenic acid, or preformed in the diet, largely from fish, particularly oily 
fish. Levels of DHA (DHA status) can be determined by its measurement in blood and 
tissues. Circulating DHA status correlates with fish intake, even in the West of 
Scotland where consumption is low and intakes of DHA and oily fish are below 
current recommendations.
Fetal and neonatal DHA status is dependent on maternal DHA status. Maternal 
supplies of DHA are transferred to the fetus via the placenta, and to the neonate via 
breast-milk. There is evidence that maternal DHA is mobilized, particularly during the 
early stages of pregnancy, to ensure the fetus accretes sufficient DHA. This appears to 
be unsustainable, such that by term, maternal DHA status is lower relative to mid­
pregnancy and to the fetus. Babies who are inadequately supplied with DHA either in 
utero or postnatally accumulate lower amounts in blood and tissue, and may be at a 
disadvantage with regards to neurodevelopment. Depletion of maternal DHA status 
may further affect subsequent pregnancies.
In this study expectant mothers were supplied with preformed DHA, at a dosage 
comparable with current dietary recommendations in a palatable and convenient form, 
to determine its effects on the nutritional status of both mother and fetus.
Hypotheses
This study aimed to test the hypothesis that maternal DHA supplementation enriches 
maternal DHA status and thereby increases the amount available to the fetus and 
neonate, as reflected in:
(a) maternal red blood cells (RBC) and plasma
(b) placental and umbilical cord tissue
(c) (fetal) umbilical cord RBC and plasma
(d) breast milk
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study Design
A randomized double-blind, placebo-controlled trial was undertaken in which 100 
expectant mothers were randomized to receive either fish oil (n=50) or placebo (n=50) 
capsules from 15 weeks gestation until term. The fish oil capsules contained 40% 
DHA (200mg/day); the placebo consisted of high oleic sunflower oil containing 81% 
oleic acid (400mg/day).
Maternal venous blood samples were obtained at 15 and 28 weeks gestation and at 
birth. Umbilical cord blood, umbilical cord tissue and placental tissue were collected 
at delivery. Breast milk was obtained soon after birth.
Study Participants
All pregnancies were singleton and delivered at term. Mothers were representative of 
the Glasgow population in terms of socio-economic status (SES). The two maternal 
groups were similar with regard to maternal age, anthropometry, SES, fish 
consumption, smoking and alcohol habits. Their infants were of comparable 
gestational age and anthropometry, and were matched in gender and feeding practice.
Methods
The fatty acid composition of total lipids in RBC, plasma, cord/placental tissue and 
breast milk was analysed. Fatty acids were extracted via a modified Folch extraction 
and derivatized with methanolic hydrochloric acid. Fatty acid methyl esters (FAME) 
were analysed by gas chromatography mass spectrometry (GC-MS) and quantified in 
both relative and absolute terms: results were expressed as % total fatty acids (% TFA) 
and as concentrations (nmol/ml for RBC, plasma and breast milk, nmol/g for placenta). 
Values were obtained for 19 individual fatty acids. In addition, the n-6 and n-3 PUFA 
classes were each summed (total n-6 and total n-3 fatty acids respectively) and 
expressed relative to each other (ratio n-6/n-3 fatty acids).
Differences between the fish oil and placebo groups were tested using Mann-Whitney 
2-sample rank tests, with a chosen significance level of p<0.05. The longitudinal 
changes in maternal status and the differences between mother and fetus were assessed 
by one-sample Sign tests at a significance level of p<0.01.
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Results
There were no significant differences between groups in baseline samples at 15 weeks. 
Both groups exhibited an increase in the concentration and % of DHA in maternal 
RBC and plasma between 15 and 28 weeks, followed by a decrease between 28 weeks 
and term. However, at 28 weeks, the concentration of DHA was 22% higher in plasma 
(p=0.02) and 13% higher in RBC (p=0.02) in the fish oil compared to the placebo 
group. At term, RBC DHA concentration remained 42% higher (p=0.02) in the fish oil 
supplemented group. DHA also accounted for a higher % TFA in RBC of fish oil 
supplemented mothers at 28 weeks (p=0.003) and at term (p=0.01). Total n-3 fatty 
acids were elevated, with a concomitant lower n-6/n-3 ratio, in the fish oil group at 28 
weeks and at birth in both maternal RBC and plasma, for both relative and absolute 
measurements (all p<0.05). Thus, fish oil supplementation enhanced the overall 
maternal DHA and n-3 fatty acid status.
There were no significant differences between groups in DHA as a % TFA or 
concentration in cord blood, placental tissue, cord tissue, or breast milk. In both 
groups, DHA (% TFA and concentration) was higher in cord than maternal RBC and 
plasma at birth. The relative and absolute amounts of DHA in cord plasma and RBC 
were most similar to the maximal maternal DHA observed at 28 weeks.
The early increase in maternal DHA (between 15 and 28 weeks) was greater in the fish 
oil group; the subsequent decline in maternal status following mid-gestation (between 
28 weeks and term) was less in the fish oil group. The matemo-fetal difference was 
also less marked in the fish oil group. Fish oil supplementation thus enhanced 
maternal ability to provide the fetus with DHA during the second trimester, and limited 
the third trimester depletion of maternal stores and status, ensuring a more favourable 
maternal status by term such that the matemo-fetal gradient was less severe.
Conclusions
Maternal DHA status is maximal in mid-trimester and declines to term. The extent of 
this decline is limited in supplemented compared to unsupplemented mothers. The 
relationship between mid-trimester maternal and term cord blood DHA suggests that 
timing of maternal supplementation is important, and is most likely to be beneficial if
xxvn
it begins before mid-gestation. Maternal DHA supplementation enhances maternal 
DHA status and may aid preferential transfer of DHA from mother to fetus. 
Maintenance of a higher DHA status at term may also enhance maternal DHA status in 
subsequent pregnancies.
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Chapter 1
Fatty Acid Structure and Function
1.1 DEFINITIONS OF LIPIDS
1.1.1 Introduction
“Lipid” is a term applied to a group of substances that have in common not a chemical 
structure, but a “solubility characteristic” (Stedman’s Dictionary 1997). Lipids are 
insoluble in water but soluble in nonpolar (organic) solvents, such as alcohols, ethers 
and chloroform, which are themselves immiscible with water (Gurr 1993, Jensen 
1989a, Stedman’s Dictionary 1997). Thus classes of lipids include heterogeneous 
substances, such as fatty acids, acylglycerols, phospholipids, glycolipids, sphingolipids, 
steroids and fat-soluble vitamins (A, D, E, K) (Gurr 1993, Jensen 1989a).
The various classes of lipids differ in their biological functions. In general, lipids serve 
either an energy storage (acylglycerols) or a structural (phospholipid, cholesterol) role. 
Lipids may also be converted to compounds involved in cell signaling and regulation, 
such as prostaglandins, leukotrienes and steroid hormones. The role of lipids in health 
and disease has been the subject of numerous detailed reviews (Food and Agriculture 
Organization/FAO & World Health Organization/WHO 1980, Health Education 
Authority/HEA 1994).
The nature and structure of three specific classes of lipids -  fatty acids, acylglycerols 
and phospholipids - are discussed further below, with attention to the nutritional 
relevance of these species.
1.1.2 Fatty Acids
Fatty acids are compounds of hydrocarbon chains which have at one end a methyl 
group (CH3) and at the other, a carboxyl group (COOH) (Figure 1). The hydrocarbon 
chain allows lipid solubility, while the carboxyl moiety confers acidic properties on the 
fatty acid (British Nutrition Foundation/BNF 1992).
HO - C - R or HO - C AAAAV
Figure 1. Basic structure of a fatty acid. The functional carboxyl group is shown. R or 
AAAAA denotes the hydrocarbon chain, including the methyl group, which varies in 
length, number and position of double bonds and so is notated without specification 
when depicting fatty acids in general.
1.1.2(a) Chain length
The hydrocarbon chain can contain 2-30 carbon atoms (C), but the most common 
naturally occurring fatty acids contain an even number of carbon atoms between 12 and 
22 (Cl 2-22) (BNF 1992, Gurr 1993, HEA 1994). The length of the hydrocarbon chain 
serves as the basis for the classification of fatty acids into short, medium or long (and 
occasionally, very long) species. There are, however, some discrepancies in the 
literature as to chain length classification: for example, medium-chain fatty acids have 
been defined as C8-10 (Gurr 1993), C8-12 (HEA 1994), C8-14 (Hamosh et al 1984), 
or as C l0-14 (BNP 1992). Some authors also refer to fatty acids of chain length of 
C20+ as very long chain. On the basis that short-chain fatty acids are those of a 
volatile nature, and that chains of less than C16 are saturated, the classification below 
has been adopted for the purpose of this review:
Short Medium Long
Cl-6 C8-14 Cl 6-22
1.1.2(b) Saturation
Fatty acid hydrocarbon chains may also vary in the number of bonds between 
constituent carbon atoms. Carbon atoms are capable of forming four covalent bonds. 
When each carbon atom (except the terminal ones) are bonded to adjacent carbon 
atoms via single covalent bonds, each C can also bond to two hydrogen atoms (H) (or 
three for terminal carbons), thus the four possible covalent bonds are complete. The 
bonding capacity of each C is “saturated” and the chain is “saturated” with hydrogen
i.e. a saturated fatty acid. If two adjacent carbon atoms form an ethylenic double bond, 
they are only able to bond to one hydrogen each. The hydrocarbon chain as a whole 
has the capacity to bond more hydrogen should the double bond “break”, thus the chain 
is not saturated with hydrogen i.e. an unsaturated fatty acid. When the hydrocarbon 
chain contains one double bond, the fatty acid is called monounsaturated; when it 
contains two or more double bonds, it is called polyunsaturated. The double bond 
sequence is usually methylene-interrupted.
The ethylenic double bond can itself give rise to variations of fatty acids, as it can 
adopt two geometrical configurations or isomers (BNF 1992) (Figure 2). When the
two hydrogen atoms bonded to the two carbons involved in the double bond are on the 
same side of the molecule as each other, there is a “kink” in the hydrocarbon chain. 
This is called the cis or Z configuration. When the hydrogen atoms are on opposite
sides from each other, the chain has a straight configuration, called the trans or E
configuration. The cis isomer occurs in naturally occurring lipids, while the trans 
isomer is “mechanically” introduced during the commercial production of fats (Bender 
1997, BNF 1992).
r y y
- C  = C -  “ C = Ç -
H
(a) (b)
Figure 2. Fatty acid isomers in (a) cis configuration, (b) trans configuration.
1.1.2(c) Nomenclature
There is a systematic method of naming fatty acids: nomenclature encompasses chain 
length, saturation, isomerism, double bond position and metabolic relationships. The 
details of these conventions are discussed elsewhere (BNF 1992, F AO & WHO 1980, 
Salway 1994) and are summarized as follows (Figure 3):
1. Systematic chemical name - derived from the name of the parent hydrocarbon, 
based on chain length. The final “e” is substituted with “anoic” for saturated fatty 
acids, “enoic” for monounsaturates, “dienoic” for polyunsaturates with two 
double bonds, “trienoic” for polyunsaturates with three double bonds, etc.
2. Identification of carbon atoms from the carboxyl end - by either
(a) labeling the carboxyl carbon as Ci and continuing numerically (C2, 
C3 etc.) along the chain until the methyl carbon (Figure 3(a))
(b) labeling the carbon atom adjacent to the carboxyl carbon as the 
alpha carbon (a), and continuing along the chain (p, y etc.) until the 
methyl carbon which is labeled the omega carbon (co) (Figure 3(b)). 
Convention has now adopted the symbol “n” to denote Q (the upper 
case of co). In this system, the carboxyl carbon is not labeled, as it is 
part of a functional group rather than the hydrocarbon chain.
3. Position of double bonds - either
(a) relative to the carboxyl end, with the delta symbol A followed by a 
superscript number which denotes the first C of the pair in the double 
bond, as numbered from the carboxyl Ci
(b) relative to the methyl end, with the symbol co (or n) followed by the 
number which denotes the first C of the pair in the double bond, as 
numbered from the methyl carbon (o)-C or n-C which is numbered co- 
1 or n-1).
4. Identification of unsaturated fatty acids by isomerism - cis and trans, or c and t, 
before the double bond location, denotes the configuration of the fatty acid.
5. Metabolic relationships - since fatty acids are lengthened by adding carbon atoms 
at the carboxyl end, the actual position of the double bonds does not change 
relative to the methyl end, but differs relative to the total number of carbon 
atoms. If the co-C at the methyl end is counted as co-1 (n-1), the first carbon in 
the double bond can be denoted by numbering from the methyl end {e.g. n-3) 
(Figure 3(c)). Fatty acids can thus be considered related if their first double bond 
from the methyl end is in the same position relative to the co-C. This allows fatty 
acids to be identified as belonging to a particular “family”, e.g. n-3, n-6 and n-9 
families.
(a)
HO - C
CeC2
(b)
HO - 0 '(0
(c)
(à)
HO - C
HsCAAAAAMC - C - OH
t
©
n-1
a
Figure 3. Fatty acid nomenclature. The various systems of classification shown are:
(a) numbering the carbon atoms sequentially starting from Cl, the carboxyl carbon,
(b) labelling the carbon atoms sequentially starting from Ca, the carbon adjacent to 
the carboxyl carbon, (c) labelling the double bonds sequentially starting from Cm, the 
methyl carbon. The systems are summarised in (d).
Combinations of these conventions allow fatty acids are to be referred to by both their 
systematic chemical names and abbreviated formulae, as well as by common names. 
The full systematic nomenclature combines the type of isomer with the positions of the 
double bonds from the carboxyl end and the actual systematic name. Thus, for 
example, a fatty acid of 18C chain length with a double bond in the cis configuration 
between carbons 9 and 10 from the carboxyl end is denoted cz>“9-octadecenoic. 
Although this system does not include the designation of family or type, it can be 
deduced since the length of the chain and position of the double bond are known. 
Thus, if the double bond occurs 9 to 10 carbons along from the carboxyl end in an 18C 
chain, it is therefore 9 carbons along from the methyl end, i.e. at n-9. Omission of the 
isomer type before the name implies that all double bonds present are in the cis 
configuration.
Shorthand notation of fatty acids consists of the number of carbons in the chain (x), 
followed by a colon, the number of double bonds (y), and then the position of the first 
double bond relative to the methyl end (n) to denote the family to which the fatty acid 
belongs (n-m), such that the general formula is x;yn-m (FAO & WHO 1980). By this 
notation, for example, cw-9-octadecenoic is denoted 18:ln-9.
The common name of a fatty acid does not impart any specific information regarding 
its size or type, and may be derived from other aspects such as the source of the fatty 
acid; for example ci.s-9-octadecenoic (18:ln-9) is derived from olive oil and hence 
referred to as oleic acid.
The nomenclature and formulae of fatty acids are summarized in Tables 1-3.
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1.1.2rdl Essentiality
The designation of unsaturated fatty acids as belonging to a particular family on the 
basis of the position of the first double bond relative to the methyl carbon (n) is of a 
greater biological importance than a system of nomenclature. The metabolism of fatty 
acids involves the addition of more carbons to the hydrocarbon chain (elongation) and 
more double bonds within the chain (desaturation), processes catalyzed by enzymes 
(see Chapter 3, Section 3.1.3 Fatty Acid Synthesis). The enzymes that introduce 
double bonds relative to the methyl carbon (n-1) at n-3, n-6 and n-9 are all present in 
plant cells, whereas animal cells only have enzymes capable of inserting double bonds 
after the n-6 position {i.e. not at n-3 or n-6). It is therefore essential that animals obtain 
fatty acids with double bonds in the n-3 and n-6 positions from their diet. However, 
animals do not need to obtain all n-3 and n-6 fatty acids preformed, as they are capable 
of elongating the chains and adding double bonds at positions other than at n-3 and n-
6. The shortest hydrocarbon chain which can contain multiple double bonds is one of 
18C. The first fatty acids in the n-3 and n-6 families are therefore a-linolenic acid 
(aLA, 18:3n-3) and linoleic acid (LA, 18:2n-6), respectively. From these, animals can 
derive longer and more unsaturated fatty acids in each family thus aLA and LA are 
required from the diet, i.e. are essential fatty acids (EFA). There is evidence that a lack 
of dietary LA gives rise to deficiency disorders, although this is controversial in the 
case of aLA, whose true essentiality may arise more from its role in development 
(Koletzko 1987) and as a source of DHA (Spector 1999).
LL2feI Forms
Fatty acids can exist as individual moieties as free/non-esterified fatty acids (FFA/ 
NEFA), and as components of the other classes of lipids, including acylglycerols and 
phospholipids.
1.1.3 Acylglycerols
The carboxyl group of a fatty acid can form an ester linkage with glycerol (a three 
carbon alcohol) (Figure 4) (Bender 1997) to form an acyglycerol. The combination of 
one, two and three fatty acids with glycerol forms a monoacylglycerol, a diacylglycerol 
and a triacylglycerol respectively. These were previously refen*ed to in older literature
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as glycerides, but acylglycerols are the officially approved nomenclature (Gurr 1993, 
Manson & Weaver 1997).
H CHoOH
I I
H - C - OH HO - CH
I I
H - 0  - OH CHgOH
H - C - OH
H
Figure 4. Structure of glycerol.
Most of the lipid obtained from the diet is in the form of triacylglycerols. In addition, 
lipid is stored in adipose tissue as triacylglycerols. Hence, the commonly used term 
“fat” usually refers to triacylglycerols. Triacylglycerols are hydrophobic.
1.1.31a) Nature and Fattv Acid Composition
The fatty acids on a triacylglycerol are not necessarily the same and adopt specific 
distributions (Figure 5) (BNF 1992, Manson & Weaver 1997) (see Chapter 3, Section
3.1.4 Triacylglycerol Synthesis, Table 14). The position of each fatty acid on the 
glycerol moiety of a triacylglycerol is denoted by stereospecific numbering, 
abbreviated to Sn (Manson & Weaver 1997) or sn (Jensen 1989a). The distribution of 
fatty acids on the glycerol molecule may not always be random, and certain fatty acids 
are preferentially located at a specific position. This has implications for the 
absorption and metabolism of dietary fats, particularly in neonates (see Chapter 3, 
Section 3.1.2 Infant Fat Digestion and Absorption) (Amate, Ramirez & Gil 1999, 
Camielli et al 1995, Nelson & Innis 1999).
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I f?
H - ^Sn-^ -  O  - C  - R  
O 
H - Csn.2 - O  - C  - R'
o
H - C sn - 3  - O  - C  - R"
H
Figure 5. Structure of a triacylglycerol. R, R' and R" denote different fatty acyl chains 
at the Sn-l, 2 and 3 positions respectively. Sn denotes stereospecific numbering.
The fatty acids present in a triacylglycerol determine its characteristics and the nature 
of the fat of which it is a component. If the majority of the fatty acids are saturated, the 
fat is referred to as saturated fat; such fats are largely derived from animal sources and 
are generally solid at room temperature. Triacylglycerols rich in trans unsaturated fatty 
acids are also solid at room temperature and are obtained from partially hydrogenated 
fats produced by processing. The presence of cis unsaturated fatty acids imparts 
certain characteristics, including lowering the melting point of the fatty acid. Such 
unsaturated fats therefore tend to be liquid at room temperature (the definition of an 
oil). Unsaturated fats are commonly obtained from non-animal foods, such as 
vegetable sources (vegetable fats or oils) or fish (fish oils). Unsaturated fats or oils 
may differ further in the nature of the predominant fatty acids, which may be either 
monounsaturated or polyunsaturated; the polyunsaturates may themselves be derived 
from a particular family, principally the n-3 or n-6 families. Thus, oils can contain 
more or less of certain fatty acids and so be a source of the discrete fatty acid classes.
The triacylglycerols stored in the body by adipocytes are subject to dietary influences, 
and their fatty acid composition and hence nature are reliant on that of dietary 
triacylglycerols.
1.1.4 Phospholipids
Of the other compounds classified as lipids, most have a more structural role (Gurr 
1993), particularly as components of cell membranes. They can be obtained from the
12
diet in much smaller quantities than triacylglycerols, in the cell membranes of the food 
ingested. Such structural fats account for 5-8% of body weight and specific organs, 
notably the brain, have a high content of structural fat (Health Education 
Authority/HEA 1994).
The most abundant lipids in membranes are phospholipids, which consist of two fatty 
acids esterified to a molecule of glycerol, the third hydroxyl group of which is 
esterified to phosphate, which is itself esterified to a hydrophilic base (Figure 6). The 
base (or alcohol) group may be choline, ethanolamine, serine or inositol, giving rise to 
the phospholipids, phosphatidyl choline (PC), phosphatidyl ethanolamine (PE), 
phosphatidyl serine (PS) and phosphatidyl inositol (PI) respectively (Bender 1997, 
Houslay & Stanley 1982).
I ,9
H - Csn-1 - O - C - R 
O 
H - Csn-2 - O - C - R' 
OH
II
H - C  - 0 - P - O  - B a s e
Figure 6. Structure of a phospholipid. R and R' denote different fatty acyl chains at the 
Sn~l and 2 positions respectively. Sn denotes stereospecific numbering.
Phospholipids are amphiphilic/ambiphilic/amphipathic as they contain a polar/charged 
hydrophilic base and nonpolar aromatic/alipathic hydrophobic fatty acids (BNF 1992, 
Gurr. 1993, Houslay & Stanley 1982).
1.1.4(al Membrane Structure and Function
In aqueous solution, the hydrophobic fatty acids of phospholipids aggregate to expel 
water molecules. They “turn in” to one another to form a bilayer, in which their acyl 
chains form a hydrophobic core (Figure 7). Van der Waal’s forces between the acyl 
chains of adjacent phospholipids allow them to pack closely together (Stryer 1988).
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The hydrophilic phosphorylated alcohol unit (polar head group) of each phospholipid 
exists on the surface of such bilayers.
glycerol + base 
fatty acid
Figure 7. Schematic representation of a phospholipid and a phospholipid bilayer. The 
hydrophobic acyl chains of the fatty acids and the hydrophilic phosphorylated base are 
shown.
These lipid membranes form permeability barriers into which proteins can insert; such 
proteins are involved in cell signaling and recognition processes. Lipid and protein 
molecules are mobile along the plane of the membrane (Gurr 1993, Houslay & Stanley 
1982, Stryer 1988). Such lateral diffusion (Stryer 1988) gives rise to different 
constituents on either side of the membrane and hence to membrane asymmetry. In 
this type of asymmetrical bilayer sheet (Singer and Nicolson fluid mosaic model of 
biological membranes), the function of the membrane proteins is influenced by the 
fatty acid composition and cholesterol content, which affect membrane fluidity 
(Houslay & Stanley 1982, Stryer 1988). Tissue specific patterns of the fatty acid 
content of membrane phospholipids are observed and thus implicated in physiological 
functions. Moreover, phospholipid composition is subject to less dietary influence 
than that of triacylglycerols, with extreme conditions required to produce change in 
phospholipid fatty acids (FAO & WHO 1980).
1.2 FUNCTIONS OF LIPIDS
The functions of lipids and their constituent fatty acids have been defined as energy 
storage, energy-providing, metabolic and structural (BNF 1992). The mechanisms and 
biochemistry by which they achieve these essential functions are beyond the scope of 
this discussion. The various roles of lipids are summarized, with emphasis on their 
contribution to neural function, below.
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1.2.1 Lipids in Energy and Metabolism
Lipids can be stored as triacylglycerols in adipose tissue and breast milk, which can 
then be mobilized and oxidized to obtain energy (see Chapter 3, Section 3.1.5 Fatty 
Acid Oxidation). As with all tissues, adipose possesses unique characteristics (Pond 
1999), which are outwith the scope of this discussion; the lipids of breast milk are 
discussed later (see Chapter 5, Section 5.2 Fatty Acid Status of Breast Milk).
The metabolic role of lipids pertains to their contribution to eicosanoid metabolism and 
to cell signaling via the inositol cycle and generation of second messengers. Both n-6 
and n-3 families are precursors of eicosanoids (prostaglandins, prostacyclins, 
thromboxanes, leukotrienes, lipoxins), their absolute and relative amounts 
determinants of eicosanoid metabolism (Rubin & Laposata 1992). Eicosanoids are 
physiologically active in the inflammatory response, platelet aggregation, 
vasodilation/constriction and muscle function. The role of fatty acids in eicosanoid 
metabolism and its relevance to pregnancy (Ogburn Jr. 1998) and infancy (Sellmayer & 
Koletzko 1999) has been discussed in detail elsewhere. The myriad of effects 
mediated by lipids within the immune (Various 1998) and cardiovascular (Leaf & 
Weber 1988, Marckmann & Gronbæk 1999) systems have been reviewed, as has the 
evidence for their beneficial effects (de Deckere et al 1998, Simopoulos 1999a, Uauy 
& Valenzuela 2000).
1.2.2 Lipids In Cell Membrane Structures
Lipids have a definite structural role as components of cell membranes, exerting an 
influence on membrane conformation and stability. This has led to the implication of 
membrane lipids as determinants of membrane nature or fluidity (Manku et al 1983); 
the more correct interpretation, however, may be of membrane “molecular order and 
mobility” (Watts 1997). Phospholipids account for approximately 80% of membrane 
lipids, with phosphatidylcholine and phosphatidylethanolamine the predominant 
classes of phospholipids. Specific fatty acids adopt selective positioning within 
phospholipid molecules, which are in turn preferentially incorporated into membranes.
The shape of the phospholipid molecule is determined by the size of both its base 
group (choline, ethanolmine etc.) and constituent fatty acids; phospholipid shape can
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itself influence membrane structure and function (Watts 1997). In addition, the degree 
of unsaturation within a fatty acid contributes to the “packing” of the lipids within the 
membrane bilayer. Unsaturated fatty acids do not adopt a linear conformation and 
introduce “local deformations” (Watts 1997) to the bilayer, which affect membrane 
permeability. Moreover, lipids are not static membrane components, but are capable of 
a high degree of diffusion within the bi layer, conferring both fluidity and asymmetry on 
the membrane.
By determining much of the membrane’s conformation and nature, lipids influence the 
environment of membrane proteins. Lipids and proteins are also capable of interaction 
and lipids may not only provide the optimal environment for protein but may also 
facilitate protein activity and function (BNF 1992). Membrane lipids may thus be as 
important as their protein neighbours in the regulation of membrane and hence cellular 
processes (Futerman, Ghidoni & van Meer 1998).
Such functionality dictates the need for selectivity by cell membranes of both lipid 
classes and their constituent fatty acids. This gives rise to the characteristic patterns of 
fatty acid composition of cell membranes, particularly in neural tissues such as the 
brain and retina (see Chapter 3, Section 3.2.5 Fetal Lipid Accretion), where a high 
concentration of DHA is implicated in neurotransmission (Cockbum 1997).
The human brain, from various ages of the human spectrum, displays specific patterns 
of fatty acid composition (Svennerholm 1968). Brain FA are distributed between the 
major PL in a specific manner, and within each PL species in a tissue specific manner 
between cerebral gray and white matter, with white matter containing less PUFA. 
Moreover, levels of PUFA from the n-6 and n-3 families vary with age; n-6 PUFA 
increase until adulthood then decrease, with concomitant increase in n-3 PUFA 
(Svennerholm 1968).
The conservation of brain DHA (& AA) patterns between species suggests a 
prerequisite for brain function. Brain size and development may therefore have been 
determined by the availability of DHA in the evolutionary past, implicating DHA in 
distinguishing humans from other species (Broadhurst, Cunnane & Crawford 1998a,
1 6
Crawford et al 1992 & 1999), a theory not without controversy (Broadhurst, Cunnane 
& Crawford 1998b, Gurr 1998).
DHA co-exists in the outer rod cells of the retina with the photoreceptor rhodopsin. 
The function of rhodopsin appears to be dependent on the presence of DHA, which 
may facilitate the optimal spatial environment within the bilayer for rhodopsin to 
function (Dratz & Holte 1992, Watts 1997).
The precise reason(s) for the specific presence and requirement of DHA in the 
membranes of neural tissues is unknown. It has been postulated that DHA interacts 
with membrane proteins in a specific manner, that it forces the membrane to adopt a 
certain conformation which induces stability and/or it is involved in neuronal signaling 
(Kim & Edsall 1999, Kurlak & Stephenson 1999). The continual diffusion of lipids 
within the membrane bilayer is, however, cited as evidence that protein-lipid 
interactions would be transient and contribute little to modulating protein function 
(Crawford et al 1999). Regulation of gene expression may offer an alternative 
mechanism for the functionality of DHA (Uauy, Mena & Rojas 2000). Whatever the 
mode of action, since a lack of DHA (cis-4,7,10,13,16,19-docosahexaenoic) leads to 
incorporation of 22:5n-6 DP A (cis-4,7,10,13,16-docosapentaenoic), it has been 
postulated that the molecular requirement for DHA resides in its methyl end and n-3 
double bond (Spector 1999).
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Chapter 2
N-3 PUFA Intakes and Requirements
2.1 INTRODUCTION
The sources of each fatty acid in the human diet were summarised in Tables 1-3 
(Chapter 1, Section 1.1.2(c) Fatty Acid Nomenclature). Although the parent n-3 EFA, 
a-linolenic acid (aLA, 18:3n-3) can be derived from plant sources (vegetable seed 
oils), its longer and more unsaturated derivatives, such as EPA (20:5n-3), DP A (22:5n- 
3) and DHA (22:6n-3), can only be found in appreciable amounts in fish oils. The 
sources of and requirements for n-3 PUFA in the human diet are outlined and 
discussed.
2.2 CLASSIFICATION OF FISH AND DEFINITION OF FISH OILS
Fish can be classified in various ways according to whether they are found in fresh or 
sea water, whether they are bony or cartilaginous, and/or whether they are pelagic 
(occur near the surface of the water) or demersal (deep in the water). However, the 
most common classification when considering dietary fish categorises fish as either 
white and lean, or oily. Essentially the pelagic/demersal classification translates into 
oily and lean respectively (Sargent 1997).
Fish oils are the edible fats found in fish; they are referred to as oils because they are 
liquid at room temperature. Fish contain these oils mainly in the form of 
phospholipids and triacylglycerols (Stansby 1973). The phospholipids are generally 
intracellular, occurring in the cell membranes of tissue and flesh, and have structural 
and functional roles. The triacylglycerols are stored as energy reserves and since fish 
have no adipose tissue, are deposited either in the flesh or in the liver. Fish which 
contain these triacylglycerol depots in their liver have very few fats, other than the 
phospholipids, in their flesh {i.e. their flesh is lean), while 50-80% of the weight of the 
liver may be accounted for by oil (Stansby 1973). Thus it is the oils found in their 
livers {i.e. fish liver oil) which are a rich source of n-3 fatty acids. Species of lean fish 
include cod, haddock, plaice and whiting. In contrast, some fish store reserve 
triacylglycerols in their flesh and up to 20% of their wet weight is comprised of oil 
(Sargent 1997), hence they are referred to as oily, fatty or oil-rich fish. The 
composition of fish oils varies with season, species and diet (Sargent 1997, Stansby 
1973), but all fish oils share the characteristic of high n-3 levels. Thus the distinction 
between oily and lean fish is made on the basis of where their oil is stored (flesh or 
liver) and hence the relevance to the human diet, since humans consume the flesh
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rather than the livers of fish. The content of selected n-3 PUFA in various species of 
fish is known; when considering the human diet, the types of fish commonly 
consumed, the ways in which they are prepared and the portion size consumed must be 
taken into account (Table 4).
2.3 ORIGINAL SOURCES OF N-3 PUFA OBTAINED FROM FISH OILS
Fish obtain n-3 LCPUFA from their own diet. Marine phytoplankton (microscopic 
plants) are the source of long chain n-3 products in the food chain, containing large 
amounts in their chloroplast membrane lipids. Species of phytoplankton differ in 
which PUFA they synthesise; the reason for DHA production is unknown but may 
pertain to the motility and photostatic (light seeking) behaviour of the phytoplankton 
(Sargent 1997). Marine zooplankton (microscopic animals) feed on phytoplankton and 
store the lipids obtained in their oils. Fish then ingest the zooplankton and so obtain 
preformed n-3 LCPUFA. Manipulation of the diet of farmed fish by providing an 
adequate supply of marine oils, and therefore preformed n-3 PUFA, can thus ensure 
fish destined for human consumption contain adequate amounts of n-3 PUFA (Sargent 
1997).
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Food
a L A  
(18;3n-3) 
g per 
100g“
EPA 
(20;Sn-3) 
g per 
100g“
DHA 
(22:6n-3) 
g per
100g“
Average 
Portion 
Size (g)"
a L A  
(18;3n-3) 
g per 
Portion
EPA 
(20;Sn-3) 
g per 
Portion
DHA 
(22:6n-3) 
g per 
Portion
bass, sea, raw 0 0.1 0.4
caviare, bottled in brine, drained trace 0.5 0.8 19 0.10 0.15
clams, canned in brine, drained tiace 0.1 trace
cockles, boiled 0 trace trace 4 0.00
cockles, bottled in vinegar, drained 0 0.1 trace 25 0.00 0.03
cod, coated in batter, frozen, baked 0.1 0 0.1 100 0.10 0.00 0.10
cod, raw trace 0.1 0.2
cod, steamed trace 0.1 0.2 120 0.12 0.24
crab, boiled trace 0.5 0.5 40 0.20 0.20
eel, jellied 0.1 0.2 0.2 70 0.07 0.14 0.14
fish cakes, frozen 0.2 trace 0.1 50 0.10 0.05
fish fingers, cod, frozen 0.1 0.1 0.1 28 0.03 0.03 0.03
fish paste 0 0 0 10 0.00 0.00 0.00
haddock raw trace 0.1 0.1
haddock, steamed trace 0.1 0.1 120 0.12 0.12
herring, grilled 0.2 0.7 0.8 119 0.24 0.83 0.95
herring, raw 0.2 0.8 1
kipper, grilled 0.3 1.3 1.5 130 0.39 1.69 1.95
kipper, raw 0.3 1.1 1.3
lemon sole, steamed trace 0 0.1 170 0.00 0.17
lobster, boiled 0.1 0.2 0.1 85 0.09 0.17 0.09
mackerel, grilled 0.2 0.8 1.2 160 0.32 1.28 1.92
mackerel, raw 0.2 0.7 1.1
monkfish, raw trace trace 0.1
mussels, boiled trace 0.4 0.2 40 0.16 0.08
m ussels, canned/bottled, drained trace 0.3 0.1 139 0.42 0.14
m ussels, raw trace 0.3 0.1
pilchards, canned in tomato sauce 0.1 1,2 1.2 110 0.11 1.32 1.32
plaice, frozen, steamed trace 0 0.1 130 0.00 0.13
plaice, grilled trace 0 0.1 130 0.00 0.13
plaice, raw trace 0 0.1
prawns, boiled trace 0.1 0.1 60 0.06 . 0.06
prawns, frozen, raw trace 0.1 tiace
roe, cod, hard, raw trace 0.2 0.3
roe, herring, soft, raw trace 0.2 0.4
salmon, pink, canned in brine, drained 0.1 0.5 0.8 45-100 0.05-0.1 0.23-0.5 0.36-0.8
salmon, raw 0.2 0.5 1.3
salmon, red, canned in brine, drained 0.1 0.7 0.9 45-100 0.05-0.1 0.32-0.7 0.41-0.9
sardines, canned in oil, drained 0.4 0.9 0.8 100 0.40 0.90 0.80
sardines, canned in tomato sauce 0.2 0.9 0.7 100 0.20 0.90 0.70
sardines, grilled 0.1 1 1.2 86 0.09 0.86 1.03
sardines, raw 0.1 0.9 1.1
shrimps, boiled trace 0.4 0.3 50 0.20 0.15
shrimps, canned in brine, drained trace 0.2 0.1 50 0.10 0.05
taramasalata 5.2 0.2 trace 45 2.34 0.09
trout, rainbow, grilled 0.1 0.2 0.7 155 0.16 0.31 1.09
trout, rainbow, raw 0.1 0.2 0.8
tuna, canned in brine, drained trace trace O.I 45-100 0.05-0.1
tuna, canned in oil, drained 0.9 O.I 0.3 45-100 0.41-0.9 0.05-1.0 0.14-0.3
tuna, raw 0 0.3 1.1
whelks, boiled trace 0 0.1 30 0.00 0.03
whiting, raw trace 0 0.1
whiting, steamed trace 0 0.1 85 0.00 0.09
winkles, boiled 0.1 0,1 trace
Table 4. Selected species of fish and their n-3 PUFA content.  ^Data from Holland, 
Brown & Buss (1993);  ^ portion sizes from Ministry of Agriculture, Fisheries and 
Food (MAFF) (1993). Values for PUFA will vary with season, and are approximate 
only.
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2.4 CURRENT N-3 PUFA INTAKES IN THE HUMAN DIET
The contribution of the various food groups to total fat and fatty acid intake in the diet 
of British adults is summarised in Table 5. No significant differences in intakes of 
total fat or classes of fatty acids exist between women in the various regions of the 
U.K. (Gregory et al 1990). Fish contributes an average of 3% of the total daily fat 
intake; n-3 PUFA account for an average of 0.7% total energy. Of the average daily n- 
3 PUFA intake, 14% is obtained from fish, with oily fish accounting for 7% of daily n- 
3 intake. Current intakes of total n-3 are approximately 1.7g/day (Gregory et al 1990). 
Thus if oily fish consumption provides 7% of a total 1.7g n-3 intake, the mean intake 
of n-3 LCPUFA (obtainable only from fish) is O.lg/day; this intake is elevated in 
regular consumers of oily fish/once per week, to 0.2-0.3g/day or 2g/week.
Average daily fat intake in g (% of total intake)
<— -Fatty Acids — ->
Total Fat Saturated Trans MUFA PUFA
n6 n3
Milk and milk products 13.4(15) 8.5 (23) 0.5 (10) 3.3 (12) 0.2 (2) 0.1 (6)
Fat spreads (including butter and margarine) 14.1(16) 6.2 (17) 1.4 (30) 3.0(11) 2.4 (20) 0.3 (15)
Meat and meat products 21.5 (24) 83 (23) 0.9(18) 8.3 (31) 2.0 (17) 0.3 (19)
Fish and fish dishes 2.5 (3) 0.6 (2) 0.1(1) 0.9 (3) 0.5 (4) 0.2(14)
Eggs and egg dishes 3.6 (4) 1.1(3) 0.1(2) 1.4 (5) 0.5 (4) 0.0 (2)
Cereal products 16.9(19) 6.6(18) 1.3 (27) 4.7 (18) 2.6 (22) 0.3 (17)
Vegetables (including roast and fried) 9.7(11) 2.4 (6) 0.3 (6) 3.2(12) 2.8 (24) 0.4 (22)
Fruit and nuts 0.7 (1) 0.1 (0) 0.0 (0) 0.3 (1) 0.2 (2) 0.0(1)
Sugar, confectionery and preserves Z 3 G ) 1.3(4) 0.2 (3) 0.6 (2) 0.1(1) 0.0(1)
Beverages 0.2 (0) 0.2 (0) 0.0 (0) 0.0 (0) 0.0 (0) 0.(0)
Other 3.1 (3) 1.2 (3) 0.1 (2) 0.9 (3) 0.5 (5) 0.0 (2)
Total 88 36.5 4.8 26.7 11.7 1.6
Table 5. The contribution of food groups to daily intake of fat and fatty aeids by 
adults. Reproduction of Table 3.7 from the BNF Task Force Report (BNF 1992), 
using data from Gregory et al 1990.
However, fish intake in the adult population of Britain is low at approximately 150g 
per week (21 g per day) (Gregory et al 1990). Most of this (60%) is accounted for by 
white fish, with oily fish contributing only 23% of total fish intake (Gregory et al 
1990). Approximately one third of British adults consume one portion (average 135g) 
of oily fish per week, although an equal number of men and women do so (Gregory et 
al 1990).
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2.5 REQUIREMENTS FOR N-3 PUFA
The definition of “requirements”, and the rationale and criteria for establishing them is 
problematic, and further complicated by the way in which they are expressed, for 
example as a population "average", minimum/maximum, or acceptable daily intake. In 
addition, the units in which the requirements are expressed vary, and include 
expression in units relative to energy intake (% total energy intake) or in absolute 
weight (g/day, g/week). These issues and the difficulties in comparing reference 
values from various Reports are considered in more detail elsewhere (BNF 1992, 
Roche 1999).
There are two main reference sources for recommended levels of PUFA intake 
applicable to the U.K. The 1991 Department of Health (DoH) Committee on Medical 
Aspects of Food Policy (COMA) report on dietary reference values (Department of 
Health/DoH 1991) based its considerations solely on EFA levels required to prevent 
EFA deficiency, and therefore set values primarily for minimum requirements, stating 
that there was no evidence that higher levels were any more beneficial. The COMA 
panel recommended a minimum intake of n-3 PUFA as 18:3n-3 amounting to 0.2% of 
total energy. It made no recommendations for PUFA other than the EFA.
In comparison, the BNF Task Force Report on unsaturated fatty acids (UFA) (BNF 
1992) considered all UFA and their roles in various aspects of health and disease, and 
made recommendations for infants, pregnant and lactating women, and the general 
adult population. The report considered EFA separately from their LCPUFA 
derivatives; under the term n-3 LCPUFA, it includes 18:4n-3, 20:4n-3, 20:5n-3, 22:5n- 
3 and 22:6n-3 and defines total n-3 PUFA as 18:3n-3 in combination with the 
LCPUFA. It therefore produced more comprehensive recommendations than the 
COMA report, including minimum and maximum recommended intakes for 18:3n-3, 
n-3 LCPUFA and total PUFA (Table 6). The Task Force report included a higher 
minimum recommended intake for 18:3n-3 (0.5% total energy) than the 1991 COMA 
report, resulting in recommended total n-3 PUFA intakes ranging from 0.5-4.5% total 
energy. The maximum requirement for 18:3n-3 was based on toxicity studies; the 
maximum LCPUFA intake recommended (2% total energy) could be obtained on 
regular consumption of oily fish. For n-3 LCPUFA, no lower limit was set as the n-3 
status of vegetarians appears adequate, although whether this is due to a low
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arachidonic acid intake and/or metabolic adaptation is unknown. Assuming daily total 
energy intakes of 2550kcal and 1940kcal for males and females respectively {i.e. the 
estimated average requirement/EAR for energy set by the 1991 COMA report), the 
Task Force provided both relative and absolute recommendations (Table 7).
1991 COMA 1992 BNF Task 
Force
Average population intake of MUFA 12.0 12.0
Minimum individual intake of MUFA Not given 0
Maximum individual intake of MUFA Not given 20.0
Average population intake of n-6 PUFA as 18:2n-6 6.0 6.0
Minimum individual intake o f n-6 PUFA as 18;2n-6 1 3
Maximum individual intake o f n-6 PUFA 10 10
Average population intake o f n-3 PUFA as 18:3n-3 Not given 1.0
Minimum individual intake o f n-3 PUFA as 18:3n-3 0.2 0.5
Maximum individual intake o f n-3 PUFA as 18:3n-3 Not given 2.5
Average population intake of long chain n-3 PUFA Not given 0.5
Minimum individual intake of long chain n-3 PUFA Not given Not given
Maximum individual intake of long chain n-3 PUFA Not given 2.0
Minimum individual intake of total n-3 PUFA 0.2 0.5
Maximum individual intake of total n-3 PUFA Not given 4.5
Average population intake o f total PUFA 6.0 7.5
Minimum individual intake of all PUFA 1.2 3.5
Maximum individual intake o f all PUFA 10 14.5
Table 6. Comparison of recommended intakes of unsaturated fatty acids for healthy 
adults made by the COMA Report (1991) and the BNF Task Force (1992). Values are 
for fatty acids as % total energy. Adapted from Table 22.6 from the BNE Task Force 
Report (BNF 1992).
Fatty Acid
Average Population 
Intake (% Total 
Energy) % Total 
energy
-Safe R anges----------
<-------------g/day
Men Women
18:2n-6 6 3-10 8-26 6-20
18;3n-3 1 0.5-2.5 1-6 1-5
n-3 LCPUFA 0.5 0-2.0 0-5 0-4
All PUFA 7.5 3.5-14.5 9-38 7-29
MUFA 12 0-20 0-51 0-39
Table 7. BNF Task Force recommended intakes of unsaturated fatty acids for healthy 
adults. Assumed intakes of 2550kcal/d and 1940kcal/d for men and women 
respectively. Reproduction of table 22.5 from the BNF Task Force Report (BNF 
1992).
Recommendations for infants were based on the average contribution of PUFA to the 
total energy of human breast milk summarised in Table 8. Assuming a 6 month old
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infant weighs 6kg and consumes 800ml milk per day, which has a fat content of
4. Ig/100ml and an energy content of 69kcal/100ml, the Task Force also derived 
absolute values for PUFA (Table 9). Thus, milk deriving 0.4% of its energy from 
18;3n-3 and 0.2% of its energy from DHA would provide 40mg of aLA and 20mg 
DHA per kg body weight of the infant. The Task Force considered two opposing 
arguments: (a) that there is evidence that all infants require preformed DHA, assuming 
that infants have minimal ability to elongate/desaturate aLA to DHA; (b) that there is 
no evidence of developmental problems in children receiving formulae with no or 
minimal DHA and that “it is impossible to know how many of these never achieved 
their full intellectual or visual potentials”. The Task Force concluded by advising that 
DHA should be present in all formulae in equivalent amounts to that in breast milk 
(0.2% total energy) (Table 9).
Linoleie acid a-Linolenic acid Arachidonic acid DHA
18:2n-6 18:3n-3 20:4n-6 22:6n-3
All UK omnivores 4.4 0.39 0.18 0.21
All UK vegetarians 12.4 0.87 0.25 0.10
Table 8. Fatty acid composition of human milk in the U.K. Values are for fatty acids 
as % total energy. Reproduction of Table 22.3 from the BNF Task Force Report (BNF 
1992).
Similarly, the opposing arguments regarding pregnant and lactating women concerned 
the apparent need for an increased intake versus the metabolic adaptations of 
pregnancy which may limit PUFA oxidation and/or increase accumulation, followed 
by enhanced mobilisation during lactation. The recommendations were thus that 
counselling should be offered pre-conceptionally, during pregnancy and during 
lactation to ensure intakes similar to the recommended average intake for the general 
population (Table 9).
24
Women
Pre-pregnant, pregnant No specific increased recommendation for PUFA but counselling to ensure that
and lactating recommendations for average population intakes are met, i.e. average total PUFA
intakes of at least 7.5% to be achieved.
Infants and children
Pre-term and full-term Formulae should contain quantities o f linoleie acid, arachidonic acid, alpha
infants not on human linolenic acid and DHA to replicate the amounts found in human milk:
milk
Linoleie acid (18;2n-6) 4% of total energy (377mg/kg body weight
with safe range o f 280 to 
1130mg/kg body weight) 
Arachidonic acid (20:4n-6) 0.2% o f total energy (20mg/kg body weight)
Alpha linolenic acid (18:3n-3) 0.4% o f total energy (40mg/kg body weight)
DHA(22:6n-3) 0.2% o f total energy (20mg/kg body weight)
Children on mixed diets The polyunsaturated fatty acid composition of the diet should replicate that of
_________________________ human milk until more information is forthcoming
Table 9. Summary of BNF Task Force (1992) recommendations for PUFA intakes in 
special groups. Reproduction of table 22.7 from the BNF Task Force Report (BNF
1992).
2.6 ACHIEVING N-3 PUFA RECOMMENDATIONS
When considering the role of PUFA in the aetiology and prevention of cardiovascular 
disease, the DoH COMA Report of 1994 (DoH 1994) recommended that the average 
intake of n-3 LCPUFA, mainly EPA and DHA, be increased to 0.2g/day (1.5g/week), 
i.e. levels achieved by those eating oily fish once per week and approximating to 0.1% 
total energy. The DoH thus recommends the consumption of two portions of fish per 
week, of which one should be oily. Adoption of such recommendations would 
effectively double the number consuming oily fish per week in the population.
To meet the higher BNF Task Force recommendations for n-3 LCPUFA, males would 
need to consume approximately 1-3 portions (150-480g) per week and females 1-3 
portions (120-380g) per week of oil-rich fish (herring, salmon, mackerel, pilchards, 
sardines) (British Nutrition Foundation/BNF 1993) (see Table 4 for n-3 PUFA 
composition and portion sizes of dietary fish).
However, there has been public concern regarding the level of environmental 
contaminants, such as polychlorinated dibenzo-/7-dioxins/dioxins (PCDD), 
polychlorinated dibenzofurans (PCDF) and polychlorinated biphenyls (PCB), in fish 
and fish products. Although fat content is only one factor which influences dioxin and 
PCB accumulation in fish (Ministry of Agriculture, Fisheries and Food/MAFF &
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Department of Health/DOH 1999), oily fish have been found to contain slightly higher 
concentrations of these chemicals (MAFF & DOH 1999). Exposure to such 
contaminants for an adult consuming a high level of oily fish (97.5^  ^ percentile) 
remains within U.K. and WHO recommended limits (MAFF & DOH 1999). 
Nonetheless, DoH recommendations are that adults should consume one portion of 
oily fish per week, since this will comply with COMA recommendations based on 
health benefits without approaching U.K. or WHO limits for dioxins and PCBs (DOH 
1999). The contaminant methylmercury has been found to increase with maternal 
consumption of seafood, and to be associated with an increased risk to 
neurodevelopment in the neonate, although this was observed in a population with a 
high component of marine food including whale in the diet (Steuerwald et al 2000). 
As a result, it is difficult to persuade an already reluctant population to consume even 
one portion of oily fish and hence comply with recommended n-3 PUFA intakes.
Such contaminants can be removed in the industrial preparation of purified fish oils. 
As an alternative to dietary fish, the BNF (1993) acknowledges the use of fish oil 
capsules (or liquids) and suggests consumption of 4 or 5 Ig capsules per day to 
achieve BNF Task Force (1992) n-3 LCPUFA recommendations. Fish oil capsules 
available to the general public in retail outlets vary greatly in composition. Typically 
they are Ig in size and provide a total of 0.25-0.3g n-3 fatty acids per capsule (BNF
1993). The highest dosage available appears to be in capsules containing lOOOmg of 
fish oil, with a DHA content of up to 250mg and a maximum EPA content of 350mg 
(The Boots Company PLC, Nottingham, U.K.). Most capsules are intended to be 
consumed once per day, although it is possible that they are actually consumed in 
greater quantities.
The manipulation and enrichment of foods, and the potential use of biotechnology and 
algal sources may provide novel methods of increasing n-3 intake (Bored et al 1999, 
Kris-Etherton et al 2000, Sanders 2000, Simopoulos 1999b), but their contribution is, 
as yet, negligible.
2.7 POSSIBLE ADVERSE EFFECTS OF N-3 PUFA INTAKE
Despite concerns regarding toxic contaminants, increased risk of lipid peroxidation, 
and an antithrombotic effect, the consumption of high levels of fish oil have not been
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unequivocally associated with adverse effects (Eritsland 2000). Since environmental 
contaminants are removed on refinement of fish oils, the use of purified supplements 
may actually be more desirable than high levels of fish consumption in heavily 
industrialised areas. There has been no evidence to suggest that increased fish intake 
induces auto-oxidation and produces carcinogenic effects (Leaf & Weber 1988). In 
addition, plasma antioxidant levels are unaffected by a high fish intake (Anttolainen et 
al 1996). The inclusion of a suitable antioxidant within a refined fish oil product may 
alleviate any potential risk (Turley et al 1998); supplements on general sale are 
generally made from oils derived from fish flesh rather than fish livers, and so are low 
in vitamins A and D (BNF 1992).
The suggestion that the antithrombogenesis induced by high n-3 PUFA intakes, while 
preventing ischaemic heart disease, may increase the risk of haemorrhagic stroke 
(Pedersen et al 1999) has not been substantiated. Although high doses of n-3 PUFA 
(3-4g EPA per day with or without DHA) are associated with prolonged bleeding time, 
blood loss in supplemented surgical patients was not increased, and there is no 
evidence that this is clinically significant (Simopoulos 1991). Moreover, the ingestion 
of aspirin produces a greater increase in bleeding time than does the ingestion of fish 
oils, and no incidences of bleeding during clinical trials of fish oils have been reported 
(Leaf & Weber 1988). Supplementation studies do however, generally exclude 
participants prescribed drugs with antithrombocytic functions, such as non-steroidal 
anti-inflammatories, to prevent supplement-drug interaction. Similarly, in 
supplementation studies during pregnancy, women with a history or risk of abruption 
or post-partum haemorrhage are excluded.
It is worth noting that “no epidemiological data indicate that the intake of a reasonable 
quantity of fats of marine origin carries a specific risk factor for human health” (FAO 
&WHO 1980).
2.8 POSSIBLE IMPLICATIONS OF N-3 INTAKE FOR DURATION AND 
OUTCOME OF PREGNANCY
The role of EFA and LCPUFA in pregnancy and fetal growth has recently been 
reviewed (Jumpsen, Van Aerde & Clandinin 1997, Sattar, Berry & Greer 1998). The 
putative relationship between n-3 PUFA, gestational length and birth weight was first
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considered following the association between a high marine diet and RBC n-3 levels in 
the Faroese population, and the observation that both gestational length and birth 
weight were greater in the Faroe Islands compared to Denmark, Since dietary PUFA 
can modulate the metabolism of prostaglandins, which are implicated in the onset of 
labour, the hypothesis arose that n-3 PUFA intake and status could be associated with 
the length of gestation and the subsequent weight attained (Olsen et al 1986).
In Danish mothers, the frequency of fish consumption in the month prior to 36 weeks 
gestation was not related to gestational length (Olsen, Olsen & Frische 1990). In non- 
smokers, however, fish consumption did correlate with placental weight, birth weight 
and head circumference, i.e. indices of fetal growth. However, when intakes of n-3 
PUFA in Danish mothers ranged from 0-0.75g/d, no associations were found between 
intake or maternal RBC status at 30 weeks gestation and gestational length or birth 
weight (Olsen et al 1995b). Frequent consumption of oily fish throughout pregnancy 
(up to 55g/d oily fish and 2.9g/d n-3) did not affect gestational length (Sanjuijo, 
Matorras & Perteagudo 1995). Supplementation with n-3 fatty acids during the last 
trimester (mean 2.6g/d, range 0.9-3.Ig/d n-3 during weeks 26-35) has been shown to 
be safe and to have no effect on gestational length (Connor, Lowensohn & Hatcher 
1996). A similar dose and duration of supplementation (2.7g/d n-3 during weeks 24- 
38) in high risk pregnancies also failed to affect gestation and birth weight (Onwude et 
al 1995).
Conversely, the n-3/n-6 ratio in maternal RBC total lipids at term has not been 
correlated with gestational age in Faroese mothers, but has been positively so in 
Danish mothers. The question was subsequently raised as to whether this was due to 
statistical error or a dose-response relationship (Olsen et al 1991). However, gestation 
was significantly longer in Danish women supplemented with fish oil (2.7g/d n-3) 
from 30 weeks gestation compared to those receiving olive oil or no supplement 
(Olsen et al 1992). Since the effect was greatest in those mothers with the lowest 
baseline intake of fish, it has been suggested that there is indeed a dose-response 
relationship between n-3 intake and effect, which reaches saturation level on high 
intakes, such as in Faroese women (Olsen et al 1992).
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There has been some suggestion that the high LA intake, and hence potential synthesis 
of AA, in vegetarian women may shorten gestation (Reddy, Sanders & Obeid 1994), 
but evidence for such an effect is lacking (Sanders 1999). Supplementation with LA 
(3g/d), in combination with a vitamin-mineral supplement, during the second and third 
trimesters did not affect gestation or infant anthropometry, including birth weight, 
suggesting that maternal nutrition affects fetal development much earlier in pregnancy 
(Doyle et al 1992).
Other outcomes of pregnancy possibly related to n-3 intake include complications or 
adverse outcomes. Within the Canadian Inuit population, those communities with a 
high marine diet have significantly lower blood pressure during labour, and a lower 
incidence of pregnancy-induced hypertension (PIH) (Gerrard et al 1990). However, 
supplementation with 3g/d EPA from the first trimester until delivery did not reduce 
the incidence of either PIH or intra-uterine growth retardation (lUGR) in a high risk 
population (Bulstra-Ramakers, Huisjes & Visser 1994).
Several studies have supplemented mothers with 2.7g/d n-3 in the last trimester and 
monitored the effect on various outcomes. At this dose and time-point, fish oil 
supplementation exerted no significant effects on blood lipids, urate, coagulation or 
fibrinolysis (Sorensen et al 1994). Similarly no effects on the normal third trimester 
rise in blood pressure (Salvig, Olsen & Secher 1996), or on the incidence of either PIH 
or lUGR (Onwude et al 1995) have been observed. Moreover, supplementation with 
2.7g/d from 20 weeks did not reduce recurrence, nor did 6.1g/d from 33 weeks reduce 
risk, of either lUGR or PIH (Olsen et al 2000).
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Chapter 3
Fatty Acid Metabolism
3.1 ASSIMILATION AND METABOLISM OF FAT
90% of the dietary fat ingested by the adult, and 98% of that ingested by the breast-fed 
infant is in the form of triacylglycerol. In both cases, the remainder of the total fat 
consumed is cholesterol, cholesteryl esters, phospholipids and free fatty acids. The 
reactions, control and aberrations of lipid metabolism have been reviewed extensively 
(Carey & Hemell 1992, Hamosh 1998, Stanley 1998a, Wolfe 1998). The processes 
involved in fat digestion are essentially the same in both the adult and infant, although 
newborns, because of their special diet (milk) and immaturity of exocrine pancreatic 
function, cope with fats in a manner unique to neonatal life. For this reason, the 
digestive and absorptive processes of the adult and infant will be reviewed separately, 
to draw attention to the differences between maternal and neonatal metabolism. 
Intermediary lipid metabolism -  synthesis and oxidation -  is also discussed, with 
emphasis on the implications for and the fate of LCPUFA.
3.1.1 Adult/Maternal Fat Digestion and Absorption
3.1.1(a) Gastric Digestion
On ingestion, the hydrophobic nature of triacylglycerols prevents them from mixing 
with the water phase of the gastric contents. Digestive enzymes are hydrophilic and 
therefore soluble in an aqueous solution. Only minimal digestion of ingested fat can 
occur in the stomach, without mixing of the triacylglycerol substrates with the required 
enzymes. The peristaltic action of the stomach increases the dispersion of the fat 
molecules in the aqueous environment, thereby increasing contact between the 
enzymes and substrates.
Lingual lipase (Table 10) is secreted by the serous glands of the tongue and can 
function in the acidic environment of the stomach, which is devoid of bile salts (BNF 
1992, Gurr 1993). Lingual lipase catalyses the slow hydrolysis of the Sn-3> fatty acid 
on the triacylglycerol. The concurrent action of gastric lipase, secreted from the gastric 
mucosa, hydrolyses short- (C4-6) and medium- (C8-14) chain saturated, and long- 
chain unsaturated (C l6-22) fatty acids at the Sn-2> position (Bmbleton & Pouton 1997, 
Hamosh et al 1992). Saturated fatty acids are not released on lipolysis in the stomach 
(Hamosh et al 1992). The net result of lipase action in the stomach is the production of 
unsaturated 1,2-diacylglycerol and non-esterified fatty acids (Figure 8). However,
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most ingested triacylglycerol escapes hydrolysis in the stomach and enters the 
duodenum still fully esterified.
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3.1.1(b) Intestinal Digestion
The mucosal cells of the duodenum and jejunum secrete the hormone cholecystokinin 
in response to luminal fats. Cholecystokinin slows gastric motility, thus decreasing the 
rate at which chyme enters the intestine. Secretin is also produced by duodenal 
mucosal cells, stimulating the secretion of bicarbonate from the pancreas, which 
neutralizes the pH of chyme. Thus optimal “time” and pH conditions are created in the 
duodenum to facilitate lipolysis.
However, the immiscibility of the hydrophobic lipids maintains their separation from 
the water phase of intestinal contents and therefore from the digestive enzymes. For 
efficient digestion, the fats must be emulsified, that is, dispersed and stabilized in 
aqueous solution. The release of bile from the gallbladder, in response to 
cholecystokinin stimulation, helps to achieve this.
Bile acids are synthesized in the liver (Table 11). Chenodeoxycholic acid and cholic 
acid are derived from cholesterol and conjugated to the amino acids taurine and 
glycine, producing the primary bile acids glycochenodeoxycholic acid, 
taurochenodeoxycholic acid, glycocholic acid and taurocholic acid. Secondary bile 
acids, lithocholic and deoxycholic acids, are produced when intestinal bacteria 
metabolize primary bile acids, and are recirculated in bile (Bender 1997). The sterol 
portion of bile is lipophilic, while the amino portion is hydrophilic. Thus bile acids can 
bind to the lipid molecules while remaining stable in the water, drawing the lipid 
molecules into solution. Any long chain unsaturated fatty acids released on 
triacylglycerol digestion by gastric lipase also help to stabilize the enzyme-bile-fat 
complex (Bmbleton & Pouton 1997, Hemell & Blackberg 1992).
Bile Acid Amino Acid Primary bile acid (salt) Secondary bile acid (salt)
Chenodeoxycholic acid 
Cholic acid
Glycine
Taurine
Glycine
Taurine
Glycochenodeoxycholic (-ate) 
Taurochenodeoxycholic (-ate) 
Glycocholic (-ate) 
Taurocholic (-ate)
} Lithocholic (-ate)
} Deoxycholic (-ate)
Table 11. Classification of bile acids and salts.
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The emulsified lipids are susceptible to the action of a variety of enzymes, all of which 
are secreted by pancreatic exocrine cells in response to cholecystokinin. Pancreatic 
lipase (Table 10), which is dependent on and stabilized by its cofactor colipase, acts at 
the Sn-l and Sn-3 positions of triacylglycerol to produce 2-monoacylglycerol and non- 
esterified fatty acids (Bmbleton & Pouton 1997, Hamosh et al 1992, Manson & 
Weaver 1997, Tso & Weidman 1987). Non-enzymatic isomerization of 2- 
monoacylglycerol to 1-monoacylglycerol (Bmbleton & Pouton 1997) provides a 
suitable substrate for pancreatic lipase, allowing more complete hydrolysis of dietary 
triacylglycerols (Figure 8). In vitro studies have suggested that selective hydrolysis by 
pancreatic lipase depends not only on the Sn- position, but on the fatty acid itself. 
Pancreatic lipase hydrolyses the essential C l8 fatty acids more efficiently than their 
longer chain derivatives. To this end, eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) are resistant to pancreatic lipase hydrolysis, regardless of 
their Sn- position (Hemell & Blackberg 1992).
Pancreatic cholesteryl ester hydrolase (cholesterol esterase) hydrolyses cholesterol 
esters to cholesterol and non-esterified fatty acids. The C2 fatty acid of phospholipids 
are removed by phospholipase A%, producing a lysophospholipid whose Cl fatty acid is 
subsequently removed by lysophospholipase to produce a glycerylphosphorylbase 
which is either absorbed or excreted (Tso & Weidman 1987).
3.1.1(c) Jejunal Absorption
Lipids then enter the jejunum, where absorption occurs. Glycerol, short- (C4-6) and 
medium-chain (C8-10) fatty acids are readily absorbed across the bmsh border of the 
intestinal mucosa (BNF 1992, Gurr 1993). Fatty acids of chain length longer than C12, 
cholesterol, 2-monoacylglycerols and bile salts form mixed micelles, which aid 
absorption of lipid moieties. The bile salt components of the micelles pass into the 
ileum where they are absorbed. Via the enterohepatic circulation, portal blood 
transports them to the liver, where they are re-secreted into bile and once again enter 
the duodenum.
The initial phase of lipid absorption is a passive process, down a concentration gradient 
across the apical membrane of enterocytes (BNF 1992, Tso & Weidman 1987). This is
34
achieved in two steps: firstly, by binding of fatty acids (possibly in the preferred order 
of long chain polyunsaturated to long/medium/short-chain saturated fatty acids) to fatty 
acid binding protein (FABP); secondly, by re-esterification of free fatty acids into 
phospholipids and triacylglycerols within the cell.
Rates of lipid absorption vary, according to their fatty acid composition. Animal 
studies suggest that the total amount of dietary fat and its degree of saturation influence 
the rate of absorption (BNF 1992). In humans, the rate and efficiency of fatty acid 
absorption can be considered dependent on both the site and nature of the fatty acid. 
The Sn- position of each fatty acid on the triacylglycerol molecule influences 
preferential lipase digestion, and hence absorption. The type of fatty acid can also 
affect absorption (BNF 1992, Ling & Weaver 1997). Unsaturated fatty acids (UFA) 
are absorbed in preference to saturated fatty acids (SFA) across the intestinal mucosa, 
probably due to increased gastric lipolysis and/or émulsification by bile salts (Ling & 
Weaver 1997), and/or their binding by FABP and re-esterification (BNF 1992).
3.1.1(d) Plasma Circulation
Once absorbed, the fates of the different classes of lipid in the intestinal mucosa differ. 
Glycerol, short- and medium-chain fatty acids are released directly into the portal 
bloodstream and transported to the liver, where they are oxidized.
Long-chain fatty acids are converted into fatty acyl CoA derivatives by fatty acyl CoA 
synthetase. Specific acyltransferases then re-esterify these derivatives to 
monoacylglycerols which can then be reassembled into triacylglycerols. Cholesterol 
and lysophospholipids are reacylated to similarly reform their original cholesteryl 
esters and phospholipids respectively (BNF 1992, Tso & Weidman 1987).
The reconstituted triacylglycerols and cholesteryl esters are water-insoluble and thus 
need to be in a form in which they can enter the circulation. To achieve this, proteins, 
phospholipids and cholesterol accumulate around the triacylglycerols and cholesteryl 
esters, forming lipoprotein vesicles. There are various classes of lipoprotein (Table 
12), chylomicrons being those responsible for the transport of dietary lipids from the 
intestine to peripheral tissues, including muscle, adipose, renal and cardiac tissues
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(Nestel 1987, Gaw et al 1995). The chylomicrons, on release from the cells of the 
intestinal mucosa, enter the lymph system via intestinal lacteals. Lymph transports the 
chylomicrons to the thoracic duct, where they join the left subclavian vein and enter the 
bloodstream. The selective absorption and incorporation into chylomicrons of fatty 
acids may account for the similarities and variations observed between the fatty acid 
composition of the diet compared to adipose tissue (Summers et al 2000).
Lipoprotein Composition Density
(g/ml)
Apolipoproteins Origin Function
Chylomicron 2% Protein 
83% TAG 
8% Cholesterol 
7% Phospholipid
<0.95 A-I, B48, C-II, E Intestine Transport of 
dietary TAG
Very low density 
lipoprotein (VLDL)
Intermediate density 
lipoprotein (IDL)
7% Protein 
50% TAG 
22% Cholesterol 
20% Phospholipid
0.95-1.006
1.006-1.019
B iooj C-II, E 
B, C ,E
Liver,
intestine
VLDL
catabolism,
liver
Transport of 
endogenously 
produced TAG
Low density 
lipoprotein (LDL)
20% Protein 
10% TAG 
48% Cholesterol 
22% Phospholipid
1.019-1.063 Bioo VLDL
catabolism,
liver
Transport of 
cholesterol to 
peripheral 
tissues
High density 
lipoprotein (HDL)
50% Protein 
8% TAG 
20% Cholesterol 
22% Phospholipid
1.063-1.210 A-I, A-II Intestine,
liver
Reverse 
transport of 
cholesterol from 
peripheral 
tissues to liver
Table 12. Classification of lipoproteins. TAG -  triacylglycerol.
3.1.1(e) Peripheral Tissue Accretion
On reaching the peripheral tissues, the triacylglycerol components of the chylomicrons 
cannot cross the cell membrane: they must first be degraded to release non-esterified 
(free) fatty acids and glycerol. This is mediated by the action of lipoprotein lipase 
(LPL) on the surface of tissue cells, which is activated in the post-prandial state by 
insulin. The expression and activity of LPL is tissue-specific and related to nutritional 
state, accounting at least in part for the differences in metabolism between tissues 
(Fielding & Frayn 1998, Karpe et al 1998).
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The transport of fatty acids across the cell membrane is most probably mediated by 
more than one mechanism (McArthur et al 1999), the relative contributions of which 
may vary according to cell type (Abumrad, Harmon & Ibrahimi 1998). The passive 
diffusion (“flip-flop”) of fatty acids across the membrane is dependent on fatty acid 
concentration and ionization (Hamilton 1999). Facilitated transport may be mediated 
by fatty acid binding proteins (such as plasma membrane fatty acid binding 
protein/FABPpm) alone and/or in combination with fatty acid transport protein(s) 
(FAT?) (Abumrad et al 1998). Several putative FABP and FATP have been identified, 
including leptin (Campbell et al 1998b). In addition, once inside the cell, fatty acids 
may be subject to intracellular transport by diffusion and/or cytoplasmic proteins 
(McArthur et al 1999). The combination of such specific transportation into and 
within cells may enable cells to direct fatty acid movement and so facilitate the 
positioning of fatty acids in specific functional sites within membranes, or within cell 
organelles for storage/oxidation.
Such facilitated transport may be of particular relevance to LCPUFA. The non- 
esterified fatty acids and glycerol released by LPL action on dietary triacylglycerol can 
be re-esterified within the cell to re-form triacylglycerols, a reaction dependent on the 
activation of fatty acids by fatty acyl CoA synthetase. Indeed, the conversion of fatty 
acids to fatty acyl CoA by fatty acyl CoA synthetase is required not only for re­
assembly of dietary triacylglycerols, but also for de novo triacylglycerol synthesis and 
fatty acid oxidation. Long-chain fatty acyl CoA synthetase is a cell membrane protein 
(Gargiulo, Stuhlsatz-Krouper & Schaffer 1999) and although its role in the regulation 
of fatty acid metabolism has not been fully elucidated, it may function to ensure a 
concentration gradient across the cell membrane which facilitates efficient cellular 
uptake of non-esterified fatty acids, particularly LCPUFA. In addition, transport of 
fatty acids across the cell membrane by FATP, followed by rapid estérification by long- 
chain fatty acyl CoA synthetase could enhance intracellular LCPUFA transport by 
specific cytosolic FABP or acyl-CoA binding proteins (Gargiulo et al 1999).
Once absorbed, fatty acids are available to undertake various roles, including storage 
and/or oxidation, elongation and/or desaturation, eicosanoid formation and membrane 
synthesis. The fate of each fatty acid is largely determined by its nature, specifically
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chain length and degree of saturation (Jones et al 1999). Short- and medium-chain 
saturates are either oxidized or stored for energy. Dietary linoleie (18:2n-6) and 
linolenic (18:3n-3) acids are incorporated into either triacylglycerols for adipose tissue 
storage, or into phospholipids for cell membrane structure. Alternatively, when 
required, these essential fatty acids (EFA) can be elongated and desaturated to their 
LCPUFA derivatives. LCPUFA are spared from oxidation and incorporated into 
phospholipids, with preformed dietary LCPUFA incorporated in preference to those 
derived from dietary EFA (FAO & WHO 1980).
3.1.2 Infant Fat Digestion and Absorption
The newborn infant must adapt from dependence on glucose as its principal source of 
energy in utero, to the use of fat as its major energy substrate after birth. Saturated 
fatty acids are the main source of energy for the neonate, while long-chain 
polyunsaturated fatty aeids (LCPUFA) are used for membrane synthesis (Ling & 
Weaver 1997). However, complete fat digestion by the neonate is limited by low 
pancreatic lipase activity and low bile salt production, relative to adults (BNF 1992, 
Hamosh et al 1992, Hemell & Blackberg 1992). Neonates can, in part, compensate for 
this through initial gastric hydrolysis of lipids, which is proportionally more important 
to neonates than to adults (Tso & Weidman 1987).
3.1.2(a) Gastric Digestion
Lingual lipase is activated by sucking and in response to ingested fat. Both lingual and 
gastric lipase are active in the absence of bile salts and within a pH range of 2.3-6.5 
(Hamosh et al 1992, Manson & Weaver 1997) (Table 10). Thus, they can function in 
the near neutral environment of the neonate’s stomach, as well as in the more acidic 
environment of the adult’s stomach. Indeed, the homology of both physical and 
functional characteristics between lingual and gastric lipase has led to debate regarding 
their distinction and relative eontributions, and to their collective classification as 
“preduodenal lipase” (Manson & Weaver 1997).
The hydrophobic nature of preduodenal lipase and its inability to hydrolyze 
phospholipids and cholesteryl esters allows the enzyme to become embedded in the 
phospholipid surface of the milk fat globule (Hamosh et al 1992). Without dismpting
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the integrity of the membrane, preduodenal lipase can catalyze the hydrolysis of fatty 
acids from the Sn-3 position of the triacylglycerol to produce 1,2-diacylglycerol. Only 
very limited hydrolysis by preduodenal lipase occurs at positions Sn-l and Sn-2 
(Hamosh et al 1992). Studies show that gastric lipolysis by infants preferentially 
releases medium chain fatty acids (MCFA), monounsaturated fatty acids (MUFA) and 
long chain polyunsaturated fatty (LCPUFA) acids from the triacylglycerol. Gastric 
lipolysis of breast milk fat is more efficient that that of formula milk fat; this may be 
attributable to the relative ease with which lipase can access the triacylglycerol within 
the breast milk globule compared to the formula fat globule (Armand et al 1996).
3.1.2(b) Intestinal Digestion
On passage of chyme into the duodenum, preduodenal lipase is inactivated by 
pancreatic trypsin. Although pancreatic lipase is secreted from 30 weeks gestation, its 
activity in neonates remains low (Hamosh et al 1992, Manson & Weaver 1997). Its 
dependeney on colipase and bile salts further limits the efficiency of pancreatic lipase 
in neonatal fat digestion. The binding of pancreatie lipase to intact fat globules is, 
however, stabilized by any LCPUFA released on gastric hydrolysis (Hemell & 
Blackberg 1992). Thus, it can still hydrolyze triacylglycerols at the Sn-l and Sn-3 
positions, producing NEFA and 2-monoacylglycerol (Hamosh et al 1992).
Human milk confers a unique advantage to breast-fed infants, eompared to formula-fed 
infants, with regard to fat digestion. This is beeause breast milk contains a lipase 
which is activated in the duodenum by primary bile salts (Hamosh et al 1992, Hemell 
& Blackberg 1992, Manson & Weaver 1997), hence it is called bile salt stimulated 
lipase (BSSL) (Table 10). Seereted throughout lactation, the concentration of BSSL 
varies between lactating mothers’ milks (Manson & Weaver 1997). The higher 
concentration of BSSL in the colostmm of mothers of preterm infants suggests a 
compensatory role in augmenting the immature preduodenal and pancreatic lipases of 
preterm infants. Moreover, the action of BSSL is non-specific and efficient hydrolysis 
occurs at the Sn~l, -2 and -3 positions of the triacylglycerol (Figure 8). The action of 
BSSL is therefore not dependent on the nature and/or position of the fatty acid. In 
vitro and model experiments suggest that BSSL can increase the efficiency of neonatal 
fat absorption even in the absence of bile salts. Thus BSSL can aid pancreatic lipase
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by digesting any remaining intact triacylglycerol, as well as the mono- and 
diacylglycerols resulting from hydrolysis by preduodenal and pancreatic lipase action, 
to produce NEFA and glycerol. BSSL has been shown to play a role in the digestion of 
other classes of milk lipid (Nyberg et al 1998).
Despite their low concentrations, bile salts contribute significantly to neonatal fat 
digestion. By stabilizing the hydrolysis products of preduodenal lipase, bile salts create 
an emulsion in which the relative surface area of the lipid droplets is increased to aid 
hydrolysis by pancreatic lipase and BSSL. An insufficient bile salt pool may be a 
limiting factor to complete fat digestion in the preterm infant.
3.1.2(c) Jejunal Absorption and Plasma Circulation
As in the adult, the products of fat digestion (non-esterified fatty acids, glycerol, 
monoacylglycerol) diffuse into the brush border of the neonatal intestinal mucosa. 
Absorption, binding to FABP, reconstitution of triacylglycerol and transport as 
chylomicrons occurs in infants as in adults. The selective incorporation into and 
release from chylomicrons of LCPUFA may contribute to their possible transport from 
the liver to neural tissues (Hemell 1990).
Human milk contains both medium-chain saturated (MCSFA) and long-chain 
polyunsaturated fatty acids (LCPUFA). The absorption of MCSFA without the aid of 
bile salts provides the neonate with a ready source of energy (BNF 1992). Of the 
absorbed produets, short- and medium-chain fatty acids are oxidized either 
immediately, or are stored in adipose tissue where they remain available for future 
oxidation. Endogenous desaturation and/or elongation of LCPUFA may occur before 
they are used in the synthesis of membranes or eicosanoids.
3.1.2(d) Colonic Metabolism
An appreciable amount of ingested fat remains unabsorbed and passes into the colon 
(Ling & Weaver 1997), particularly in the preterm infant. Colonic bacteria can 
metabolize fatty acids via lipolysis, hydrolysis and desaturation. Conversion of fatty 
acids to toxic hydroxy-fatty acids may stimulate colonocyte proliferation, and may 
contribute to the genesis of colon cancer (Ling & Weaver 1997). This seems to be
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increased when the intake of saturated fat is high, and decreased when LCPUFA intake 
is high.
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3.1.3 Fatty Acid Synthesis
A healthy diet normally meets all fatty acid requirements. If, however, dietary intake is 
inadequate, it may not provide the type or amount of all fatty acids required. The body 
must therefore be able to synthesize complete fatty acids, or elongate and/or desaturate 
fatty acids that have been ingested. In times of fasting, the body can synthesize fatty 
acids de novo from glucose and amino acids (see Hellerstein 1999 for review o f de 
novo lipogenesis).
All tissues possess the enzymatic activities required for fatty acid synthesis, although 
not equally so (Bézard et al 1994). The main sites of fatty acid synthesis are the liver 
and lactating mammary glands (BNF 1992, Hamosh et al 1992, Salway 1994), with 
less occurring in adipose and renal tissue. Much of lactating mammary gland function 
is devoted to de novo fatty acid synthesis. To ensure an adequate supply of substrates, 
prolactin “upregulates” LPL, thus increasing the uptake of non-esterified fatty acids for 
elongation/desaturation. A maternal diet low in fat leads to a higher concentration of 
MCSFA in human milk as compared to a high fat maternal diet. Octanoic (8:0) and 
decanoic (10:0) acids are produced exclusively by the mammary glands and are 
therefore markers of endogenous maternal fat synthesis (Gurr 1993).
The synthesis of fatty acids involves the successive addition of 2C units to the carboxyl 
end of the C-chain. The 2C units are obtained from acetyl coenzyme A (acetyl Co A). 
While the main reactions of fatty acid synthesis occur in the endoplasmic reticulum of 
the cytosol (Bender 1997, Stryer 1988), its substrate acetyl CoA is first produced in the 
mitochondria by the oxidation of pyruvate (from glycolysis) or by the degradation of 
parent fatty acids, ketone bodies or amino acids. However, acetyl CoA cannot cross 
the mitochondrial membrane. To overcome this, citrate synthase catalyses the 
condensation of acetyl CoA with oxaloacetate (OAA) to form citrate and CoA. 
Transportation of citrate across the mitochondrial membrane and into the cytosol 
allows it to be cleaved by citrate lyase into cytosolic acetyl CoA and OAA.
Acetyl CoA carboxylase carboxylates acetyl CoA to form malonyl CoA. This biotin- 
dependent enzyme (Salway 1994) is “activated” when the diet is rich in carbohydrate 
and low in fat, and “deactivated” when the diet is high in fat or when fasting, thereby
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regulating fatty acid synthesis. The next steps rely on the multienzyme fatty acid 
synthase for catalysis; one of the seven monomers of this complex is acyl carrier 
protein (ACP). ACP, in a two-stage process, reacts with individual acetyl CoA and 
malonyl CoA units to form acetyl-ACP and malonyl-ACP, respectively. The reaction 
of acetyl-ACP and malonyl-ACP decarboxylates the malonyl group, producing 
acetoacetyl-ACP. Acetoacetyl-ACP is then successively reduced, dehydrated and 
reduced again to form the 4C unit of butyrl-ACP.
Butyrl-ACP then cycles through the sequential addition of six more malonyl CoA 
units, by the same processes as above, until a saturated 16C molecule is produced. 
This product is palmitate, which mitochondrial elongase enzymes can elongate by 
adding more 2C units. Mitochondrial desaturase enzymes can insert double bonds into 
saturated fatty acids to produce unsaturated derivatives (Figure 9). For example, 
palmitate can be desaturated to palmitoleate (16:ln-7).
Desaturase enzymes (Table 13) act at specific positions on the acyl chain of the fatty 
acid, and are named according to the position at which they introduce double bonds 
(Sprecher 1992) relative to the carboxyl end (denoted A). As discussed previously (see 
Chapter 1, Section 1.1.2 Fatty Acids), fatty acids are metabolically related if the first 
double bond relative to the methyl end (n) occurs in the same position (n-3, n-6 etc.). 
Since desaturase enzymes cannot catalyze the insertion of double bonds other than at 
their specific site, the conversion of the fatty acids from one metabolic family to 
another is precluded (Figure 9).
Enzyme Position Substrate Activity in Humans
A4-desaturase AC4-5 C22 4-
A5-desaturase AC5-6 C20 +
A6-desaturase AC6-7 CIS +
A9-desaturase AC9-10 C16-18 -
Table 13. Desaturase enzymes.
Humans lack the desaturase enzymes which catalyze the insertion of double bonds 
beyond AC9 and CIO (or n-9 in an 18C chain), i.e. at AC 12-13 and AC 15-16 (Gurr 
1993). Thus, humans cannot insert double bonds at n-3 or n-6 positions. Linoleic acid
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(cis-9,12-octadecadienoic, double bonds at AC9-10/n-9 and AC12-13/n-6) and a- 
linolenic acid (cis-9,12,15-octadecatrienoic, double bonds at AC9-10/n-9, AC12-13/n-6 
and AC15-16/n-3) are therefore essential constituents of the diet, i.e. essential fatty 
acids (EFA).
The conversion of EFA to their longer and more unsaturated derivatives occurs in 
adults consuming an ad lib diet (Salem et al 1999). In the fetus and neonate, levels of 
elongase and desaturase enzymes may be lower (Rodriguez et al 1998), although they 
are physiologically active during gestation (Rodriguez et al 1998) and within the first 
week of life (Salem Jr. et al 1996), even in preterm neonates (Camielli et al 1996, 
Sauerwald et al 1997b). Whether preterm infants convert dietary EFA to a lesser 
extent than term infants is debatable (Innis et al 1999). Derivatives of linoleic and a- 
linolenic acid - arachidonic acid (AA), and eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) respectively - are synthesized in only limited amounts, 
and may not adequately meet requirements (Camielli et al 1996, Salem Jr. et al 1996). 
These LCPUFA may thus be conditionally essential to the fetus and neonate (BNF 
1992).
The ability of the desaturase enzymes to act on various unsaturated fatty acids (UFA) 
leads to competition between the substrates for the enzymes. A6-desaturase has a 
preferred affinity for a-linolenic (n-3) > linoleic (n-6) > oleic (n-9) acids. Thus, when 
sufficient a-linolenic and linoleic acids are present in the diet, the conversion of oleic 
acid to its derivatives is negligible. An indicator of essential fatty acid deficiency is 
therefore the ratio of 20:3n-9 (Mead acid) to 20:4n-6 (AA) (triene/tetraene ratio), 
because the n-9 pathway will predominate only when a-linolenic and linoleic acids are 
deficient in the diet. The metabolism of fatty acids, and hence the fatty acid 
composition of membrane phospholipids, is therefore subject to dietary control. The 
levels of dietary linoleic and a-linolenic acids appear to determine their conversion to 
their LCPUFA derivatives, in both adults and neonates (Innis et al 1999, Li et al 1999, 
Sauerwald et al 1996). In both malnutrition and obesity, elongase and desaturase 
activities are modified, compromising EFA conversion and metabolism (Decsi, Molnar 
& Koletzko 1998, Holman et al 1981). Perturbations of the cmcial A6-desaturase have
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been implicated in eczema and diabetes (Horrobin 1993). Other factors regulating the 
activity of elongase and desaturase enzymes have been described (Bézard et al 1994), 
and may include age and gender (Babin et al 1999, Bolton-Smith, Woodward & 
Tavendale 1997), but have not been fully elucidated.
There is some evidence that fatty acid synthesis does not occur exclusively in the 
endoplasmic reticulum, (Sprecher & Chen 1999). The action of the putative A4- 
desaturase may instead he accounted for by a multi-step process which elongates 
22:4n-6 and 22:5n-3 to their 24C derivatives, which are then further desaturated 
(Sauerwald et al 1997a). These fatty acids may then enter the peroxisomes and 
undergo retroconversion, a process of partial degradation similar to (^-oxidation 
(removal of a 2C unit) (Sauerwald et al 1997b). This would generate 22:5n-6 and 
22:6n-3, which are then able to return to the endoplasmic reticulum for metabolism 
(Carlson 1997, Innis et al 1999). The mechanisms controlling the preferential 
movement of 24C fatty acids to the peroxisomes, and the subsequent selectivity with 
which 22:5n-6 and 22:6n-3 are returned to the endoplasmic reticulum for incorporation 
into cell membranes have not been elucidated (Sprecher, Chen & Yin 1999). There is 
evidence that this alternative pathway for LCPUFA synthesis is active in infants, 
including those bom prematurely (Sauerwald et al 1997b), although the contribution of 
the “classical” and “alternative” pathways has yet to be quantified (Sauerwald et al 
1997a). The retroconversion of C24 to C22 fatty acids is implicated in fatty acid 
synthesis, while that of C22 to C20 fatty acids may be a prerequisite for p-oxidation 
(see Section 3.1.5 Fatty Acid Oxidation).
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3.1.4 Triacylglycerol Synthesis
In addition to being the main form in which lipid is found in the diet, triacylglycerols 
are also the major form in which fatty acids are stored and transported. Short and 
medium chain fatty acids, obtained either from the diet or from de novo synthesis, are 
reconstituted into triacylglycerols before storage within adipocytes. Similarly, non- 
esterified fatty acids must be in the form of triacylglycerols before secretion into breast 
milk.
The formation of fatty acyl CoA from fatty acids and CoA, catalyzed by fatty acyl CoA 
synthetase, converts the fatty acids into an “activated” form. The fatty acid moieties of 
two separate fatty acyl CoA complexes esterify to glycerol phosphate at the Sn-\ and 
Sn-2 positions, forming diacylglycerol phosphate. The glycerol used is obtained from 
glucose in the liver and adipose tissue when the concentrations of insulin and glucose 
are high (Salway 1994). Dephosphorylation of diacylglycerol phosphate produces 
diacylglycerol, to which a third fatty acid from another fatty acyl CoA is added. This 
completes the triacylglycerol molecule (Figure 10).
The fatty acids on each of the three Sn- positions of the triacylglycerol molecule may 
differ, although their distribution is not entirely random. Their Sn- position, to an 
extent, reflects the tissue in which the triacylglycerol molecule has been synthesized 
(Table 14). The triacylglycerols made for storage purposes in adipose tissue show a 
preference at Sn-\ for a saturated fatty acid (SFA) and at Sn-2 for an unsaturated fatty 
acid (UFA), with Sn-3 having no preference regarding saturation (BNF 1992). In 
comparison, the triacylglycerols contained in breast milk have preferential binding at 
Sn-\ of UFA, at Sn-2 of SFA and random assignment at Sn-2.
Human milk fats Human storage fats Cows’ milk fats
Sn-1 UFA SFA Random
Sn-2 SFA UFA Random
Sn-3 Random Random Short-chain fatty acid
Table 14. Assignment of fatty acids at 5«-positions of triacylglycerol molecules.
Triacylglycerols synthesized in the liver are exported as very low density lipoproteins 
(VLDL) (Table 12) and destined for tissues where oxidation occurs. Those synthesized
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in adipose tissue are stored as a fuel reserve. Triacylglycerols stored in white adipose 
tissue provide the main energy reserve for the other tissues of the body and undergo 
slow turnover, rather than remain inert in storage (Gurr 1993). Triacylglycerols stored 
in brown adipose tissue, which is predominant in babies, contribute to thermogenesis, 
which is particularly important in neonates in whom shivering does not occur.
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3.1.5 Fatty Acid Oxidation
To utilize fatty acids for energy, cells must obtain them from stored triacylglycerols 
within adipose tissue (in the fasting state), or from circulating triacylglycerols in 
chylomicrons (in the fed state).
During periods of fasting or energy-restriction, circulating insulin levels are low and 
glucagon levels are high. Glucagon binds to the surface of adipose cells and stimulates 
the second messenger cyclic adenosine monophosphate (cAMP). This, in turn, 
activates a cAMP-dependent protein kinase which phosphorylates and activates 
hormone-sensitive lipase (HSL). HSL catalyses the hydrolysis of Sn-\ and Sn-2 fatty 
acids in the stored triacylglycerol, producing glycerol and free fatty acids. 
Transportation of glycerol to the liver allows its conversion to dihydroxy-acetone 
phosphate (DHAP), which enters the pathway of gluconeogenesis, producing glucose 
for oxidation in erythrocytes and cerebral tissue (Salway 1994). The NEFA are 
secreted from the adipocytes and transported, bound to albumin, to other tissues.
Conversely, in the post-prandial state, the antagonistic action of insulin prevents 
activation of HSL, instead activating lipoprotein lipase (LPL). Circulating 
chylomicrons are taken up by the tissue cells where LPL hydrolyses the triacylglycerols 
to free fatty acids and glycerol. The glycerol is transported to the liver and used as 
DHAP in glycolysis.
In either case, the resulting non-esterified fatty acids within tissue cells are oxidized to 
release adenosine triphosphate (ATP) in a process called p-oxidation. This is the 
oxidation of the p-carbon of each fatty acid chain, with the sequential removal of 2C 
units as acetyl CoA. In order to enter the mitochondrial matrix where p-oxidation 
occurs, the fatty acids are converted to fatty acyl CoA in the cytosol, by estérification 
with coenzyme A as catalyzed by fatty acyl CoA synthetase.
Fatty acyl CoA then crosses the outer mitochondrial membrane. When it reaches its 
inner face, carnitine acyltransferase I transfers the fatty acid to carnitine, forming 
acylcamitine and releasing CoA (Borum 1987). Acylcamitine is transported across the 
inner mitochondrial membrane by carnitine acylcamitine translocase. The fatty acid is
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transferred to another CoA, by carnitine acyltransferase II, to reform carnitine and fatty 
acyl CoA. Free carnitine cycles back to the inner mitochondrial membrane surface, 
where it can cross back over to the outer mitochondrial membrane. This “carnitine 
shuffle” (Figure 11) is a point of regulation in fatty acid oxidation (Rasmussen & 
Wolfe 1999), as it will not proceed when malonyl CoA is present {i.e. during fatty acid 
synthesis) or when the CoA is acylated {i.e. the process is saturated and sufficient fatty 
acids are present). The role of carnitine and its particular relevance to neonatal 
metabolism has been reviewed (Stanley 1998h).
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Figure 11. The "carnitine shuffle". Transport of fatty acids as fatty acyl CoA across the 
mitochondrial membranes before entering p-oxidation in the mitochondrial matrix.
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The fatty acyl CoA enters the mitochondrial matrix, where the four step P-oxidation 
process occurs (Figure 12). The initial step is oxidation by acyl-CoA dehydrogenase, 
an enzyme specific for short, medium or long chain fatty acids. This removes two 
hydrogen atoms from fatty acyl CoA, with concomitant release of flavin adenine 
dinucleotide (FADH2). This is followed by a hydration reaction, and then another 
oxidation, this time producing nicotinamide adenine dinucleotide (NADH). Thiolysis 
by CoA produces acetyl CoA and a fatty acyl CoA. The fatty acyl CoA recycles 
through these four steps, until the last 2C group becomes acetyl CoA (Tso & Weidman 
1987). (Most fatty acids undergoing oxidation have an even number of C atoms. If, 
however, the original fatty acid had an odd number of C atoms, the last 3C group 
enters the tricarboxylic acid (TCA) cycle.)
On the rare occasion that long chain polyunsaturated fatty acids (LCPUFA) are used 
for oxidative energy production, they undergo a slightly different initiation into the 
oxidative process -  retroconversion to shorter or more saturated fatty acids. Primarily, 
they enter carnitine-independent peroxisomal oxidation, which shortens the fatty acids, 
thus C22 fatty acids are converted to C20 species. The shorter derivatives form fatty 
acyl CoA complexes, which are transported out of the peroxisome and into the 
mitochondria via a carnitine-dependent pathway, and hence enter mitochondrial p- 
oxidation (BNF 1992, Borum 1987).
The acetyl CoA, FADH2 and NAHD that are generated during P-oxidation enter the 
TCA cycle, each generating 12, 2 and 3 ATP respectively. Fewer FADH2 and NADH 
molecules are produced on oxidation of UFA, thereby producing less energy (Champe 
& Harvey 1994), which is the reason that LCPUFA are a poor substrate for energy 
production.
To enter the TCA cycle, acetyl CoA must react with oxaloacetate (OAA). Under 
conditions of insufficient OAA, as in low carbohydrate states such as fasting and 
diabetes, or when excess acetyl CoA is produced, the liver can convert acetyl CoA into 
ketone bodies. This is the collective term for acetoacetate, 3-hydroxybutyrate and 
acetone. These then circulate to peripheral tissues and can be used by skeletal muscle.
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renal cortex, cerebral and cardiac muscle tissues for oxidation via the TCA cycle to 
produce ATP.
The oxidation of EFA may serve more than one purpose. The production of ketones 
from EFA apparently stimulates the recycling of their hydrocarbon chains following p- 
oxidation into the cholesterol and fatty acids generated by de novo lipogenesis in brain 
tissue. EFA oxidation may thus actually induce the synthesis of essential brain lipids 
(Cunnane et al 1999).
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3.2 LIPID METABOLISM DURING PREGNANCY AND FETAL PUFA 
SUPPLY
3.2.1 Introduction
Pregnancy is a unique challenge to metabolism, requiring interaction and balance 
“between three distinct yet interdependent entities -  mother, placenta, and fetus” 
(Coleman 1989). The physiology of pregnancy, its associated metabolism and 
complications have been extensively reviewed (Jansson & Powell 2000, King 2000, 
Knopp, Bonet & Zhu 1998). The adaptations which facilitate matemal/placental/fetal 
lipid metabolism are discussed, with emphasis on LCPUFA transport.
3.2.2 Overview of Physiology
Changes in maternal metabolism facilitate the transfer of vital nutrients, including 
lipids, across the placenta. The structure of placenta is unique with its outer layer of 
bipolar membranes of differing orientation and nature. The microvillous membranes 
are directed towards the maternal circulation, with the basal membranes facing the fetal 
circulation. Differences in the nature of the microvillous and basal membranes are 
implicated in the differential transport of nutrients between mother and fetus.
Accumulation of LCPUFA by the fetus elevates the fetal level of these fatty acids 
above that observed in the mother; indeed, the levels of LCPUFA increase 
progressively between maternal liver, placenta, fetal liver and fetal brain (Crawford, 
Hassam & Williams 1976). Such preferential accumulation or biomagnification 
(Crawford et al 1976) of LCPUFA by the fetus was considered to have arisen as a 
result of selective fatty acid uptake, oxidation and synthesis by the placenta in 
combination with fetal liver synthesis, but the contribution of maternal metabolism and 
LCPUFA mobilization with preferential placental transfer to the fetus is now 
recognised (Campbell, Gordon & Dutta-Roy 1996, Dutta-Roy et al 1996).
Since the placenta has no A5- or A6-desaturase activity, it cannot synthesize all classes 
of fatty acids; the fetus must therefore derive its LCPUFA from the maternal 
circulation or from its own elongation/desaturation reactions. Several factors have 
been shown to be involved in the control of lipid transfer from mother to fetus, 
although the relative importance of each has yet to be determined. Such contributing
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factors include the transplacental gradient of NEFA and TAG (determined at least in 
part by maternal and/or fetal concentrations), fetal albumin concentration, placental 
metabolism of lipids, and fetal utilization of lipids (Kimura 1998). Moreover, the 
contribution of placental lipid transfer to fetal fatty acid status is undetermined, with 
conflicting evidence that it accounts for 20-100% of fetal requirements, in a species- 
specific manner (Kimura 1998).
3.2.3 Maternal Adaptations and Metabolism
Maternal weight gain during pregnancy varies between countries and between the 
developing and developed worlds (BNF 1994). The average overall gain during 
pregnancy in British women is 12.5kg, of which 3.5kg fat is estimated to be stored 
(Hytten & Leitch 1971). These fat depots accumulate in early to mid pregnancy due to 
enhanced maternal lipogenesis in adipose tissue. Such anabolism declines in the last 
trimester, when the mother enters a more catabolic state as a result of enhanced 
enzymatic lipolysis (Herrera & Muni 11a 1997). The NEFA and glycerol subsequently 
released are transported to the liver for TAG synthesis, accounting for the 
hypertriglyceridemia (particularly in VLDL form) observed during the last trimester.
3.2.4 Placental Transport and Metabolism
Of the lipids in the maternal circulation, the placenta is impervious to phospholipids 
and triacylglycerol and is capable of transferring NEFA only. In order to liberate 
NEFA from maternal TAG, the placenta possesses lipoprotein lipase (LPL) activity. 
Found exclusively on the microvillous membrane (Bonet et al 1992), placenta LPL 
hydrolyses maternal TAG-rich lipoproteins, including VLDL. The selectivity of 
placenta LPL for TAG packaged in post-hepatic lipoproteins may be a protective 
mechanism in defence of the fetus (Dutta-Roy et al 1996).
The available NEFA then require transport across the placenta. As mentioned 
previously, fatty acid binding proteins (FABP) are involved in the facilitated transport 
of NEFA across cell membranes and plasma membrane FABP (FABPpm) has been 
identified in many tissues. The placenta contains a unique placenta FABPpm (p- 
FABPpm), distinct from FABPpm (Campbell et al 1997), which is found exclusively on 
the microvillous membrane (Campbell & Dutta-Roy 1995). This protein has been
58
shown to preferentially bind LCPUFA (Campbell et al 1997, Campbell, Gordon & 
Dutta-Roy 1998), and therefore may account for the specific binding sites on and 
preferential uptake by the placenta membrane for LCPUFA (Campbell et al 1996) in a 
saturable process (Crabtree et al 1998). Such selectivity is not observed in liver cells 
(Dutta-Roy 2000).
Following uptake, fatty acids are subject to metabolism within the placenta cells, and 
may be utilized for placental lipid synthesis or lipolysis requirements, or transported to 
the fetus. The mechanisms controlling these processes have not yet been elucidated. 
Similarly, it is not known whether fatty acids are transferred to the fetus directly or 
whether intermediate metabolism is required (Coleman 1989). The form and transfer 
mechanisms by which fatty acids are transported from the placenta to the fetus also 
remain unknown (Dutta-Roy 1997).
However, fatty acid translocase (FAT) and fatty acid transport protein (FATP) have 
been found in both placental membranes (Campbell et al 1998a), as have several 
isomers of cytoplasmic FABP. These intracellular proteins may help “direct” NEFA; 
DHA and AA have been found to. be differentially incorporated into the lipids classes, 
with DHA preferentially packaged within TAG as opposed to PL (Crabtree et al 1998). 
Moreover, another TAG hydrolase, distinct from LPL, has been found to be active in 
placental cells, and has been implicated in releasing NEFA from TAG stored in the 
placenta (Waterman, Emmison & Dutta-Roy 1998).
3.2.5 Fetal Lipid Accretion
The contribution of placental transfer and fetal synthesis to fetal LCPUFA 
accumulation is not known (Clandinin 1999). It has been estimated that the minimum 
levels of fatty acids required during the last trimester for the de novo synthesis of 
tissues are 3.6g/week (522mg/d) for n-6 and 469mg/week (67mg/d) for n-3 fatty acids 
(Clandinin et al 1981). For the accumulation of adipose tissue, approximately 2.8g of 
n-6 and 390mg of n-3 fatty acids must accrue each week in utero (Clandinin 1999).
Intra-uterine accretion of EFA and PUFA occurs in the liver, where they may be 
metabolized to LCPUFA. The rate of intra-uterine fatty acid accretion by the liver is
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thought to be 13.5mg/week and 3.8mg/week for the n-6 and n-3 families respectively, 
most of which is accounted for by LCPUFA (Clandinin, Chappell & Van Aerde 1989, 
Clandinin et al 1981). The relative contributions of placental transport and/or liver 
synthesis to hepatic fatty acid accumulation have not been quantified (Clandinin et al 
1989). From animal studies, it is evident that despite transfer of both aLA and DHA 
between mother and fetus, fetal tissues incorporate more preformed DHA {i.e. obtained 
from mother) than DHA derived de novo from aLA (Greiner et al 1997).
Indeed, the capacity of the fetal liver to synthesize LCPUFA is not known. Both A5- 
and A6-desaturases are expressed in the fetal liver during the second and third 
trimesters; the activity of each fluctuates during the second trimester and then remains 
level during the third trimester (Rodriguez et al 1998).
The accumulated fatty acids are mobilized from the liver and accrue in the structural 
lipids of other fetal tissues, particularly those of the nervous system, during the last 
trimester (Clandinin et al 1989). More of the LCPUFA derivatives than parent EFA 
are found in the phospholipids of these tissues (Clandinin et al 1989, Svennerholm 
1968), in humans and other animals (Crawford et al 1992). The ubiquitous presence of 
LCPUFA, particularly AA and DHA, in cell membrane phospholipids suggests they 
are vital structural components capable of influencing membrane fluidity and 
excitability (BNF 1992, Hemell 1990). DHA is concentrated in the brain and retina, 
accounting for 20 to 60% of total phospholipid fatty acids in these tissues, a level 
observed in the brain and retina of many mammalian species (Crawford et al 1999, 
Hemell 1990).
The form in which DHA is transported to the brain and retina, and the cellular uptake 
mechanisms used by these tissues to obtain DHA have not been elucidated (Bazan 
1992). In addition, the cellular interactions required within the tissues to ensure DHA 
supply to the neurons and photoreceptors are not fully understood (Delton- 
Vandenbroucke, Grammas & Anderson 1999), although the retina at least appears to 
have specific mechanisms for DHA uptake and incorporation (Rotstein, Aveldano & 
Politi 1999). DHA may be transported from the liver to the brain and retina within 
lipoproteins (Hemell 1990); the photoreceptor cells of the retina have indeed been
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found to possess a receptor for LDL (Bazan 1992). The presence of FABP and acyl- 
CoA synthetase specific for DHA may contribute to the preferential accumulation in 
these tissues (BNF 1992).
In addition to immature fetal liver metabolism, neither the fetal retina nor brain initially 
synthesize DHA, and their capacity to do so is a function of gestational age. Thus, 
placental transfer is crucial (Clandinin 1999), particularly during the earlier gestational 
period when growth is slower and the fetus able to store LCPUFA obtained via the 
placenta. Premature infants are compromised as a result of both being denied 
LCPUFA via the placenta and their immature metabolism; the potential for deficiency 
in the preterm infant is thus a matter of much concern to neonatologists (Crawford et al 
1993, Crawford 2000), and the relevance of appropriate pre- and early ante-natal 
maternal nutrition is clear (Crawford 1993, Crawford et al 1993).
For n-3, n-6 and n-9 PUFA families, accretion in brain tissue increases with gestation, 
until maximum rates at term (Koletzko 1992, Martinez 1992). The amounts of n-6 and 
n-9 PUFA accumulating in the brain are approximately twice that of n-3 PUFA 
(Martinez 1992, Svennerholm 1968).
Estimation of the brain’s accumulation of fatty acids in the last trimester varies from 
33mg/week (Clandinin et al 1980) to 41mg/week (Clandinin et al 1981) for n-6 PUFA, 
and 15mg/week (Clandinin et al 1980) to 22mg/week (Clandinin et al 1981) for n-3 
PUFA. In the last trimester of 26 to 40 weeks gestation, 80% of the DHA present in 
the fetal brain is assimilated (Clandinin et al 1980), i.e. coincidental with the brain 
growth spurt (Hemell 1990). Animal studies indicate that in other primates, as in the 
human fetus, DHA accumulation in brain tissue occurs mainly in late gestation, when 
developmental and functional changes are in process (Green et al 1999).
The retina also accumulates high levels of PUFA, with most active assimilation 
occurring after 24 weeks gestation (Koletzko 1992). DHA occurs mainly in the outer 
segment of rod photoreceptor cells. Its presence in the phospholipids of these cells, 
particularly phosphatidylethanolamine (Craig-Schmidt, Stieh & Lien 1996), implicates 
it in the membrane fluidity of these signal-transducing cells (Koletzko 1992). DHA is
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synthesized by the retinal pigment epithelium (Anderson et dl 1994, Innis et al 1999) 
which can transport DHA and other nutrients to the retina. On release from the rod 
photoreceptors during membrane biogenesis, DHA is preferentially incorporated into 
TAG, and AA into PL (Anderson et al 1994), a pattern similar to that of the 
preferential incorporation of these two LCPUFA by placental cells (Crabtree et al 
1998, see above). The retinal pigment epithelium stores the DHA and transports it 
back to the photoreceptor cells, where it is re-integrated into new membranes, 
providing the retina with an efficient process to conserve DHA (hmis et al 1999). The 
role of DHA in the aetiology of retinal degenerations is controversial (Anderson et al 
1999).
3.3 POSTNATAL FAT ACCUMULATION
3.3.1 Introduction
Fat accounts, on average, for 71% of the total weight gained by the human fetus 
(Ziegler et al 1976). The term human fetus of 3500g is 16% fat and by four months 
postpartum, the infant (6.5kg) is 25% fat. The human infant gains 25g/d when breast 
feeding, and ingests around 37g of lactose and 21g of fat each day (Weaver & 
Stephenson 1998). 35% of weight gain during the first six months of postnatal life is 
fat. 90% of all energy retained by growing tissues of the term baby is comprised of 
lipid (Weaver & Stephenson 1998). The fat accumulated is deposited mostly as white 
adipose tissue and in the membranes that make up the brain and nervous tissue 
(Weaver & Stephenson 1998).
The postnatal period is as critical as gestation to the accumulation of LCPUFA 
(Connor 2000). It has not been possible to quantify the proportion of fatty acids 
obtained via the placenta, endogenous synthesis and/or breast milk to the accretion of 
LCPUFA by the fetus and neonate (Innis, Hrboticky & Foote 1989).
Levels of LCPUFA do not increase for the first month postnatally, but do so between 
the first and third months (Clandinin et al 1989). Lower LCPUFA status has also been 
observed in postnatal plasma lipids, compared to cord plasma (Decsi & Koletzko
1994). If the rate of neonatal hepatic synthesis is either limited, or slower than the 
mobilization of LCPUFA from the liver to the tissues, the lack of immediate postnatal
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accretion could be accounted for (Clandinin et al 1989). Evidence from studies on 
preterm, formula-fed infants suggests that it is the immaturity of the 
elongation/desaturation metabolism which causes the delay in extra-uterine accretion 
(Hemell 1990).
DHA accretion can be accomplished in breast-fed infants by utilization of the 
preformed DHA present in breast milk, or by either enzymatic conversion of a- 
linolenic acid (C18:3n-3), mobilization of subcutaneous tissues or hepatic fatty acid 
residues (Weaver & Stephenson 1998). The formula-fed infant, however, is not 
subject to a dietary source of DHA and therefore relies on the latter mechanisms to 
obtain adequate DHA.
3.3.2 Adipose Tissue
Storage lipid accumulates in adipose tissue, a form of connective tissue consisting of 
fat cells (adipocytes) which contain fat globules. There may be single (unilocular fat) 
or multiple (multilocular fat) fat globules within the cell. Unilocular fat, or “white” 
adipose tissue, is found in subcutaneous tissue and along the course of small blood 
vessels. Multilocular fat, or “brown” adipose tissue, accumulates in the thoracic and 
scapular regions and along the course of the large blood vessels. The fat content of 
adipocytes is mainly in the form of triacylglycerol.
By term, 80% of total fat is subcutaneous and 20% is in deep body sites (Widdowson 
1985). Brown fat accounts for 7% (Weaver & Stephenson 1998) or 35-40g of total fat 
at term (Sparks 1984). There is an increase in the size, number and fat content of 
adipose cells after birth (Weaver & Stephenson 1998). During the first postnatal 
months, when fat is being deposited rapidly, the composition of plasma lipids, 
subcutaneous adipose tissue and brain reflect the composition of milk ingested 
(Weaver & Stephenson 1998, Widdowson et al 1975).
3.3.3 Brain Tissue
The brain is 60% stmctural lipid, 85% of which is found in the cerebmm. The brain 
increases in size by 750g during infancy, from 350g (10% of body weight at birth) to 
1 lOOg (still 10% of body weight at 12 months), attributable mainly to nerve cell growth
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and proliferation and myelination (Weaver & Stephenson 1998). For this, the brain 
requires 60% of the total energy intake during the first year postpartum, obtaining the 
energy from dietary fat (Cockbum 1994).
Extrapolation from published data has led to estimation of the increase in brain DHA 
content in the first 6 months postpartum as 905mg in breast-fed and 450mg in formula- 
fed infants (Cunnane et at 2000a & b). The rate of total body DHA accumulation in 
breast-fed infants has been estimated as lOmg/d in the first six months postpartum 
(Cunnane 1999, Cunnane et al 2000b), with 5mg/d required for the brain alone 
(Cunnane, Francescutti & Brenna 1999, Cunnane et al 2000b). Considering 
“obligatory losses” of an assumed 50-60% of absorbed DHA, the authors postulate a 
dietary intake of 20mg/d would be required to meet this, a level provided by DHA in 
breast milk at 0.2% fatty acids (Cunnane 1999, Cunnane et al 1999, Cunnane et al 
2000a & b). The authors stress that this amount is not based on association with 
function, but is intended to approximate the rate of DHA accumulation in breast-fed 
infants (Cunnane et al 2000b). For the infant fed formula containing aLA but devoid 
of supplementary DHA, the conversion of ingested aLA to de novo DHA would be 
required to proceed at a rate of 5%, a rate much greater than predicted to occur and 
therefore, the authors argue, evidence for DHA supplementation of infant formulae 
(Cunnane 1999, Cunnane et al 1999, Cunnane et al 2000a & b).
Infant formula containing aLA at less than 1% fat may be similar to breast milk in its 
composition of aLA, but may be inadequate to meet the elevated LCPUFA 
requirements of infants deprived of preformed DHA (Bjerve et al 1992, Innis et al 
1989). The conversion (or bio equivalence) rate of aLA to DHA in the brain of infant 
baboons was estimated at 0.23% (Su et al 1999).
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Chapter 4
Biomarkers of Fatty Acid Status
4.1 INTRODUCTION
The contribution of animal studies to the understanding of fatty acid metabolism and 
status has been considerable, although their possible limitations must be appreciated 
when extrapolating to humans (Innis 2000). Several human biochemical indices of 
fatty acid status have been studied, each with its own validity and merit depending on 
the rationale for its use.
Generally, human fluids and tissues contain more than one class of lipid, which may be 
analysed separately or without distinction. Thus, each lipid fraction 
(triacylglycerols/TAG, phospholipids/PL, cholesterol esters/CE, non-esterified fatty 
acids/NEFA) or total lipids (total fatty acids/TFA) may be analysed. Moreover, fatty 
acid quantification may be relative or absolute. Relative amounts quantify each fatty 
acid as a proportion or percentage of all the fatty acids present in the lipid fraction 
analysed (e.g. % DHA in TAG fatty acids); absolute quantification expresses the 
concentration (mole) or actual weight (g) of each fatty acid in a standard amount of 
sample (e.g. mmole or mg DHA per ml or mg sample). The need for clarity regarding 
the lipid fraction analysed and the expression of results is highlighted by the variation 
in composition between fractions, and the difference in observed effects depending on 
the expression of results (Lopes et al 1991). The methods of quantification and their 
application are discussed further in Chapter 8 Materials and Methods.
4.2 CIRCULATING LEVELS OF FATTY ACIDS
Cells and tissues, including those of the nervous system, can obtain LCPUFA from 
preformed LCPUFA (from the diet by adults, via placental transfer from mother by the 
fetus, and from breast milk by the neonate), mobilization of adipose reserves, 
endogenous conversion of dietary EFA in the specific tissue, and/or EFA conversion in 
peripheral tissues {e.g. the liver, especially in the fetus and neonate). The relative 
contribution of these sources is not known (Innis 1991), however, in all cases, the 
transport of LCPUFA or their parent EFA is mediated by plasma. Plasma levels may 
not reflect tissue accretion, and by inference requirement, but do indicate the potential 
amount available to the tissues. Thus, although the fatty acid composition of plasma is 
not a specific proxy for that of tissues, it is a valid measure of fatty acid status. 
Moreover, since certain tissue samples are not as readily obtainable (see Section 4.3 
Tissue Levels of Fatty Acids), it may be more useful to correlate diet and outcome
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with circulating levels in larger studies than to perform smaller studies on tissue 
samples.
Plasma fatty acid composition has been shown to be a reliable biomarker (Ma et al 
1995a), reflecting short-term dietary PUFA intake (Bjerve et al 1993, Dougherty et al 
1987, Pauletto et al 1996). Serum lipids have been shown to accurately reflect the 
differential dietary intake of distinct populations (Torres et al 2000), with serum 
triacylglycerols indicative of recent diet (days) due to their rapid turnover, and serum 
phospholipids and cholesterol indicating dietary intake over the preceding weeks and 
months (Zeleniuch-Jacquotte et al 2000).
Devoid of a nucleus, the main site of lipids in the red blood cell (RBC) is the cell 
membrane, thus phospholipids are the predominant erythrocyte lipids. RBC do not 
synthesize fatty acids or phospholipids and so incorporate fatty acids/phospholipids 
only after they have been metabolized by other cells. RBC fatty acid composition does 
not therefore reflect dietary intake immediately, but does indicate previous intake. 
Total RBC lipid analysis is considered a suitable index of dietary intake (Dougherty et 
£z/  1987).
Correlation between fish consumption, dietary n-3 PUFA and plasma fatty acid status 
has been shown (Ma et al 1995b). Fish intake as infrequent as once per week 
influences plasma fatty acid concentrations (Bonaa, Bjerve & Nordoy 1992). In 
particular, dietary EPA and DHA correlate well with their corresponding levels in both 
plasma (Anttolainen et al 1996, Bonaa et al 1992, Ma et al 1995b) and RBC (Romon 
et al 1995). Supplementation of non-pregnant women with fish oils revealed that 
DHA increased in plasma and RBC in a dose-dependent manner (Otto, Houwelingen 
& Homstra 2000). Fish oil supplementation, even in cases of malnourishment, 
enhances RBC n-3 status relative to pre-supplementation and to non-supplemented 
controls (Smit et al 2000a). There is some variability in the observation that 
circulating levels of AA are negatively correlated with intake of fish (Romon et al
1995) or fish oils. Plasma aLA and EPA have also been shown to be responsive to 
dietary intakes (Li, Mann & Sinclair 1999).
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Circulating levels of fatty acids in relation to dietary intakes have been studied in great 
detail in neonates. This is partly attributable to the interest in postnatal diet and 
development, and also because neonates provide a unique opportunity for observation 
and intervention due to their exclusive diet of milk, whether breast or formula, until 
weaning. There is a wealth of data on the effect of neonatal dietary intake on fatty acid 
status, although the studies differ in the age of the infants, the diet (breast milk, 
standard or supplemented formula), the age at which the samples are taken, and the 
lipid fraction analysed (Table 15). Some studies have been observational, comparing 
breast-fed to standard commercial formula-fed infants, who were not randomized but 
whose respective diets were pre-assigned by parental choice. Other studies have 
involved some intervention whereby those infants whose mothers elected to formula 
feed were randomised to either a standard formula, or to a supplemented formula with 
a modified fatty acid composition often closer to that of breast milk.
Infant LCPUFA status, particularly DHA, is correlated with breast milk composition, 
even when maternal milk is low in EFA and LCPUFA (Smit et al 2000b). Differences 
have been noted in the levels of circulating fatty acids between infants receiving high 
or low intakes of breast milk, with those receiving greater amounts exhibiting higher 
total LCPUFA levels, in particular DHA and AA (Leaf et al 1996). Moreover, 
neonatal plasma and RBC DHA is correlated with breast milk DHA in a dose- 
dependent but saturable manner (Gibson, Neumann & Malcrides 1997).
On comparison of those fed breast milk versus standard formula, breast fed infants 
have been repeatedly shown to have overall higher LCPUFA levels, and circulating 
levels reflect the composition of breast milk; the status of standard formula-fed infants 
reflects their diet which typically provides some EFA, but no LCPUFA. These 
findings have been noted in both term (Bakker, van Houwelingen & Homstra 1999, 
Birch et al 1993, Granot, Golan & Berry 2000, Jorgensen et al 1996, Mal<rides et al 
1993 & 1994) and preterm (Foreman-van Drongelen et al 1995b, Birch et al 1993) 
infants.
Such findings have led to the experimental use of formulae supplemented with EFA 
and/or LCPUFA, and comparisons of infants receiving standard or supplemented 
formula milks have been undertaken. Supplemented formulae have been shown to
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result in higher PUFA status than standard formulae (Carslon, Werkman & Tolley 
1996), in an apparent dose-related response (Jensen et al 1997). In addition, 
supplemented formulae appear to be as effective as breast milk in determining 
LCPUFA status (Bondia-Martinez et al 1998). Generally, infants fed breast milk or 
supplemented formula (EFA or LCPUFA) achieve higher status than those fed 
standard formula, with differential effects of breast milk, supplemented formula and 
standard formula reported (Agostoni et al 1995, Auestad et al 1997, Birch et al 1992, 
Birch et al 1998, Carlson et al 1996, Faldella et al 1996, Jorgensen et al 1998, 
Makrides et al 2000a, Uauy et al 1990). With regards to the supplement added, 
variations and combinations of EFA and LCPUFA have been used, the type and 
amount of supplementary fatty acids exerting influence over circulating levels. 
Perhaps most notably, differential results have been demonstrated between formulae 
supplemented with DHA alone or in addition to AA (Auestad et al 1997, Birch et al
1998).
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In adults, age and anthropometric indices, such as body mass index (BMI), have not 
been found to be associated with circulating levels of FA (Berry et al 2001, Romon et 
al 1995, Theret et al 1993). There have been conflicting reports of the effect of 
cigarette smoking on circulating FA status, with the most consistent observation being 
of lower levels of linoleic acid (18:2n-6) in the plasma (Ma et al 1995b, Pawlosky et al 
1999) and RBC (Theret et al 1993) of smokers. Other studies have found either no 
association (Romon et al 1995), a positive correlation with MUFA (Berry et al 2001, 
Simon et al 1996) and n-9 PUFA (Simon et al 1996), and a negative association with 
AA and DHA (Simon et al 1996).
The effect of alcohol has been similarly umesolved, ranging from no effect observed 
(Berry et al 2001, Hjartaker, Lund & Bjerve 1997) to varying effects on SFA (Ma et al 
1995b, Simon et al 1996). Most consistently, a positive association has been noted 
with palmitoleic acid (16:ln-9) in RBC (Romon et al 1995, Theret et al 1993) and 
serum (Simon et al 1996), while a negative association with 18:2n-6 has been observed 
in RBC (Romon et al 1995, Theret et al 1993), plasma (Ma et al 1995b) and serum 
(Simon et al 1996). One possible explanation for these variations may lie in the 
observation that alcohol intake had no effects on fatty acid status when moderate, but 
did so when high (60g/d or more) (Simonetti et al 1993).
Circulating levels of fatty acids are thus reliable indices of dietary intake in humans of 
varying age. Alcohol and cigarette smoking should, however, be taken into 
consideration when studying dietary and circulating fatty acids (Simon et al 1996).
4.3 TISSUE LEVELS OF FATTY ACIDS
4.3.1 Relation to Growth and Development
Whether circulating levels reflect tissue accretion is a matter of debate. A correlation 
between RBC and cerebral cortex DHA was observed in neonates (Makrides et al 
1994). There is conflicting evidence from animal and human studies as to whether 
circulating (plasma and/or RBC) levels of DHA correlate with brain DHA (Cunnane 
1999). It has been argued that circulating levels cannot indicate brain levels since 
plasma levels do not reflect requirement, merely intake and transport (Cunnane et al 
2000b). This has led to the consideration of human tissue data as necessary to 
establish the relationship between dietary, circulating and tissue levels, and to provide
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evidence for the need to supplement infant formulae (Cunnane 1999, Cunnane & 
Francescutti 1999).
However, sampling of certain tissues, such as brain and retinal tissue, can only be 
achieved at autopsy. The use of these tissues assumes that tissue composition reflects 
requirement, but the circumstances under which such specimens are available preclude 
tissue composition from becoming related to developmental outcomes, such as visual 
function, developmental score etc.
Much work has been concerned with the fatty aid status of neonatal tissue, again 
largely in response to the putative role of fatty acids in development. The fatty acid 
composition of brain tissue has been shown to reflect that of the diet in an age or dose- 
dependent manner. Breast-fed infants had higher levels of DHA in their cerebral 
cortex than formula fed infants (Farquharson et al 1992, Makrides et al 1994). 
Cerebral DHA varied with age and duration of breast feeding (Farquharson et al 
1995a, Makrides et al 1994). For formula-fed infants, DHA was correlated with the 
level of aLA in the formula (Farquharson er al 1995a). The lower DHA in the formula 
fed groups was compensated for by increased incorporation of the structurally similar 
DP A (22:5n-6), in a manner negatively correlated with dietary DHA and aLA.
In cerebral white matter, DHA was again dependent on diet and age, declining with 
age more evidently in the formula-fed group. DP A also declined with age but did so 
more rapidly in the breast-fed group (Farquharson et al 1996). Similarly in cerebellar 
gray and white matter, DHA was higher in breast-fed than formula-fed infants; of 
those receiving formula, DHA increased with the aLA content of the formula. In 
cerebellar gray matter, DP A was preferentially incorporated in response to low DHA 
(Jamieson et al 1999). The levels of LA, aLA, AA and DHA all appear to be age and 
dietary related in both neonatal adipose (Farquharson et al 1993) and hepatic tissue 
(Farquharson et al 1995b).
Levels of LCPUFA in brain, adipose and hepatic tissue thus reflect the LCPUFA 
content of infant feeds. No such dietary related differences have been observed
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between breast- and formula-fed infants in the DHA content of the retina (Makrides et 
al 1994).
Breast milk is also a reliable index of FA status, and the variation in its fatty acid 
composition in response to numerous factors is discussed in more detail in a later 
section (see Chapter 5, Section 5.2 Fatty Acid Status of Breast Milk). Problems arise 
when the analysis of breast milk is used to extrapolate the requirements of all infants. 
Breast milk of mothers delivered at term may indicate dietary fatty acid levels 
adequate for thriving neonates consuming sufficient volumes of milk. However, the 
needs of premature infants may be greater, due to their immature development and 
lower adipose stores (Innis 2000). Term breast milk should thus not be assumed as 
appropriate for preterms; milk from mothers delivered prematurely may be more 
suitable.
There is therefore great difficulty in determining the amounts of fatty acids required 
for appropriate growth and development of the fetus and neonate since no single index 
is universally adequate. The value of the various biochemical indices of FA 
composition in the study of growth and development is discussed in detail elsewhere 
(Innis 1991, Innis 1992b).
4.3.2 Relation to Storage and Potential Status
Adipose tissue may be sampled with minimum discomfort (Beynen & Katan 1985, 
Berry et al 1986) and is “ethically appropriate” (Cunnane & Francescutti 1999). Due 
to the slow turnover of its constituent lipids, adipose tissue may indicate long-term 
dietary habits (BNF 1992) and may overcome some of the limitations incurred with 
dietary analysis, particularly when considering fish and n-3 PUFA intake (Marckmann 
1999). However, for intervention studies, prolonged time periods are required to 
detect an effect of dietary manipulation or supplementation on the composition of 
adipose tissue, and to relate adipose fatty acids to those of the circulation and other 
tissues (Mantizoris et al 1995).
4.4 CONCLUDING REMARKS
It has been suggested that since several factors (diet, synthesis, turnover) determine the 
fatty acid composition of each sample type (RBC, plasma, adipose, breast milk, brain
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tissue) more than one index of status should be used to reflect dietary intake (Beysen 
& Fielding 1999). Each sample type may thus be considered a valid “snapshot” of 
fatty acid status.
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Chapter 5
Maternal and Fetal Fatty Acid Status
5.1 MATERNAL AND FETAL FATTY ACID STATUS
5.1.1 Introduction
There is a correlation between the dietary intakes of fish and n-3 fatty acids and RBC 
fatty acid composition of pregnant women (Olsen et al 1995a). In particular, the RBC 
ratio of n-3 EPA, DP A and DHA to n-6 AA can be used to rank intakes, even when the 
average intake is relatively low (Olsen et al 1995a). Plasma PL composition also 
reflects dietary intake during pregnancy (Al et al 1995b). Biomarkers of dietary fatty 
acids are thus reliable even in pregnancy. Certain biomarkers are specific to 
pregnancy and the fetus, such as blood and tissue from the umbilical cord and the 
status of the placenta itself. Moreover there are several other factors which influence 
the status of both mother and fetus. The assessment of fatty acid status during 
pregnancy, and the determinants of and relationship between maternal and fetal status 
are discussed.
5.1.2 Maternal Fatty Acid Status
5.1.2(a) Relative to Non-pregnant Female Status
In comparison to non-pregnant women, pregnant mothers have similar n-6 PUFA but 
increased EPA and DHA levels when quantified in absolute concentrations in plasma 
total lipids at term (Wang, Kay & Killam 1991). Plasma PL of pregnant women are 
lower in the relative levels of all n-6 and n-3 PUFA, but not Mead acid (20;3n-9), in 
comparison to non-pregnant women. The maternal fatty acid profile remains deviated 
6 weeks postpartum, regardless of lactation, although it begins to return to the non­
pregnant “norm” (Holman, Johnson & Ogburn 1991).
5.1.2(b) Changes during Pregnancv and with Parturition
In a study of early pregnancy (up to 10 weeks gestation), the absolute amounts of 
plasma PL fatty acids significantly increased compared to pre-pregnancy levels, with a 
46% increase in plasma DHA (Otto et al 2001). Significant increases were not 
observed in RBC PL; RBC DHA was elevated but not significantly. With regards to 
their relative levels in both plasma and RBC PL, total SFA remained unchanged, LA 
decreased, and n-6 and n-3 LCPUFA increased. These changes could not be explained 
by dietary intakes, which remained constant, and indeed, the increase in % DHA was 
such that the correlation between dietary intake and RBC or plasma DHA was no 
longer evident. It has been suggested that these findings indicate that pregnancy-
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associated hyperlipidemia starts early in gestation and that there are metabolic 
adaptations (increased synthesis and/or incorporation) that ensure adequate DHA for 
fetal requirements (Otto et al 2001).
In perhaps the most comprehensive study to date on the pregnancy-associated changes 
in maternal fatty acid status, plasma PL were obtained throughout pregnancy from 10 
weeks gestation until delivery and then at 6 months postpartum (Al et al 1995c). 
Expression of the results in both absolute (mg/L) and relative (% TEA) terms has 
enabled the differential patterns of change to be appreciated. Absolute amounts of 
total fatty acids, total n-6, total n-3, total SFA, total MUFA, LA, AA and DHA all 
increased between the first trimester to term in maternal plasma PL (Al et al 1995c). 
Postpartum declines were noticed in all of these, although the level of total fatty acids, 
total n-6, total SFA, total MUFA, LA and AA decreased to first trimester levels, while 
total n-3 and DHA were lower postpartum than during early pregnancy (Al et al 
1995c).
These patterns were not however reflected in the relative amounts of the fatty acids in 
maternal plasma PL. Total n-6, total n-3 and AA all decreased during pregnancy while 
LA remained constant and total SFA and MUFA increased. DHA, however, 
accounted for the largest increment but only until 18 weeks gestation when its relative 
amount fell. By 6 months postpartum, total n-6, MUFA, LA and AA were all similar 
to their mid-gestation levels, but maternal total n-3 and DHA were lower than in early 
pregnancy. The transient increase in DHA followed by its decline suggested that there 
was maternal mobilization of DHA followed by preferential transfer to the fetus (Al et 
al 1995c).
Indeed, elevated maternal PUFA in the NEFA fraction of plasma and RBC have been 
observed, particularly in the second trimester when RBC DHA and AA were maximal 
(Ashby, Robinette & Kay 1997). Moreover, several studies have noted decreases in 
maternal RBC and/or plasma % DHA levels between time-points within the last 
trimester and subsequent term delivery following healthy pregnancies (Al et al 1995a). 
In addition, the last trimester decline in plasma PL % DHA has been observed in 
pregnancies with gestational diabetes mellitus (Wijendran et al 1999).
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Inverse associations between LA and AA, LA and DHA, aLA and AA and aLA and 
DHA have been observed in the individual PL of both maternal plasma and RBC 
during the last trimester (Ghebremeskel et al 2000). In addition, AA was positively 
correlated with DHA in plasma and RBC PL. Perhaps, however, the most important 
aspect of these findings is that they were observed in both British and Korean mothers, 
despite their dietary differences, and in their babies (see Section 5.1.3 Fetal Fatty Acid 
Status) in each population. Since these relationships were particularly evident for 
RBC PL, the authors suggest that the AA and DHA contents of membranes are 
regulated in both mother and fetus, and by maternal status and supply to fetus 
(Ghebremeskel et al 2000). However, the fatty aids were quantified based on peak 
area and thus the results were presumably obtained on analysis of the relative amounts. 
Given that as the proportion of one fatty acid increases or decreases, there must be a 
reciprocal change in another, it is possible that the relationships observed are 
dependent on the manner in which the individual fatty acids are quantified.
The post-partum decline in PUFA status is particularly evident in plasma PL, where 
DHA decreases following parturition and does so to a greater extent in lactating 
mothers, such that their DHA status is lower than that of non-lactating mothers and 
non-pregnant women (Otto et al 1999).
There is apparently no effect of labour on plasma or RBC fatty acid composition (Al et 
al 1990, Holman et al 1991). No significant differences in maternal fatty acid status 
have been noted following either vaginal or caesarean section delivery (van der 
Schouw et al 199\)
5.1.2(c) Factors Affecting Maternal Status
(i) Parity
There is conflicting evidence as to whether circulating maternal DHA status (relative 
and/or absolute) is inversely related to parity (Al, van Houwelingen & Homstra 1997, 
van den Ham, van Houwelingen & Homstra 2001, van Houwelingen, Ham & Homstra
1999). The relative (% TFA) and absolute (mg/L) levels of plasma PL DHA during 
pregnancy and at parturition have been shown to be lower in multi gravida compared to 
primigravida mothers (Al et al 1997). Indices of DHA sufficiency and deficiency did 
not vary between primigravida and multigravida mothers. Matemal plasma PL DHA
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as a % TFA was negatively correlated with the number of pregnancies. However, a 
subsequent study failed to detect a difference between parous and nulliparous non­
pregnant women in absolute (mg/L) RBC or plasma PL levels of total fatty acids, and 
in the % DHA in plasma PL (van den Ham et al 2001). RBC PL % DHA was 
significantly lower in parous women, but there was no difference in the DHA 
sufficiency index (ratio of DHA to DPA/22:5n-6) between parous and non-parous 
women. In addition, no relation between RBC or plasma DHA and the number of 
pregnancies was detected and no effect of time between successive pregnancies was 
observed (van den Ham et al 2001). While it appears that circulating DHA returns to 
non-pregnant levels in both primiparous and multiparous women within one year 
postpartum, it remains to be seen whether the same is true for tissue DHA (van 
Houwelingen et al 1999). This could explain why parity affects the DHA status of 
pregnant and not non-pregnant parous women; while circulating DHA status of non­
pregnant parous and non-parous women would remain similar, a putative depletion of 
DHA stores following pregnancy would explain the lower DHA status of multigravida 
mothers during pregnancy. Parity may therefore not directly effect matemal status in 
the non-pregnant state, but rather may limit mobilization of matemal stores during 
subsequent pregnancies.
(ii) Maternal Diet
Matemal PUFA status at term has been shown to vary with fish and/or n-3 
consumption, either throughout or for defined periods during pregnancy. Mothers 
consuming an above average amount of oily fish ingested greater quantities of n-3 
PUFA, which became manifest in a higher % EPA and DHA, and lower AA in RBC 
PL, compared to mothers consuming less oily fish than average (Sanjuijo et al 1995). 
The increased % EPA and DHA, and ratio of n-3 LCPUFA to AA, in RBC total lipids 
of Faroese mothers compared to Danish mothers reflects the large marine and n-3 
intake of the Faroe Islands (Olsen et al 1991).
Mothers supplemented with n-3 PUFA between weeks 26 and 35 of gestation 
increased their % DHA in both RBC and plasma total lipids over the period of 
supplementation, while the DHA status of unsupplemented mothers remained 
unchanged. As a result, by the end of supplementation, those mothers receiving 
supplements were significantly higher in RBC and plasma DHA than unsupplemented
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mothers. Moreover, the DHA of supplemented mothers at delivery remained elevated 
at a level significantly higher than their unsupplemented comparisons (Connor et al
1996).
Supplementation of mothers with fish oil for 10 weeks until term significantly changed 
matemal plasma PL PUFA status relative to that of unsupplemented mothers (van 
Houwelingen et al 1995). Higher % n-3 PUFA and lower n-6 PUFA, including DPA 
(n-6), as well as lower Mead acid were observed in supplemented mothers. The % of 
n-3 PUFA in matemal plasma PL at 37 weeks gestation correlated with matemal levels 
at delivery (van Houwelingen et al 1995).
Both vegetarian and diabetic (type I, insulin dependent diabetes mellitus/IDDM) 
mothers display fatty acid pattems different from non-diabetic omnivorous mothers, 
but similar to each other, in their RBC total lipids at term. Relative levels of n-6 and 
n-3 PUFA, including DHA, are lower in vegetarian and diabetic compared to 
omnivorous mothers. These differences can be explained by the lower PUFA intakes 
of vegetarians, but not so in the diabetic mothers whose dietary composition resembled 
that of healthy omnivores, suggesting that metabolic differences exist in IDDM (Lakin 
et al 1998).
(in) Maternal Lifestyle/Habits
Differences in fatty acid composition between smokers and non-smokers have not been 
detected in matemal plasma PL (Al et al 1995c). An elevated % of 18:0 (stearic acid) 
was noted in the plasma total lipids of non-smokers who had a healthy pregnancy 
delivered at term (Matorras et al 1994). The EFA and LCPUFA status of RBC 
membranes remains unchanged following smoking, alcohol consumption, or smoking 
with alcohol consumption during pregnancy, although the possibility exists that the 
apparent lack of effect is due to metabolic adaptations to ensure adequate mobilization 
of fatty acids (Smuts et al 1999).
(iv) Gestation
Mothers who delivered prematurely at 34 weeks had higher RBC % levels of LA, AA, 
DPA (n-6), DHA, but lower levels of 16:0, 18:0, 18:1 and aLA than control mothers at 
34 weeks who went on to deliver at term (Reece et al 1997). Maternal RBC LA, AA,
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DPA (n-6) and DHA were all higher at preterm delivery than term delivery. Similarly 
in plasma, the % contribution of LA, AA and EPA were each higher at preterm than 
term deliveries.
(v) Health o f Mother and Fetus
Gestational diabetes mellitus (GDM) has been associated with varying pattems of 
matemal fatty acid status (Wijendran et al 1999). During the last trimester, plasma PL 
from mothers with GDM had lower relative and absolute n-6 LCPUFA, aLA and DPA 
(n-3), but higher DHA. However, % DHA was related to both dietary intake and pre­
pregnancy BMI, such that when these were considered as covariâtes, the differences in 
% and concentration of DHA between GDM and normal maternal plasma were not 
significant (Wijendran et al 1999).
Mothers suffering from pregnancy-induced hypertension (PIH) had lower % LA in 
semm PL and CE, as well as higher DPA (n-3), DHA and total n-3 in semm PL, than 
mothers without this condition (van der Schouw et al 1991). Further analyses and the 
observation that the fetal status was not markedly different from normal, have 
suggested that these differences arose as a result of matemal metabolic adaptations 
occurring, at least in part, in PIH mothers to ensure an adequate fetal PUFA status (van 
der Schouw et al 1991).
These findings were largely repeated in a study of matemal plasma analysis during 
pregnancy and at term. Differences in the absolute amounts of fatty acids in plasma 
PL between mothers with and without PIH were not apparent during gestation, but a 
marked decline in LA, aLA and total n-6 in PIH mothers by term led to a significantly 
reduced aLA level compared to control mothers (Al et al 1995a). Relative fatty acid 
levels were also similar throughout pregnancy but differed at delivery in PIH and 
normal pregnancies, with lower LA and aLA in hypertensive mothers (Al et al 1995a). 
The % DHA in plasma PL from the PIH mothers increased between 32 weeks 
gestation and delivery, in direct contrast to the decline in % DHA seen over this time 
in the normal pregnancy group. The authors argue that this elevation in DHA occurred 
after the onset of PIH and is therefore unlikely to be causal, but may have occurred 
either to ensure adequate mobilization/transfer of DHA, or in response to the stress of
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PIH (Al et al 1995a). Severity of hypertension did not further affect matemal fatty 
acid status (Al et al 1995a).
Matemal fatty acid status is modulated in pre-eclamptic toxaemia (PET). The absolute 
amounts of LA, aLA and EPA were lower in matemal plasma total lipids at terra 
following pregnancy with PE compared to normal pregnancy (Wang et al 1991). 
Higher absolute amounts of palmitic (16:0), oleic (18:ln-9) and LA in semm NEFA 
have also been observed in PET (Lorentzen et al 1995). The relative amount of LA 
was, however, decreased in semm PL and TAG in mothers with PET. These 
differences were observed both during early pregnancy in a prospective cohort who 
later developed PE and in late pregnancy in a retrospective cohort diagnosed with PET. 
The authors thus suggest that the altered fatty acid status is not a consequence of but a 
contributing factor to PET (Lorentzen et al 1995).
Mothers who had an intrauterine growth retardation (lUGR) pregnancy had a higher % 
EPA but no differences in the absolute amounts of n-6 or n-3 PUFA in their plasma 
lipids when compared to controls (Matorras et al 1994). The reasons for this are 
unknown, indicating that further studies are required to elucidate the changes in 
matemal status in relation to lUGR (Matorras et al 1994).
5.1.3 Fetal Fatty Acid Status
Blood obtained from the umbilical cord following delivery is indicative of 
fetal/neonatal fatty acid status. RBC and plasma from the umbilical arteries do not 
differ significantly from that obtained from the umbilical vein (Al et al 1990).
The relative amounts of both LA and aLA have been inversely correlated with AA and 
DHA in cord plasma and RBC PL, while cord blood AA has been positively correlated 
with DHA. Moreover, these relationships were observed in both term and preterm 
infants, suggesting that mechanisms exist to ensure appropriate fetal AA and DHA 
levels (Ghebremeskel et al 2000).
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5.1.3(a) Factors Affecting Fetal Status
(i) Parity
DHA, measured in absolute (mg/L) or relative (% TFA) terms, in umbilical cord 
plasma PL did not differ between neonates of primigravida and multigravida mothers 
(Al et al 1997). The % DHA in relation to DPA (22:5n-6) (DHA sufficiency index) 
was lower in neonates of multigravida mothers and negatively correlated with the 
number of pregnancies; conversely, the DHA deficiency index (% 22:5n-6/22:4n-6) 
was higher in cord plasma PL from multigravida mothers and was positively correlated 
with number of pregnancies.
(ii) Maternal Diet
Fetal fatty acid status is greatly influenced by matemal diet. Cord RBC PL following 
pregnancy in which mothers consumed oily fish more frequently were characterised by 
a higher % EPA and lower AA than was observed when matemal fish consumption 
was lower than average (Sanjurjo et al 1995).
Cord RBC and plasma total lipids obtained following pregnancy in which mothers 
were supplemented with n-3 PUFA from weeks 26 to 35 had significantly higher % 
DHA than in cord blood from an unsupplemented pregnancy (Connor et al 1996). 
Matemal fish oil supplementation from 30 weeks gestation until term significantly 
increased the percentage of all n-3 PUFA and decreased all n-6 LCPUFA in umbilical 
cord plasma PL relative to unsupplemented pregnancies (van Houwelingen et al 1995).
The % DHA is reduced and that of DPA (n-6) is elevated in cord plasma PL of 
neonates bom to vegetarian mothers, who have high LA and low EPA/DHA intakes 
(Reddy et al 1994). Given that vegetarian intakes of A A, EPA and DHA may be nil 
(Sanders 1999), the presence of these fatty acids in cord blood suggests that 
endogenous synthesis is occurring. However, given that the dietary LA/aLA ratio is 
high in vegetarians, excessively high maternal LA consumption should be avoided to 
prevent inhibition of DHA synthesis (Sanders 1999).
High matemal intake of LA, either from habitual diet or supplementation, increases 
both the absolute and relative levels of individual and total n-6 PUFA, while 
decreasing n-3 levels in umbilical plasma PL (Al et al 1995b). However, matemal
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plasma PL LA and n-3 status at 20 weeks gestation is correlated with corresponding 
umbilical plasma and arterial wall status, such that matemal supplementation with LA 
from the 20^ ^^  week of gestation does not increase neonatal LA status. This suggests 
that the timing of matemal intake an important consideration, particularly when 
supplementation is undertaken (Al et al 1995b).
(Hi) Genetics
There are suggestions that genetic influences contribute to neonatal fatty acid status 
(Homstra et al 1992). The cord plasma PL of Canadian Inuit neonates exhibit higher 
relative levels of SFA and MUFA, with lower n-3 and n-6 PUFA, compared to Dutch 
infants. In particular, the Inuit neonates have lower % DHA and AA, but higher levels 
of the precursors LA and DHGLA (20;3n-6), as well as Mead acid (20:3n-9), despite 
the substantial marine component of the matemal diet. Moreover, cord plasma fatty 
acid content varies with matemal diet within the Inuit population, with higher n-3 
PUFA found in communities where matemal fish consumption is greater. Thus, while 
matemal diet is a contributing factor, it may not be the only determinant of neonatal 
FA status, as it is possible that genetic differences, in particular low A5-desaturase 
activity, have evolved to ensure that n-3 levels do not become excessive when 
matemal supply is plentiful (Homstra et al 1992).
Neonates with a family history of atopy have been shown to differ in their umbilical 
plasma and RBC fatty acid composition from neonates free of atopic risk, but the 
precise pattem of these differences has varied between studies (Beck, Zelczak & 
Lentze 2000).
(iv) Maternal Lifestyle/Habits
No differences in cord plasma PL fatty acids have been detected between neonates 
bom to mothers who smoked or not (Al et al 1995c). Cord plasma total lipids were, 
however, lower in % DHA following a pregnancy in which mothers did not smoke 
(Matorras et al 1994).
Matemal smoking has been associated with elevated Mead acid levels in cord RBC 
membranes of preterm neonates; matemal alcohol consumption was coincident with a 
non-significantly lower cord DHA status. In combination, however, matemal alcohol
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consumption and smoking were associated with significantly reduced cord RBC DHA 
which continued to decline further postnatally (Smuts et al 1999). Several reasons 
have been suggested to explain these observations, including increased transfer and/or 
uptake of DHA in compensation for the effects of alcohol and tobacco. However, 
there remains the possibility that the circulating RBC are not indicative of other 
tissues, whose fatty acid composition may have been compromised (Smuts et al 1999).
(v) Gestation
Umbilical plasma PL % LA has been found to be negatively correlated, while AA, 
DPA (n-3) and DHA were positively conelated with gestational age (Al et al 1995a). 
Interestingly, both the relative and absolute amounts of total n-3 and DHA in cord 
plasma PL were positively correlated with age (Al et al 1995c). Indeed, from analysis 
of both prenatal and umbilical samples, it has been observed that both the absolute and 
relative amounts of DHA in plasma PL increase with gestation (van Houwelingen et al 
1993).
Increasing gestation also corresponds with increasing n-3 LCPUFA in cord plasma 
TAG (Berghaus, Demmelmair & Koletzko 2000). Gestational-age dependent 
relationships have been noted for % n-3 and n-6 EFA and LCPUFA in umbilical cord 
plasma TAG and CE; DHA in the TAG fraction, however, was constant and did not 
increase with gestation (Hoving et al 1994).
(vi) Health o f Mother and Fetus
Neonates bom following an lUGR pregnancy showed no differences in the fatty acid 
composition (absolute and relative amounts) of their plasma total lipids compared to 
neonates of an appropriate WGA (Matorras et al 1994). Similarly, the relative fatty 
acid compositions of cord serum PL, TAG and CE were not altered following 
pregnancy involving PIH (van der Schouw et al 1991), possibly because there is 
matemal adaptation to ensure an efficient matemal-fetal gradient. In cord plasma PL, 
the absolute amounts of fatty acids did not differ following normal or PIH pregnancy, 
although the % DHA was higher in PIH neonates (Al et al 1995a).
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5.1.4 Relationship between Maternal and Fetal Blood Status
5.1.4(a) Comparison of Mother and Offspring
Several authors have noted the depletion of EFA and enrichment of LCPUFA in the 
neonate compared to mother (Koletzko, Demmelmair & Socha 1998). Generally, 
levels of LA and aLA are higher while AA and DHA are lower in matemal compared 
to cord plasma and RBC. Higher fetal levels of Mead acid (20:3n-9) have also been 
observed (van der Schouw et al 1991).
Lower EFA and higher LPCUFA in plasma TAG (Berghaus et al 2000) and plasma PL 
(Al et al 1990) have been observed in umbilical cord compared to matemal plasma. 
Umbilical plasma TAG and CE have higher % n-3 and n-6 LCPUFA and Mead acid, 
but lower % EFA than the corresponding lipid fractions in matemal plasma. 
Moreover, these observations were made for neonates bom from 23 weeks until term 
(Hoving et al 1994).
While absolute amounts of total fatty acids, SFA, MUFA, n6, n3, LA, AA and DHA 
were lower in umbilical plasma PL compared to matemal plasma at delivery, neonatal 
levels did not differ from matemal levels at 6 months postpartum, which were assumed 
to be indicative of matemal pre-conceptional levels (Al et al 1995c). Moreover, 
umbilical plasma PL relative amounts of SFA, n-3, AA and DHA were all higher, 
while n-6 and LA were lower, than matemal levels throughout and following 
pregnancy. Thus although neonates may have lower absolute amounts of fatty acids, 
the relative enrichment of LCPUFA and depletion of EFA suggests preferential 
transfer from mother to fetus.
The findings in plasma have been largely replicated in RBC. Several differences 
between matemal and cord RBC total lipids at term delivery have been noted, 
including lower matemal relative amounts of LA, AA, DPA (22:5n-6) and DHA, and 
higher aLA and EPA (Reece et al 1997). However, the only significant differences 
were a lower % AA and higher % EPA in mothers than neonates.
Furthermore, elevated fetal % AA and DHA has been observed in all semm lipid 
fractions in both noimal and PIH pregnancies (van der Schouw et al 1991). However, 
these pattems were slightly different in the case of neonates delivered prematurely.
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Mothers delivering at preterm had significantly higher % LA and AA and lower DHA 
in their plasma PL than did cord plasma. Matemal RBC total lipids were, however, 
higher in % LA and lower in AA, EPA and DHA than cord RBC (Reece et al 1997).
5.1.4(b) Correlation of Fatty Acid Status of Mother and Offspring 
Correlations have also been detected at delivery between matemal and cord plasma PL 
in the % of SFA, MUFA, n-6, n-3, LA, DPA (n-6), AA and DHA (Al et al 1990, Al et 
al 1995c, van Houwelingen et al 1995). Matemal plasma TAG % LA was positively 
correlated with that of cord plasma when delivery occurred after 34 weeks gestation; 
LA in matemal and cord plasma CE fractions were similarly related when delivery 
occurred at term (Hoving et al 1994). The % DHA in cord RBC and plasma has been 
correlated not only with matemal blood DHA, but also with matemal dietary n-3 
(Connor et al 1996). In neonates bom appropriate WGA, correlations between 
matemal and cord plasma total lipids were observed for % 14:0 (myristic acid) and 
EPA. A similar matemal-fetal relationship for % EPA was also observed in lUGR 
pregnancies, in which matemal and fetal oleic (% and absolute) and palmitoleic (%) 
acids were also correlated (Matorras et al 1994).
5.1.5 Fatty Acid Status of Placental Tissue
Placental tissue resembles the umbilical cord vessels in its fatty aid composition (Al et 
al 1990). It can be argued that since synthesis and transfer by the placental is central 
to fetal accretion of fatty acids, analysis of placental tissue provides an opportunity to 
“track” fatty acid pattems from mother to placenta to fetus.
Whether placental tissue is subject to the same differential compositions between 
populations as noted above for blood samples should indicate whether the composition 
of the matemal circulation is modified by the placenta before reaching the fetus. The 
relative level of 18:0 is higher in preterm than term placental tissue (Reece et al 1997).
Placental tissue from vegetarian and diabetic mothers is characterised by higher % 
EFA and lower LCPUFA (particularly from the n-3 family) in total lipids than that of 
non-diabetic omnivorous mothers. This may be attributable to lower dietary intakes of 
the vegetarian mothers, and metabolic differences of the diabetic mothers (Lakin et al 
1998).
85
5.1.6 Fatty Acid Status of Umbilical Cord Tissue
Umbilical cord vessels have been analysed on the basis that their continuing growth 
and lack of a vasa vasorum, coupled with the inability of tissue to synthesize fatty 
acids de novo, allows the vessels to reflect the fatty acid status of fetal blood over a 
prolonged period of time (Crawford et al 1989, Foreman-van Drongelen et al 1995a, 
Homstra et al 1989). In the umbilical cord, the vein is the afferent (supplying) vessel, 
conducting blood from the placenta to the fetus, while the arteries are the efferent 
(draining) vessels, retuming blood from the fetus back to the placenta. This has lead to 
the suggestion that umbilical venous wall lipids provide an indication of longer term 
fatty acid supply to the fetus, while umbilical arterial wall lipids reflect the fatty acid 
status of the blood retuming from the fetus to the mother, and hence the fetal fatty acid 
status (Foreman-van Drongelen et al 1995a, Homstra et al 1992).
The fatty acid composition of the umbilical artery compared to vein was found to be 
lower in % n-6 and n-3 PUFA, but higher in n-7 and n-9 fatty acids as well as 20:3n-9 
(Mead acid) and 22:5n-6 (DPA), the indicators of n-3 and n-6 deficiency, and DHA 
deficiency respectively (Al et al 1990, Homstra et al 1989). In addition, all umbilical 
vessels have less LA and n-6 PUFA but more Mead acid than do adult colonic arteries 
and veins (Homstra et al 1989). These observations have led investigators to suggest 
that neonatal EFA status is marginal and may be inadequate for fetal requirements. 
Although the actual reasons for the apparent fatty acid deficiency are not known, it has 
been speculated that matemal diet and its influence on matemal-fetal transfer is 
important in ensuring that a poor fetal status does not prevail (Al et al 1990).
Umbilical cord tissue has also been analysed whole, without dissection and separation 
of vessels. The differential pattems of fatty acid composition observed between 
omnivorous, vegetarian and diabetic mothers in the total lipids of whole cord tissue 
(Lakin et al 1998) suggests that analysis of the entire tissue is capable of reflecting 
matemal dietary and metabolic differences.
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5.1.6(a) Factors Affecting Umbilical Vessel Status
(i) Maternal Status
The relative amounts of PL n-3 in umbilical arterial and venous walls have been 
correlated with the levels in rhatemal plasma PL (van Houwelingen et al 1995).
(ii) Parity
DHA, as % TFA, was lower in PL of cord arterial and venous vessel walls from 
multigravida compared to primigravida mothers (Al et al 1997). The DHA deficiency 
index (% 22;5n-6/22:4n-6) and the DHA sufficiency index (% 22:6n-3/22:5n-6) were 
also more favourable in the cord vessels of primigravida mothers. DHA relative levels 
(% TFA) and sufficiency indices were negatively correlated with the number of 
pregnancies.
(Hi) Maternal Diet
Phospholipids from both umbilical arterial and venous vessel walls were enriched in 
EPA and DHA, and reduced in DPA (n-6), following matemal fish oil supplementation 
during the last trimester (van Houwelingen et al 1995). In addition, matemal fish oil 
supplementation does not differentially affect the fatty acid composition of umbilical 
arterial tissue PL relative to that of the umbilical vein (van Houwelingen et al 1995).
As a consequence of high matemal LA intake, the concentration and relative amount 
of n-6 PUFA are higher, while that of n-3 PUFA are lower, in umbilical vessels (Al et 
1995b). A matemal vegetarian diet results in cord artery PL with lower % SFA and 
DHA, and higher n-6 LCPUFA and Mead acid, a fatty acid pattem which closely 
resembles that of the matemal diet (Reddy et al 1994).
(iv) Genetics
Despite a higher matemal consumption of marine foods, Canadian Inuit neonates have 
lower % n-3 and n-6 PUFA, except for higher LA and DHGLA, in the PL of their cord 
vessels compared to Dutch neonates. In combination with similar findings in cord 
plasma PL (see above), it has been suggested that genetic determinants also contribute 
to fetal fatty acid status (Homstra et al 1992).
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(v) Gestation
Gestational age has been positively correlated with % DHA and negatively with % 
Mead acid (20:3n-9) in the umbilical arterial wall PL (van Houwelingen et al 1995). 
Furthermore, in umbilical arterial wall PL, % DPA (n-6) was negatively and % 
DHGLA, adrenic acid, AA and DHA were all positively correlated with gestational 
age (Al et al 1995a). The relative amount of LA in umbilical venous wall PL has been 
negatively correlated with gestational age, while that of both AA and DHA has been 
positively correlated (Al et al 1995a).
The relative and absolute amounts of n-6 and n-3 PUFA are reduced in the cord tissue 
PL of preterm compared to term infants, and more markedly so in the umbilical 
arteries compared to vein. In addition, indices of EFA deficiency, including Mead acid 
(20:3n-9) and DPA (22:5n-6), are elevated in preterm cord vessels (Foreman-van 
Drongelen et al 1995a). These findings may, in part, be explained by the positive 
correlation between n-3 or n-6 PUFA (arterial and venous) and gestational age in 
premature infants.
(vi) Singleton and Multiple Pregnancies
Multiple and singleton pregnancies do not differ in the absolute amounts of fatty acids 
present in umbilical vessel PL; there are, however, differences in their relative fatty 
acid levels (Foreman-van Drongelen et al 1996). Arterial and venous cord tissues have 
lower n-6 and n-3 PUFA, but higher n-9 PUFA following multiple pregnancies. As a 
result, the EFA status and EFA deficiency indices are less favourable in the cord tissue 
from multiple compared to singleton pregnancies. Although there is no differentiation 
between twins and triplets, the cord fatty acid composition of quintuplets is even 
poorer. These observations may be further indications that fetal requirements strain, 
and may even exceed, matemal supply and that matemal status is a limiting factor in 
fetal status (Foreman-van Drongelen et al 1996).
(vii) Health o f Mother and Fetus
Neither absolute nor relative fatty acid levels in umbilical arterial and venous tissues 
differed following PIH compared to normal pregnancies (Al et al 1995a). PET has 
been shown to be associated with abnormal cord vessels. The relative levels of n-3
and n-6 PUFA are lower in arterial and venous tissues following pregnancy with PE 
(Velzing-Aarts et al 1999).
5.2 FATTY ACID STATUS OF BREAST MILK
5.2.1 Introduction
In addition to its macronutrient content, breast milk contains a multitude of non­
nutritive components including hormones, enzymes and immunoglobulins. The nature 
(Table 16) and composition (Table 17) of breast milk changes during lactation.
Time postpartum Milk Appearance Maximal concentration of
Birth-5d Colostrum Thick, creamy colour Proteins, immunoglobulins
6d-15d Transitional Thin, white colour Lactose, water-soluble vitamins
16d-Weaning Mature Thinner, blue/white colour Fat, calories
Table 16. Changes in breast milk with time postpartum.
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Nutrient per lOOg Colostrum Transitional Mature
Energy kJ 236 281 289
kcal 56 67 69
Water g 88.2 87.4 87.1
Protein g 2.0 1.5 1.3
Carbohydrate g 6.6 6.9 7.2
Starch g 0 0 0
Total sugars g 6.6 6.9 7.2
Fibre g 0 0 0
Fat g 2.6 3.7 4.1
Saturated g 1.1 1.5 1.8
Monounsaturated g 1.1 1.5 1.6
Polyunsaturated g 0.3 0.5 0.5
Cholesterol mg 31 24 16
Nitrogen g 0.31 0.23 0.2
Sodium mg 47 30 15
Potassium mg 70 57 58
Calcium mg 28 25 34
Magnesium mg 3 3 3
Phosphorous mg 14 16 15
Iron mg 0.07 0.07 0.07
Copper mg 0.05 0.04 0.04
Zinc mg 0.6 0.3
Chloride mg N 86 42
Manganese mg Tr Tr Tr
Selenium ug N 1
Iodine ug N N 7
Retinol ug 155 85 58
Carotene 
Vitamin D
ug
ug N N 0.04
Vitamin E mg 1.30 0.48 0.34
Thiamin mg Tr 0.01 0.02
Riboflavin mg 0.03 0.03 0.03
Niacin mg 0.1 0.1 0.2
Tryptophan mg 0.7 0.5 0.5
Vitamin B6 mg Tr Tr 0.01
Vitamin B 12 ug 0.1 Tr Tr
Folate ug 2 3 5
Pantothenate mg 0.12 0.20 0.25
Bio tin ug Tr 0.2 0.7
Vitamin C mg 7 6 4
Table 17. Nutrient composition of human breast milk (data from Holland et al 1991).
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The properties of breast milk and the impact of feeding on both mother and infant have 
been the subject of much discussion (Emmett & Rogers 1997, Heinig & Dewey 1996 
& 1997, Rogers, Emmett & Golding 1997, Whitehead & Paul 2000). The energy 
content of breast milk increases with lactation, and is estimated to be 530kcal/l at 6 
weeks lactation, rising to 580kcal/l at 3 months lactation (Goedhart & Bindels 1994). 
The metabolizable energy intake decreases from 98kcal/kg/d at 5 weeks to 89kcal/kg/d 
at 11 weeks (Lucas et al 1988). However, the increase with age in infant body weight 
and volume of milk consumed, ensures a net increase in total metabolizable energy 
obtained. Total carbohydrate content of breast milk provides 40-50% of the energy in 
milk (Lawrence 1994).
Fat is present in human milk at concentrations of 2-4g/100ml (Table 17). Human milk 
fat accounts for 45-50% of total milk energy. It has been calculated that the average 
amount of total fat ingested by infants of 1-6 months age, based on a breast milk 
volume of 670-900ml/day, is 29-38g/day (Dewey & Lonnerdal 1983).
The fat content of breast milk is important as an energy source; its fatty acid 
composition is important with regard to the provision of EFA and LCPUFA. The lipid 
content of breast milk has been reviewed extensively (Jensen 1989a & b, Jensen 1999), 
including those factors identified as influencing composition (World Health 
Organization/WHO 1985). Breast milk contains EFA and LCPUFA whereas infant 
formulae only contain EFA; breast milk thus provides LCPUFA during early postnatal 
life when accumulation of LCPUFA is high, and is the first potential source of 
LCPUFA in early postnatal life.
5.2.2 Total Lipids
There are various classes of lipids in milk, contained within the milk fat globule which 
is synthesized in the mammary gland (Mepham 1987). Triacylglycerols, contained in 
the core of the milk fat globule, account for 98% of the fat in breast milk (Hachey et al 
1987, Jensen 1989a, Hamosh & Bitman 1992, Hamosh et al 1992, Innis 1992a, 
Goedhart & Bindels 1994). Small amounts of diacylglycerols, monoacylglycerols and 
non-esterified fatty acids may be present in breast milk (Jensen 1989a). Phospholipids 
account for 0.5-1% of total milk lipids (Hachey et al 1987, Jensen 1989a) and are 
present in concentrations of 150-200mg/l (Hamosh et al 1984). Phospholipids are
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associated with the milk fat globule membrane; they are derived from de novo 
synthesis within the mammary gland, inserted into the membranes of the milk 
secreting cells and their intracellular Golgi apparatus, which envelop the milk fat 
globules on their extrusion from the mammary cells (Hamosh et al 1984, Mepham 
1987).
Cholesterol is the main sterol present in breast milk, and is found at relatively high 
concentrations of 100-150mg/l (Hamosh et al 1984, Goedhart & Bindels 1994). This 
has raised many questions on lipid metabolism and the putative “early origins” 
hypothesis of later disease (Goedhart & Bindels 1994, Huisman et al 1996). 
Cholesterol is obtained from the circulation and from de novo synthesis by the 
mammary gland and, as with phospholipids, is found in the milk fat globule membrane 
derived from the apical cell and Golgi membranes (Hamosh et al 1984, Mepham 
1987).
5.2.3 Fatty Acids
5.2.3(a) Within Triacvlglvcerols
The fatty acids present in milk triacylglycerols are arranged in a specific positional 
distribution (Innis 1992a, Goedhart & Bindels 1994). Thus, each fatty acid has a 
preferred site {Sn-l, 2 or 3) at which to be esterified on the triacylglycerol. The most 
abundant triacylglycerols in breast milk are those with the combinations of fatty acids 
16:0/18:1/18:1 or 16:0/18:1/18:2 at the Sn-\, 2 and 3 positions respectively (Winter et 
al 1993). These are suitable substrates for preduodenal lipase, which acts at the Sn-?> 
position to preferentially release medium chain and long chain unsaturated fatty acids, 
rather than saturated fatty acids. The long chain fatty acid released helps to stabilise 
fat globules in the duodenum, allowing pancreatic lipase to act at the Sn-\ and -3 
positions. Pancreatic lipase releases C l8 essential fatty acids (EFA) in preference to 
their longer, more unsaturated derivatives. This, and the fact that the unsaturated fatty 
acids (UFA) present in milk have a high coefficient of absorption (ESPGAN 1991), 
suggest that breast milk and the infant digestive system are suitably adapted to each 
other (Weaver 1992 & 1993).
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5.2.3(b) Sources
The fatty acids present in the triacylglycerols of milk are derived from maternal diet, 
maternal adipose stores and de novo synthesis within the mammary gland. Stable 
isotope tracer studies have allowed quantification of the contribution made by these 
sources. Medium chain saturated fatty acids (MCSFA, C<16) synthesized in the 
mammary gland account for 10-12% of total fatty acids, while LCPUFA derived from 
the diet comprise 29% of total fatty acids. The remaining 59% of fatty acids are 
derived from both tissue synthesis and adipose tissue (Hachey et al 1987).
The incorporation of dietary LA into milk accounts for approximately 30% of milk 
LA, a rate which remains stable throughout lactation. The conversion of the dietary n- 
6 EFA to its LCPUFA metabolites also remains stable with time (Demmelmair et al
1998). There is a delay of 6-10 hours before dietary fats are incorporated into and 
appear in breast milk (Emken et al 1989, Fidler et al 2000b). The relationship between 
weight gain during pregnancy, and hence maternal fat deposition, and fat content of 
milk is unclear (Michaelsen et al 1994). The amounts (%) of both EFA in colostrum 
and mature milk are correlated with their respective levels in maternal white adipose 
tissue (Pugo-Gunsam et al 1999). There is some evidence to suggest that as de novo 
synthesis of MCSFA increases, the proportions of n-6 and n-3 EFA and LCPUFA are 
“protected” by preferential incorporation into milk TAG at the expense of stearic 
(18:0) and oleic (18:ln-9) acids (Schmeits et al 1999b).
5.2.3(c) Contributions
The fatty acid content of human milk is affected by many factors (WHO 1985, Jensen 
1989a); its variability and the reporting of the relative (% fatty acid) fatty acid 
composition makes it difficult to define concentrations. However, percentage 
contributions of individual fatty acids to total fatty acid content have been assessed in 
many studies on mature breast milk from Europe, Africa, Asia and America, The 
relative contributions of the fatty acid classes can be summarized as follows (ESPGAN 
1991, Goedhart & Bindels 1994, Innis 1992a, Koletzko Thiel & Abiodun 1992):
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• Saturated fatty acids (SFA) account for 45-53% of total fatty acids, including 
palmitic acid at 20-24% of total fatty acids
• Monounsaturated fatty acids (MUFA), particularly oleic acid (18:ln-9), account for 
30-38% of total fatty acids
• Total n-3 and n-6 polyunsaturated fatty acids (PUFA) account for 13-16% of total 
fatty acids including;
• linoleic acid (18:2n-6) as 11-16% of total fatty acids
• a-linolenic acid (18:3n-3) as 1% of total fatty acids
• arachidonic acid (20:4n-6) as 0.5-0.7% of total fatty acids
• docosahexaenoic acid (22:6n-3) as 0.3-0.6% of total fatty acids.
As with non-processed foods in the adult diet, the quantities of trans fatty acids in 
breast milk are low. Obtained from maternal dietary sources, the relative amounts of 
trans fatty acids are negatively correlated with EFA levels in breast milk (Innis & King
1999).
5.2.4 Factors Influencing Total Lipid and Fatty Acid Composition
5.2.4(a) Suckling
The amount of total milk lipid increases during a feed from foremilk to hindmilk 
(Jensen 1989a, Drury & Crawford 1990, Lawrence 1994) from approximately 
2mg/100ml to 4mg/100ml. The second breast suckled at a feed produces foremilk 
with more lipid than that suckled first (Hall 1979). It has been suggested that the 
rising fat content of milk acts as a “satiety signal”, but whether these variations are 
involved with appetite and thirst control in breast-fed babies is debatable (Hall 1975). 
The fatty acid composition remains constant throughout a feed (Gibson & Kneebone
1980) and does not differ between breasts (Hall 1979), thus a sample taken at any time 
during a feed is indicative of the fatty acid composition of the whole feed.
5.2.4(b) Diurnal Rhvtlim
Total milk lipid content increases from morning to aftemoon (Hall 1979, Jensen 
1989a). However, the time at which fat content peaks varies with the geographical 
location of the population studied (Harzer et al 1983). Whether this is a function of
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dietary intake is a matter of debate (Hall 1979, Harzer et al 1983). Diurnal rhythm does 
not influence fatty acid composition (Hall 1979, Harzer et al 1983).
5.2.4(c) Stage of Lactation
The amount of total lipid increases from colostrum to mature milk, then stabilizes. 
Most studies are in agreement with the levels of fat in colostrum, transitional and 
mature milk, as shown in Table 17 (Bitman et al 1983, Harzer et al 1983). Prolonged 
lactation with supplementary foods (weaning) is associated with a decline in the 
volume of milk but not its fat content (Dewey, Finley & Lonnerdal 1984).
Of the lipid classes, only triacylglycerols remain constant in concentration (98-99% of 
total fat), with cholesterol and phospholipids decreasing as lactation continues (Bitman 
et al 1983). This may however be due to an increase in fat globule size 
(volume/surface diameter), with a concomitant decrease in the surface thickness of the 
fat globule. Since the surface area of the fat globule is related to the membrane 
surrounding it, thinning of the membrane could account for the relatively lower 
amount of cholesterol and phospholipids seen (Riiegg & Blanc 1981, Simonin, Rüegg 
& Sidiropoulos 1984).
With regards to fatty acid composition, the total contributions of saturated, 
monounsaturated and polyunsaturated fatty acids do not change over time (Makrides et 
al 1995b). However, within each subclass of fatty acid type, variations exist. The 
percentage contribution of medium chain saturated fatty acids (MCSFA) synthesized 
de novo increases with lactation (Boersma et al 1991, Finley et al 1985, Gibson & 
Harzer et al 1983, Kneebone 1981). Whether this is due to the higher concentrations 
of essential fatty acids (EFA) and polyunsaturated fatty acids (PUFA) in phospholipids 
and cholesterol than in triacylglycerols (Drury & Crawford 1990, Hamosh et al 1992), 
or to maturation of mammary gland fatty acid synthetase activity, is not known. The 
relative amount of monounsaturated fatty acids (MUFA) decreases with ongoing 
lactation (Gibson & Kneebone 1981).
Of the polyunsaturates, both the essential LA and aLA increase during lactation, 
although the opposite is true of their long chain metabolites (Gibson & Kneebone
1981). Thus, the percentage contributions of LCPUFA, particularly DHGLA (20:3n-
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6), AA (20;4n-6), EPA (20:5n-3), DP A (22:5n-3) and DHA (22:6n-3), are all higher in 
colostrum than mature milk (Boersma et al 1991, Makrides et al 1995b, Ronnenberg & 
Skara 1992), and within the first month compared to later (Xiang et al 1999). It has 
therefore been suggested that as colostrum provides a source of “ready made” 
LCPUFA while the infant’s metabolism is immature, mature milk provides sufficient 
parent EFA for the infant to synthesize a new pool of long chain metabolites.
The absolute amounts of EFA increase during the first month of lactation, in parallel 
with the increase in total fat, and stabilize for the remainder of lactation. Although the 
% AA and DHA decline in the first month postpartum, their concentrations remain 
relatively stable (Marangoni et al 2000). Since the LCPUFA are more evident in PL 
than the other lipid classes, the decline in relative PL levels may account for this 
observation (Agostoni et al 1999). Moreover, these findings suggest differential 
patterns in relative and absolute amounts of milk fatty acids, indicating that both 
measurements are relevant and pertinent (Marangoni et al 2000).
In most studies, the ratio of n-6:n-3 PUFA is reported to increase in mature milk 
(Ronnenberg & Skara 1992). This appears to be due to a constant level of the n-6 
family and a decreased level of the n-3 family (Ronnenberg & Skara 1992, Serra et al 
1997).
5.2.4(d) Geo graph V
Many studies have been undertaken in several countries. Results that differ 
significantly between countries can apparently be explained by dietary differences (Al- 
Othman et al 1996, Borschel et al 1986, Innis & Kuhnlein 1988, Laryea et al 1995, 
Pugo-Gunsam et al 1999, Serra et al 1997, Xiang et al 1999). The main differences 
seen are in the relative contributions of saturated and unsaturated fatty acids, with 
increased saturated fatty acids due to enhanced synthesis by mammary tissue when fat 
content of diet is low (Drury & Crawford 1990). As mentioned above, there may be an 
association between geography or location and diurnal rhythm (Jensen 1989a) which 
further occludes any potential variation with geography. However, although regional 
differences within a country have been observed, the similar LA/aLA ratio of all 
regions (Fidler, Salobir & Stibilj 2000a) suggests that geographical location is not the 
overriding determinant of breast milk composition.
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5.2.4(e) Maternal Diet
The total fat content of breast milk is independent of maternal fat intake (Vuori et al
1982). Studies of undernourished mothers reveal that the total amount of fat in milk is 
not affected by maternal dietary restriction (Jensen 1989a). However, there are 
changes within the fatty acid composition with an increased proportion (but not 
absolute mg/1) of saturated fatty acids (SFA) and a decreased proportion of EFA in the 
milk of undernourished mothers (Drury & Crawford 1990, Schmeits et al 1999a). This 
suggests that except in extreme undernourishment, the amount of fat remains relatively 
constant, with increased endogenous synthesis of SFA by the mammary gland to 
compensate. If, however, the volume of milk produced by a malnourished mother is 
low, then the increase in medium chain saturated fatty acids (MCSFA) will not be 
effective in augmenting the infant’s intake (Borschel et al 1986). Supplementation of 
Gambian mothers with low energy intake failed to significantly increase either the 
volume of breast milk produced, or its fat concentration (Prentice et al 1980, Prentice 
et al 1983).
Lactating mothers in The Gambia traditionally consume a low fat diet (16% of total 
energy intake) which contains a high proportion of oleic acid from groundnuts. 
Analysis of their breast milk showed a concomitantly high predominance of oleic acid, 
followed by palmitic and linoleic acids (Prentice et al 1989). Despite the low 
contribution of fat to the maternal intake and the dietary restrictions imposed during 
the rainy season, long chain fatty acid profile of the breast milk resembled that 
associated with a maternal medium fat diet, while the proportion of saturated fatty 
acids synthesized de novo by the mammary gland were lower than expected on such a 
low fat diet. Thus, mobilization of maternal body fat to ensure an adequate supply of 
EFA and their LCPUFA derivatives in breast milk was probably occurring. These 
findings agree with the theory that fatty acid composition is indicative of maternal diet 
when energy consumption is adequate, and of maternal adipose tissue when energy 
consumption is low (Hambraeus 1990).
A study on the effect of vegetarian and vegan diets on breast milk composition 
(Sanders & Reddy 1992) concurred with previous reports that vegetarian and vegan 
diets are slightly lower in fat than omnivorous diets, obtaining 30-35% total energy
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from fat. The intake of a-linolenic acid was variable but was usually higher than in 
omnivorous diets. There was a higher proportion of ClO-14 saturated fatty acids but 
lower proportion of C l6-18 saturated fatty acids in breast milk from vegans than 
omnivores. This may perhaps reflect increased de novo synthesis of ClO-14 saturated 
fatty acids which tend to be lower in maternal vegan intake. Breast milk from vegan 
mothers had a higher proportion of linoleic and a-linolenic acids than that of 
omnivorous mothers. This is in agreement with an earlier study in which linoleic acid, 
derived mainly from vegetable fat, was higher in the breast milk of vegetarian than 
omnivorous mothers (Finley et al 1985). The ratios of both linoleic;a-linolenic and 
total n-6;n-3 were higher in vegan breast milk (Sanders & Reddy 1992), The n-6 
PUFA, particularly DHGLA and AA were similar in vegans, vegetarians and 
omnivores, although vegans had lower DHA i,e. n-3. This suggests that since vegans 
have no dietary sources of DHA and AA, adequate amounts are made from their EFA 
precursors and secreted into milk (Makrides, Neumann & Gibson 1996a).
Comparison of breast milk from Inuit women consuming a diet rich in fish oil sources 
(marine mammal flesh) with Canadian women from Vancouver consuming a “typical” 
North American diet, revealed that EPA (20;5n-3) and DHA (22;6n-3) were elevated 
in breast milk from Inuit women (Innis & Kuhnlein 1988). N-6 fatty acids were not 
altered. This led the authors to suggest that there is no competition between n-3 and n- 
6 fatty acids for inclusion in breast milk (Innis & Kuhnlein 1988). Breast milk from 
mothers who ate fish at least occasionally has been shown to have higher levels of 
DHA than that from mothers who abstain from fish (Finley et al 1985).
Several studies have shown that supplementation of lactating mothers with fish oil 
supplements increased the proportion of EPA (20;5n-3) and DHA (22;6n-3) in breast 
milk (Jensen et al 1992). The effect of fish oil supplementation depends on the dose 
consumed, until stabilisation or saturation of milk levels, and may persist following 
cessation (Harris, Connor & Lindsey 1984). Fish oil supplements providing all n-3 
PUFA (EFA and LCPUFA) subsequently elevated the % levels of total and individual 
n-3, while decreasing total n-6 (Henderson et al 1992). Cod liver oil supplements, 
containing high proportions of EPA and DHA in particular, incurred a dose-related 
increase in the relative amounts of these fatty acids in breast milk, while the proportion
of AA remained unchanged (Helland et al 1998). Supplementation with DHA as the 
only PUFA (200mg/d from weeks 4-6 postpartum) caused a linear increase in both the 
relative and absolute amount of DHA in breast milk, without affecting the content of 
other fatty acids (Fidler et al 2000b). When a range of DHA doses (0.2-1.3mg/d), all 
without EPA, were given as supplements, breast milk % DHA increased in a dose 
dependent manner; breast milk % AA and total lipids were not affected (Makrides et al 
1996a). The effects of supplementation on breast milk composition are discernible 
within a short period of time (hours-days) (Fidler et al 2000b, Helland et al 1998). 
Such maternal supplementation during lactation also modulates the fatty acid 
composition of maternal plasma and RBC, and of infant RBC in a manner correlated to 
intake and breast milk levels (Helland et al 1998, Henderson et al 1992, Makrides et al 
1996a). Reassuringly, supplementation of lactating mothers with n-3 oils does not 
affect levels of the anti-oxidant vitamins A and/or E in maternal or infant plasma or in 
breast milk (Helland et al 1998, Henderson et al 1992, Makrides et al 1996a).
5.2.4(f) Season
In studies of Gambian mothers, milk volume and total fat concentration are decreased 
by the end of the rainy season (Prentice, Prentice & Whitehead 1981, Prentice 1980). 
Although the rainy season is a time of low nutritional intake (Paul & Müller 1980, 
Prentice 1980), seasonal variations in fat concentrations were correlated only with 
maternal subcutaneous fat stores, which were not themselves correlated to maternal 
energy intake. Since the rainy season involves increased energy expenditure, as well 
as decreased energy intake, perhaps subcutaneous fat, and hence fat concentration, are 
dependent more on energy output than intake (Whitehead 1979). Evidence for this can 
be seen in the nutritional supplementation of lactating Gambian mothers, which 
eliminated the intake deficits of the rainy season thus equalizing seasonal intakes 
(Prentice et al 1980): despite remaining at a higher weight than unsupplemented 
mothers, those supplemented still displayed the characteristic weight loss of the rainy 
season. Quite what contribution season would make on its own, when intake, 
expenditure and season are not correlated, (as in Western countries) is not clear. 
Moreover, correction for season and stage of lactation revealed that each individual 
mother produced milk with a relatively constant fat concentration.
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5.2.4(g) Socio-economic Status
Total breast milk fat is not affected by socio-economic status. Fatty acid composition 
is again a reflection of the diet consumed according to the socio-economic group to 
which the mother belongs - for example, mothers of low socio-economic status 
consuming a high carbohydrate diet have increased C l2-14 SFA {i.e. lauric and 
myristic acids) in their milk, reflecting increased de novo synthesis in the breast (Brasil 
et al 1991). Diet and geography must also be considered with socio-economic status, 
as the dietary intake will reflect both economic level and cultural habits. For example, 
in some countries, lower socio-economic groups will have a high fat intake, whereas, 
in other countries a high carbohydrate intake will be more characteristic of low socio­
economic status (Borschel et al 1986).
5.2.4(h) Paritv
Parity has striking effects on the composition of the milk of lactating Gambian mothers 
(Prentice et al 1981, Prentice et al 1989). Maternal intake of energy and fat were not 
affected by parity. However, the proportion of endogenously produced saturated fatty 
acids in breast milk decreased with increasing parity. This effect could not be 
explained by differences in diet and nutritional status, suggesting that the ability to 
synthesize fatty acids de novo is lost with parity. There are some limitations in 
extrapolating effects of parity on breast milk from The Gambia to the West, as the 
timings of pregnancies in these societies differ (Jensen 1989a). Studies in Sudan 
(Laryea et al 1995) and Saudi (Al-Othman et al 1996) show increased saturated fatty 
acids with increasing parity. When controlling for other variables, Laryea et al (1995) 
showed no significant influence of parity on MUFA, but an increase in PUFA with 
parity. Al-Othman et al (1996) demonstrated a decline in total UFA and MUFA with 
parity, and an increase in PUFA with parity of eight or more, compared to parity of 
less than four.
5.2.4(i) Maternal Age
Although mammary glands are not sufficiently developed to sustain breast feeding 
until 18 months after the first menstrual period (Stout 1992), this does not seem to 
affect either total fat or FA composition (de Nobrega 1992). When age is controlled 
for socio-economic level, there is no difference in the total fat or fatty acid 
composition of breast milk of adolescent as opposed to adult mothers (Brasil et al
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1991). Adequate nutritional counselling may improve both the dietary intake and the 
success of lactation by adolescent mothers (Lipsman, Dewy & Lonnerdal 1985).
5.2.4(i) Length of Gestation
Breast milk from mothers who have delivered pre-term infants does not differ in total 
fat content in comparison to that from mothers who deliver at term, suggesting that 
preterm milk may provide equal calories, although preterm infants have higher energy 
requirements.
Bitman et al (1983, 1984) found that both term and preterm milks share the same 
pattern with regard to ongoing lactation: total lipids and MCSFA increase from 
colostrum to mature milk, while LCPUFA of C20-22, cholesterol and phospholipids 
all decrease with maturity. However, the initial contributions of MCSFA, LCPUFA, 
cholesterol and phospholipids were higher in early preterm milk (Bitman et al 1983 & 
1984), but by day 21, both term and preterm milks had similar LCPUFA levels. 
Whether this is a disadvantage caused by immaturity of the mammary glands, or an 
advantage attributable to the evolutionary design of milk specifically for the preterm 
infant, is debatable (Jensen 1999).
In contrast, Ronnenberg and Skara (1992) found that preterm colostrum had lower 
saturated fatty acids and n-3 PUFA, but a higher n-6:n-3 ratio, than term colostrum. 
Luukkainen, Salo & Nikkari (1994) found that SFA and MUFA remained stable in 
both tern and preterm milks throughout the first six months of lactation. Preterm and 
term milks had similar levels of LA and aLA, which increased with lactation. While 
LCPUFA of C20-22 decreased in both groups between the first week and the first 
month of lactation, there were no further changes in the preterm levels. The LCPUFA 
of the tenn milks, however, continued to decrease until six months postpartum, giving 
rise to differences in the LCPUFA levels between preterm and term milks at the end of 
the six months of lactation.
5.2.4(k) Maternal Health and Disease
(i) Insulin Dependent Diabetes Mellitus
Several studies of the milk of mothers with insulin dependent diabetes mellitus 
(IDDM) show that although there is no difference in total milk lipid, there are
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differences in fatty acid compositions in the breast milk of women with IDDM 
(Jackson et al 1994). LCPUFA (in particular, DHGLA and AA) transiently increase in 
the breast milk of IDDM mothers within the first seven days of lactation, but then 
show a sustained decrease, to the extent that LCPUFA were lower in mature IDDM 
than control milk. The initial increase in LCPUFA can be explained by a delay in 
establishing lactation in IDDM mothers, but it is not clear whether the greater decrease 
in LCPUFA profile is caused by differences in maternal dietary essential fatty acid 
intake or altered fatty acid metabolism. These changes were not correlated with any 
parameters of IDDM such as severity, glycosylated haemoglobin, post-prandial 
glucose or insulin dosage. In contrast to the LCPUFA, the proportion of MCSFA 
(ClO-14) was similar in both groups until 14 days postpartum, with an elevation 
thereafter in the breast milk of IDDM mothers. However by controlling for gestational 
age, it has been suggested that the rise in MCSFA was due to the earlier deliveries of 
IDDM mothers, since MCSFA are also higher in preterm milk (Hamosh & Bitman
1992).
(ii) Cystic Fibrosis
In a comparison of breast milk samples firom mothers with cystic fibrosis with that of 
mothers without, total fat was slightly lower, compared to that from healthy controls, 
but within an acceptable range (Bitman et al 1987). The main differences noted were a 
decreased proportion of linoleic acid and AA, but an increased proportion of 16:2n-7, 
a-linolenic acid (18:3n-3), eicosadienoic acid (20:2n-6), adrenic acid (22:4n-6), DP A 
(22:5n-6) and clupanodonic acid (also DP A, 22:5n-3) in the breast milk of mothers 
with cystic fibrosis. It is not clear whether this is attributable to differences in maternal 
intake, maternal malabsorption or abnormal fatty acid metabolism (as higher levels of 
A6-desaturase enzymes are found in mothers with cystic fibrosis).
(Hi) Type 1 Hyperlipoproteinemia
Lipoprotein lipase (LPL) deficiency could putatively prevent transfer of dietary 
LCPUFA from maternal blood to milk, thus accounting for the increased MCSFA, and 
decreased total fat, LA and LCPUFA in the breast milk of mothers with type 1 
hyperlipoproteinemia (Berger et al 1983, Myher, Kuksis & Steiner 1984, Steiner, 
Myher & Kuksis 1985).
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(iv) Hypobetalipoproteinemia
Breast milk from a mother with this condition contained decreased total fat, EFA and 
LCPUFA, but increased short and medium chain fatty acids (Wang & Illingworth 
1987). Thus the lack of apolipoprotein B and hence chylomicrons and very low 
density lipoprotein (VLDL) that characterize hypobetalipoproteinemia, may prevent 
acquisition of LCPUFA from the circulation, resulting in a compensatory increase in 
mammary gland synthesis of saturated fatty acids.
(v) Infection
Systemic maternal infection does not affect the macro- or micronutrient content of 
breast milk (Zavaleta et al 1995). Localized breast infection may transiently decrease 
total fat content of milk (Ramadan, Salah & Eid 1972) , but volume and composition 
of milk from the unaffected breast is not compromised, with composition returning to 
normal once dysfunction has resolved (Prentice & Prentice 1984).
(vi) Atopy
Breast milk samples from mothers who do not have active atopic dermatitis but whose 
infants do, reflect previous studies of the plasma fatty acids of infants with atopic 
dermatitis (Businco et al 1993). Thus, SFA, MUFA, LA and aLA were all raised in 
the breast milk of mothers with atopic children. Conversely, the LCPUFA products 
(EPA, DP A, DHA for n-3, and DHGLA, AA, GLA for n-6) were all decreased. In 
addition, breast milk from mothers who themselves were atopic had lower relative 
amounts of n-6 fatty acids, particularly AA, when compared to non-atopic mothers 
(Thijs et al 2000). However, the ratio of LA to its LCPUFA was comparable 
regardless of mothers’ atopic status, and supplementation with borage oil, a source of 
LA and GLA, rapidly increased breast milk GLA and DHGLA but not AA in the milk 
of atopic mothers. This suggests that the putative defect in EFA metabolism, which 
has been implicated in the aetiology of atopy due to the potential consequences for 
prostaglandin, interleukin and immunoglobulin E (IgE) regulation, may indeed exist 
(Thijs e? a / 2000).
(vii) Exercise
Aerobic exercise by lactating women does not affect either the volume or composition 
of breast milk (Dewey et al 1994).
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5.3 RELATIONSHIP BETWEEN INFANT PUFA INTAKE AND 
DEVELOPMENT
There have been several attempts to define the relationship between dietary PUFA and 
development in the neonate. Such studies have compared breast with formula fed 
infants and/or supplemented with standard formulae. However, studies have differed 
according to whether they have involved preterm or term neonates, the age at which 
the neonates were studied, and the functional outcome measured. With regards to 
visual development, both acuity (Carlson et al 1993b, Hofftnan et al 1993, Makrides et 
al 2000b) and attention (Carlson & Workman 1996, Workman & Carlson 1996) have 
been assessed. Other indices of neonatal development have included growth (Carlson 
et al 1992 & 1993a, Makrides et al 1999, Martinez et al 1999), developmental quotient 
(DQ) (Agostoni et al 1996 & 1997), Bayley scales of mental and/or psychomotor 
development (Birch et al 2000, Makrides et al 2000b, Scott et al 1998), vocabulary 
(Scott et al 1998), auditory and nerve physiology (Bougie et al 1999), and problem 
solving (Willatfs et al 1998a & b).
Few studies have detected differences in developmental outcome between infants fed 
breast milk, supplemented formulae or standard formulae. In those that have reported 
a difference in development, optimal outcomes were associated with breast milk and 
supplemented formulae, particularly in preterm neonates. However, these studies were 
often incomparable in terms of both the experimental formulae provided and the 
indices of development measured (Gibson & Makrides 1998 & 2000b, Makrides, 
Neumann & Gibson 1996b). This has led to much debate regarding the conflicting 
results (Gibson & Makrides 1999a, Heird, Prager & Anderson 1997, Jorgensen, 
Lauritzen & Fleischer-Michaelsen 1999). Indeed, this topic has been critically 
reviewed many times (Carlson 1999, Carlson & Neuringer 1999, Femstorm 1999, 
Gibson & Makrides 1999b, Jacobson 1999, Lauritzen et al 2001, Neuringer 2000, 
SanGiovanni et al 2000a, Uauy et al 1992, 1994 & 1996, Wainwright 1992, Xiang & 
Zetterstrdm 1999), underlining the uncertainty of the published findings.
Statistical considerations (Gore 1999), sample size (Morley 1998) and the differences 
in statistical power of such studies (Tolley and Carlson 2000) have led to the 
recognition of meta-analysis as the most appropriate method of elucidating a
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relationship between diet and development. Both visual (SanGiovanni et al 2000b) 
and cognitive development (Anderson, Johnstone & Remley 1999) have been the 
subject of separate published meta-analyses. Systematic reviews and meta-analyses by 
the Cochrane Collaboration have been undertaken to assess the benefit of 
supplementing infant formulae to both preterm (Simmer 2001a) and term (Simmer 
2001b) neonates. Both Cochrane reviews concluded that supplementation was safe; 
although supplementation may increase early visual maturation in preterm neonates 
(Simmer 2001a), no long term benefit to vision, growth or cognitive development were 
evident in either preterm (Simmer 2001a) or term (Simmer 2001b) neonates. 
Supplementation of infant formula does, however, remain at the forefront of nutritional 
debate (Heird 1999, Koletzko & Sinclair 1999) and has been comprehensively 
reviewed elsewhere (Forsyth 1998).
It should be noted that many studies of infant and child development compare the 
developmental indices of dietary groups without including any biochemical indices of 
fatty acid status. In addition, previous studies have considered the relationship 
between postnatal diet and development; development in relation to fetal nutrition and 
has not been assessed. The inter-dependency of maternal and fetal nutrition, and hence 
the effect of maternal supplementation during pregnancy, has therefore not been 
addressed when considering infant development, although there is evidence to suggest 
that maternal ante-natal nutrition influences later visual development (Williams et al 
2001).
5.4 PERSPECTIVE AND CONCLUDING REMARKS
The contribution of maternal diet to maternal status and the subsequent impact of 
maternal status on that of the fetus is unquestionable. That adequate accumulation of 
EFA and LCPUFA in utero is necessary for the development of fetal tissues is 
obvious. Postnatal changes in neonatal circulating PUFA levels are determined by 
status at birth and by postnatal diet in both term (Guesnet et al 1999) and preterm 
(Foreman-van Drongelen et al 1995c) infants. The relationship between breast milk 
PUFA composition and brain growth (Xiang et al 2000), and the inadequacy of 
weaning foods as sources of LCPUFA (Jackson & Gibson 1989) highlight the 
importance of breast milk as the postnatal source of LCPUFA.
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The inter-dependency of maternal and fetal nutrition is thus cause to examine the 
possibility that manipulation of maternal diet will enhance both maternal and infant 
PUFA status and provide a means by which to optimise infant development.
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Chapter 6
Study Design
6.1. AIMS
The study was designed to provide information that would help to define 
recommended PUFA intakes and/or supplementation programmes aimed at optimising 
maternal and fetal DHA status.
6.2 HYPOTHESES
The study aimed to test the hypotheses that supplementation of pregnant mothers with 
DHA:
(1) increases maternal blood, placental tissue, umbilical cord tissue and breast milk 
DHA,
(2) increases fetal blood DHA,
(3) improves neonatal and infant visual development.
6.3 STUDY DESIGN
A randomized, double-blind, placebo-controlled trial was undertaken, in which 100 
pregnant women, including 25% expected to undergo caesarean sections, were 
enrolled at 15 weeks gestation. At this time a (baseline) blood sample was obtained 
and the women randomized to receive either a fish oil supplement (rich in DHA) or a 
high oleic acid sunflower oil placebo (50 in each treatment group) (Table 18).
The mothers were asked to continue the supplements until delivery, and further blood 
samples were obtained from them at 28 weeks gestation and delivery. Samples of 
umbilical cord blood, cord tissue and placenta were also obtained at delivery. Prior to 
discharge home, breast milk samples were obtained from breast-feeding mothers.
It had been hoped to obtain maternal adipose tissue in the event of caesarean section. 
However, the adipose tissue samples obtained were too few in number and insufficient 
in size to allow satisfactory analysis.
The study thereafter monitored neonatal and infant visual development, using visual 
evoked potentials (VEP) and electroretinograms (ERG), at birth, two and six months. 
At subsequent post-partum visits at 2 and 6 months, additional samples of maternal 
blood, maternal breast milk, and maternal and infant buccal cells were obtained. The 
postnatal part of the study is not part of this dissertation.
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Age o f  fetus/infant 15 wk 28 wk Birth^ 2 mo 6 mo
Fatty acid fish oil capsules
Supplements ........placebo capsules...............
B lood Samples O O O D O O
Placenta & Cord •
Breast M ilk O O O
Buccal Cells O D O D o n
VEP □ □ □
ERG □ □ □
Table 18. Summary of study protocol.
6.4 SAMPLE SIZE CALCULATION
The DHA status of non-pregnant and unsupplemented women within the Glasgow 
population was found to be generally low and with little variation. In 136 non­
pregnant women, mean RBC DHA was 4.57% TFA (SD 0.82) (Berry et al 2001). 
Assuming the same range of values at 15 week gestation, we hypothesised that 
supplementation of mothers would increase maternal DHA status by 20% of baseline 
(approximately ISD), from mean 4.57% TFA to 5.48% TFA.
To detect such a ISD difference between the two study groups, with significance level 
(p) of 0.05 and power of 90%, the following calculation was performed (du V Florey
1993):
take a  (significance level) as 0.05
take p as 0.1 or 10% (power = 100-^=90%)
take s (standard deviation) as 0.82
take d (difference of interest, equal here to ISD) as 0.82
If n= 2(multiplier of a  + multiplier of P)^s^/d
= 2(1.96+ 1.28)^0.82^/0.82^
= 2(10.4976)0.6724/0.6724
= 20.9952 X 0.6724 
0.6724
= 20.9952
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Thus, to detect a ISD difference in RBC DHA as % TFA, the number required in each 
group at the final end-point of the study (6 months postpartum) was 21.
Assuming a 20% ‘drop-ouf rate between the time points of 15 weeks, 28 weeks, term, 
2 and 6 months (Shepherd 1998), the following calculation was used to determine the 
initial number required:
15 weeks 100 - 20% = 80
28 weeks 80 - 20% = 64
Birth 64 - 20% = 51
2 months 51 - 20% = 41
6 months 41 -r 2 = 20.5
Thus, by recruiting a total of 100 participants at 15 weeks, in each group by 6 months 
n=21.
6.5 RANDOMIZATION
Randomization of participants to receive either fish oil or placebo capsules was 
achieved by using a table of random numbers (Table 5.4 from Pocock 1983). The 
table lists permuted blocks of numbers 0 to 19; numbers 10 to 19 were ignored, to 
allow randomization in blocks of ten, based on numbers 0 to 9. An arbitrary starting 
point within the table was identified, and random rows of numbers were used. The 
required sample size of 100 was divide into blocks of 10, and the random numbers 
were assigned to each block of ten. A member of departmental staff external to the 
study assigned treatments on the basis of the random odd or even numbers. Thus, an 
equal number in each treatment group were obtained per block of ten participants 
recruited, and treatments were assigned on the basis of random number rather than 
sequence of recruitment. The randomization code remained unknown throughout the 
study, until after the samples were collected and analysed.
6.6 SUPPLEMENTS
A previous study of non-pregnant women in the Glasgow area revealed that 30% did 
not consume any fish (Berry et al 2001). Of those who did consume fish, the usual 
intake would be one portion per week, with the most common types consumed being
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haddock, cod or canned tuna, all of which contain only 0.1 or 0.2g DHA per lOOg of 
food. Considering that an average portion (MAFF 1993) of cod or haddock is 120g, 
which would provide 0.24g DHA, and that the average 45-lOOg portion of canned 
tuna would provide approximately 0.1 g DHA, current DHA intakes in our study 
population were expected to be low. The total n-3 PUFA from such dietary sources of 
fish would however approximate to O.lg/day, equivalent to the average British adult 
intake of n-3 from fish. Adherence to the recommended intake of one portion of oily 
fish per week, or supplementation with an equivalent amount of DHA, would 
therefore at least double the amount of DHA consumed in the study population.
It appeared prudent that, rather than providing an unfeasibly high mega-dose of fish 
oil/DHA which could be obtained only from consumption of a large number of 
capsules, the dose provided should be similar to the recommended intake, which can 
normally be achieved through dietary sources alone without additional 
supplementation. Thus supplementation by an amount of DHA which could be 
obtained on consuming one portion of oily fish per week, or a portion of white fish or 
tuna several times per week, would allow examination of both biochemical and 
developmental responses to the recommended intake. Hence the rationale on which 
the dietary n-3 recommendations for the study population of expectant mothers and 
their infants are based could be considered.
The dose of DHA chosen for supplementation was 200mg per day, an amount 
previously used in supplementation studies (Makrides et al 1996a). Such an amount 
would at least double the average intake in the study population while providing an 
amount of DHA obtainable fi'om consumption of fish, including white fish, and 
fulfilling the DoH recommendations for n-3 LCPUFA intake of 0.2g/day. The fish oil 
used to obtain this dose was a blended fish oil, Marinol D40, which typically provided 
lOOmg DHA in 323mg of oil per capsule and contained 40% of its fatty acids as DHA 
(Table 19). Participants consumed two capsules per day. The amount of EPA per 
capsule (approximately 20mg) was not sufficient to have any pharmacological effect 
on bleeding time or platelet aggregation (DoH 1994).
The placebo could not contain DHA, EPA, aLA or any other n-3 PUFA which could 
be converted to DHA. It was also advisable to have low levels of n-6 fatty acids in the
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placebo, in order to avoid inducing competition for metabolism between 
supplementary n-6 and dietary n-3 fatty acids in the placebo group. The placebo used 
therefore contained sunflower oil with high levels of oleic acid and no significant 
amounts of LCPUFA (high oleic sunflower oil, 323mg) (Table 19). Participants 
consumed two capsules per day, the same number of capsules as those receiving fish 
oil supplements.
Due to the teratogenic effects of high concentrations of vitamin A, the antioxidant 
used for capsule stability was vitamin E. The presence of gelatine in the capsule shell 
material was unavoidable, and may have precluded some vegetarian and ethnic 
mothers in the study population from participating.
Both fish oil and placebo capsules were donated by R.P. Scherer Limited (Swindon, 
U.K.). Capsule composition was certified by the manufacturer and also analysed by 
GC-MS using the same methodology as for sample analysis (see Chapter 8 Materials 
and Methods) (Table 19). The shells of the both the active and placebo capsules were 
composed of the same material and composition, and weighed approximately 159mg. 
The capsules were identical in appearance and could not be distinguished on the basis 
of odour, etc. Study participants reported no side effects, such as reflux or after-taste, 
after capsule consumption.
I l l
Marinol D40 Active Supplement HOSF Placebo
Fatty Acid (%TFA) Manufacturer’s Data GC-MS Manufacturer’s Data GC-MS
C14;0 3.7 5.1 0.0
€16:0 6.7 10.3 4 5.2
C16:ln-7 4.3 4.3 0.2
€18:0 2.4 3.0 5 4.7
€18:ln-9 15.6 10.4 81 77.6
€18:2n-6 1.2 1.6 7.2 11.2
€18:3n-3 0.8 0.7 0.5
€18:4 1.4
€20:0 0.1 0.2 0.3
€20:1 2
€20:5n-3 7.2 0.0
€22:1 2.7
€22:5n-6 4.1 0.6 0.0
€22:6n-3 40.4 56.9 0.0
Sum of Above 92.6 93.3 97.2 99.8
Others 9.4 6.72 3 1.22
Total 102.0 100.0 100.2 101.0
Table 19. Composition of active supplement and placebo capsules, according to 
certification by the manufacturer and analysis by GC-MS, Marinol D40 -  fish oil 
capsule; HOSF -  high oleic sunflower oil.
6.7 INCLUSION AND EXCLUSION CRITERIA
Mothers who were expected to deliver their babies at term, including 25% by 
caesarean section, and planned to feed their babies on breast and/or formula milk were 
eligible to participate in the study. Mothers with diabetes, twin pregnancies, pre- 
eclampsic toxaemia (PET), a past history of abruption or postpartum haemorrhage 
(PPH), allergy to fish products, a thrombophilic tendency or who were receiving drugs 
that affect thrombocyte function (non-steroidal anti-inflammatory drugs/NSAID e.g. 
aspirin, ibuprofen) were excluded from the study. Samples collected at delivery fi'om 
pregnancies that concluded prematurely before 36 weeks, or in which the neonate had 
an Apgar score of less than 7 at 10 minutes, weight below the 3"^  ^ centile for 
gestational age, visual, medical or developmental problems were not included in the 
final analysis of results.
6.8 ETHICAL APPROVAL
Prior to commencement of the study, approval was obtained from both Glasgow 
University Ethics Committee and Yorkhill Research Ethics Committee.
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6.9 STUDY IDENTIFICATION
In order to make the study identifiable to both hospital staff and participants amongst 
the many concurrent studies within the hospital, the study was given a distinct 
identity. The study was known as the FOMI study (FOMI -  Fish Oils for Mothers and 
Infants), and could be identified by its distinctive logo used on all letter headings, 
leaflets and posters.
6.10 MEDICAL AND NURSING STAFF
Hospital staff involved in the care of the study population, including consultant 
obstetricians, antenatal clinic midwives and administrative staff, labour suite and 
postnatal ward staff were advised of the study. It was particularly necessary to base 
with staff to facilitate efficient enrolment with minimum disruption to the clinic 
routine, and to ensure that the required samples were obtained at the time of delivery.
6.11 STUDY PARTICIPATION
Leaflets (Appendix 1 Introductory Leaflet) introducing the study were distributed to 
all mothers enrolling (booking) at approximately 10 weeks gestation at the antenatal 
clinic of the Queen Mother’s Maternity Hospital, Glasgow, Scotland. Posters 
advertising the study were also displayed in the clinic area. The next routine visit to 
the antenatal clinic was generally scheduled for 28 weeks gestation, but 75% of 
mothers attended at approximately 15 weeks gestation for an a-fetoprotein (AFP) 
screening test.
At their AFP appointment, suitable participants were identified from their medical 
case notes and were invited to participate in the study. At this time, the study was 
explained in full detail; if a mother indicated her desire to participate, informed 
consent was obtained (Appendix 2 Consent Form). The participant was provided with 
a bottle of capsules, randomized according to enrolment order, and a leaflet with 
advice on capsule consumption (Appendix 3 Advice Leaflet). The medical case notes 
of the participant were labelled and details of the study added (Appendix 4 Case Note 
Consent). A sample of blood was obtained when the participant underwent 
venepuncture for her AFP test.
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After enrolment a letter was sent to the participant acknowledging her involvement. 
Both the hospital consultant and GP of the participant were notified of her 
participation. Prior to her 28 weeks clinic appointment, the participant was contacted 
by telephone. If wishing to withdraw from the study, the participant was sent a letter, 
her consultant and GP notified, and her medical case notes amended. If the participant 
was continuing in the study, it was arranged that she would be seen at either the 
hospital clinic or her GP surgery to assess her compliance and diet, and to provide her 
with a second bottle of capsules. The required blood sample was obtained at the time 
of routine venepuncture.
Before her estimated delivery date (EDD), the participant was telephoned to determine 
her compliance with capsule consumption and her wish to continue or withdraw from 
the study. Samples were obtained at delivery in labour suite. Mother and baby were 
subsequently visited in the postnatal wards prior to discharge home, and details 
regarding the baby obtained from medical notes and mother.
The participants received no financial incentives to participate or continue in the 
study, although gifts were given to each infant at 2 and 6 months and travelling 
expenses for the postpartum visits were provided.
6.12 DIET AND LIVING HABITS OF PARTICIPANTS
Details regarding the participant’s dietary intake of fish, smoking and exercise 
patterns, and alcohol consumption were collected using a questionnaire (Appendix 5). 
Although the application of food frequency questionnaires in assessing long-term diet 
and overall eating patterns is complex (Hu et al 1999, Tseng 1999, Willett et al 1985, 
Willett et al 1988), they are useful in ranking individuals (Schaefer & Augustin 2000). 
The information required for this study i.e. type, amount and overall frequency of fish 
consumption, was easily and best attainable by this method (Hjartâker, Lund & Bjerve
1997). Quantification of the portion size of fish consumed was achieved using 
appropriate material from the Food Atlas (Nelson, Atkinson & Meyer 1997).
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6.13 ACKNOWLEDGEMENT OF STUDY PARTICIPANTS AND HOSPITAL 
STAFF
Women taking part in the study did so of their own volition, and at a time of particular 
importance to them. It is important to acknowledge that for many women, pregnancy 
may not be regarded as an easy time to participate in clinical studies (Mohanna & 
Tunna 1999). It is therefore appropriate that the mothers who consented to consuming 
the study capsules and allowing sample collection are referred to not as subjects, but 
as participants, in the fullest sense of the word (Boynton 1998, Chalmers 1999, 
Jackson 1999).
The participants have understandably expressed their interest in the findings of the 
study, and will be informed of the conclusions as promptly as possible. The results of 
the study will also be disseminated to all the medical and nursing departments aware 
of and of assistance to the study.
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Chapter 7
Study Participants
7.1 ENROLMENT
100 women were invited to take part in the study when attending the ante-natal clinic 
for an elective AFP test at approximately 15 weeks gestation (mean 15+4 weeks/109 
days, SD 3 days, range 14+6/104 days to 17+0/119 days, Table 20). This time point 
was chosen to allow supplementation during the second and third trimesters, and also 
because it was the most convenient of the mothers’ clinic visits.
15 weeks 28 weeks Delivery
Fish Oil 
Group
Placebo
Group
Fish Oil 
Group
Placebo
Group
Fish Oil 
Group
Placebo
Group
n 50 50 33 36 31 31
Mean 110(15+5) 109 (15+4) 199 (28+3) 198 (28+2) 280 (40+0) 281 (40+1)
SD 4 2 5 4 10(1+3) 9 (1+2)
Min 104 (14+6) 105 (15+0) 190 (27+1) 183 (26+1) 254 (36+2) 256 (36+4)
Max 119(17+0) 115(16+2) 217(31+0) 209 (29+6) 295 (42+1) 292 (41+5)
Median 110(15+5) 109(15+4) 198 (28+2) 198 (28+2) 281 (40+1) 281 (40+5)
Mode 109 (15+4) 109(15+4) 195 (27+6) 200 (28+4) 285 (40+5) 287 (41+0)
Table 20. Time of antenatal sampling and delivery in days (weeks + days) after 
conception for all those enrolled who continued to take part in the study.
7.2 WITHDRAWALS AND EXCLUSIONS
Of the 100 original participants, 29 withdrew from the study before their next routine 
ante-natal clinic appointment (Table 21) at approximately 28 weeks gestation (mean 
28+2 weeks/198 days, SD 5 days, range 26+1/183 days to 31+0/217 days, Table 20). 
A further seven participants withdrew between 28 weeks gestation and birth, and two 
infants in the placebo group were excluded following delivery (Table 21): one was 
delivered prematurely (34+5 weeks/243 days) and one was below the 3"^  ^ centile for 
weight for gestational age (0.57* centile).
Number of Participants Number Withdrawn Exclusions
Gestation Whole
Study
Sample
Fish Oil 
Group
Placebo
Group
Whole
Study
Sample
Fish Oil 
Group
Placebo
Group
Whole
Study
Sample
Fish Oil 
Group
Placebo
Group
15 weeks 100 50 50 0 0 0
28 weeks 71 35 36 29 15 14 0 0 0
Birth 62 31 31 7 4 3 2 0 2
Table 21. Numbers and withdrawal rates in study sample and treatment groups.
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7.3 MATERNAL CHARACTERISTICS
On enrolment, information on previous obstetric history was recorded, and parity 
defined as one or more pregnancies, regardless of outcome. 42 women were 
nulliparous; of the 58 parous women, the mean time-period between their last previous 
pregnancy and the current (study) pregnancy was 3.45 years (SD 3.1, range 0.5 to 11 
years. Table 22). All pregnancies were singleton and 13 participants were expected to 
deliver by caesarean section. There were no significant differences between fish oil 
and placebo groups in terms of numbers of parous women (chi-square 1.478, p>0.2), 
mean number of years between previous and current pregnancies (t-test, p=0.2), or 
expected delivery mode (chi-square 0.796, p>0.2) (Table 23).
Whole Study 
Sample
Fish Oil Group Placebo Group
Nulliparous 42 18 24
Parous 58 32 26
Interval between last and current 3.5 (2.9) 3.9 (3.2) 2.9 (2.5)
pregnancies (Years, mean (SD)) (n=50) (n=27) (n=23)
Table 22. Obstetric history of whole study sample and both treatment groups. Parity
was defined as one or more pregnancies, regardless of duration or outcome.
Whole Study Fish Oil Placebo
Sample Group Group
Expected Delivery Mode (n=100) 
SVD 87 (87%) 45 (90%) 42 (84%)
Caesarean section 13 (13%) 5 (5%) 8(16%)
Actual Labour (n=62, 31 in each group) 
Spontaneous 49 (79%) 24 (77%) 25 (81%)
Induced 13 (21%) 7 (23%) 6 (19%)
Actual Delivery Mode (n=62, 31 in each group) 
SVD 35 (56%) 19(61%) 16 (52%)
Assisted 11(18%) 3 (10%) 8 (26%)
Caesarean section 16 (26%) 9 (29%) 7 (22%)
Table 23. Expected and actual modes of delivery for the study participants. Absolute 
numbers and percentages are shown. SVD - spontaneous vaginal delivery. Assisted 
delivery describes the use of forceps (low- or mid-cavity, rotational) or ventouse 
extraction.
The height and weight of participants were recorded from their medical notes. The 
height and weight of all mothers attending the antenatal clinic were recorded at the 
time of initial clinic booking, at approximately 10 weeks gestation. Because data on 
participants’ pre-pregnancy weight relied on their own self-report, the weight recorded 
by nursing staff at time of booking was recorded. There were no significant
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differences in maternal height (t-test, p=0.36) or weight (t-test, p=0.98) between fish 
oil and placebo groups (Table 24).
Height (m) Weight at Booking (kg)
Whole
Study
Sample
(n=100)
Fish Oil 
Group 
(n=50)
Placebo
Group
(n=50)
Whole
Study
Sample
(n=100)
Fish Oil 
Group 
(n=50)
Placebo
Group
(n=50)
Mean 1.66 1.65 1.66 68.12 68.16 68.09
SD 0.07 0.08 0.06 11.64 12.55 10.79
Min 1.51 1.51 1.52 44.70 44.70 52.00
Max 1.85 1.85 1.77 103.40 103.40 99.50
Median 1.67 1.66 1.67 66.35 66.35 66.35
Mode 1.67 1.63 1.67 58.00 58.00 62.20
Table 24. Heights and weights of study participants, as recorded by nursing staff at 
time of booking (approx. 10 weeks gestation).
7.4 FISH INTAKE, ALCOHOL AND SMOKING
Participants completed a detailed questionnaire (Appendix 5) regarding diet, exercise, 
smoking and alcohol intake. Qualitative dietary information regarding types of fish, 
cooking oil and spreading fats was collected using a food frequency questionnaire, 
with quantitative data regarding portion sizes collected using appropriate material from 
the Food Atlas (Nelson et al 1997). Frequency and type of fish consumed was also 
assessed at 28 weeks gestation and delivery (Table 25). At each time point, 
participants were asked to report any fish consumed within the 24-36 hours prior to 
sample collection. There were no significant differences in frequency of fish intake at 
15 weeks (chi-square 0.077, p>0.2), 28 weeks (chi-square 1.066, p>0.2) or delivery 
(chi-square 1.939, p>0.2) between fish oil and placebo groups.
1 1 8
Gestation 15 weeks 28 weeks Delivery
Frequency 
of Fish 
Intake
Whole
Study
Sample
(n=100)
Fish Oil 
Group 
(n=50)
Placebo
Group
(n=50)
Whole
Study
Sample
(n=71)
Fish Oil 
Group 
(n=35)
Placebo
Group
(n=36)
Whole
Study
Sample
(n=56)
Fish Oil 
Group 
(n=29)
Placebo
Group
(n=27)
Never 5 (5%) 2 (4%) 3 (6%) 1 (1%) 0 (0%) 1 (3%) 1 (2%) 0 (0%) 1 (4%)
<Once per 
week
43
(43%)
22
(44%)
21
(42%)
25
(35%)
14
(40%)
11
(31%)
18
(32%)
12
(41%)
6 (22%)
Once per 
week
27
(27%)
13
(26%)
14
(28%)
27
(38%)
14
(40%)
13
(36%)
13
(23%)
5 (17%) 8 (30%)
Twice or 
more per 
week
25
(25%)
13
(26%)
12
(24%)
18
(25%)
7 (20%) 11
(31%)
24
(43%)
12
(41%)
12
(44%)
Table 25. Frequency of fish consumption, in the whole study sample and in the 
randomized treatment groups, during gestation and at time of delivery. Absolute 
numbers and percentages are shown.
Although quantitative information regarding exercise, alcohol and smoking was 
collected, for the purposes of statistical analysis, this information was categorised into 
Yes/No (Table 26). There were no significant differences in the numbers of alcohol 
consumers (chi-square 0.045, p>0.2), smokers (chi-square 0.065, p>0.2) or those 
undertaking exercise (chi-square 0.364, p>0.2) between fish oil and placebo groups.
Alcohol Smoking Exercise
Whole Fish Oil Placebo Whole Fish Oil Placebo Whole Fish Oil Placebo
Study
Sample
(n=100)
Group
(n=50)
Group
(n=50)
Study
Sample
(n=100)
Group
(n=50)
Group
(n=50)
Study
Sample
(n=100)
Group
(n=50)
Group
(n=50)
No 67 34 33 81 40 41 45 21 24
Yes 33 16 17 19 10 9 55 29 26
Table 26. Lifestyle characteristics of study participants. Alcohol consumption during 
pregnancy was defined as 0 units per week - no, 0.5 or more units per week - yes; 
smoking during pregnancy was defined as 0 cigarettes per day - no, 1 or more 
cigarettes per day - yes; exercise was defined as 0 hours per week - no, 0.5 or more 
hours per week - yes.
Participants were also asked to record any other dietary supplements taken at any time 
during gestation (Table 27). Information regarding the type of supplement consumed 
was recorded. However, since quantitative data regarding fi-equency of supplement 
consumption relied on the participants’ self-report, supplement consumption was
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categorised depending on type, regardless of dosage and frequency. There were no 
significant differences between fish oil and placebo groups in the numbers of those 
consuming other supplements (chi-square 0.065, p=0.799).
Whole Study Sample 
(n=100)
Fish Oil Group 
(n=50)
Placebo Group 
(n=50)
None 81 41 40
Vitamin/ Herbal 15 7 8
Evening Primrose Oil 2 2 0
Fish GiF Cod Liver Oil 5 2 3
Table 27. Numbers in study sample consuming supplements other than those given in 
study. NB. One woman in the placebo group took both vitamin and other fish oil 
supplements, one woman in the fish oil group took both evening primrose oil and 
herbal supplements, and one woman in the fish oil group took both evening primrose 
oil and cod liver oil supplements.
7.5 SOCIO-ECONOMIC STATUS
Socio-economic status was measured using the Carstairs score (Carstairs and Morris, 
1990) (Table 28). This score is based on Scottish residential postcodes and categorises 
the deprivation of areas based on four standard census variables believed to represent 
material disadvantage -  male unemployment, no car, overcrowded housing and low 
social class (class IV or V, semi- or unskilled occupation). A Z-score is available for 
each postcode sector area, and these values can be ranked into Deprivation Categories 
(DEPCAT) on a scale of 1 to 7, with 1 the most affluent and comparable to social class 
I, and 7 the most deprived, comparable to social class V.
The Carstairs score and deprivation categories used here are based on the 1991 census 
(Greater Glasgow Health Board). The distribution of DEPCAT scores within the study 
sample was not significantly different to that within Glasgow (chi-square 12.137, 
p=0.06), therefore the study sample can be considered as representative of the socio­
economic status of the population of Glasgow. Fish oil and placebo groups were not 
significantly different (chi-square 1.796, p>0.2) when DEPCAT scores were 
considered in categories of affluent (DEPCAT 1 and 2), middle (DEPCAT 3 and 4) 
and deprived (DEPCAT 5, 6 and 7).
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DEPCAT
Score
Glasgow Postcode 
Sectors with 
DEPCAT Score 
(n=151)
Whole Study 
Sample (n=100)
Fish Oil Group 
(n=50)
Placebo Group 
(n=50)
1 14 (9%) 14 (14%) 6(12%) 8(16%)
2 14 (9%) 18 (18%) 7(14%) 11 (22%)
3 13 (9%) 8 (8%) 3 (6%) 5 (10%)
4 21 (14%) 20 (20%) 13 (26%) 7(14%)
5 11 (7%) 4 (4%) 3 (6%) 1 (2%)
6 35 (23%) 21 (21%) 10(20%) 11 (22%)
7 43 (29%) 15 (15%) 8 (16%) 7 (14%)
Table 28. Socio-economic status of study sample. DEPCAT Score 1 - most affluent, 7 
- least affluent.
7.6 COMPLIANCE WITH CAPSULE CONSUMPTION
At 15 and 28 weeks gestation, participants were given a bottle containing 200 
capsules. Compliance in consumption of study capsules was assessed by asking 
participants to return these bottles at the following study time-point (28 weeks 
gestation and delivery, respectively). The number of capsules and time period over 
which they were consumed were determined, indicating the dosage obtained (Cleland 
et al 1992).
7.7 DELIVERY
Of the 62 women remaining in the study at the time of delivery, 13 (21%) underwent 
inducement of labour. In total, 35 (56%) delivered by SVD, 11 (18%) had an assisted 
delivery, and 16 (26%) had a caesarean section (5 elective, 11 emergency) (Table 23). 
Mean gestation was 40 weeks/280 days (SD 1+2 weeks/9 days, range 36+2 weeks/254 
days to 42+1 weeks/295 days. Table 20). There were no significant differences in 
gestational length (t-test, p=0.8), type of labour (chi-square 0.097, p>0.2) or actual 
delivery mode (chi-square 2.78, p>0.2) between fish oil and placebo groups.
7.8 INFANT CHARACTERISTICS
All infants had an Apgar score of 7 or more at ten minutes after birth. Five infants 
(three in fish oil group, two in placebo group) required phototherapy for neonatal 
jaundice; four infants (two in each treatment group) required additional non-urgent 
medical attention {e.g. antibiotics).
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There were no significant differences in the sexes of the infants (chi-square 1.042, 
p>0.2) or rate of breast-feeding between the fish oil and placebo groups (chi-square 
0.295, p>0.2) (Table 29).
Whole Study 
Sample (n=62)
Fish Oil Group 
(n=31)
Placebo Group 
(n=31)
Gender
Male 28 16 12
Female 34 15 19
Feeding
Exclusive Breast Milk 41 19 22
Exclusive Formula Milk 20 11 9
Breast + Formula Milk 1 1 0
Table 29. Characteristics of infants. Mode of feeding was recorded prior to discharge. 
N.B. The infant receiving both breast and formula milks received only 70ml of formula 
within the first 24 hours after delivery, then continued to be exclusively breast-fed. 
For the purposes of statistical analysis, this infant was considered as breast-fed.
7.9 INFANT ANTHROPOMETRY
Measurements of infant anthropometry (weight, length and occipital frontal 
circumference (OFC)), recorded within the first 24 hours following delivery, were 
obtained from medical case notes. For these indices, standard deviation scores (SDS) 
and centiles compared to British 1990 growth reference data were obtained using the 
British 1990 Growth Reference Programme (Child Growth Foundation, 1996). There 
were no significant differences in actual infant birth weight (t-test, p=0.22), length (t- 
test, p=0.12) or OFC (t-test, p=0.74) between fish oil and placebo groups (Table 30). 
There were no differences between groups in SDS for infant weight (t-test, p=0.17), 
length (t-test, p=0.089) or OFC (t-test, p=0.74) (Table 30).
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Weight (g) Length (cm) OFC (cm)
Whole
Study
Sample
(n=62)
Fish
Oil
Group
(n=31)
Placebo
Group
(n=31)
Whole
Study
Sample
(n=57)
Fish
Oil
Group
(n=27)
Placebo
Group
(n=30)
Whole
Study
Sample
(n=61)
Fish
Oil
Group
(n=30)
Placebo
Group
(n=31)
Measurement
Mean 3603 3529 3677 53 53 54 35 35 35
SD 473 531 403 2 3 2 1 1.4 1.5
Min 2800 2280 2760 47 47 49 31 31 31
Max 4550 4550 4370 58 58 57 38 . 38 38
Median 3600 3500 3700 53 53 54 35 35 35
Mode 3840 2850 3840 55 54 55 35 35 35
SDS
Mean 0.3 0.1 0.4 1.3 1.1 1.6 0.0 -0.1 0.1
SD 1.0 1.0 0.9 1.2 1.3 1.1 1.1 0.9 1.3
Min -1.9 -1.9 -1.7 -2.5 -2.5 -1.7 -2.8 -2.8 -2.5
Max 1.9 1.6 1.9 3.7 3.6 3.7 2.6 1.5 2.6
Median 0.3 0.2 0.4 1.4 1.2 1.7 0.1 0.1 0.2
Mode 1.2 2.8 2.9 0.31 -0.4
Centile
Min 3 3 4 0.6 0.6 5 0.3 0.3 0.6
Max 97 95 97 100 100 100 100 93 100
Table 30. Infant anthropometry, 
standard deviation score.
OFC " occipital frontal circumference; SDS -
7.10 BLOOD, TISSUE AND BREAST MILK SAMPLES
Antenatal maternal blood samples were collected at enrolment (n=97) and 28 weeks 
gestation (n=62) (Table 31). Maternal blood samples (n=59) were obtained within 
(mean) 20 hours of delivery (SD 31 hours, range 2 hours prior to delivery to 96 hours 
following delivery). 73% of maternal blood samples were obtained within 24 hours of 
delivery; 85% were obtained within 48 hours. Analytical problems occurred for three 
samples of maternal red blood cells (RBC), due to insufficient sample volume (less 
than 1ml RBC). These samples were obtained from separate individuals: (1) a mother 
in the fish oil group at 15 weeks gestation; (2) a mother in the fish oil group at delivery 
and (3) a mother in the placebo group at delivery. These RBC samples were excluded 
from the final statistical analyses; their corresponding plasma samples were of 
sufficient volume and were included in the analyses.
Placenta (n=53), umbilical cord tissue (n=53) and umbilical cord blood (n=56) were 
obtained within 2 hours of delivery. Breast milk samples (n=26) were obtained within 
1 to 7 days (mean 3, SD 1) following delivery: 85% of breast milk samples were 
obtained within the first 4 days following delivery.
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Those individuals from whom samples were obtained were representative of their 
treatment group and the whole study sample at each time point. There were no 
significant differences between fish oil and placebo groups in terms of time of 
maternal blood sample (t-test, p=0.35) or breast milk sample (t-test, p=0.14) following 
delivery.
Number of Samples % of Total Possible
Gestation Sample Whole
Study
Sample
Fish Oil 
Group
Placebo
Group
Whole
Study
Sample
Fish Oil 
Group
Placebo
Group
15 weeks Maternal RBC 96/100 47/50 49/50 96 94 98
Maternal plasma 97/100 48/50 49/50 97 96 98
28 weeks Maternal RBC 63/71 30/35 33/36 89 86 92
Maternal plasma 63/71 30/35 33/36 89 86 92
Birth Maternal RBC 57/62 29/31 28/31 92 94 90
Maternal plasma 59/62 30/31 29/31 97 97 94
Umbilical cord RBC 56/62 27/31 29/31 95 87 91
Umbilical cord plasma 56/62 27/31 29/31 95 87 91
Placenta tissue 53/62 26/31 27/31 86 87 85
Umbilical cord tissue 53/62 26/31 27/31 84 84 85
Adipose tissue 5/16 4/9 1/7 31 44 14
Breast milk 26/42 12/20 14/22 63 60 65
Table 31. Numbers of samples obtained at each time point from the whole study 
sample and in each group. Expressed as absolute numbers, and as a percentage of the 
number possible in each group. RBC - red blood cells.
124
Chapter 8
Materials and Methods
8.1 METHODS OF FATTY ACID ANALYSIS
8.1.1 Introduction
Some lipids are easily accessible for analysis, for example in samples of oils, which 
are by definition liquid at room temperature. In contrast, lipids in biological materials, 
such as human fluids and tissues, are constituents of heterogeneous samples, contained 
within cells and structures, amid proteins and organelles. Thus, it is necessary to 
separate and extract these integral lipids free from the non-lipid substances present in 
the tissue. The first stage in fatty acid analysis is therefore the extraction process, in 
which lipids are obtained with minimum contamination by other substances.
Unless the lipid is present in the tissue as a particular type {e.g. in breast milk and 
adipose tissue, lipid is present mainly in triacylglycerol form; in red blood cells/RBC 
phospholipids are the predominant lipid class), the extracted lipid will contain all types 
of lipid. Classes of lipid (triacylglycerols, non-esterified fatty acids, phospholipids) 
can be distinguished and separated from the mass of total lipids by various 
chromatographic methods, e.g. thin layer chromatography (TLC) or preparative high- 
performance liquid chromatography (HPLC).
Once the total or required class of lipids have been isolated, the fatty acids must be in a 
suitable form for analysis. Current methods of fatty acid analysis employ gas 
chromatography (GC) to separate, coupled with either a flame ionisation detector 
(FID) or a mass spectrometer (MS) to detect individual fatty acids. These methods 
require the fatty acids to be in the form of a volatile derivative, e.g. methyl esters (fatty 
acid methyl esters/FAME). Fatty acids must therefore undergo méthylation to produce 
their respective FAME. Since FAME are derived from fatty acids, the conversion of 
fatty acids to FAME is termed the derivatization procedure.
This chapter reviews the processes of lipid extraction, FAME derivatization, and 
subsequent analysis by GC-MS. The validation and details of the actual methodology 
used are described.
8.1.2 Lipid Extraction
The use of chloroform and methanol in lipid extraction is widely documented, and the 
nature and dynamics of their interaction well understood (Bligh & Dyer 1959). Folch
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et al (1951) originally developed a method of isolating lipids from brain tissue by 
homogenizing the tissue in a 2:1 chloroform:methanol (v/v) mixture, followed by 
purification of lipid matter free from non-lipid substances by water. Folch, Lees and 
Sloane Stanley (1957) later refined this technique with the addition of mineral salts to 
aid the removal of non-lipid contaminants without incurring loss of lipids. Fatty acids 
are of an amphipathic nature, having both a hydrophobic hydrocarbon chain and a 
hydrophilic carboxyl group (COOH) that dissociates at pH 4.5 (COO ). In long chain 
fatty acids, the hydrophobic element predominates, causing the fatty acids to be 
insoluble in water, a polar solvent. Chloroform and methanol are solvents that 
dissolve ionic or polar solutes. Fatty acids, including those of long chain length, are 
soluble in chloroform, while other cellular components are precipitated by methanol. 
The addition of chloroform and methanol to a biological sample extracts the lipids by 
the formation of a biphasic solution, consisting of an upper aqueous/methanol layer, 
and a lower layer of chloroform containing lipids. Upon removal of the top layer, 
addition of a salt solution aids removal of residual non-lipid contaminants, methanol 
and water, and encourages the polar lipids into the non-polar solvent phase. The 
solution again separates into layers, and a lower layer of chloroform containing lipids 
can be retrieved.
The method of Folch et al (1957) has been widely adopted and modified (Bligh & 
Dyer 1959, Dodge & Phillips 1967). Indeed, “a modified Folch extraction is now the 
method of choice when total lipids are needed” (Jensen 1989a). A modified Folch 
extraction consists of mixing the sample with chloroform: methanol (2:1, v/v), 
followed by centrifugation to separate the phases, with removal of the top layer, and 
washing the bottom layer with dilute aqueous salt solution to remove non-lipid 
components. The use of potassium chloride (KCl) at an appropriate concentration has 
been established (Folch et al 1957, Dodge & Phillips 1967). The inclusion of 
antioxidants within the solvents prevents fatty acid autooxidation, and aids the 
reproducibility of analyses (Dodge & Phillips 1967).
Once the chloroform/lipid layer has been obtained, the amount of lipid must be 
quantified, to facilitate analysis of a defined weight of lipid. This requires evaporation 
of the chloroform solvent in order to concentrate the lipid mass. Methods for the 
removal of the chloroform include the use of heat under a stream of nitrogen
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(containing less than 5mg/kg of oxygen) (International Union of Pure and Applied 
Chemistry 1977a), a vacuum centrifuge and a rotary vacuum evaporator (Dodge & 
Phillips 1967). The dry vyeight of the lipid can be calculated by performing the 
evaporation process in previously weighed glassware. The weight of lipid recovered is 
thus the difference between the initial weight of the empty vial, and the subsequent 
weight with the dried sample.
8.1.3 Derivatization
Polar groups, such as the COOH group of fatty acids, can only be applied directly to 
gas chromatography columns if they are volatile (C<14). In order to make long chain 
fatty acids volatile, the polar groups can be derivatized by means of méthylation, 
producing FAME that can be resolved by GC.
Several agents have been used for the méthylation of fatty acids, and their application 
in the derivatization of all lipid classes documented (Eder, Reichlmayr-Lais & 
Kirchgessner 1992). Most commonly, méthylation is catalysed by boron trifluoride- 
methanol, methanolic sulphuric or hydrochloric acid, and methanolic sodium 
methoxide. Boron trifluoride-methanol may have some limitations in the 
derivatization of certain phospholipids (Eder et al 1992), and may incur loss of short 
and medium chain fatty acids, as well as the production of artefacts (Kohn et al 1996). 
Sodium methoxide is efficient even at ambient temperature (Alexander & Justice Jr. 
1985, Eder et al 1992), but its use is limited when appreciable amounts of free fatty 
acids are present in the sample, such as in human breast milk (Kohn et al 1996).
Anhydrous methanolic hydrochloric acid (methanolic HCl, MeOH/HCl) is an 
established catalyst (International Union of Pure and Applied Chemistry 1977a) and 
has wide application in méthylation catalysis, provided conditions are suitably 
anhydrous to ensure the solubilization md estérification of even non-polar lipids such 
as triacylglycerols. The presence of an additional solvent aids solubilization of non­
polar lipids, facilitating estérification by methanolic HCl (Kohn et al 1996).
The relative levels of saturated. Cl 8 monounsaturated, and long chain PUFA appear to 
be stable regardless of the derivatization agent, and results obtained using the various 
agents should be comparable (Kohn et al 1996). However, the use of methanolic HCl
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when absolute quantification of fatty acids is required appears preferable (Kohn et al 
1996). Although methanolic hydrochloric acid and methanolic sulphuric acid are of 
similar efficacy (Eder et al 1992), the use of methanolic HCl has already been 
established in this laboratory (Farquharson et al 1996).
To facilitate estérification, temperature and time conditions must be appropriate. 
Several studies have investigated the optimal conditions; only sodium methoxide will 
efficiently esterify at room temperature, while boron trifluoride and methanolic HCl 
require heating. Heating is traditionally performed using heating blocks, although 
alternatives such as microwave oven irradiation (Jeyashoke, Krisnangkura & Chen
1998) may now be used.
8.1.4 Gas Chromatography
Once the fatty acids are in a suitable form for analysis, they must be separated into 
their distinct molecular species in order to be identified and quantified. 
Chromatography is a separation technique dating back to the ancient times of Pliny the 
Elder, and was developed in the 1940s through the work of 1952 Nobel Prize 
(Chemistry) Laureates A.J.P. Martin and R.L.M. Synge. It separates the compounds or 
analytes (in this case, fatty acids) in a solute (mixture of compounds to be separated) 
based upon their partition or distribution between two physically distinguishable 
phases. These phases are a mobile phase and a stationary phase, which provide a 
driving force and retardation effects respectively. The ratio of the concentration of the 
solute in the mobile phase to that in the stationary phase is called the partition 
coefficient. The analytes separate because their relative distribution between the two 
phases differ. The development and application of chromatography is widely covered 
by major biochemistry textbooks (Fowlis 1995, Freifelder 1982, Wilson 1994).
The stationary phase or sorbent may be in the form of a solid, gel or immobilized 
liquid held stationary by attachment to a solid support or matrix. When the stationary 
phase is contained within a tubular system {i.e. column), the type of chromatography is 
called column chromatography. The mobile phase may be in a liquid or gaseous form. 
In column chromatography, a mixture of the mobile phase and solute passes through 
the column.
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One form of column chromatography is gas chromatography. In gas chromatography, 
the stationary phase is either a solid or a liquid, and the mobile phase is a gas (carrier 
gas). In gas liquid chromatography (GLC), the column (usually glass) is packed with 
an inert support coated with a liquid phase (therefore it is also known as packed- 
column gas chromatography).
In capillary gas chromatography (GC), the column is usually made from fused silica, 
with the stationary phase bonded directly to the silica column (thus there is technically 
no support or liquid). The silica tube is thin {i.e. a capillary), with an external diameter 
of 0.2-0.8mm and an internal diameter (id) of 0.05-0.5mm (most commonly 0.25mm 
or 0.32mm id). The length of the capillary column ranges up to 100m, with 15-30m 
most typical. The outer surface of the column is protected with a coating material, 
usually polyimide. The stationary phase bonded to the inside of the capillary forms a 
film, the thickness of which (film thickness) affects the ratio of the stationary to 
mobile phases, and hence analyte separation. Film thickness varies from O.l-l.Opim. 
Thermally stable polymers in liquid or gel form are used as the stationary phase; the 
most common materials are polysiloxanes (non-polar) and polyethylene glycols 
(polar). Phases of varying polarity are available, with a polar phase required for 
FAME chromatography.
In comparison to GLC, GC offers greater resolution and increased sensitivity, creating 
the advantage of a higher degiee of precision, at a higher speed. In addition, the fused 
silica of GC columns is more robust than the glass of GLC columns.
In GC, the sample is injected as a solution of (volatile) analytes in (volatile) solvent. 
To allow the analytes to be present in the gas phase, they must be in a volatile state 
prior to injection, hence the requirement for long chain fatty acids to be in forms such 
as methyl esters (FAME). The carrier gas must be dry and free of oxygen, and is 
usually nitrogen, hydrogen or helium. On injection, the solute enters a chamber, which 
is heated independently from the column to ensure vaporisation, usually to 150-250°C, 
20-30°C greater than the maximum oven temperature. The injection system found on 
a capillary GC operates in split/splitless mode. In split mode, only part of the 
vaporised mixture of carrier gas and solute enters the column, with the remainder
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being diverted to waste via a valve (split valve). The ratio of the amount diverted to 
the amount entering the column is called the split ratio, and is typically 50:1 or 100:1. 
Thus, in split mode, a small but representative sample of the solute is chromatographed 
and analysed. In splitless mode, the split valve is closed to ensure that the entire 
sample enters the column; this achieves greater sensitivity.
Once the vaporised solute reaches the column, the analytes redistribute or partition 
between the gaseous mobile and the stationary phase according to the partition 
coefficient of their molecular species. The column is in a thermostatically controlled 
oven, as temperature influences analyte volatility. The initial oven temperature is 
usually below that of the injector, but rises at a pre-determined rate. The analytes all 
spend the same amount of time in the gaseous phase, but are retained for different 
lengths of time by the stationary phase. Each analyte is thus eluted at a different rate 
and has a characteristic retention time. As the analytes leave the column in order of 
their retention time, their presence is detected by a detector system which records each 
separate analyte as a peak on a chart or chromatogram (Figure 13).
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Analyte Data - Fatty acid methyl esters
1. C4:0 (Butiyic)
2. C6:0 (Caproic)
3. C8:0 (Caprylic)
4. C l0:0 (Capric)
5. 011:0 (Undecanoic)
6. 012:0 (Lauric)
7. 013:0 (Tridecanoic)
8. 014:0 (Myristic)
9. 014:1 (Myristoleic)
10. 015:0 (Pentadecanoic) 
11.015:1 fris-10-Pentadecenoic)
12. 016:0 (Palmitic)
13. 016:1 (Palmitoleic)
14. 017:0 (Heptadecanoic)
15. 017:1 (cis-10-Heptadecenoic)
16. 018:0 (Stearic)
17.018:ln9c (Oleic) 
18.018:ln9t (Elaidic)
19. 018:2n6c (Linoleic)
20. 018:2n6t (Linolelaidic)
21. 0 18:3n6 (g-Linolenic)
22. 018:3n3 fr-Linolenic)
23. 020:0 (Aiachidic)
24. 020: ln9 (cis-11-Eicosenoic)
25. 020:2 (cis-11,14-Eicosadienoic)
26. O20:3n6 (cis-8,11,14-Eicosatrienoic)
27. O20:3n3 (cis-1 l;14,17-Eicosatrienoic)
28. O20:4n6 (Arachidonic)
29. O20:5n3 (cis-5,8,11,14,17-Eicosapentaenoic)
30. 021:0 (Henicosanoic)
31. 022:0 (Behenic)
32. 022:ln9 (Erucic)
33. 022:2 (cis-13,16-Docosadienoic)
34. 022:6n3 (cis-4,7,10,13,16,19-Docosahexaenoic)
35. 023:0 (Tricosanoic)
36. 024:0 (Lignoceric)
37. 024:ln9 (Nervonic)
Figure 13. Typical chromatogram of fatty acid methyl esters obtained by GC. 
Obtained from Supelco at www.sigma-aldrich.com/saws.nsf/Su.pProducts. showing 
chromatogram of Supleco 37 Component Fame Mix.
In order to detect each peak as a specific analyte, several methods have been used, 
including flame ionisation detectors (FID), with identification based on retention time. 
The most conclusive method of identification is the mass spectrometer. Ions can be 
separated based on their mass/charge (M/Z) ratio, and the deflection of ions of equal 
velocity in a magnetic or electrostatic field depends on their mass. Bombarding the
131
analytes with an electron beam (ionisation source), allows the mass spectrometer to 
generate ions which can be separated by an analyser such as a quadrupole mass filter 
and detected by an electron multiplier. The relative amount of each ion can be 
measured, generating a spectrum based on mass (mass spectrum), which is 
characteristic of that compound and can be compared to known spectra, allowing 
conclusive identification of the analytes. A mass spectrometer is more sensitive than a 
flame ionisation detector, and also allows definitive identification of compounds when 
used in conjunction with a library of the spectra of known compounds or standards.
When using MS, the carrier gas in the GC must be helium. The eluted sample from a 
GC system can be directly channelled into the ionisation source of a mass spectrometer 
via a heated tube (transfer line). This combination of systems to separate and identify 
compounds is known as gas chromatography mass spectrometry (GC-MS), and allows 
concurrent compound identification as the chromatograph is being developed.
Once the analytes have been identified, they must be quantified. To do this, the 
chromatographic and identification data are transferred to computerised data systems 
or integrators. The area of the peak of each analyte on the chromatogram (peak area) 
is proportional to the amount of the given analyte, but proportionality is not constant 
and varies with each analyte (hence the need for accurate identification). 
Quantification can be relative or absolute, and both methods rely on peak area.
The most common method of relative quantification is to integrate all the peaks in a 
chromatogram, and to express each peak as a percentage of the total peak area.
% Analyte A = Peak area A x  100____________
%(Peak area A + Peak area B  )
Such results are expressed as area percentages: each analyte is expressed as an area 
percentage of total analytes. For fatty acid analysis, each fatty acid is thus expressed 
as a percentage of total fatty acids (% TFA). Since the amount of each analyte is 
therefore dependent on and relative to all the analytes included, the results will vary 
when different analytes are measured. Unless the same analytes are consistently
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analysed, it is difficult to compare relative results from different analyses or 
laboratories (Cabré et al 1992).
Absolute quantification requires initial calibration using varying and known amounts 
(concentrations) of an analyte, or mixture of analytes, in pure or reference form 
(standard) to produce several chromatograms with different peak sizes. A standard 
curve can then be constructed to relate amount/concentration to peak area. Such 
calibration data can be stored and used to determine the absolute amount from the peak 
area in the sample. The standard used for the calibration is physically separate from 
{i.e. an external standard) but similar to the sample, containing the types and 
concentrations of analytes believed to be in the sample. To ensure calibration best 
reflects day-to-day variation in the methodology, the external standard should be 
processed concurrently with the sample, thus an external standard is used to calibrate 
the quantification of each batch of samples analysed. The external standard should be 
analysed by GC-MS before the batch of samples, and then re-analysed after the 
samples to determine any changes in the system.
Peak area is, however, subject to variation in the preparation (in this case, extraction 
and derivatization) and chromatographic procedures. To overcome this, a known 
concentration of an analyte similar to, but of a different molecular species from, the 
analyte(s) in the sample is added to the sample, i.e. an internal standard. The internal 
standard is added either before the preparation process begins to ensure any loss of the 
standard is equal to loss of the analyte, or prior to analysis. The internal standard must 
also be present in the external standard, although not necessarily in the same 
concentration as it is added to the samples. This allows the ratio of the peak areas of 
the internal standard and/or analyte in the sample to be compared to the corresponding 
peaks in the calibration standard. In the external standard, the peak areas relate to 
known concentrations of the internal standard and each analyte. To account for 
differences in detector response, a calibration or response factor for each compound in 
the external standard is calculated as follows:
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Response factor for Analyte = Area Anaiyte in e s  Concentration is  in e s
X _______
Area is  in e s  Concentration Analyte in e s
(IS - internal standard, ES -  external standard)
The response factor (RF) can then be used in the calculation of absolute amount or 
concentration of each analyte in the sample:
Concentration of Analyte = Area Analyte in sample ^ Concentration is  in sample
A r e a  is  in sample R R  Analyte in ES
(IS -  internal standard, RF -  response factor, ES -  external standard)
8.2 VALIDATION OF METHODS
Validation of the methods used is an important component of laboratory technique. 
The methods used for the analysis of umbilical cord tissue have been validated and 
practised extensively (Cerolini et al 1996, Noble & Speake 1997, Speake et al 1999), 
The methods used for sample analysis undertaken at Yorkhill were validated as 
described in the following section.
8.2.1 Standards
From the published literature, the levels of fatty acids present in various human tissues 
were compared (Table 32). Non-esterified fatty acids (NEFA) in propanol were mixed 
together in concentrations similar to those found in human tissues. This produced a 
NEFA standard of known composition, for use in method validation and subsequent 
sample analysis as an external standard. Inclusion of a reference standard of 
“composition similar to that of the fatty matter to be analysed” in the analysis process 
is recommended (International Union of Pure and Applied Chemistry 1977b). NEFA 
15:0 and 17:0 were included in the standard for use as internal standards (International 
Union of Pure and Applied Chemistry 1977b). The external standard will be referred 
to as Standard H (Table 33).
All free fatty acids were obtained from Sigma-Aldrich (Dorset, U.K.).
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Tissue RBC
(non-
pregnant
women)*
Plasma
(non-
pregnant
women)*
Umbilical
cord
arterial
RBC^
Umbilical
cord
arterial
plasma^
Umbilical
cord
venous
plasma^’^ ’
4.5,6,7,
Umbilical
cord
artery
vessel
wall"'''"'"''
.7.8
Umbilical 
cord vein 
vessel
^all2.3.4.5.7 
.8
Placenta^ Breast
Milk^
Lipid Total Total PL PL PL PL PL PL Total
fraction lipids lipids lipids
Fatty Acid
10:0 0.77
12:0 1.1 6
14:0 0.2 3 0.8 8
15:0 0.7 0.7 0.27
16:0 28.9 25.3 26 18 20.5 21
16:ln-7 2.8 1.2 2.4 1.6 1.06
17:0 0.4 1.1 1.1
18:0 14.0 6.5 13 13.5 16 7
18:ln-9 17.6 22.3 11 15 11 35
18:2n-6 12.9 33.8 5.9 7.5 8 1.17 2.3 9.5 12
18:3n-3 0.5 0.9 0.9
18:3n-6 0.2 0.1 0.1
20:0 0.9 0.5 0.4
20:ln-9 0.2 0.9 0.6
20:2n-6 0.35 1.3 0.42
20:2n-9 0.6 1.1 0.6
20:3n-6 1.5 1.3 2.1 4.4 4.8 1.5 2.2 4.3
20:3n-9 0.6 0.9 1.0 3.1 0.9 0.2
20:4n-3 0.09 0.1
20:4n-6 15.6 1.4 14.0 18.6 15 12 16 21.1 0.7
20:5n-3 0.5 0.5 0.2 0.7 0.8 0.07 0.1 0.3
21:0 0.2 1.3 0.45
22:0 0.9 0.9 0.75
22:ln-9 0.3 0.3 0.3
22:3n-9 0.3 0.1 1.7 0.5
22:4n-6 2.4 4.0 1.9 1.2 2.5 4.5 1.6
22:5n-3 1.9 1.8 1.1 1.0 0.3 0.7 1.3
22:5n-6 0.2 1.4 1.4 1.5 3.2 2.6 1.0
22:6n-3 4.5 1.2 4.7 6.1 6 5 5.5 4.8 0.5
23:0 0.2 0.1
24:0 0.9 1.8 1.3
24:ln-9 2.0 4 3.5
24:2n-6 0.58 0.2
24:3n-3 0.1 0.2
Table 32. Relative fatty acid levels (% fatty acids) in various human tissues.
 ^Berry et al 2001 
^ Al et al I995h 
 ^Homstra et al 1992 
 ^van Houwelingen et al 1995 
 ^Auestad et al 1997
 ^Al et al 1990 
 ^Al et al 1995a 
 ^Reddy et al 199)
 ^Homstra et al 1989
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Fatty Acid
Fatty acid concentration 
(nmol) in Standard 
equivalent to Img lipid
% Total Fatty Acids 
excluding C15:0 and C17:0 
(including C15:0 and 
C17:0)
% Total Fatty Acids on 
Analysis (Mean)
C15:0 517 - (4.98)
C17:0 463 - (4.98)
C10:0 145 1.05(1.00) 0.65
C12:0 125 1.05(1.00) 1.02
C14:0 548 5.24 (4.98) 6.25
C16:0 1953 20.96(19.92) 21.98
C16:l 197 2.09(1.99) 2.46
C18:0 1320 15.72 G4.94) 21.09
C18:l 1773 20.96 G9.92) 20.75
C18:2 1339 15.72(14.94) 14.76
C18:3 90 1.05(1.00) 4.26
C20:0 80 1.05(1.00) 1.29
C20:3n-6 163 2.09(1.99) 0.64
C20:4n-6 82 5.24 (4.98) 1.03
C20:5n-3 83 1.05(1.00) 0.60
C22:4n-6 151 2.09(1.99) 0.88
C22:5n-3 30 0.42 (0.40) 0.22
C22:6n-3 305 4.19(3.98) 2.10
Table 33. Composition of non-esterified fatty acid standard prepared in the laboratory 
(Standard H).
8.2.2 Validation of Lipid Extraction Procedure
8.2.2(a) Sample Concentrating by Drying under Nitrogen
The use of nitrogen as a drying/sample concentrating agent was determined by 
comparing the drying of FAME of known composition under nitrogen at 45°C, to 
drying in a Heto vacuum centrifuge.
Values obtained for area % and concentration (nmole) were lower for the FAME 
samples dried in the vacuum centrifuge than for those dried under nitrogen. Volatile 
and polyunsaturated fatty acids, which generate smaller peak areas on GC-MS 
analysis, were most susceptible to loss when dried in the vacuum centrifuge.
Drying under nitrogen at 45°C was therefore considered an efficient method of sample 
concentrating, and incurred fewer losses than other available methods.
8.2.2(b) Extraction Yield Test
To determine the loss of fatty acids incurred during lipid extraction, i.e. extraction 
yield, samples which had undergone both extraction and derivatization procedures 
were compared to samples which were derivatized only.
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Replicates of a NEFA standard of known composition (Standard H), a triacylglycerol 
standard (tri-15), and two NEFA (C l5:0 and C l7:0) were either a) extracted and 
derivatized or b) derivatized only. Extraction yield was determined by expressing the 
mean value for peak area or concentration (nmole) for the appropriate fatty acids in the 
extracted/derivatized samples as a percentage of the corresponding values in the 
derivatized only samples.
The mean values for peak area of fatty acids in the extracted/derivatized samples were 
lower than those in the samples derivatized only (mean extraction yield 53%, range 27- 
79%). Extraction yields were similar for NEFA and triacylglycerols, thus there were 
no apparent differential losses. The mean values for concentration of fatty acids in the 
extracted/derivatized samples were comparable to those in the derivatized only 
samples (54-114% extraction yield, mean 96%)).
Thus, despite losses incurred during extraction procedures, the inclusion of an internal 
standard allows appropriate values for fatty acid concentration to be obtained. 
Expression of individual peak areas as a % of total peak area {i.e. area %) is not 
affected by extraction yield.
8.2.3 Validation of FAME Derivatization Procedure
Lipids from a fish oil of known composition (R.P, Scherer Limited, Swindon, U.K.) 
were derivatized using either methanolic HCl, sodium methoxide or boron tri-fluoride. 
Results from GC-MS analysis of all fatty acids for all three methylating agents were 
compared, and found to be similar. The procedure was repeated using red blood cell 
samples, and similar conclusions reached. Thus the use of methanolic HCl yielded 
results comparable to those obtained with other methylating agents. Moreover, the use 
of methanolic HCl for derivatization was previously established in this laboratory 
(Berry et al 2001, Farquharson et al 1996). Methanolic HCl was therefore used as the 
methylating agent for all subsequent derivatization procedures performed at Yorkhill.
A lipid sample of certified composition (Supelco 37 Component FAME Mix (Supelco 
Cat No 47885-U, Sigma-Aldrich Company Ltd., Dorset, U.K.), was analysed by GC- 
MS to determine whether the results obtained following derivatization are comparable
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to those of the manufacturer. The results obtained (area as % total fatty acids/ %TFA) 
were compared with, and found to be comparable to, the certified results supplied by 
the manufacturer. The derivatization protocol and GC-MS analysis technique were 
thus considered appropriate.
8.2.4 Validation of GC-MS Analytical Procedure
8.2.4(a) Linearitv Tests - High and Low Concentration Standard Curves 
To determine whether the actual amount of each fatty acid present in the 
extracted/derivatized sample will be reflected in the value for peak area obtained, and 
whether these values can be used to accurately calculate concentration, linearity tests 
were performed.
Aliquots of a NEFA standard of known concentration, all equal to Img of fat, but with 
different amounts of each fatty acid relative to the internal standard {i.e. relative 
amount), representing the standard at half, full and double concentrations, were 
derivatized and analysed by GC-MS. The relative amount of each fatty acid was 
plotted against either its eorresponding peak area or concentration, and correlation 
analyses were performed.
Values obtained for peak area and concentration were correlated to “relative amount” 
(mean 0.99). Thus, the peak area for any fatty acid is related to its actual amount in 
the sample, and can be used to accurately calculate fatty acid concentration.
8.2.4(b) Analvtical Precision for Measures of Peak Area and Concentration 
Samples of RBC, plasma, placenta tissue and breast milk, to which internal standards 
(tri-15 and C l7:0) were added, were extracted and derivatized in parallel with reagent 
blanks and a NEFA standard of known composition (Standard H). For the three 
replicates of each sample type, reagent blank and standard, the mean and standard 
deviation values for area % and concentration of selected fatty acids was calculated. 
The coefficient of variation (CV (%), ((SD/Mean) x 100)) for each fatty acid was 
obtained. The mean peak area or concentration was plotted against its CV (%) for all 
sample types, to illustrate precision of area % and concentration. Selected values for 
DHA CV (%) are plotted against DHA peak area (Figure 14) and coneentration (Figure
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15). The overall mean values for the mean CV (%) for the selected fatty acids are 
shown in Table 34.
CV (%) for Peak Area CV (%) for Concentration
C15;0 3.6 2.7
C16;0 2.6 1.6
C17:0 1.6
C18:0 2.4 1.3
C18:l 2.7 1.7
C18:2 2.3 1.3
C22:5n-3 17,2 17.0
C22:6n3 8.7 8.7
Table 34. Mean coefficient of variation (CV) for all sample types and standards for 
selected fatty acids measured as both peak area and concentration.
For the major fatty acids, precision of analysis was 3% or better. Analytical precision 
was slightly worse for LCPUFA, due to the small amounts present in the samples, but 
was within acceptable limits.
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8.3 COLLECTION, INITIAL PREPARATION AND STORAGE OF SAMPLES
8.3.1 Blood Samples: Red Blood Cells and Plasma
Venous maternal or umbilical cord blood (5ml) were collected in potassium EDTA 
(15mm X 54mm screw-top vials, Teklab, U.K.). Samples were centrifuged at 550 x g 
(2500rpm) for 5 minutes. Plasma was removed and transferred into a sterile vessel 
with no anticoagulant. Sterile saline (2.5ml) (0.15M NaCl) was added to red blood 
cells (RBC) and centrifuged at 550 x g for 5 minutes. The saline layer was removed 
and discarded. This process was repeated a further twice, such that RBC were washed 
in this manner a total of three times. Both plasma and RBC were stored at -70°C until 
analysis.
Fatty acid content does not change on storage of samples at -20°C in the intermediate 
term (12 months) (Olsen et al 1991), or at -80°C in the long term (12 years) 
(Zeleniuch-Jacquotte et al 2000), indicating the stability of samples stored at an 
appropriate temperature for prolonged periods.
8.3.2 Placental Tissue
Within two hours of delivery, a transverse section (from fetal to maternal side) of 
placental tissue (approximately 5cm^) was dissected free of decidua and major vessels, 
and stored in a sterile Universal container (30ml, Bibby Sterilin, R. and J. Wood, U.K.) 
on ice. Tissue was rinsed with sterile saline to remove surface blood clots and/or 
obstetric cream. Three aliquots of tissue (approximately Ig wet weight each) were 
dissected and stored in sterile Eppendorf tubes (1.5ml, Teklab, Durham, U.K.) at -70°C 
until homogenization. The remainder of the tissue was stored in the Universal 
container at -70°C for future reference.
Each aliquot of placental tissue was freeze-dried overnight (Micro Modulyar Freeze 
Drier, Edwards, U.K.). The aliquots were weighed to obtain the dry weight of tissue 
(approximately 0.2g). The weight of water in the original aliquot was determined by 
subtracting the dry weight from the wet weight; the weight of water was expressed as a 
percentage of the wet weight (mean 85%). The three aliquots of freeze dried tissue 
were removed from the Eppendorf tube, mixed together and ground to a homogeneous 
powder in a Potter-Elvehjem homogenizer (borosilicate glass mortar and 
PTFE/stainless steel pestle; Merck Ltd., Leics., U.K.); each Eppendorf tube was rinsed
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with 1.5ml sterile saline to remove residual tissue and the contents added to the glass 
mortar. A further 1.5ml sterile saline was added to the powdered tissue in the glass 
mortar, and the final contents were homogenized, thus suspending approximately 3g of 
placental tissue (wet weight) in a total of 6ml sterile saline. The homogenate was 
stored at -70°C until analysis.
8.3.3 Umbilical Cord Tissue
Within two hours of delivery, approximately 5cm of umbilical cord, free of internal 
blood clots, was collected in a sterile Universal container and kept on ice, before 
rinsing with sterile saline (Velzing-Aarts et al 1999). Cord vessels were cannulated 
and flushed with sterile saline to remove any remaining blood. Cord tissue was stored 
in a fresh Universal container at ~70°C until analysis.
Previous studies have analyzed the fatty acid composition of umbilical cord veins 
separately from umbilical cord arteries. This requires complex and time-consuming 
dissection. Moreover, dissection of the vessels free from Wharton’s jelly is difficult 
and may be unnecessary: the small amount of lipid present in the jelly and the 
similarity of its fatty acid composition to that of the blood vessels, suggests that the 
presence of jelly material is unlikely to affect the fatty acid composition of the vessels 
(Homstra et al 1989). Although previous studies have shown differences in the PUFA 
content of umbilical arteries compared to the umbilical vein, no difference was found 
in the DHA content of the vessels. The effect of maternal fish oil supplementation 
does not differ between umbilical arterial and venous tissue (van Houwelingen et al 
1995). In addition, there is some evidence that umbilical cord tissue may vary as much 
with genetic differences as with maternal dietary patterns and fatty acid status 
(Homstra et al 1992). Our study postulates that maternal DHA supplementation will 
increase the amount of DHA received by the fetus (via the umbilical vein) and hence 
fetal DHA status (assessed by umbilical arteries), thus one would expect all cord 
vessels to have a higher DHA status in the fish oil supplemented group. Thus 
concomitant analysis of venous and arterial cord vessels should indicate the overall 
status of the fetus. As a result, eord tissue was analyzed in its entirety, without 
dissection of vessels and Wharton’s jelly, as a supplementary tissue, as opposed to the 
main indicator of fetal fatty acid status.
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Umbilical cord tissue was homogenized using a mechanical homogenizer (Silverson, 
Chesham, U.K.) in 20ml of chloroform/methanol (1:1) containing BHT prior to 
estérification and derivatization, at the Scottish Agricultural College (see below).
8.3.4 Breast Milk
Breast milk samples (approximately 2ml) were manually expressed by mothers into a 
sterile Universal container, within seven days of delivery. Samples were stored at - 
70°C to prevent triacylglycerol hydrolysis by lipases. Samples were thawed at 4°C 
overnight, prior to analysis. This temperature prevents rapid thawing which activates 
lipolysis, and samples can be stored at 4°C for approximately one week before 
bacterial contamination becomes problematic (Jensen 1989b).
8.3.5 Sample Analyses
The fatty acid composition of RBC, plasma, placenta tissue and breast milk samples 
was analyzed in the University Department of Child Health laboratory at Yorkhill 
Hospital. Umbilical cord tissue samples were analyzed by Dr. Brian Speake at the 
Scottish Agricultural College (SAC) at Auchincruive, Ayr. The methods used in the 
analysis of all samples are described.
8.4 MATERIALS AND METHODS
8.4.1 Samples analysed at Yorkhill 
8.4.1(a) Reagents
The solvents used were methanol and chloroform (Fisher Scientific, Leics., U.K.). The 
estérification agent used was anhydrous methanolic hydrochloric acid (methanolic 
HCL, MeOH/HCl, 3M) (Supelco, Sigma-Aldrich Company Limited, Dorset, U.K.): 
HCl cleaves esters while MeOH donates a methyl to form FAME.
The antioxidant butylated hydroxytoluene (2,6-di-^erf-butyl-^-cresol, BHT) (BDH 
Chemicals Limited, Poole, U.K.) was added to all solvents (50mg per L) to prevent 
lipid oxidation (Dodge and Phillips 1967), since polyunsaturated fatty acids rapidly 
oxidise on exposure to air.
The salts used were sodium chloride (NaCl, 9g per L deionised water i.e. 0.9%, 
0.15M) (BDH Chemicals Limited, Poole, U.K.) and potassium chloride (KCl, 2.5g per
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L deionised water le. 0.25%, 0.03M) (Sigma, Sigma-Aldrich Company limited, 
Dorset, U.K.).
All reagents used were analytical grade.
Oxygen-free nitrogen (BOC Gases Limited, Surrey, U.K.) was used as the evaporation 
agent to prevent lipid oxidation.
8.4.Ub) Standards
A 15:0 triacylglycerol (tri-15) standard (Sigma-Aldrich, Dorset, U.K.) was used as the 
internal standard to determine fatty acid concentration within samples (International 
Union of Pure and Applied Chemistry 1977b). The standard was required to be in the 
triacylglycerol form for lipid extraction. The desired concentration of tri-15 was 
150nmole of tri-15 per mg lipid. For each sample type analysed, the amount of sample 
used in the extraction procedure was known to yield approximately 3mg of lipid. 
Therefore, 450nmole of tri-15 were added to a given amount of tissue assumed to 
contain 3mg of lipid, prior to extraction, thus equivalent to 150nmole per mg lipid. 
This was obtained using either 45pi of a lOmM solution or 90pl of a 5mM solution of 
tri-15 in propanol/hexane (1:1 v/v).
A non-esterified fatty acid 17:0 standard (Sigma-Aldrich, Dorset, U.K.) was used as an 
internal standard to aid quantification of loss during the derivatization/methylation 
procedure (International Union of Pure and Applied Chemistry 1977b). 450nmole of 
17:0 were added per 2mg of lipid prior to derivatization, thus producing a 
concentration of 225nmoles of 17:0 per Img lipid. This was obtained using 12pl of a 
lOmg/ml solution of 17:0 in propanol.
A reference NEFA standard of known concentration was derivatized with each batch 
of samples as an external standard (International Union of Pure and Applied Chemistry 
1977b). This standard was the NEFA standard used in the validation studies, which 
was of similar composition to the fatty acid levels found in various human tissues 
(Standard H). The purpose of this was three-fold: to determine repeatability of the 
results, to allow quantification of loss during derivatization procedures, and to allow
145
determination of fatty acid concentrations within each sample. The amount of external 
standard derivatized was equivalent to Img of lipid.
For each batch of samples, a reagent blank {te. all components, solvents etc. except 
sample) was included throughout the extraction/derivatization procedures and 
processed during GC-MS analysis, in order to check for memory in the glassware used 
during extraction/derivatization, or in the GC-MS column.
8.4.1(c) Glassware
All glass vials used during the extraction/derivatization process were obtained from 
Chromacol Limited (Herts., U.K.). Hewlett Packard GC-MS vials and inserts were 
used during analysis.
Glassware was cleaned using an alkali detergent, Decon 90 (Decon Laboratories 
Limited, Sussex, U.K.) All glassware was fully immersed in a Decon 90 solution of 
either 3% (if used for plasma and breast milk samples) or 5% (for RBC and placenta 
samples), and allowed to soak in solution for approximately 12 hours (usually 
overnight). On removal from Deeon solution, glassware was rinsed thoroughly (at 
least three times) in free-flowing water, until all residue was removed, and then dried 
in a hot-air drier (LEEC).
8.4.1(d) Extraction Procedure
The procedure for lipid extraction was based on a modified Folch extraction in 
chloroform : methano 1 (2:1) with washing in KCl, as outlined by Dodge & Phillips 
(1967). The procedure for each sample type is described below.
(i) Red Blood Cells (RBC)
RBC samples were removed from storage at -70°C and thawed overnight at 4°C. RBC 
(1ml) were transferred to a clean vial (10ml screw cap) and 450nmole of tri-15 internal 
standard was added.
NaCl (0.5ml, 0.15M) was added to each sample to aid partitioning into solvent phase. 
Samples were mixed thoroughly and 2.5ml methanol containing BHT was added to 
rupture cell membranes. Samples were mixed thoroughly (WhirliMixer, Model No.
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SGP202010J, Fisons Scientific Equipment, Leics., U.K.) and left to stand for 10 
minutes.
Chloroform containing BHT (2.5ml) was added. Samples were mixed, left to stand for 
10 minutes to allow phases to separate, and then centrifuged at 550 x g (2500rpm) for 
5 minutes (Mistral 30001, MSE, U.K.).
The resulting supernatant of methanol, chloroform and lipids was separated from the 
pellet of haem and protein and transferred to a fresh vial, to which 2.5ml of chloroform 
containing BHT was added. After mixing, 1.5ml 0.03M KCl was added to remove 
non-lipid components. The samples were mixed then centrifuged at 550 x g for 5 
minutes. The mixture separated into two phases: an upper aqueous/methanol layer and 
a lower chloroform/lipid layer. The top layer was discarded, and the lower 
chloroform/lipid layer transferred to a pre-weighed vial, then placed under nitrogen at 
45°C (Dri-Block DB-3, Techne (Cambridge) Limited, Cambridge, U.K.) to remove the 
chloroform.
(ii) Plasma
Plasma samples were removed ftrom storage at -70°C and thawed overnight at 4°C. 
Plasma (1ml) was transferred to a clean vial and 450nmole of tri-15 internal standard 
was added.
Methanol containing BHT (1.25ml) was added and after thorough mixing 2.5ml 
chloroform containing BHT was added. The samples were mixed and left to stand for 
10 minutes.
Chloroform containing BHT (2,5ml) was added to dissolve the lipids. Samples were 
mixed and left to stand for 10 minutes to allow phases to separate. The solution 
became bi-phasic, with a top aqueous/methanol layer and a dense lower layer of 
chloroform/lipids. KCl (0.75ml, 0.03M) was added to encourage the polar lipids into 
the chloroform and remove non-lipid contaminants. Samples were mixed, centrifuged 
at 550 X g for 5 minutes and the top aqueous/methanol layer discarded. The bottom 
layer was transferred into a fresh vial and 1.5ml methanol/water mixture (1:1) was 
added to dissolve protein. Samples were mixed and centrifuged at 550 x g for 5
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minutes. The mixture again separated into two phases: an upper aqueous/methanol 
layer and a lower chloroform/lipid layer. The top layer was discarded, and the lower 
chloroform/lipid layer transferred to a pre-weighed vial, then dried under nitrogen at 
45°C.
(Hi) Placenta
Homogenised placenta samples were removed from storage at -70°C and thawed 
overnight at 4°C. Aliquots (Ig) were transferred to a clean vial and 450nmole of tri-15 
internal standard was added.
Since saline/NaCl had already been added to suspend the homogenised tissue, no 
further NaCl was added. Extraction then proceeded as for RBC samples, from the 
addition of methanol containing BHT onwards,
(iv) Breast Milk
Breast milk samples were removed from storage at -70°C and thawed overnight at 4°C. 
An aliquot (200ul) was transferred to a clean vial and 450nmole of tri-15 internal 
standard were added.
NaCl (400ul, 0.15M) was added to aid partitioning of lipids into solvent phase. 
Samples were mixed and 1.25ml methanol containing BHT was added. Following 
thorough mixing, 2.5ml chloroform containing BHT was added to dissolve lipids. 
Samples were mixed and left to stand for 10 minutes to allow phases to separate. The 
solution became bi-phasic with an upper aqueous/methanol layer and a lower 
chloroform/lipid layer. KCl (0.75ml, 0.03M) was added to encourage the polar lipid 
into the solvent phase and remove non-lipids. Samples were mixed and centrifuged at 
550 X g  for 5 minutes. The mixture again separated into two phases: an upper 
aqueous/methano 1 layer and a lower chloroform/lipid layer. The top layer was 
discarded, and the lower chloroform/lipid layer transferred to a pre-weighed vial, then 
dried under nitrogen at 45 °C to remove the chloroform.
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8.4.1(e) Derivatization (Méthylation) Procedure
The pre-weighed vial containing the extracted lipid sample was reweighed to 
determine the yield of lipid, and chloroform added to produce a solution of 2mg 
lipid/lOOul chloroform. Dissolution to a standard concentration facilitated recovery of 
a known quantity of lipid for analysis. The presence of another solvent also aids 
estérification of all lipid classes by methanolic HCl.
An aliquot of lipid/chloroform extract (lOOul, 2mg lipid) was transferred to a fresh vial 
and 450nmole of 17:0 internal standard added. The external standard (Standard H, 
equivalent to Img lipid) was added to a fresh vial. Methanolic HCl (1ml, 3M) was 
added as estérification reagent to the samples and external standard.
Samples were placed in an oil bath (Multi-Blok Heater, Lab-Line, U.K.) at 100°C for 
45 minutes and sealed with screw-caps and parafilm to prevent evaporation. On 
removal from the oil bath, samples were cooled to room temperature and 2.5ml 
distilled water was added to aid transfer of the residue. Petroleum spirit (1.5ml, BP 
40-60°C) was added to aid extraction of the oily FAME from the water/HCl. After 
mixing and centrifuging at 550 x g  for 5 minutes, the top petroleum spirit layer was 
transferred to a fresh vial. A further 1.5ml petroleum spirit was added to the original 
extract and mixed/centrifuged again. The top layer was then removed and added to the 
first petroleum spirit layer. The pooled petroleum spirit layers were evaporated to 
dryness under nitrogen at 45°C. Hexane (0.7ml) was added to dissolve the dried lipid. 
An aliquot was transferred to a 2ml glass vial and analysed by GC-MS; the remainder 
was stored at -70°C for future reference.
8.4.1(f) Gas Chromatogranhv-Mass Spectrometry
Fatty acid methyl esters were identified and quantified using gas chromatography mass 
spectrometry (GC-MS). The GC (Hewlett Packard 5890 Series II) was used in split 
mode (ratio 20:1). The carrier gas was helium (Grade A 99.996% pure, BOC, Surrey, 
U.K.), at a flow rate of Iml/min. The analytical column was a fused silica capillary 
column (BPX70, length 30m, internal diameter 0.25mm and film thickness 0.25pm; 
SGE Europe Ltd.). GC injector temperature was 250°C, and the injection volume was 
2pl. The GC temperature programme was as follows: initial temperature of 120°C for
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2 minutes, increasing by 4°C per minute to 180°C, then by 2°C per minute to 194°C, 
followed by 30°C per minute to 240°C which was maintained for 1 minute. The total 
GC run time for each sample was 26.53 minutes. The temperature of the transfer line 
between the GC and MS was 280°C. The MS (Hewlett Packard 5972) with electron 
impact ionisation, was operated in scanning mode,
8.4.2 Samples analysed at SAC, Ayr
The sample was homogenised using a mechanical homogenizer (Silverson, Chesham, 
U.K.) in 20ml of chloroform/methanol (1:1) containing BHT, then an additional 10ml 
of chloroform were added to produce a chloroform/methanol ratio of 2:1 (v/v). The 
homogenate was filtered through filter paper into a measuring cylinder and the filter 
paper washed with another 10ml chloroform/methanol (2:1). The total volume of the 
homogenate/extract was measured. KCl (0.88%) was added in a volume equal to 25% 
of the total volume. The sample was shaken by hand, and left at room temperature 
overnight to allow the layers to separate. The top aqueous/methanol layer was 
discarded, and the lower layer chloroform/lipid layer dried in a rotary evaporator 
(Buchi, Flawil, Switzerland). The lipids were dissolved in 10 ml chloroform, 5ml of 
which were removed and weighed in a flask to obtain the gravimetric weight of the 
total lipid. The remaining (non-dried) 5ml of chloroform/lipid were used for further 
analysis.
The solution of total lipids was added to 50ml flasks and 1ml internal standard added. 
The standard used was non-esterified 15:0 in methanol (0.3 mg/ml). The 
chloroform/lipid extract was dried by rotary evaporation. Fatty acids were converted 
to fatty acid methyl esters by refluxing at 60°C for 30 minutes with 4ml 
methanol/toluene/sulphuric acid (20:10:1). On cooling to room temperature, 10ml 
water and 10ml hexane were added. The sample was shaken, transferred to a test tube 
and the layers allowed to separate. The top hexane layer was transferred to another 
test tube containing a few grains of drying agent (sodium sulphate/sodium bicarbonate, 
4:1), and left for 30 minutes at room temperature. The hexane layer was again 
transferred to another test tube and the volume reduced under nitrogen.
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The samples (Ipl) were injected into a Chrompack CP9001 GC containing a capillary 
column (Carbowax, length 30m, internal diameter 0.25mm, film thickness 0.25jam; 
Alltech, Camforth, U.K.). The carrier gas was nitrogen. Initial oven temperature was 
185°C, maintained at 185°C for 2minutes after injection, then increased at 5°C/min up 
to 230°C, held at 230°C for 24minutes. The GC was connected to a computer with an 
EZ Chrom Data System, which integrates the peaks and calculates % w/w of fatty 
acids. Standard fatty acid methyl ester mixtures containing all the fatty acids reported 
(Sigma, Sigma-Aldrich Company Limited, Dorset, U.K.) were run to identify retention 
times of each fatty acid peak. A proportion of the samples was also analysed by GC- 
MS (Fisons MD800) to confirm the identification.
8.4.3 Results
Since all the fatty acids in a lipid sample containing all the lipid classes 
(triacylglycerols, phospholipids etc.) present in the original tissue were measured, the 
results pertain to the total lipids of each tissue. Thus, total RBC lipids, total plasma 
lipids, total placenta lipids, total cord tissue lipids and total breast milk lipids were 
analysed.
Results were expressed both as relative and absolute amounts. The area of each fatty 
acid peak in the chromatograph was expressed as a percentage of the total peak area 
(as per Equation 1), thus each fatty acid is expressed as a percentage of total fatty acids 
(%TFA).
% Fatty Acid A == Peak area A x 100____________
E(Peak area A + Peak area B  )
Equation 1. Calculation of peak area as a percentage of total peak area.
For umbilical cord tissue, the fatty acids measured were different from those measured 
in the other tissues (Table 35). A total of 19 fatty acids were measured in RBC, 
plasma, placenta and breast milk samples, while 23 fatty acids were measured in the 
cord tissue. Of these, 15 fatty acids were commonly measured in all tissues. The 
results for cord tissue analysis are therefore expressed as per the 15 common fatty 
acids {i.e. each fatty acid as a % of 15 total fatty acids, compared to 19 total fatty 
acids). This illustrates the aforementioned problem of the dependency of relative
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amounts on the species of fatty acids measured, and the difficulty encountered in 
comparing results from different analyses.
Fatty Acids Measured in RBC, Plasma, 
Placenta and Breast Milk Samples
Fatty Acids Measured in Umbilical 
Cord Tissue Samples
10:0
12:0
14:0 14:0
16:0 16:0
16:ln-7 16:ln-7
17:0
17:ln-7
18:0 18:0
18:ln-7
18:ln-9 18:ln-9
18:2n-6 18:2n-6
18:3n-3 18:3n-3
gl8:3n-6
18:4n-3
20:0 20:0
20:ln-9
20:2n-6
20:3n-6 20:3n-6
20:4n-6 20:4n-6
20:5n-3 20:5n-3
22:ln-9
22:4n-6 22:4n-6
22:5n-6 22:5n-6
24:0
24:ln-9
22:5n-3 22:5n-3
22:6n-3 22:6n-3
Table 35. Fatty acids measured in samples analysed at Yorkhill, compared to those 
measured in umbilical cord tissue samples analysed at SAC, Ayr.
The concentration of each fatty acid was calculated based on the inclusion of internal 
and external standards as follows:
Response factor for FA = Area fa in es Concentration is in es
Area is in hs Concentration fa in es
Equation 2. Calculation of response factor for each fatty acid (FA -  fatty acid, IS 
internal standard, ES -  external standard).
Concentration of FA = Area fa Concentration is in sample
Area is in sample KF fa in ES
Equation 3. Calculation of concentration for each fatty acid (FA -  fatty acid, IS 
internal standard, RF -  response factor, ES -  external standard).
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Please note that for 22;5n-6 (DPA), 24:0 and 24:1, no standards were available for 
these fatty acids, preventing their inclusion in the external standard. Hence, the 
concentration of these fatty acids could not be calculated.
Concentrations were expressed in nmole per ml (nmol/ml) of RBC, plasma or breast 
milk, and per g wet weight tissue (nmol/g) for placenta. For RBC and plasma, 1ml of 
tissue was analysed and concentrations were therefore calculated directly. For breast 
milk, 200ul were analysed and correction to 1ml was achieved by multiplying 
concentrations obtained on calculation by a factor of 5. For placenta, approximately 
Ig homogenate was analysed; the wet and dry weight of tissue in the homogenate 
analysed was known. Thus concentrations were calculated for the amount of 
homogenate analysed and each sample multiplied by the appropriate factor to convert 
the weight of tissue present in the homogenate to Ig wet weight of tissue. Cord tissue 
samples were analysed off-site, and the calculation of concentrations is not included 
here.
The use of both relative and absolute methods of quantification permits the most 
comprehensive analysis and interpretation of the data. For each individual sample, the 
% TFA accounted for by each fatty acid is not directly related to the concentration of 
the fatty acid; for example, RBC DHA accounted for 4.1% TFA and had a 
concentration of 377nmol/ml in one sample, but was 5.8% TFA with a concentration 
of 219nmol/ml in another. Correlation of % TFA values with concentrations varies for 
the different fatty acids. The average correlation coefficients (r) for the correlation of 
area % TFA values with concentration for oleic acid (18:ln-9), AA (20:4n-6) and 
DHA were 0.3, 0.5 and 0,6 respectively. Moreover, correlation of % TFA and 
concentration varied with the tissue sampled, for example the mean correlation 
coefficient for DHA in RBC was 0.8, plasma 0.5, placenta 0.3 and breast milk 0.9. 
Previous authors (A1 et al 1995b) have noted that the differences between 
supplemented and placebo groups in the relative amounts of fatty acids were not 
necessarily observed on consideration of absolute amounts.
Fatty acid metabolism occurs in membranes and is mediated by enzymes for which the 
fatty acids compete. The fatty acid present in the greatest amount within the 
membrane undergoes metabolism, thus it is the amount of the fatty acid relative to
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those surrounding it, and not its actual amount within the entire cell or tissue, which 
determines metabolism (A1 et al 1995b, Holman 1986). The expression of fatty acids 
in relative terms is therefore appropriate when considering metabolism. Conversely, 
the use of absolute quantification is useful when considering the nutritional 
implications of fatty acid composition, such as with human breast milk and/or infant 
formulae (Kohn et al 1996), Some authors have suggested that both relative and 
absolute measurements are required when considering maternal-fetal transfer of fatty 
acids (A1 et al 1990, Matorras et al 1994).
By presenting the results of fatty acid analysis in both relative and absolute terms, it is 
possible to determine whether the amount of a particular fatty acid relative to others is 
influencing metabolism and possibly development, or whether an effect is observed 
above a certain threshold of fatty acid concentration.
8.5 STATISTICAL METHODS
8.5.1 Biochemical Variables
The results of fatty acid analyses (% TFA and concentrations) were expressed for 
individual fatty acids, as a sum of each PUFA class, and as the ratio of the PUFA 
classes. Fatty acids from both the n-6 and n-3 classes were summed (total n-6 and 
total n-3) in order to detect any differences not evident when considering the individual 
fatty acids. Several ratios have been employed when examining fatty acid status (BNF 
1992), The polyunsaturated/saturated ratio (P/S) considers total PUFA relative to total 
saturates, but does not account for MUFA, whose contribution can be considered by 
using the ratio of total unsaturates to total saturates (U/S). However neither U/S nor 
P/S ratios account for the differences between the distinct metabolic families of PUFA 
(especially n-3 and n-6).
The ratio of 20:3n-9 to 20:4n-6 (triene/tetraene ratio) is useful when considering EFA 
deficiency, but limited when EFA are known to be sufficient. The n-6/n-3 ratio has 
many derivatives including the ratio of LA/aLA, which does not consider the 
“potency” of their respective longer chain derivatives (BNF 1992). Furthermore, it is 
of limited value when the study objective was to supplement with DHA. The ratio of 
total n-3 LCPUFA (20:5n-3 EPA, 22:5n-3 DPA and 22:6n-3 DHA) to AA (20:4n-6) 
may be a useful marker when studying the effect of high n-3 intake on AA levels
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(Olsen et al 1991, 1995a, 1995b) but does not account for differential changes in total 
n-6 PUFA. Since the sums of total n-6 and total n-3 were calculated, the relative 
difference between these was of relevance, hence the ratio of n-6/n-3 was calculated.
8.5.2 Distribution of Data
Distribution of fatty acid values (% TFA and concentrations) were checked graphically 
(SPSS 9.0 for Windows) and by calculating whether approximately 70% of results fell 
within Mean ± SD (Fowler, Cohen & Jarvis 1998). Values were found to be non- 
normally distributed, indicating that the use of non-parametric statistical tests was the 
appropriate method of analysis. Median values are quoted throughout and 95% 
confidence intervals for the median were obtained by Wilcoxon Sign Ranked 
Confidence Intervals.
8.5.3 Effect of Variables on DHA
Parity, the interval between successive pregnancies and dietary fish intake have all 
been previously reported to influence DHA status. Mann-Whitney 2-sample rank tests 
were performed to detect the influence of these variables on DHA status in the whole 
study population, regardless of supplementation group. A significance value of p<0.05 
was chosen. These variables were not considered further because the supplement and 
placebo groups were comparable in all underlying variables.
8.5.4 Analysis between Groups: Mann-Whitney Tests
Mann-Whitney 2-sample rank tests were used to detect significant differences between 
the fish oil and placebo groups. A significance level of p<0.05 was chosen for 
between group analyses because this was related to the initial calculation of sample 
size required to detect a 1 SD of difference between groups in DHA status (see Chapter 
6, Section 6.4 Sample Size Calculation).
8.5.5 Analysis within Groups (Paired Data): Sign Tests
For the longitudinal changes within each group, the null hypothesis was that the 
median difference over time was zero. To obtain the difference between samples over 
time, the values for the later samples were subtracted from those of the earlier samples. 
The same method was used to calculate the differences between maternal and 
umbilical cord values. The differences were found to be non-symmetrically
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distributed, preventing the use of one-sample Wilcoxon Signed Rank tests of the 
median, which require the data to be approximately symmetrical in distribution 
(Altman 1991). Thus one-sample Sign tests of the median were performed to detect 
whether the difference was significantly different from the hypothesised median 
difference of zero (0.00).
Due to the large number of tests performed on the differences between maternal levels 
over time and between maternal and umbilical cord levels, only individual fatty acids 
were tested; the sums for total n-3 and total n-6 fatty acids, as well as the n-6/n-3 ratio, 
were not tested for changes within each group. Although correction of the significance 
level for multiple statistical testing with non-parametric statistics is not as formal a 
procedure as for parametric methods (e.g. Bonferroni correction), it was considered 
appropriate to lower the level of significance for the within group testing. Thus, due to 
the large number of tests performed, a significance level of p<0.01 was chosen for 
within group analyses.
8.5.6 Statistics Programme
All statistical analyses were performed using Minitab for Windows Version 10.51 
software (1995, Minitab Inc., PA, U.S.A).
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Chapter 9
Results of Supplementation Study
9.1 DHA AND OTHER VARIABLES
9.1.1 DHA and Parity
Participants were divided into two groups on the basis of parity. Nulliparous women 
were those for whom the current pregnancy was their first and only; parous women 
were defined as those with any previously confirmed pregnancy, regardless of 
outcome or duration. Mann-Whitney tests were performed to test for differences in 
DHA status in all samples collected between the nulliparous and parous participants 
(Table 36).
Those with a previous obstetric history did not differ in maternal DHA status during 
gestation or at birth from those with no previous obstetric history. Placental tissue and 
breast milk DHA were also similar in both groups. Cord plasma DHA did, however, 
differ between the groups; DHA accounted for a higher % TFA (p=0.02), and was of a 
higher concentration (p=0.01), in cord plasma obtained from nulliparous women.
% TFA Concentration
Nulliparous Parous P Nulliparous Parous P
RBC 15 weeks 2.9 (n=41) 2.7 (n=55) 0.23 179 (n-41) 125 (n-55) 0.63
RBC 28 weeks 3.8 (n=28) 3.9 (n=35) 0.56 192 (n-28) 187 (n-35) 0.92
RBC Birth 2.6 (n=26) 2.7 (n=31) 0.64 153 (n-26) 150 (n=31) 0.69
RBC Cord 4.4 (n=23) 4.1 (n=33) 0.12 282 (n-23) 219 (n-3 3) 0.09
Plasma 15 weeks 1.6 (n=41) 1.6 (n=56) 0.49 132 (n-41) 134 (n-56) 0.51
Plasma 28 weeks 1.9 (n=28) 1.8 (n=35) 0.26 213 (n=28) 181 (n-35) 0.13
Plasma Birth 1.3 (n==26) 1.4 (n=33) 0.96 158 (n-26) 163 (n-33). 0.82
Plasma Cord 3.6 (n=23) 2.8 (n=33) 0.02 701 (n-23) 350 (n-33) 0.01
Placental Tissue 3.6 (n=21) 3.6 (n-3 2) 0.74 6408 (n-21) 5171 (n-3 2) 0.32
Cord Tissue 6.3 (n==20) 5.9 (n-3 3) 0.28
Breast Milk 0.3 (n=10) 0.2 (n-16) 0.77 3710 (n-10) 2711 (n-16) 0.98
Table 36. Median values for DHA as a % TFA and its concentration (nmol/ml for 
RBC, plasma and breast milk, nmol/g for placental tissue) in samples from nulliparous 
and parous participants.
9.1.2 DHA and Interval between Pregnancies
For parous participants, the interval between their last previous pregnancy and the 
current pregnancy was calculated in years. Classification was then made on the basis 
of whether the interval was of more or less than 1 year. Mann-Whitney tests were 
performed between those with an interval of 1 year or less between pregnancies, and 
those with more than 1 year between pregnancies (Table 37).
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There were no differences in DHA status of RBC, plasma, tissue or breast milk 
samples between those whose last previous pregnancy was less than 1 year before the 
current pregnancy, and those whose last previous pregnancy was more than 1 year 
before.
% TFA Concentration
1 year or less More than 1 P 1 year or less More than 1 P
RBC 15 weeks 3.1 (n=14) 2.7 (n-33) 0.09 172 (n-14) 125 (n-33) 0.18
RBC 28 weeks 3.8 (n=8) 4.0 (n-25) 0.85 187 (n-8) 187 (n-25) 0.66
RBC Birth 2.50 (n-6) 2.8 (n=22) 0.19 95 (n-6) 161 (n-22) 0.12
RBC Cord 3.8 (n-7) 4.1 (n-23) 0.59 209 (n-7) 228 (n-23) 0.22
Plasma 15 weeks 1.6 (n-15) 1.8 (n-33) 0.49 109 (n-15) 140 (n-33) 0.20
Plasma 28 weeks 1.6 (n=8) 1.8 (n-25) 0.34 179 (n-8) 192 (n-25) 0.95
Plasma Birth 1.30 (n-8) 1.3 (n-22) 0.91 168 (n-8) 153 (n-22) 0.66
Plasma Cord 2.8 (n-7) 2.5 (n-23) 0.49 428 (n-7) 222 (n-23) 0.49
Placental Tissue 3.6 (n-7) 3.6 (n-22) 0.61 6990 (n-7) 5467 (n-22) 0.40
Cord Tissue 5.8 (n-8) 5.9 (n-22) 0.29
Breast Milk 0.2 (n=4) 0.3 (n=10) 0.10 1603 (n-4) 2980 (n=22) 0.14
Table 37. Median values for DHA as a % TFA and its concentration (nmol/ml for 
RBC, plasma and breast milk, nmol/g for placental tissue) in samples from parous 
participants whose last previous pregnancy was 1 year or less, or more than 1 year, 
prior to the current pregnancy.
9.1.3 DHA and Frequency of Fish Consumption
Frequency of dietary fish intake was recorded at 15 weeks gestation, 28 weeks 
gestation and birth. At each time, fish intake frequency was classified as either: never 
or less than once per week, or once or more per week. Mann-Whitney tests were 
performed to determine differences in DHA status between those who consumed fish 
less than once per week, and those who consumed fish once or more per week at each 
time (Tables 38-40).
Consumption of fish once or more per week was associated with a higher % of DHA 
in both maternal RBC (p=0.003) and plasma (p=0.02) at 15 weeks. DHA 
concentration was not significantly higher at 15 weeks in those who consumed fish 
once or more per week. Moreover, weekly fish consumption was not associated with 
higher DHA status after supplementation began Le. at either 28 weeks or birth.
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% TFA Concentration
Never or less 
than once per 
week
Once or more 
per week
P Never or less 
than once per 
week
Once or more 
per week
P
RBC 15 weeks 
Plasma 15 weeks
2.4 (n-44) 
1.6 (n-45)
3.1 (n-52) 
1.8 (n-52)
0.003
0.02
106 (n=44) 
124 (n=45)
147 (n=52) 
144 (n=52)
0.33
0.14
Table 38. Median values for DHA as a % TFA and its concentration (nmol/ml) in 
samples from participants whose consumption of fish was classified as (1) never or 
less than once per week, or (2) once or more per week, at 15 weeks gestation.
% TFA Concentration
Never or less Once or more P Never or less Once or more P
than once per per week than once per per week
week week
RBC 28 weeks 3,8 (n-24) 3.9 (n-3 9) 0.63 189 (n=24) 187 (n-39) 0.69
Plasma 28 weeks 1.7  (n-24) 1.9 (n-39) 0.14 199 (n-24) 208 (n-39) 0.35
Table 39. Median values for DHA as a % TFA and its concentration (nmol/ml) in
samples from participants whose consumption of fish was classified as (1) never or
less than once per week, or (2) once or more per week, at 28 weeks gestation.
% TFA Concentration
Never or less Once or more P Never or less Once or more P
than once per per week than one per per week
week week
RBC Birth 2.8 (n-16) 2.7 (n-35) 0.58 161 (n-16) 152 (n-35) 0.54
RBC Cord 4.3 (n-17) 4.3 (n-3 4) 0.65 233 (n-17) 262 (n-34) 0.29
Plasma Birth 1.4 (n-17) 1.3 (n-3 6) 0.75 146 (n-17) 179 (n=36) 0.10
Plasma Cord 2.5 (n-17) 3.1 (n-34) 0.07 222 (n-17) 528 (n-34) 0.07
Placental Tissue 3.6 (n-17) 3.7 (n-32) 0.35 6408 (n-17) 5939 (n-32) 0.89
Cord Tissue 5.8 (n-16) 6.3 (n-32) 0.23
Breast Milk 0.20 (n-8) 0.3 (n-16) 0.28 2561 (n-8) 3503 (n-16) 0.69
Table 40. Median values for DHA as a % TFA and its concentration (nmol/ml for 
RBC, plasma and breast milk, nmol/g for placental tissue) in samples from 
participants whose consumption of fish was classified as (1) never or less than once 
per week, or (2) once or more per week, at time of birth.
9.1.4 DHA and Recent Fish Consumption
Most recent fish consumption prior to obtaining a maternal blood sample at both 15 
weeks and 28 weeks gestation was determined as to whether it occurred within the 24- 
hour period prior to sampling. Thus, consumption was classified as either more than 
24 hours before sampling, or 24 hours or less prior to sampling. Mann-Whitney tests 
were performed to determine any differences in DHA status between those who had 
consumed fish and those who had not, in the previous 24 hours (Tables 41 & 42).
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Fish intake in the 24 hours prior to sampling was associated with a higher DHA status 
(both as a % TFA and a concentration) in maternal plasma at 15 weeks gestation. 
However, this effect was not observed at 28 weeks, following the commencement of 
supplementation.
The effect of recent fish intake on DHA status was not tested on the samples obtained 
at birth. The reasons for this were; (a) maternal blood samples were not always 
obtained within 24 hours of birth and therefore fish intake prior to delivery was not 
always equivalent to fish intake prior to sampling; (b) some mothers did not consume 
any food in the 24 hours prior to delivery, and (c) maternal recall of intake in the 24 
hours preceding delivery/ sampling was often questionable, given the circumstances.
% TFA Coucentratiou
More than 24 
Hours
24 Hours or 
Less
P More than 24 
Hours
24 Hours or 
Less
P
RBC 15 weeks 
Plasma 15 weeks
2.8 (n=69) 
1.6 (n-70)
2.9 (n-27)
1.9 (n=27) ,
0.10
0.004
144 (n-69) 
122 (n-70)
137 (n=27) 
154 Cn=27)
0.37
0.005
Table 41. Median values for DHA as a % TFA and its concentration (nmol/ml) in 
samples from participants who had consumed fish more than 24 hours prior to 
sampling, or 24 hours or less before sampling at 15 weeks gestation.
% TFA Coucentratiou
More than 24 
Hours
24 Hours or 
Less
P More than 24 
Hours
24 Hours or 
Less
P
RBC 28 weeks 
Plasma 28 weeks
3.8 (n-35) 
1.7 (n-35)
4.2 (n=12) 
1.8 (n-12)
0.63
0.14
177 (n-35) 
208 (n-35)
198 (n-12) 
231 (n-12)
0.68
0.35
Table 42. Median values for DHA as a % TFA and its concentration (nmol/ml) in 
samples from participants who had consumed fish more than 24 hours prior to 
sampling, or 24 hours or less before sampling at 28 weeks gestation.
9.1.5 Concluding Remarks
DHA status in the study population varied with underlying factors as expected. 
Maternal DHA status has not been consistently related to parity in previous studies 
(A1 et al 1997, van Houwelingen et al 1999); the effect of parity on neonatal status has 
been noted previously (A1 et al 1997). The variation in plasma and RBC DHA with 
fish consumption has been demonstrated consistently (Anttolainen et al 1996, Ma et al 
1995b, Romon et al 1995). These findings indicate that the relationship between 
DHA and parity or diet is physiologically appropriate and that the study population
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are therefore "normal". Since there were no significant differences between the fish 
oil and placebo groups in these or other factors, such as anthropometry, gestational 
length etc., these factors were not considered further by, for example, multivariate 
analysis.
9.2 ANALYSES BETWEEN FISH OIL AND PLACEBO GROUPS
9.2.1 RBC Fatty Acids: % Total Fatty Acids (Relative Levels) (Figure 16)
9.2. Ua) Maternal RBC at 15 weeks gestation (Table 43)
The two randomised groups were not significantly different in the % of total fatty 
acids (% TFA) for any fatty acids measured, in their baseline RBC samples. DHA 
accounted for median 2.8% TFA in the fish oil group, and 2.9% TFA in the placebo 
group (p=0.80).
Fish Oil Group Placebo Group P
Median 95% Cl Range Median 95% Cl Range
C10:0 0.0 (0.0, 0.0) 0 .0 -0 .0 0.0 (0.0, 0.0) 0.0 - 0.0
C12:0 0.0 (0.0, 0.0) 0 .0 -0 .0 0.0 (0.0, 0.0) 0.0 - 0.0
C14:0 0.2 (0.2, 0.3) 0 .0 -0 .7 0.0 (0.1, 0.3) 0 .0 -0 .6 0.41
C16:0 32.4 (32.0, 33.8) 27.1 -40.8 32.9 (32.5, 34.4) 28 .2 -41 .2 0.52
C16;ln-7 0.1 (0.1, 0.4) 0 .0 -3 .2 0.1 (0.1, 0.3) 0 .0 -3 .9 0.56
C18;0 16.8 (16.5, 17.5) 13.7-22.1 16.9 (16.7, 17.4) 15.3 - 19.9 0.88
C18:ln-9 13.4 (13.4, 14.5) 11.0- 18.5 13.2 (13.0, 13.8) 10.3 - 18.4 0.12
C18:2n-6 9.1 (8.8, 9.6) 6 .7 -11 .8 9.0 (8.7, 9.3) 6 .8 -1 2 .0 0.49
C18;3n-3 0.0 (0.0, 0.0) 0.0 - 0.6 0.0 (0.0, 0.0) 0.0 - 0.7
C20:0 0.5 (0.3, 0.5) 0.0 - 92.0 0.6 (0.3, 0.6) 0 .0 -0 .8 0.19
C20:3n-6 1.2 (1.0, 1.2) 0 .0 -2 .2 1.0 (1.0, 1.1) 0 .0 -2 .1 0.20
C20:4n-6 10.9 (10.6, 11.4) 6.9 - 14.9 10.9 (10.4, 11.4) 6 .4 -13 .8 0.89
C20:5n-3 0.1 (0.1, 0.2) 0.0 - 0.7 0.0 (0.1, 0.2) 0.0 - 0.6 0.25
C22:4n-6 1.9 (1.6, 2.1) 0 .0 -4 .0 1.7 (1.6, 2.1) 0 .4 -4 .1 0.74
C22:5n-6 0.0 (0.0, 0.1) 0.0 - 0.4 0.0 (0.0, 0.0) 0.0 - 0.3
C24:0 3.7 (3.1, 3.9) 0.0 - 5.5 3.9 (3.2, 4.1) 0.4 - 6.4 0.56
C24;ln-9 4.3 (4.0, 4.7) 1.1 -6 .9 4.6 (4.1, 4.9) 1 .8 -7 .7 0.78
C22;5n-3 1.0 (0.9, 1.2) 0 .0 -1 .9 0.9 (0.9, 1.1) 0.0 - 1.7 0.60
C22:6n-3 2.8 (2.4, 3.0) 1 .0 -6 .7 2.9 (2.5, 3.1) 0 .9 -4 .6 0.80
Total n-3 3.9 (3.4, 4.4) 1 .0 -8 .7 4.0 (3.4,4.3) 1.1 -6 .6 0.86
Total n-6 23.5 (22.7, 23.9) 18.0-26.8 23.0 (22.2, 23.5) 15.7-27.3 0.29
Ratio n6/n3 5.8 (5.6, 7.5) 3.1 - 19.9 5.8 (5.6, 7.2) 3 .5-19 .1 0.92
Table 43. Percentage total fatty acids in maternal RBC total lipids at 15 weeks 
gestation for both groups (n=47 for fish oil group, n=49 for placebo group), p  values 
were obtained on performing Mann-Whitney tests between the groups. 95% Cl -  
Wilcoxon confidence interval for the median.
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9.2.1(b) Maternal RBC at 28 weeks gestation (Table 44)
Following supplementation for (mean) 13 weeks, the groups differed in DHA as a % 
TFA in their RBC. The fish oil group had a significantly higher % DHA (p=0.003), 
with a median of 4.2%, compared to the placebo group (median 3.3%).
The fish oil receiving mothers had a significantly higher % TFA (p=0.02) for total n-3 
fatty acids (median 5.7%), compared to the placebo group (median 5.0% TFA). As a 
result, the fish oil group had a significantly lower (p=0.008) ratio of n6 to n3 fatty 
acids, with a median of 4.0, compared to 4.6 in the placebo group.
The treatment groups also differed significantly (p=0.02) in the % of arachidonic acid 
(AA, 20:4n-6). The fish oil group was significantly lower, with a median level of 
10.6% TFA, in comparison to the placebo group (median 11.2%).
Fish Oil Group Placebo Group P
Median 95% Cl Range Median 95% Cl Range
C10:0 0.0 (0.0, 0.0) 0.0 - 0.0 0.0 (0.0, 0.0) 0 .0 -0 .0
C12:0 0.0 (0.0, 0.0) 0 .0 -0 .0 0.0 (0.0, 0.0) 0.0 - 0.0
C14:0 0.4 (0.4, 0.5) 0.0 - 0.6 0.4 (0.3, 0.4) 0.0 - 0.7 0.29
C16:0 31.4 (30.8, 32.0) 28.6 - 34.7 31.4 (30.6,31.6) 28 .8-36.1 0.53
C16:ln-7 0.7 (0.6, 0.8) 0 .0 -3 .9 0.6 (0.5, 0.7) 0 .0 - 1.1 0.20
C18:0 16.0 (15.8, 16.4) 14.5 - 17.9 16.1 (15.8, 16.4) 13.4-19.0 0.99
C18:ln-9 12.9 (12.6, 13.4) 11.6-18.9 13.4 (12.9, 13.6) 11.2-18.4 0.22
C18:2n-6 8.7 (8.3, 9.2) 6 .9 -12 .7 8.7 (8.3, 8.9) 7.4 -10.9 0.68
C18:3n-3 0.0 (0.0, 0.0) 0 .0 -0 .1 0.0 (0.0, 0.0) 0 .0 -0 .1
C20:0 0.6 (0.5, 0.6) 0.4 - 0.7 0.6 (0.5, 0.6) 0 .0 -0 .8 0.63
C20:3n-6 1.5 (1.3, 1,5) 0.7 - 2.0 1.4 (1.4, 1.7) 0 .9 -2 .6 0.30
C20:4n-6 10.6 (10.1, 10.9) 7 .9 - 12.7 11.2 (10.8,11.5) 9 .0 -1 2 .6 0.02
C20:5n-3 0.3 (0.2, 0.3) 0 .0 -0 .6 0.2 (0.2, 0.3) 0 .0 -0 .6 0.37
C22:4n-6 1.9 (1.7, 2.0) 0 .9 -2 .6 2.2 (1.9, 2.3) 0 .8 -3 .3 0.07
C22:5n-6 0.0 (0.0, 0.0) 0 .0 -0 .0 0.0 (0.0, 0.0) 0 .0 -0 .0
C24:0 4.1 (3.8, 4.3) 1 .9-5 .5 4.2 (3.9, 4.3) 2 .2 -5 .3 0.78
C24:ln-9 5.2 (4.8, 5.3) 3 .6 -8 .8 5.1 (4.9, 5.4) 3.4 - 6.4 0.79
C22:5n-3 1.3 (1.2, 1.4) 0 .7 - 1.7 1.3 (1.2, 1.5) 0 .0 - 1.9 0.34
C22:6n-3 4.2 (3.9, 4.4) 2.3 -5 .6 3.3 (3.2, 3.8) 2 .4 -5 .4 0.003
Total n-3 5.7 (5.3, 6.1) 2 .9 -7 .6 5.0 (4.7, 5.5) 2.4 - 7.3 0.02
Total n-6 23.1 (22.2, 23.4) 17.2-24.9 23.5 (22.8, 24.0) 20.2 - 26.3 0.10
Ratio n6/n3 4.0 (3.8, 4.4) 3 .0 -7 .1 4.6 (4.4, 5.3) 2 .9 -9 .5 0.01
Table 44. Percentage total fatty acids in maternal RBC total lipids at 28 weeks 
gestation for both groups (n=30 for fish oil group, n=33 for placebo group), p  values 
were obtained on performing Mann-Whitney tests between the groups. 95% Cl -  
Wilcoxon confidence interval for the median.
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9.2. Uc) Maternal RBC at Birth (Table 45)
At delivery, maternal RBC DHA accounted for 3.1% TFA in the fish oil group, and 
2.4% in the placebo group. This difference was significant at p=0.01.
Total n-3 fatty acids accounted for a significantly higher % TFA (p=0.02) in the fish 
oil group (median 3.9% TFA) than the placebo group (median 3.3% TFA). The ratio 
of n-6 to n-3 fatty acids was therefore lower in the fish oil group, with a median of 4.9 
compared to the placebo group median of 6.2 (p=0.01).
Fish Oil Group Placebo Group P
Median 95% Cl Range Median 95% Cl Range
C10:0 0.0 (0.0, 0.0) 0.0 - 0.0 0.0 (0.0, 0.0) 0.0 - 0.0
C12:0 0.0 (0.0, 0.0) 0.0 - 0.0 0.0 (0.0, 0.0) 0.0 - 0.0
C14:0 0.3 (0.2, 0.3) 0.0 - 0.6 0.3 (0.2, 0.4) 0.0 - 0.8 0.19
C16:0 35.1 (34.1,36.1) 31 .3 -43 .0 35.0 (34.4, 36.6) 30 .8 -40 .6 0.67
C16:ln-7 0.6 (0.4, 0.7) 0.0 - 4.2 0.6 (0.5, 0.8) 0.0 - 4.4 0.43
C18:0 16.1 (15.6, 16.7) 12.8 -18.3 16.1 (14.9, 16.4) 11.1 -17.8 0.45
C18:ln-9 14.7 (14.4, 15.6) 12.6- 19.5 15.1 (14.9, 16.4) 13.5 -19.4 0.10
C18:2n-6 8.7 (8.3, 8.9) 6 .0 -11 .5 8.5 (8.2, 8.9) 7.5 - 10.2 0.72
C18:3n-3 0.0 (0.0, 0.0) 0 .0 -0 .1 0.0 (0.0, 0.0) 0 .0 -0 .1
C20:0 0.5 (0.5, 0.5) 0.0 - 0.7 0.5 (0.3, 0.5) 0 .0 -0 .8 0.17
C20:3n-6 1.0 (0.9,1.2) 0.4 - 1.6 1.0 (0.9, 1.2) 0.4 - 2.2 0.92
C20:4n-6 8.5 (7.5, 9.1) 1 .8-10 .5 9.2 (7.9, 9.6) 3 .9 -11 .5 0.27
C20:5n-3 0.0 (0.0, 0.1) 0 .0 -0 .3 0.0 (0.0, 0.1) 0.0 - 0.2 0.23
C22:4n-6 1.2 (0.9, 1.2) 0 .0 -2 .0 1.1 (1.0, 1.3) 0 .0 -2 .0 0.52
C22:5n-6 0.0 (0.0, 0.0) 0 .0 -0 .0 0.0 (0.0, 0.0) 0 .0 -0 .0
C24:0 3.6 (3.5, 4.3) 2 .8 -6 .6 3.7 (3.5, 4.2) 2.5 -6 .6 0.88
C24:ln-9 5.4 (5.1, 5.9) 2 .9 -9 .2 5.0 (4.8, 5.9) 3 .9 -7 .9 0.34
C22:5n-3 0.9 (0.7, 1.0) 0 .0 -  1.4 0.8 (0.6, 0.9) 0 .0 -1 .4 0.49
C22:6n-3 3.1 (2.5, 3.5) 0.3 -4 .8 2.4 (2.0, 2.7) 0 .5 -4 .0 0.01
Total n-3 3.9 (3.3,4.5) 0,5 - 6.3 3.3 (2.7, 3.6) 0.7 - 5.3 0.02
Total n-6 19.8 (18.1,20.3) 9.7 - 22.3 19.9 (18.5, 20.7) 13.0-23.1 0.60
Ratio n6/n3 4.9 (4.5, 6.6) 3 .1 -23 .1 6.2 (5.8, 7.6) 3 .7 -1 7 .6 0.01
Table 45. Percentage total fatty acids in maternal RBC total lipids at birth for both 
groups (n=29 for fish oil group, n=28 for placebo group), p  values were obtained on 
performing Mann-Whitney tests between the groups. 95% Cl -  Wilcoxon confidence 
interval for the median.
9.2. Udi Umbilical Cord RBC (Table 46)
Umbilical cord RBC from the two groups did not differ significantly in the % TFA of 
DHA (fish oil group median 4.4%, placebo group median 4.1%, p=0.28), or indeed of 
other fatty acids.
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Fish Oil Group Placebo Group P
Median 95% C l Range Median 95% Cl Range
C10:0 0.0 (0.0, 0.0) 0.0 - 0.0 0.0 (0.0, 0.0) 0 .0 -0 .0
C12:0 0.0 (0.0, 0.0) 0.0 - 0.0 0.0 (0.0, 0.0) 0.0 - 0.0
C14:0 0.4 (0.2, 0.4) 0 .0 -0 .6 0.4 (0.2, 0.4) 0.0 - 0.7 0.55
C16:0 34.8 (34.4, 35.9) 29.7 -38.9 35.1 (34.6, 36.2) 32 .2 -41 .0 0.63
C16:ln-7 0.4 (0.3, 0.4) 0 .0 -4 .6 0.3 (0.3, 0.4) 0 .0 -4 .3 0.80
C18:0 18.1 (17.4, 18.5) 13.2-20.0 18.1 (17.4, 18.3) 15.3-19.9 0.63
C18:ln-9 11.0 (10.8, 11.5) 9.3 - 13.0 11.1 (10.5, 11.5) 8 .8 -13 .7 0.76
C18:2n-6 3.4 (3.2,4.0) 2.2 - 6.4 3.5 (3.3, 3.9) 2.4 - 7.2 0.85
C18:3n-3 0.0 (0.0, 0.0) 0 .0 -0 .1 0.0 (0.0, 0.0) 0.0 - 0.4
C20:0 0.7 (0.7, 0.8) 0 .0 - 1.0 0.8 (0.7, 0.8) 0 .5 -1 .0 0.51
C20:3n-6 2.0 (1.9, 2.3) 1 .0-3 .1 2.1 (2.0, 2.4) 1 .2 -3 .0 0.50
C20:4n-6 12.4 (11.6, 12.7) 9.2 - 14.5 12.4 (11.8, 12.8) 8 .2 -14 .3 0.66
C20;5n-3 0.0 (0.0, 0.1) 0 .0 -0 .1 0.0 (0.0, 0.1) 0 .0 -0 .3 0.88
C22;4n-6 2.5 (2.3, 2.7) 1.5 -3 .6 2.7 (2.5, 2.9) 1 .4 -3 .6 0.08
C22:5n-6 0.3 (0.2, 0.4) 0 .0 -0 .9 0.3 (0.3, 0.5) 0 .0 - 1.0
C24;0 5.9 (3.5, 6.1) 0 .6 -8 .1 5.6 (3.2, 5.7) 0 .6 -8 .3 0.29
C24:ln-9 4.1 (3.9, 4.4) 2 .8 -5 .7 4.5 (4.1, 4.7) 3 .2 -5 .9 0.13
C22;5n-3 0.3 (0.2, 0.4) 0 .0 -0 .9 0.3 (0.2, 0.4) 0.0 - 0.9 0.78
C22:6n-3 4.4 (4.1, 4.8) 1 .7 -5 .8 4.1 (3.9, 4.5) 1.8 -6 .2 0.28
Total n-3 4.6 (4.3, 5.2) 1 .7 -6 .2 4.7 (4.1, 5.0) 1.8 -7.1 0.42
Total n-6 20.8 (20.1,21.3) 16.7-23.1 21.4 (20.7,21.8) 14.0-2 .4 0.22
Ratio n6/n3 4.7 (4.1, 4.8) 3 .0 - 11.6 4.6 (4.4, 5.3) 2 .9 -7 .6 0.18
Table 46. Percentage total fatty acids in umbilical cord RBC total lipids for both 
groups (n=27 for fish oil group, n=29 for placebo group), p  values were obtained on 
performing Mann-Whitney tests between the groups. 95% Cl -  Wilcoxon confidence 
interval for the median.
164
(/)■D
c
03
LL
I
sc
8Co
O
7
6
5
4
3
2
Fish Oil Group1
I I Placebo Gorup0
N = 47 49 30 33 29 28 27 29
15 weeks 28 weeks Birth Cord
Maternal or Umbilical Cord RBC  
Figure 16. % DHA (median & quartiles) in RBC of both groups. 
Significant differences between groups - * p=0.02, **p=0.01.
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Figure 17. DHA concentration (median & quartiles) in RBC of both 
gropus. Significant differences between groups - *p=0.02, **p=0.02.
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9.2.2 RBC Fatty Acids: Concentration (Absolute Levels) (Figure 17)
9.2.2(a) Maternal RBC at 15 weeks gestation (Table 47)
Baseline concentrations of all fatty acids measured were similar in the RBC of both 
treatment groups. RBC DHA had a concentration of 144 nmol/ml in the fish oil 
group, and 134 nmol/ml in the placebo group (p=0.98).
Fish Oil Group Placebo Group P
Median 95% Cl Range Median 95% Cl Range
C10:0 0 (0, 0) 0 - 0 0 (0, 0) 0 - 0
C12:0 0 (0, 0) 0 - 0 0 (0, 0) 0 - 0
C14;0 7 (5, 12) 0 -3 1 2 (A 8 ) 0 -3 7 0.38
C16:0 855 (850, 998) 473 - 2522 873 (840, 981) 295 - 1912 0.87
C16:ln-7 7 (6,11) 0 -9 2 5 (3 ,9 ) 0 -2 1 8 0.32
C18:0 383 (362,419) 184 - 1119 372 (346, 406) 117-751 0.51
C18:ln-9 366 (348,418) 235 - 759 353 (327, 397) 120 - 675 0.38
C18:2n-6 272 (238, 284) 149 - 527 230 (220, 267) 82-471 0.41
C18:3n-3 0 (0, 0) 0 -4 5 0 (0, 0) 0 -3 0
C20:0 10 (7, 12) 0 - 3 2 11 (8, 12) 0 -2 3 0.64
C20:3n-6 111 (120, 255) 0 -8 3 7 142 (136,217) 0 -6 7 4 0.68
C20:4n-6 326 (302, 381) 118-600 319 (283, 374) 84 - 646 0.59
C20:5n-3 5 (6, 15) 0 - 5 7 0 (3, 13) 0 - 6 4 0.39
C22:4n-6
C22;5n-6
C24;0
C24:ln-9
151 (116, 183) 0 -5 2 1 112 (110, 186) 11-489 0.96
C22:5n-3 55 (47, 120) 0 -2 9 3 38 (36, 123) 0 -2 9 4 1.00
C22:6n-3 144 (122, 179) 19-363 134 (122, 185) 1 6 -407 0.98
Total n-3 205 (177, 294) 30 - 676 169 (159, 273) 23 - 695 0.66
Total n-6 893 (805, 1099) 344 - 2295 827 (758, 1048) 196- 1934 0.51
Ratio n6/n3 5 (4, 6) 2 - 1 4 5 (4 ,6 ) 2 - 2 0 0.96
Table 47. Total fatty acid concentrations (nmol/ml) in maternal RBC total lipids at 15 
weeks gestation for both groups (n-47 for fish oil group, n=49 for placebo group), p  
values were obtained on performing Mann-Whitney tests between the groups. 95% Cl 
-  Wilcoxon confidence interval for the median.
9.2.2(h) Maternal RBC at 28 weeks gestation (Table 48)
At 28 weeks gestation, maternal DHA concentration in RBC was significantly higher 
(p=0.02) in the fish oil group. The fish oil group had a median concentration of 194 
nmol/ml of DHA, while the placebo group had a median value of 171 nmol/ml.
There were no other significant differences in RBC fatty acid concentrations between 
the groups at 28 weeks, including total n-3 fatty acids. However, the ratio of n-6 to n- 
3 fatty acids was significantly lower (p=0.01) in the fish oil group (median ratio 2.8) 
than the placebo group (median ratio 3.4).
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Fish Oil Group Placebo Group P
Median 95% Cl Range Median 95% Cl Range
C10;0 0 (0,0) 0 - 0 0 (0, 0) 0 - 0
C12:0 0 (0, 0) 0 - 0 0 (0, 0) 0 - 0
C14;0 12 (11,14) 0 - 2 0 11 (9, 13) 0 - 2 4 0.38
C16:0 885 (860, 917) 701 - 1101 859 (826,911) 533 - 1104 0.39
C16:ln-7 16 (14, 18) 0 -1 0 7 15 (12, 17) 0 - 2 9 0.28
C18:0 369 (353, 390) 303 - 477 369 (351,384) 162-508 0.93
C18:ln-9 366 (345, 392) 279 - 504 365 (346, 392) 202 - 489 0.95
C18:2n-6 253 (239, 278) 173 - 342 250 (236, 262) 132 - 334 0.50
C18:3n-3 0 (0, 1) 0 - 3 0 (0, 1) 0 - 4
C20:0 11 (10, 12) 7 -1 7 11 (9, 12) 0 -1 9 0.99
C20:3n-6 126 (113, 140) 67 - 180 134 (116,158) 60 - 254 0.56
C20:4n-6 264 (250, 279) 172 - 362 277 (262, 298) 121-366 0.17
C20:5n-3 11 (9, 14) 0 -2 3 11 (7, 12) 0 -2 3 0.42
C22:4n-6
C22:5n-6
C24:0
C24:ln-9
105 (91, 112) 4 6 -1 4 1 121 (101, 127) 33 - 181 0.12
C22:5n-3 58 (51,61) 2 8 -7 5 60 (52, 66) 0 -9 0 0.34
C22:6n-3 194 (181,211) 103 -297 171 (153, 185) 89 - 275 0.02
Total n-3 257 (244, 287) 131-378 246 (213,262) 104 - 364 0.12
Total n-6 753 (708, 788) 493 - 1010 780 (723, 839) 371 - 1040 0.45
Ratio n6/n3 3 (3 ,3) 2 - 5 3 (3 ,4 ) 2 - 6 0.01
Table 48. Total fatty acid concentrations (nmol/ml) in maternal RBC total lipids at 28 
weeks gestation for both groups (n-30 for fish oil group, n=33 for placebo group), p  
values were obtained on performing Mann-Whitney tests between the groups. 95% Cl 
-  Wilcoxon confidence interval for the median.
9.2.2(c) Maternal RBC at Birth (Table 49)
At the time of delivery, maternal RBC concentration of DHA remained significantly 
higher in the fish oil group (p=0.02), with a median value of 168 nmol/ml; the placebo 
group had a median of 118 nmol/ml. The summed concentrations of total n-3 fatty 
acids were higher (p=0.03) in the fish oil group with a total median of 207 nmol/ml, as 
opposed to 149 nmol/ml in the placebo group.
Differences in the concentrations of other fatty acids remained insignificant. 
However, the fish oil group did have a significantly lower (p=0.005) ratio of n-6 to n- 
3 fatty acids (median ratio 3.2) than the placebo group (median ratio 4.0).
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Fish Oil Group Placebo Group P
Median 95% Cl Range Median 95% Cl Range
C10:0 0 (0, 0) 0 - 0 0 (0, 0) 0 - 3
C12:0 0 (0, 0) 0 - 0 0 (0, 0) 0 - 0
C14;0 10 (5, 11) 0 -1 8 10 (7, 12) 0 -2 3 0.46
C16:0 1000 (906, 1063) 485 - 1408 971 (827, 1013) 254 - 1476 0.63
C16:ln-7 16 (10, 18) 0 -1 0 9 14 (9, 17) 0 -1 1 2 0.68
C18:0 380 (337,413) 129 - 572 377 (287, 397) 7 0 -5 1 4 0.45
C18:ln-9 421 (379, 466) 198 - 676 432 (368, 476) 95 - 747 0.97
C18:2n-6 251 (227, 290) 91 - 402 242 (203, 270) 64 -411 0.36
C18:3n-3 0 (0, 0) 0 - 0 0 (0, 0) 0 - 3
C20:0 11 (8,11) 0 -1 8 9 (6, 10) 0 -1 5 0.17
C20:3n-6 81 (74, 116) 21 - 196 91 (69, 106) 1 9 -202 0.74
C20:4n-6 225 (190, 262) 19-393 236 (175, 260) 34 - 372 0.96
C20:5n-3 0 (0, 7) 0 -1 9 0 (0, 2) 0 -1 3 0.24
C22;4n-6
C22:5n-6
C24:0
C24:ln-9
57 (51,78) 0 -1 2 6 69 (50, 82) 0 -1 3 3 0.85
C22:5n-3 40 (31,49) 0 -7 8 32 (23,41) 0 -7 4 0.19
C22:6n-3 168 (128, 194) 6 -3 0 5 118 (92, 143) 6 -2 2 6 0.02
Total n-3 207 (164, 244) 9 -3 9 3 149 (118, 185) 11-298 0.03
Total n-6 639 (555, 742) 131 - 1065 612 (499, 709) 117-1040 0.63
Ratio n6/n3 3 (3 ,4 ) 2 -1 5 4 (4, 5) 2 -1 2 0.005
Table 49. Total fatty acid concentrations (nmol/ml) in maternal RBC total lipids at 
birth for both groups (n=29 for fish oil group, n=28 for placebo group), p  values were 
obtained on performing Mann-Whitney tests between the groups. 95% Cl -  Wilcoxon 
confidence interval for the median.
9.2.2fdf Umbilical Cord RBC (Table 50)
Umbilical cord RBC from the two treatment groups were not significantly different in 
the concentrations of any fatty acids. Indeed, cord RBC from the placebo group were 
slightly higher (median 263 nmol/ml) in DHA concentration than cord RBC from the 
fish oil group (221 nmol/ml), but the difference was not significant (p=0.63).
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Fish Oil Group Placebo Group P
Median 95% Cl Range Median 95% Cl Range
C10:0 0 (0 ,0) 0 - 0 0 (0 ,0 ) 0 - 0
C12:0 0 (0, 0) 0 - 0 0 (0 ,0 ) 0 - 0
C14:0 11 (6, 12) 0 -1 9 12 (7, 13) 0 -2 4 0.42
C16:0 784 (728, 906) 532 - 1375 874 (832, 989) 359-4838 0.06
C16:ln-7 13 (11,17) 0 -2 6 1 14 (12, 17) 0 -1 6 9 0.76
C18:0 328 (304, 387) 179 - 575 368 (341, 389) 0 -5 0 1 0.29
C18:ln-9 278 (253, 330) 179 - 579 306 (283, 356) 135- 1947 0.14
C18:2n-6 85 (80, 106) 4 6 -1 6 1 98 (87, 118) 27 - 554 0.43
C18:3n-3 0 (0, 0) 0 - 3 0 (0, 0) 0 -1 2
C20;0 12 (11,16) 0 -2 8 16 (14,18) 6 -3 8 0.12
C20:3n-6 482 (416, 584) 153 -939 573 (500, 662) 188 - 1244 0.18
C20:4n-6 349 (321,426) 239 - 734 420 (384, 465) 154 - 690 0.06
C20:5n-3 2 (1, 4) 0 -  13 2 (1 ,6 ) 0 -4 1 0.96
C22:4n-6
C22:5n-6
C24;0
C24:ln-9
195 (175, 251) 8 5 -5 1 5 251 (217, 295) 111-598 0.14
C22;5n-3 26 (16,33) 0 -1 1 0 19 (11,33) 0 - 6 6 0.78
C22:6n-3 221 (207, 283) 70 - 465 263 (225, 288) 98 - 478 0.63
Total n-3 255 (228,310) 7 0 -4 8 1 296 (243,311) 104 - 542 0.81
Total n-6 1150 (1008, 1371) 613-2121 1373 (1199, 1525) 480 - 3086 0.10
Ratio n6/n3 5 (4, 5) 3 - 9 5 (5 ,6 ) 3 - 8 0.07
Table 50. Total fatty acid concentrations (nmol/ml) in umbilical cord RBC total lipids 
for both groups (n=27 for fish oil group, n=29 for placebo group), p  values were 
obtained on performing Mann-Whitney tests between the groups. 95% Cl -  Wilcoxon 
confidence interval for the median.
9.2.3 Plasma Fatty Acids: % Total Fatty Acids (Relative Levels) (Figure 18) 
9.2.3(a) Maternal Plasma at 15 weeks gestation (Table 51)
Initial values of % TFA did not differ significantly in the plasma samples of the 
treatment groups. DHA accounted for 1.5% TFA in the fish oil group, and 1.7% TFA 
in the placebo group (p=0.15).
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Fish Oil Group Placebo Group P
Median 95% Cl Range Median 95% C l Range
C10:0 0.0 (0.0, 0.0) 0 .0 -0 .0 0.0 (0.0, 0.0) 0 .0 -0 .1
C12:0 0.1 (0.1, 0.2) 0.0 - 0.6 0.1 (0.1, 0.1) 0 .0 - 1.2
C14:0 1.4 (1.3, 1.6) 0 .6 -2 .4 1.2 (1.1, 1.4) 0.3 -3 .0 0.13
C16:0 29.7 (29.2, 30.6) 24.0 - 35.0 30.2 (29.4, 30.4) 25.3 - 34.2 0.91
C16;ln-7 2.3 (2.1, 2.6) 0 .9 -4 .6 1.9 (1.8, 2.2) 1.1 -4.3 0.17
C18:0 7.4 (7.2, 7.8) 5 .8 -10 .0 7.5 (7.1, 7.6) 5 .0 -10 .8 0.44
C18:ln-9 20.4 (20.0,21.5) 15.4-26.7 19.8 (19.1,20.8) 14.6-25.8 0.14
C18:2n-6 27.3 (25.4,28.1) 18.9-38.0 27.3 (26.7, 28.7) 18.9-36.9 0.25
C18:3n-3 0.5 (0.5, 0.6) 0.1 -0 .9 0.5 (0.4, 0.5) 0 .2 -1 .1 0.38
C20;0 0.3 (0.3, 0.4) 0 .0 -0 .6 0.3 (0.3, 0.4) 0 .2 -0 .6 0.78
C20:3n-6 1.6 (1.4, 1.7) 0.9 - 2.4 1.5 (1.5, 1.7) 0 .8 -3 .3 0.81
C20:4n-6 5.4 (4.9, 5.7) 3.3 -7 .8 5.4 (5.2, 5.8) 3.1 -9 .0 0.38
C20:5n-3 0.3 (0.3, 0.4) 0 .0 -2 .0 0.3 (0.3, 0.4) 0 .0 -1 .2 0.59
C22:4n-6 0.1 (0.1, 0.2) 0.0 - 0.4 0.2 (0.1, 0.2) 0.0 - 0.4 0.79
C22:5n-6 0.0 (0.0, 0.0) 0 .0 -0 .1 0.0 (0.0, 0.0) 0 .0 -0 .0
C24:0 0.2 (0.2, 0.3) 0 .0 -0 .7 0.3 (0.2, 0.3) 0 .0 -0 .8 0.29
C24:ln-9 0.9 (0.7, 0.9) 0 .0 - 1.5 0.9 (0.8, 1.0) 0.1 - 1.8 0.19
C22:5n-3 0.2 (0.2, 0.2) 0 .0 -0 .5 0.2 (0.2, 0.2) 0.0 - 0.4 0.49
C22:6n-3 1.5 (1.4, 1.8) 0 .8 -2 .9 1.7 (1.6, 1.9) 0 .7 -3 .2 0.15
Total n-3 2.5 (2.4, 3.0) 1 .2 -5 .6 2.7 (2.5, 3.0) 1 .6 -4 .7 0.57
Total n-6 35.0 (32.5, 35.4) 25 .9 -42 .4 35.1 (34.0, 36.0) 26 .0 -43 .7 0.23
Ratio n6/n3 13.4 (12.0, 14.9) 5 .8-30 .1 12.7 (12.1, 14.6) 7 .7 -21 .5 0.98
Table 51. Percentage total fatty acids in maternal plasma total lipids at 15 weeks 
gestation for both groups (n=48 for fish oil group, n=49 for placebo group), p  values 
were obtained on performing Mann-Whitney tests between the groups. 95% Cl -  
Wilcoxon confidence interval for the median.
9.2.3(b) Maternal Plasma at 28 weeks (Table 52)
There was no significant difference in DHA between groups, with medians of 1.8% 
TFA and 1.6% TFA for the fish oil group and placebo groups respectively (p=0.09).
By 28 weeks, the placebo group had a significantly higher % TFA (p=0.01) of 
dihomo-y-linolenic acid (DHGLA, 20:3n-6), compared to the fish oil group (median 
1,5% V.S. median 1.4%). The fish oil group had a significantly higher (p-0.05) % of 
total n-3 fatty acids, with a median of 3.1% compared to 2.6% in the placebo group. 
The ratio of n-6 to n-3 fatty acids was lower (p=0.04) in the fish oil group (median 
ratio 10.1) than the placebo group (median ratio 12.2).
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Fish Oil Group Placebo Group P
Media 95% Cl Range Median 95% Cl Range
ClOiO 0.0 (0.0, 0.0) 0.0 - 0.0 0.0 (0.0, 0.0) 0 .0 -0 .1
C12:0 0.1 (0.1, 0.2) 0 .0 -0 .1 0.1 (0.1, 0.1) 0.1 -0 .7
C14:0 1.6 (1.4, 1.8) 0 .7 -1 .7 1.6 (1.4, 1.7) 1 .4 -2 .3 0.43
C16:0 31.6 (30.5,31.9) 16.4 -31.6 30.7 (30.0,31.6) 30.0 - 36.4 0.48
C16:ln-7 2.5 (2.2, 3.0) 0 .9 -2 .9 2.5 (2.3, 2.9) 2 .3 -4 .7 0.90
C18:0 6.6 (6.3, 6.9) 3 .4 -6 .6 6.5 (6.3, 6.6) 6.3 - 8.0 0.61
C18:ln-9 21.5 (20.4, 22.9) 9 .8-22 .1 21.1 (20.7, 22.1) 20.7 - 25.3 0.59
C18:2n-6 25.4 (24.4, 27.3) 18.3-27.7 27.1 (25.6, 27.7) 2 5 .6 -31 .4 0.33
C18:3n-3 0.6 (0.7, 0.7) 0.3 - 0.7 0.6 ' (0.5, 0.7) 0.5 - 1.3 0.26
C20:0 0.3 (0.3, 0.4) 0.2 - 0.4 0.3 (0.3, 0.4) 0.3 - 0.6 0.43
C20:3n-6 1.4 (1.3, 1.5) 0 .9 - 1.7 1.5 (1.5, 1.7) 1 .5 -2 .2 0.01
C20:4n-6 4.2 (4.0, 4.8) 2.4 - 5.0 4.6 (4.4, 5.0) 4.4 - 7.6 0.24
C20:5n-3 0.3 (0.3, 0.5) 0.2 - 0.4 0.3 (0.3, 0.4) 0.3 - 1.8 0.14
C22:4n-6 0.1 (0.1, 0.1) 0.0 - 0.1 0.1 (0.1, 0.1) 0.1 -0 .4 0.90
C22:5n-6 0.0 (0.0, 0.0) 0.0 - 0.0 0.0 (0.0, 0.0) 0 .0 -0 .1  '
C24:0 0.1 (0.1, 0.1) 0 .0 -0 .1 0.1 (0.1, 0.1) 0.1 -0 .4 0.41
C24:ln-9 0.8 (0.7, 0.9) 0.1 -0 .8 0.7 (0.5, 0.8) 0.5 - 1.2 0.29
C22:5n-3 0.2 (0.2, 0.2) 0.0 - 0.2 0.2 (0.1, 0.2) 0.1 -0 .4 0.37
C22:6n-3 1.8 (1.7, 2.1) 1.0- 1.9 1.6 (1.5, 1.9) 1.5 -2 .9 0.09
Total n-3 3.1 (2.9, 3.4) 2 .0 -3 .2 2.6 (2.4, 3.2) 2 .4 -5 .7 0.05
Total n-6 31.7 (30.1,33.4) 23.7 - 34.2 33.3 (32.1,34.2) 32.1 -38.0 0.13
Ratio n6/n3 10.1 (9.6, 11.2) 7 .0 -1 4 .2 12.2 (11:1,14.2) 11 .1-27.0 0.02
Table 52. Percentage total fatty acids in maternal plasma total lipids at 28 weeks 
gestation maternal plasma for both groups (n=30 for fish oil group, n=33 for placebo 
group), p  values were obtained on performing Mann-Whitney tests between the 
groups. 95% Cl -  Wilcoxon confidence interval for the median.
9.2.3(c) Maternal Plasma at Birth (Table 53)
Maternal plasma DHA as a % TFA was not significantly different at the time of 
delivery between groups: the fish oil group had median 1.4% DHA, the placebo group
1.1% (p=0.06).
Maternal plasma % of palmitic acid (16:0) was significantly lower (p=0.04) in the fish 
oil group (median 32.5%) than the placebo group (median 33.7%).
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Fish Oil Group Placebo Group P
Median 95% Cl Range Median 95% Cl Range
C10:0 0.0 (0.0, 0.0) 0 .0 -0 .0 0.0 (0.0, 0.0) 0.0 - 0.0
C12:0 0.0 (0.0, 0.0) 0 .0 -0 .1 0.0 (0.0, 0.0) 0 .0 -0 .1
C14:0 1.0 (0.9, 1.1) 0 .5 - 1.8 1.0 (0.9, 1.1) 0.3 - 1.7 0.22
C16:0 32.5 (31.9, 33.1) 28 .9 -35 .5 33.7 (32.8, 34.5) 29 .0 -38 .4 0.04
C16:ln-7 2.6 (2.4, 3.1) 1.6 - 4.6 3.0 (2.8, 3.5) 1 .7-5 .5 0.10
C18:0 6.4 (6.0, 6.5) 4 .8 -7 .7 6.1 (5.8, 6.3) 4.3 - 8.6 0.12
C18:ln-9 23.1 (22.4, 24.9) 18.0-31.2 23.8 (22.8, 24.9) 19.1-30.3 0.67
C18;2n-6 26.2 (24.3,27.1) 18.7-32.1 24.2 (23.0, 25.4) 19.2-28.8 0.08
C18:3n-3 0.5 (0.4, 0.6) 0 .0 -1 .3 0.5 (0.4, 0.6) 0 .2 -1 .1 0.96
C20:0 0.3 (0.1, 0.3) 0.0 - 0.4 0.2 (0.1, 0.3) 0.0 - 0.4 0.34
C20:3n-6 1.2 (1.1, 0.3) 0.7 - 2.0 1.3 (1.1, 1.3) 0 .8 - 1.9 0.64
C20:4n-6 3.7 (3.5, 4.3) 1 .9-6 .3 3.9 (3.7, 4.2) 2 .5 -5 .3 0.63
C20:5n-3 0.2 (0.2, 0.3) 0.0 - 0.6 0.2 (0.1,0.2) 0 .0 -0 .6 0.23
C22:4n-6 0.0 (0.0, 0.1) 0.0 - 0.2 0.0 (0.0, 0.1) 0 .0 -0 .1 0.80
C22:5n-6 0.0 (0.0, 0.0) 0 .0 -0 .1 0.0 (0.0, 0.0) 0 .0 -0 .1
C24:0 0.0 (0.0,0.1) • 0.0 - 0.2 0.0 (0.0, 0.1) 0.0 - 0.2 0.70
C24:ln-9 0.6 (0.5, 0.7) 0 .0 - 1.1 0.6 (0.5, 0.7) 0 .0 - 1.0 0.64
C22:5n-3 0.1 (0.1, 0.1) 0 .0 -0 .2 0.1 (0.1, 0.1) 0.0 - 0.2 0.42
C22:6n-3 1.4 (1.2, 1.6) 0.2 - 2.2 1.1 (1.0, 1.4) 0 .6 -2 .6 0.06
Total n-3 2.4 (1.9, 2.5) 0 .2 -3 .7 1.9 (1.7, 2.2) 0 .8 -3 .9 0.07
Total n-6 30.7 (29.5, 32.1) 24.5 - 37.0 29.5 (28.1,30.7) 23.3 -34.5 0.17
Ratio n6/n3 13.9 (12.7, 17.2) 9.5 - 124.7 15.1 (14.1,20.5) 6 .8 -31 .5 0.16
Table 53. Percentage total fatty acids in maternal plasma total lipids at birth for both 
groups (n=30 for fish oil group, n=29 for placebo group), p  values were obtained on 
performing Mann-Whitney tests between the groups. 95% Cl -  Wilcoxon confidence 
interval for the median.
9.2.3(d) Umbilical Cord Plasma (Table 54)
Plasma samples from the umbilical cord of the two groups did not differ significantly 
in the percentage contribution of any fatty acids. Cord plasma from both the fish oil 
and placebo groups had a DHA level of 3.0% TFA.
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Fish Oil Group Placebo Group P
Median 95% Cl Range Median 95% Cl Range
C10:0 0.0 (0.0, 0.0) 0.0 - 0.0 0.0 (0.0, 0.0) 0 .0 -0 .1
C12:0 0.0 (0.0, 0.0) 0 .0 -0 .1 0.0 (0.0, 0.0) 0 .0 -0 .2
C14:0 1.0 (0.9, 1.0) 0.3 - 1.7 1.0 (1.0, 1.1) 0 .7 - 1.5 0.10
C16:0 33.9 (33.3, 34.5) 30.5 -37.2 33.9 (33.4, 35.0) 31.4-39.1 0.72
C16:ln-7 4.4 (4.2, 5.0) 2 .6 -6 .9 4.7 (4.4, 5.2) 2.1 -7 .8 0.53
C18:0 11.2 (10.6, 11.7) 6 .8 -13 .1 10.8 (10.0, 11.2) 6.0 -12.2 0.11
C18:ln-9 19.1 (18.1, 19.7) 13.9 - 24.9 17.7 (17.4, 19.7) 15.0-23.4 0.47
C18:2n-6 10.9 (10.5, 13.3) 7 .7 -2 3 .9 11.2 (10.4, 12.0) 7 .8 -26 .3 0.77
C18:3n-3 0.1 (0.1, 0.2) 0 .0 -0 .8 0.1 (0.1, 0.2) 0 .0 - 1.0 0.81
C20:0 0.6 (0.5, 0.7) 0 .0 - 1.0 0.6 (0.5, 0.6) 0.0 - 0.9 0.47
C20:3n-6 2.6 (2.4, 2.9) 0 .4 -3 .8 2.5 (2.3, 2.9) 1 .4-4 .3 0.63
C20:4n-6 10.6 (9.1, 11.2) 1 .9-14 .3 11.1 (9.8, 11.7) 4.1 -14.8 0.38
C20:5n-3 0.3 (0.2, 0.3) 0 .0 - 1.1 0.2 (0.1, 0.2) 0 .0 -0 .8 0.07
C22:4n-6 0.4 (0.2, 0.4) 0 .0 -0 .8 0.4 (0.3, 0.5) 0 .0 - 1.3 0.24
C22:5n-6 0.0 (0.0, 0.0) 0.0 - 0.2 0.0 (0.0, 0.1) 0.0 - 0.2
C24:0 0.2 (0.1, 0.4) 0 .0 - 1.0 0.2 (0.1, 0.4) 0 .0 - 1.0 0.78
C24;ln-9 1.1 (0.8, 1.3) 0 .0 -2 .2 0.9 (0.8, 1.2) 0 .0 -2 .1 0.64
C22:5n-3 0.1 (0.1, 0.2) 0 .0 -0 .3 0.1 (0.1, 0.2) 0.0 - 0.3 0.91
C22:6n-3 3.0 (2.5, 3.4) 0.4 - 6.0 3.0 (2.3, 3.2) 1.0- 5.1 0.49
Total n-3 3.3 (3.1, 3.9) 0.4 - 6.8 3.3 (2.7, 3.6) 1.1 -6 .2 0.41
Total n-6 25.8 (24.5, 26.2) 17 .8-31.6 26.0 (24.7, 26.9) 18.6-31.9 0.46
Ratio n6/n3 7.5 (6.6, 8.7) 3.9 - 62.5 8.2 (7.4, 10.7) 4 .2 -18 .6 0.19
Table 54. Percentage total fatty acids in umbilical cord plasma total lipids for both 
groups (n=27 for fish oil group, n=29 for placebo group), p  values were obtained on 
performing Mann-Whitney tests between the groups. 95% Cl -  Wilcoxon confidence 
interval for the median.
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Figure 18. % DHA (median & quartiles) in plasma of both groups. 
No significant differences between groups.
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Figure 19. DHA concentration (median & quartiles) in plasma of both 
groups. Significant difference between groups - *p==0.019.
174
9.2.4 Plasma Fatty Acids: Concentration (Absolute Levels) (Figure 19)
9.2.4(a) Maternal Plasma at 15 weeks gestation (Table 55)
The concentrations of DHA in the plasma of the treatment groups were remarkably 
similar at baseline: the fish oil group had a median DHA concentration of 132 
nmol/ml, while the placebo group had a corresponding median of 134 nmol/ml 
(p=0.98). There were no differences between the groups in the concentrations of total 
n-3 or total n-6 fatty acids, or in the n-6/n-3 ratio.
Baseline plasma samples differed between groups in the concentrations of saturated 
fatty acids. The fish oil group had a higher median concentration than the placebo 
group for the saturates: myristic acid (14:0) (p= 0.02, 92 nmol/ml vs. 11 nmol/ml); 
palmitic acid (16:0) (p= 0.02, 1953 nmol/ml 1618 nmol/ml); and stearic acid (18:0) 
(p= 0.02, 356 nmol/ml vs. 322 nmol/ml).
The fish oil group also had higher concentrations of the monounsaturates palmitoleic 
acid (16:ln-9) (p=0.03, median 125 nmol/ml vs. 101 nmol/ml), and oleic acid (18:ln- 
9) (p=0.004, median 1221 nmol/ml v^ . 1054 nmol/ml).
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Fish Oil Group Placebo Group P
Median 95% C l Range Median 95% C l Range
C10:0 0 (0, 0) 0 - 9 0 (0, 0) 0 - 9
C12:0 8 (8, 13) 0 -5 0 5 (4, 8) 0 -1 1 8
C14:0 92 (85, 108) 2 7 -1 9 0 77 (66, 90) 14-195 0.02
C16:0 1953 (1785,2017) 1028 - 2806 1618 (1563,1803) 837 - 2846 0.02
C16:ln-7 125 (113,149) 46 - 242 101 (91,116) 38 -238 0.03
C18:0 356 (345, 395) 228 - 562 322 (298, 348) 157 - 642 0.02
C18:ln-9 1221 (1136, 1328) 659-2142 1054 (950,1129) 154- 1897 0.004
C18:2n-6 1579 (1477, 1726) 715-2458 1437 (1350,1565) 880 - 2468 0.09
C18:3n-3 61 (52, 66) 1 1 -9 8 50 (44, 57) 14 -110 0.06
C20:0 13 (12, 14) 0 -2 8 12 (11,13) 4 -2 8 0.15
C20:3n-6 272 (257,311) 140-511 238 (234, 296) 116-540 0.27
C20;4n-6 237 (218, 260) 110-412 220 (206, 249) 113-386 0.35
C20:5n~3 23 (21,33) 0 -1 0 9 24 (21,29) 0 -  101 0.93
C22:4n-6
C22;5n-6
C24:0
C24:ln-9
12 (10, 17) 0 -4 0 13 (10, 15) 0 -3 1 0.70
C22:5n-3 14 (13, 17) 0 -3 7 13 (11,15) 0 -2 9 0.24
C22:6n-3 132 (123, 152) 48 - 230 134 (124, 148) 62 -241 0.98
Total n-3 233 (217,262) 121-396 229 (203, 247) 5 2 -4 1 3 0.36
Total n-6 2141 (2007, 2286) 1135-3119 1867 (1829,2138) 1133 - 3293 0.09
Ratio n6/n3 9 (8, 10) 5 -2 0 9 ...... (8, ,10)............. 6 -1 5 0.93
Table 55. Total fatty acid concentrations (nmol/ml) in maternal plasma total lipids at 
15 weeks gestation for both groups (n=48 for fish oil group, n=49 for placebo group). 
p  values were obtained on performing Mann-Whitney tests between the groups. 95% 
Cl -  Wilcoxon confidence interval for the median.
9.2.4(b) Maternal plasma at 28 weeks gestation (Table 56)
Following supplementation, the differences between groups in saturated and 
monounsaturated fatty acids were no longer significant. The fish oil group had higher 
concentrations of two n-3 polyunsaturates, EPA (eicosapentaenoic acid/ timnodonic 
acid, 20:5n-3) and DHA, and consequently, total n-3 fatty acids.
The difference in EPA concentration between the fish oil group (median 33 nmol/ml) 
and the placebo group (median 27 nmol/ml) was significant at p=0.04. Median DHA 
concentration in the fish oil group was 215 nmol/ml; compared to the placebo group 
median of 176 nmol/ml, this difference was significant at p=0.02. Total n-3 fatty 
acids had a median concentration of 359 nmol/ml in the fish oil group, and 275 
nmol/ml in the placebo group (p=0.006). The ratio of n-6 to n-3 fatty acids was lower 
(p=0.003) in the fish oil group (median ratio 7), compared to the placebo group 
(median ratio 8).
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Fish Oil Group Placebo Group P
Median 95% C l Range Median 95% C l Range
C10:0 0 (0, 0) 0 - 9 0 (0 ,0 ) 0 -2 5
C12:0 18 (12, 24) 0 - 6 9 11 (8, 15) 0 - 7 9
C14:0 157 (140, 179) 73 - 254 148 (124, 159) 54 - 220 0.20
C16:0 2807 (2655, 3084) 1786-4401 2546 (2425, 2939) 1196-4375 0.10
C16:ln-7 226 (179, 238) 77 - 368 183 (165,221) 48 - 477 0.35
C18;0 425 (375, 456) 243 - 653 374 (339,403) 2 1 1 -5 3 2 0.07
C18:ln-9 1621 (1464, 1790) 973 -2631 1501 (1317, 1580) 773 -2651 0.14
C18:2n-6 1886 (1679,2103) 891-8163 1645 (1498, 1881) 820-2715 0.16
C18:3n-3 82 (68, 110) 19-285 66 (54, 82) 15- 184 0.10
C20:0 19 (18, 23) 1 2 -6 7 19 (17, 22) 7 -4 5 0.50
C20;3n-6 343 (322, 382) 191-776 365 (335,414) 21 4 -5 6 2 0.44
C20:4n-6 254 (244,310) 126 - 757 303 (253, 308) 155-483 0.86
C20:5n-3 33 (30, 45) 14 - 349 27 (22, 37) 0 -1 2 8 0.04
C22:4n-6
C22:5n-6
C24:0
C24:ln-9
9 (8, 15) 0 -3 7 9 (6, 13) 0 -3 8 0.66
C22;5n-3 18 (15,21) 4 -9 5 15 (12, 19) 0 -4 8 0.18
C22:6n-3 215 (205, 265) 93 - 572 176 (155,217) 70 - 460 0.02
Total n-3 359 (334, 426) 212-1302 275 (256, 354) 98 - 624 0.01
Total n-6 2499 (2286, 2772) 1431 -9722 2387 (2124, 2589) 1261 - 3584 0.36
Ratio n6/n3 7 (6, 7) 4 -1 1 8 (7, 9) 3 - 1 6 0.03
Table 56. Total fatty acid concentrations (nmol/ml) in maternal plasma total lipids at 
28 weeks gestation for both groups (n=30 for fish oil group, n=33 for placebo group). 
p  values were obtained on performing Mann-Whitney tests between the groups. 95% 
Cl -  Wilcoxon confidence interval for the median.
9.2.4(c) Maternal Plasma at Birth (Table 57)
Maternal plasma concentrations of all fatty acids did not differ significantly between 
treatment groups at the time of delivery. Plasma from the fish oil group did have a 
higher concentration of DHA (median 172 nmol/ml) than the placebo group (median 
135 nmol/ml), but the difference was not significant (p=0.11).
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Fish Oil Group Placebo Group P
Median 95% C l Range Median 95% C l Range
C10:0 0 (0, 0) 0 - 0 0 (0, 0) 0 - 0
C12:0 0 (0 ,4 ) 0 - 1 4 0 (0 ,4 ) 0 - 1 6
C14;0 78 (70, 96) 2 1 -2 3 5 96 (77, 107) 1 8 -172 0.37
C16:0 2749 (2404, 3032) 929 - 4638 2572 (2400, 2963) 1460 - 6282 0.90
C16:ln-7 178 (155,216) 60 - 425 217 (186, 244) 7 1 -3 9 6 0.12
C18:0 445 (380, 467) 168 - 634 413 (359,448) 169-777 0.49
C18;ln-9 1853 (1610,2107) 621-3406 1750 (1594, 2003) 946 - 5282 0.77
C18:2n-6 2006 (1830, 2305) 817-3577 1830 (1640, 2157) 1089 - 3732 0.25
C18:3n-3 60 (53, 79) 0 -2 0 2 63 (57, 82) 21 - 127 0.64
C20:0 13 (8, 15) 0 -2 8 13 (8, 15) 0 -2 5 0.85
C20:3n-6 296 (255, 340) 101 - 527 308 (275, 356) 167-679 0.43
C20:4n-6 251 (219, 289) 107-455 258 (227, 288) 122-531 0.74
C20:5n-3 23 (17,31) 0 -9 1 19 (12, 26) 0 -6 1 0.32
C22:4n-6
C22:5n-6
C24:0
C24:ln-9
0 (0, 8) 0 -  17 0 (0, 7) 0 -2 3 0.91
C22:5n-3 12 (8, 16) 0 -5 4 10 (6, 13) 0 - 2 4 0.35
C22:6n-3 172 (152, 207) 29 - 1954 135 (119, 179) 4 1 -3 4 6 0.11
Total n-3 281 (237, 336) 3 0 -2 1 8 4 232 (206, 295) 7 0 -5 1 0 0.25
Total n-6 2569 (2360, 2919) 1025-4107 2384 (2171,2805) 1377-4817 0.40
Ratio n6/n3 9 (8,11) 2 -8 9 10 (9, 14) 5 -2 0 0.16
Table 57. Total fatty acid concentrations (nmol/ml) in maternal plasma total lipids at 
birth for both groups (n=30 for fish oil group, n=29 for placebo group), p  values were 
obtained on performing Mann-Whitney tests between the groups. 95% Cl -  Wilcoxon 
confidence interval for the median.
9.2.4(d) Umbilical Cord Plasma (Table 58)
Fatty acid concentrations in umbilical cord plasma from the fish oil group did not 
differ significantly from those of the placebo group. DHA concentrations were higher 
in the cord plasma of the fish oil group (median 460 nmol/ml) compared to the 
placebo group (median 397 nmol/ml), but the difference was not significant (p=0.50).
178
Fish Oil Group Placebo Group P
Median 95% CÏ Range Median 95% Cl Range
C10:0 0 (0, 0) 0 - 0 0 (0 ,0 ) 0 - 1 0
C12;0 0 (0, 1) 0 - 6 0 (0 ,1 ) 0 - 1 0
C14:0 22 (19, 26) 3 - 6 9 26 (23, 34) 3 -9 5 0.10
C16:0 833 (710,932) 362 - 1908 827 (770, 1016) 94 - 2773 0.45
C16.Tn-7 73 (69, 95) 40 - 178 87 (83, 109) 1 2-153 0.07
C18:0 198 (172, 230) 5 5 -3 1 3 208 (183,232) 2 4 -381 0.83
C18:ln-9 401 (350,463) 175 - 1204 398 (368, 506) 38 - 1821 0.72
C18:2n-6 265 (233,313) 78 - 1398 256 (233, 346) 24 - 2282 0.96
C18:3n-3 3 (2, 5) 0 -4 1 3 (2 ,4 ) 0 - 9 0 0.82
C20:0 11 (8, 12) 0 -2 5 10 (8 ,11) 0 - 1 9 0.99
C20:3n-6 76 (61, 101) 5 -2 6 9 89 (82, 136) 15 -256 0.12
C20:4n-6 147 (109, 157) 1 1 -204 165 (138, 183) 18-271 0.17
C20:5n-3 8 (5, 10) 0 -1 5 5 (4, 7) 0 -1 4 0.17
C22:4n-6 10 (6, 12) 0 - 2 0 12 (9, 15) 0 -2 7 0.12
C22;5n-6
C24:0
C24:ln-9
C22:5n-3 4 (3, 14) 0 - 3 4 8 (5, 13) 0 -3 9 0.87
C22:6n-3 460 (354, 660) 4 0 -  1335 397 (268, 555) 5 - 1299 0.50
Total n-3 467 (358, 685) 4 0 -  1384 416 (281, 583) 5 - 1346 0.47
Total n-6 519 (435, 577) 151 - 1654 559 (493, 692) 61 -2601 0.21
Ratio n6/n3 1 (1 ,3 ) 0 - 7 2 (1 ,5 ) 0 -1 3 0.14
Table 58. Total fatty acid concentrations (nmol/ml) in umbilical cord plasma total 
lipids for both groups (n=27 for fish oil group, n=29 for placebo group), p  values 
were obtained on performing Mann-Whitney tests between the groups. 95% Cl -  
Wilcoxon confidence interval for the median.
9.2.5 Placental Tissue Fatty Acids: % Total Fatty Acids (Relative Levels) (Figure 
20, Table 59)
DHA accounted for remarkably similar % TFA in the placental tissue of the two 
treatment groups. Placenta from the fish oil group had median 3.6% DHA, while that 
from the placebo group had median 3.5% DHA (p=0.11).
Myristic acid (14:0) in placenta tissue from the fish oil group (median 0.41%) was of a 
lower % TFA (p=0.02) than in the placebo group (0.45%).
The ratio of n-6 to n-3 fatty acids was lower in the fish oil group (median 8.0) than the 
placebo group (median 8.5), a difference significant at p=0.04.
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Fish Oil Group Placebo Group P
Median 95% C l Range Median 95% C l Range
C10:0 0.0 (0.0, 0.0) 0 .0 -0 .1 0.0 (0.0, 0.0) 0.0 - 0.2
C12:0 0.0 (0.0, 0.0) 0 .0 -0 .0 0.0 (0.0, 0.0) 0 .0 -0 .1
C14:0 0.4 (0.3, 0.4) 0 .0 -0 .6 0.5 (0.4, 0.5) 0.2 - 0.7 0.02
C16:0 31.7 (31.2, 32.8) 26 .9-35 .3 32.5 (31.9, 33.0) 28.1 -34.1 0.23
C16:ln-7 0.8 (0.8, 1.0) 0 .5 - 1.5 0.9 (0.8, 1.0) 0.5 - 3.0 0.56
C18:0 14.8 (14.5, 15.4) 13.5-21.7 14.4 (14.2, 14.9) 13.4-17.1 0.15
C18:ln-9 10.1 (9.8, 10.4) 8 .6 -11 .3 10.4 (10.2, 10.6) 9 .2 -11 .8 0.21
C18:2n-6 9.9 (9.4, 10.4) 6.1 - 12.4 9.6 (9.4, 10.2) 8.2 - 12.6 0.52
C18:3n-3 0.1 (0.0, 0.1) 0 .0 -0 .6 0.0 (0.0, 0.1) 0.0 - 0.4 0.18
C20:0 0.3 (0.2, 0.5) 0 .0 -1 .0 0.3 (0.2, 0.3) 0 .0 - 1.2 0.13
C20:3n-6 4.4 (4.2, 5.0) 3.5 -6 .4 4.5 (4.4, 5.0) 3.3 -7 .0 0.80
C20:4n-6 18.2 (17.7, 19.1) 14.7-21.9 18.9 (18.5, 19.4) 17.2-21.3 0.12
C20:5n-3 0.1 (0.1, 0.2) 0 .0 -0 .4 0.1 (0.1, 0.1) 0.0 - 0.4 0.67
C22:4n-6 1.0 (0.9, 1.0) 0 .4 - 1.4 1.0 (0.9, 1.1) 0 .6 -2 .8 0.33
C22:5n-6 0.1 (0.1, 0.1) 0 .0 -0 .3 0.1 (0.1, 0.2) 0.0 - 0.3 0.26
C24:0 1.4 (1.2, 1.7) 0 .4 -5 .0 1.2 (1.1, 1.4) 0.1 -2.1 0.16
C24:ln-9 1.0 (0.9, 1.3) 0.1 -3 .7 1.1 (1.0, 1.2) 0 .7 -2 .0 0.53
C22:5n-3 0.5 (0.4, 0.5) 0.3 -0 .8 0.5 (0.4, 0.5) 0 .2 -0 .8 0.72
C22:6n-3 3.6 (3.6, 4.0) 2.1 -5.5 3.5 (3.1, 3.7) 2.1 -5 .3 0.11
Total n-3 4.3 (4.1, 4.7) 2 .8 -6 .5 4.1 (3.6, 4.4) 2 .4 -5 .8 0.07
Total n-6 34.5 (33.7, 34.8) 26.5 -35.7 34.6 (34.1,35.2) 32,8 -37.4 0.34
Ratio n6/n3 8.0 (7.4, 8.2) 5.5 - 10.2 8.5 (8.1, 9.9) 5.7 - 14.3 0.04
Table 59. Percentage total fatty acids in placental tissue total lipids for both groups 
(n-26 for fish oil group, n=27 for placebo group), p  values were obtained on 
performing Mann-Whitney tests between the groups. 95% Cl -  Wilcoxon confidence 
interval for the median.
9.2.6 Placental Tissue Fatty Acids: Concentration (Absolute Levels) (Figure 21, 
Table 60)
Placental tissue DHA concentrations were high for both groups (median 6707 nmol/g 
in the fish oil group, 5190 nmol/g in the placebo group), although the difference 
between them was not significant (p=0.12).
Myristic acid (14:0) concentration was lower (p=0.04) in the placental tissue of the 
fish oil gi'oup (median 58 nmol/g) than the placebo group (median 67 nmol/g).
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Fish Oil Group Placebo Group P
Median 95% Cl Range Median 95% C l Range
Cl 0.0 0 (0, 0) 0 -3 7 0 (0, 0) 0 -3 8
C12:0 0 (0 ,1) 0 - 3 0 (0, 2) 0 - 8
C14:0 58 (42, 64) 0 -1 1 3 67 (59,75) 39 - 101 0.04
C16:0 5082 (4678, 5353) 3663 -7213 4781 (4530, 5170) 3347-6617 0.43
C16:ln-7 93 (87, 119) 5 6 -2 1 0 102 (90, 113) 4 1 -3 3 2 0.98
018:0 1599 (1525, 1771) 1191 -3425 1531 (1437, 1680) 1078 -2571 0.29
C18.Tn-9 1454 (1310, 1528) 1013-2275 1374 (1287, 1500) 929 - 2042 0.82
C18:2n-6 1510 (1423, 1630) 1131 -2053 1385 (1333, 1592) 1078 - 1959 0.35
C18:3n-3 8 (4, 17) 0 -  103 6 (3, 8) 0 -5 1 0.34
020:0 17 (13, 27) 2 - 7 7 14 (10, 17) 0 -7 2 0.16
O20:3n-6 615 (581, 726) 331 - 1090 609 (552, 702) 347- 1187 0.70
O20:4n-6 1315 (1156, 1402) 799 - 1775 . 1254 (1159, 1364) 832- 1635 0.85
O20:5n-3 35 (25, 90) 0 -2 1 5 33 (21, 63) 0 -1 9 5 0.63
022:4n-6 130 (111, 163) 47 - 284 143 (122, 168) 54 - 262 0.56
022:5n-6
024:0
024:ln-9
022:5n-3 200 (177, 279) 969-471 176 (166, 231) 83 -371 0.50
022:6n-3 6717 (5051, 7471) 1726- 12024 5190 (4223, 6090) 1798 - 9579 0.12
Total n-3 6973 (5340, 7775) 1860- 12561 5636 (4437, 6356) 1971 -9742 0.12
Total n-6 3598 (3357, 3880) 2369 - 4566 3390 (3239, 3806) 2576-4838 0.56
Ratio n6/n3 1 (0 ,1 ) 0 -  1 1 (1, 1) 0 - 1 0.17
Table 60. Total fatty acid concentrations (nmol/g) in placental tissue total lipids for 
both groups (n=26 for fish oil group, n=27 for placebo group), p  values were obtained 
on performing Mann-Whitney tests between the groups. 95% Cl -  Wilcoxon 
confidence interval for the median.
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Figure 20. % DHA (median & quartiles) in placental tissue of both 
groups. No significant difference between groups.
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of both groups. No significant difference between groups.
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9.2.7 Umbilical Cord Tissue Fatty Acids: % Total fatty Acids (Relative Levels)
(Figure 22, Table 61)
Fish oil and placebo groups had no significant differences in the % TFA measured in 
cord tissue samples. DHA accounted for median 6.3% TFA in cord tissue from the 
fish oil group, and median 5.9% TFA in that from the placebo group (p=0.19).
Fish Oil Group Placebo Group P
Median 95% C l Range Median 95% C l Range
C10:0
C12:0
C14:0 0.7 (0.7, 0.9) 0 .4 -1 .4 0.8 (0.7, 0.9) 0 .2 -  1.2 0.68
C16:0 21.9 (21.5, 22.8) 19.7-24.8 22.3 (21.2, 22.8) 17.7-24.8 0.92
C16:ln-7 10.2 (1.1, 1.3) 1.0- 1.6 1.2 (1.2, 1.3) 1.0- 1.6 0.54
C18:0 19.3 (18.9, 19.8) 18.0-21.1 19.1 (18.9, 19.9) 17.3-21.7 0.98
C18:ln-9 15.7 (15.3, 17.0) 13.8-21.3 17.0 (16.3, 17.7) 14.2 - 20.5 0.13
C18:2n-6 4.2 (4.1, 4.5) 3 .5 -5 .6 4.2 (4.0,4.5) 3 .5 -5 .8 0.60
C18:3n-3 0.6 (0.4, 0.7) 0 .0 - 1.4 0.5 (0.5, 0.7) 0.1 - 1.2 0.99
C20:0 0.9 (0.7, 1.4) 0.3 -2 .7 0.6 (0.6, 1.3) 0.3 - 2.8 0.61
C20:3n-6 2.7 (1.6, 3.3) 0.0 - 5.2 3.0 (1.5, 3.1) 0.0 - 5.6 0.65
C20;4n-6 16.3 (15.9, 16.8) 13 .9-18.4 16.5 (16.0, 16.8) 14.0-19.0 0.76
C20:5n-3 0.3 (0.3, 0.4) 0.1 -0 .7 0.3 (0.2, 0.5) 0.1 - 1.0 0.96
C22:4n-6 5.9 (5.6, 6.0) 4.8 - 6.5 5.8 (5.5, 6.1) 4 .7 -7 .5 0.75
C22:5n-6 2.5 (2.4, 2.8) 1 .9 -3 .5 2.7 (2.5, 2.9) 1 .7 -3 .6 0.57
C24;0
C24:ln-9
C22:5n-3 0.6 (0.5, 0.6) 0.3 - 0.8 0.6 (0.5, 0.7) 0.3 - 1.1 0.70
C22:6n-3 6.3 (5.9, 6.5) 4.5 -7 .4 5.9 (5.7, 6.2) 4 .6 -7 .7 0.19
Total n-3 7.7 (7.3, 8.1) 5.9 - 9.2 7.5 (7.1, 7.8) 5 .7 -9 .8 0.38
Total n-6 32.3 (30.4, 32.5) 27.0 - 35.9 30.9 (30.0,32.1) 26.5 -36.6 0.65
Ratio n6/n3 4.0 (3.9,4.3) 3.3 - 5.7 4.1 (3.9, 4.5) 3.1 -5 .3 0.76
Table 61. Percentage total fatty acids in umbilical cord tissue total lipids for both 
groups (n=26 for fish oil group, n=27 for placebo group), p  values were obtained on 
performing Mann-Whitney tests between the groups. 95% Cl -  Wilcoxon confidence 
interval for the median.
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9.2.8 Breast Milk Fatty Acids: % Total Fatty Acids (Relative Levels) (Figure 23, 
Table 62)
The contribution of DHA to % TFA was similar in the breast milk samples from the 
two treatment groups. Breast milk from the fish oil group contained DHA as median 
0.2% TFA; milk from the placebo group had 0.3% DHA (p=0.88).
Palmitic acid (16:0) accounted for a significantly lower (p=0.03) % TFA in the breast 
milk of the fish oil group (median 29.6%) than the placebo group (median 31.0%).
Fish Oil Group Placebo Group P
Median 95% Cl Range Median 95% C l Range
C10:0 0.1 (0.1, 0.3) 0 .0 -0 .6 0.0 (0.0, 0.1) 0.0 - 0.4 0.20
C12;0 3.6 (2.3, 4.3) 1.1 -5 .4 2.2 (1.7, 3.6) 0.9 -5 .6 0.25
C14:0 7.0 (5.8, 7.7) 4 .5 - 8.6 5.9 (5.3, 7.7) 4 .2 - 10.7 0.43
C16:0 29.6 (28.2, 30.4) 26 .7-31 .5 31.0 (30.3,31.8) 28 .4 -33 .4 0.03
C16:ln-7 2.3 (2.0, 2.7) 1.3 -4.1 2.3 (2.1, 3.0) 1 .9 -4 .0 0.86
C18:0 8.4 (8.0, 8.8) 6.5 - 10.6 8.0 (7.5, 8.7) 6.8 -10.0 0.38
C18:ln-9 36.0 (34.5,37.1) 32 .9- 38.9 36.8 (34.5,38.1) 30.1 -39.3 0.19
C18:2n-6 11.1 (9.9, 11.9) 8.3 - 14.0 10.5 (9.3, 10.9) 6 .7 - 12.5 0.21
C18:3n-3 0.9 (0.8, 1.0) 0 .6 - 1.3 0.9 (0.8, 1.0) 0.3 - 1.2 0.90
C20:0 0.3 (0.3, 0.4) 0.2 - 0.5 0.3 (0.3, 0.3) 0.0 - 0.4 0.31
C20:3n-6 0.4 (0.3, 0.6) 0 .2 -0 .8 0.5 (0.4, 0.6) 0.3 -0 .7 0.57
C20;4n-6 0.4 (0.3, 0.5) 0.3 -0 .7 0.5 (0.5, 0.6) 0.3 - 0.7 0.10
C20:5n-3 0.0 (0.0, 0.0) 0 .0 -0 .1 0.0 (0.0, 0.0) 0.0 - 0.0
C22:4n-6 0.1 (0.1, 0.3) 0.0 - 0.4 0.2 (0.1, 0.3) 0.0 - 0.4 0.34
C22:5n-6 0.0 (0.0, 0.0) 0 .0 -0 .0 0.0 (0.0, 0.0) 0.0 - 0.0
C24:0 0.0 (0.0, 0.1) 0 .0 -0 .2 0.0 (0.0, 0.1) 0 .0 -0 .1 0.83
C24:ln-9 0.1 (0.1, 0.2) 0 .0 -0 .3 0.1 (0.1, 0.2) 0 .0 -0 .3 0.49
C22:5n-3 0.1 (0.1, 0.3) 0 .0 -0 .6 0.1 (0.1, 0.2) 0 .0 -0 .3 0.74
C22:6n-3 0.2 (0.2, 0.6) 0.1 - 1.1 0.3 (0.2, 0.3) 0.1 -0 .5 0.88
Total n-3 1.4 ■ (1.2, 1.7) 0 .9 -2 .8 1.4 (1.1, 1.5) 0.3 - 1.7 0.86
Total n-6 11.8 (10.8, 13.1) 9 .0 -15 .1 11.6 (10.4, 12.2) 7.6 -13.4 0.41
Ratio n6/n3 8.9 (7.7, 10.1) 4 .7 - 12.0 8.8 (7.9, 10.9) 5 .7 -33 .2 0.94
Table 62. Percentage total fatty acids in breast milk total lipids for both groups (n=12 
for fish oil group, n=14 for placebo group), p  values were obtained on performing 
Mann-Whitney tests between the groups. 95% Cl -  Wilcoxon confidence interval for 
the median.
9.2.9 Breast Milk Fatty Acids: Concentration (Absolute Levels) (Figure 24, Table 
63)
DHA concentrations were slightly, and non-significantly (p=0.78) higher in the breast 
milk of the placebo group (median 2943 nmol/ml), compared to the fish oil group 
(median 2561 nmol/ml).
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The placebo group had a significantly higher (p=0.03) concentration of AA (20:4n-6) 
in breast milk (median 119 nmol/ml) than did the fish oil group (median 194 
nmol/ml). However, the concentrations of total n-3 and total n-6 fatty acids did not 
differ between the groups, nor did the ratio of n-6 to n-3 fatty acids.
Fish Oil Group Placebo Group P
Median 95% C l Range Median 95% C l Range
C10:0 209 (117, 792) 0 - 2488 120 (39, 445) 0 -1 5 8 1 0.36
C12:0 1873 (1352,3891) 627 - 6562 1977 (1245, 3401) 265 - 6320 0.09
C14:0 3803 (2513,4948) 1503 -6171 4827 (3181,5947) 1178 - 10000 0.49
C16:0 16158 (12423, 20464) 7169 -26511 22292 (16309, 25937) 7796-31938 0.08
C16:ln-7 973 (699, 1369) 397-3214 1231 (946, 1762) 440 - 2704 0.19
C18:0 3311 (2615,4238) 1893 - 5598 3966 (3104, 4876) 1523 -6539 0.19
C18:ln-9 17346 (13527,21752) 8337- 32552 22013 (17628, 26052) 8409 - 34685 0.13
C18:2n-6 5559 (4497, 7840) 2548 - 10660 6726 (5526, 7979) 3190-9530 0.55
C18:3n-3 459 (347, 747) 260 - 1235 583 (427, 721) 231 -955 0.49
C20:0 97 (80, 148) 59 - 208 134 (90, 163) 0 -2 2 3 0.43
C20:3n-6 229 (182,369) 57 - 675 361 (252, 447) 8 6 -7 1 5 0.16
C20:4n-6 119 (88, 169) 3 6 -2 6 8 194 (145,213) 57 - 245 0.03
C20:5n-3 0 (0, 68) 0 -1 8 6 0 (0, 0) 0 - 0
C22;4n-6
C22:5n-6
C24:0
C24:ln-9
55 (28, 191) 9 -4 2 0 115 (78, 191) 0 -2 9 7 0.17
C22;5n-3 213 (118,556) 0 - 2343 340 (232,553) 0 -9 4 8 0.41
C22:6n-3 2561 (1614, 5249) 669 - 16466 2943 (1979, 4360) 260 - 6000 0.78
Total n-3 3594 (2222, 6216) 988 - 19830 3893 (2661, 5561) 557 - 7564 0.70
Total n-6 6018 (4901, 8419) 2661 - 11182 7387 (5987, 8707) 3362 - 10286 0.59
Ratio n6/n3 2 (1 ,3 ) 1 - 4 2 (2 ,4) 1 -8 0.98
Table 63. Total fatty acid concentrations (nmol/ml) in breast milk total lipids for both 
groups (n=12 for fish oil group, n=14 for placebo group), p  values were obtained on 
performing Mann-Whitney tests between the groups. 95% Cl -  Wilcoxon confidence 
interval for the median.
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9.3 ANALYSES WITHIN GROUPS: LONGITUDINAL CHANGE AND THE 
RELATIONSHIP BETWEEN MATERNAL AND FETAL STATUS
9.3.1 RBC Fatty Acids: % Total Fatty Acids (Relative Levels)
9.3.1(a) Fish Oil Group: Maternal RBC at 15 and 28 weeks gestation (Figure 25)
By 28 weeks gestation, maternal DHA had increased (p<0.0001) as a % TFA in 
maternal RBC in the fish oil group, from a median of 2.9% to 4.2%.
Myristic acid (14:0) increased in the fish oil group between 15 and 28 weeks 
(p=0.004), from a baseline of 0.2% TFA to 0.4% TFA. RBC at 28 weeks also had 
increased (p=0.002) palmitoleic acid (16:ln-7), elevated from 0.1% TFA to 0.7% 
TFA. Linoleic acid (LA, 18:2n-6) significantly decreased (p=0.001) in the fish oil 
group by 28 weeks from a median 9.5% to 8.6%.
9.3.1(b) Fish Oil Group: Maternal RBC at 28 weeks and Birth (Figure 25)
By delivery, maternal RBC DHA status had declined in the fish oil group (p<0.0001) 
fi*om median 4.1% TFA to 3.4% TFA, a median decline of 0.8% TFA. Thus, at 
delivery, RBC DHA status of fish oil supplemented mothers was (median) 84% of 
their status at 28 weeks. Although maternal RBC DHA was of a higher median % 
TFA at birth (3.1%) than at 15 weeks (2.9%), the difference was not significant 
(p=0.57).
AA (20:4n-6, p<0.0001), EPA (20:5n-3, p<0.0001), adrenic acid (22:4n-6, p<0.0001) 
and DP A (22:5n-3, p=0.0001) all decreased between 28 weeks and birth, to levels 
which were also significantly lower than at 15 weeks (all p<0.01). The fish oil group 
also declined in DHGLA (20:3n-6, p<0.0001) between 28 weeks and birth. Palmitate 
(16:0, p<0.0001) and oleate (18:ln-9, p=0.0005) increased jfrom 28 weeks to birth.
9.3.1(c) Fish Oil Group: Maternal RBC at Birth and Fetal Umbilical Cord RBC 
(Figure 25)
Cord RBC firom infants in the fish oil group had a significantly higher % TFA 
(p<0.0001) of DHA than maternal RBC samples at the time of delivery. DHA 
accounted for median 4.3% TFA in cord RBC, and 3.1% TFA in maternal RBC at 
birth. Cord DHA (median 4.4% TFA) was also significantly higher (p=0.0003) than 
maternal 15 weeks DHA (median 2.9% TFA), hut there was no significant difference
1 8 8
(p=0.54) between cord (median 4.3% TFA) and maternal 28 weeks (median 4% TFA) 
% DHA.
Cord RBC was higher in stearic acid (18:0, p<0.0001), eicosanoic acid (20:0, 
p=0,0005), DHGLA (20:3n-6, p<0.0001), AA (20:4n-6, p<0.0001), and adrenic acid 
(22:4n-6, p<0.0001) as % TFA than maternal RBC at birth. Lignoceric acid (24:0) 
was also higher in cord than maternal RBC, but the difference only tended to 
significance (p=0.02).
Cord RBC was lower in % contributions of oleic acid (18:ln-9, p<0.0001), LA 
(18:2n-6, p<0.0001), nervonic acid (24:ln-9, p<0.0001), and DPA (22:5n-3, 
p<0.0001) lhan maternal RBC at birth.
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9.3.Ud) Placebo Group: Maternal RBC at 15 and 28 weeks gestation (Figure 26)
By 28 weeks gestation, the placebo group had increased (p=0.0005) their % TFA of 
RBC DHA from median 2.8% to 3.4%, a median increase of 25% of their 15 weeks 
level.
Fatty acids of chain length 14:0 (myristic, p=0.005), 16:ln-7 (palmitoleic, p=Q.0Q2), 
20:3n-6 (DHGLA, p<0.0001), 20:5n-3 (EPA, p=0.002), and 22:5n-3 (DPA, p=0.002) 
all accounted for significantly higher % TFA in RBC at 28 weeks than 15 weeks in the 
placebo group.
Fatty acids of chain length 16:0 (palmitic, p=0.007) and 18:0 (stearic, p=0.001) 
declined as % TFA in placebo group RBC between 15 weeks and 28 weeks.
9.3.He) Placebo Group: Maternal RBC at 28 weeks and Birth (Figure 26)
Maternal RBC DHA declined (p=0.0002) from a median of 3.3% TFA at 28 weeks to 
2.4% TFA at delivery, a median decrease of 1.4% TFA, 41% of the 28 weeks level. 
The difference between maternal DHA at 15 weeks (median 2.8% TFA) and birth 
(median 2.4% TFA) was not significant (p=0.85).
Palmitic acid (16:0), which had decreased as a % TFA between 15 weeks and 28 
weeks, significantly increased (p=0.0002) between 28 weeks and delivery, to % 
similar to those at 15 weeks. Conversely, after an increase between 15 and 28 weeks, 
DHGLA (20:3n-6, p<0.0001), EPA (20:5n-3, p=0.0004), and DPA (22:5n-3, 
p=0.0002) decreased between 28 weeks and birth to levels comparable to those at 15 
weeks.
Oleic acid (18.Tn-9) increased between 28 weeks and delivery (p<0.0001). AA 
(20:4n-6, p<0.0001) and adrenic acid (22:4n-6, p=0.0002) decreased between 28 
weeks and delivery, to lower than at baseline 15 weeks (p=0.0002 and 0.004 
respectively).
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9.3. Uf) Placebo Group: Maternal RBC at Birth and Fetal Umbilical Cord RBC 
(Figure 26)
RBC cord DHA was 74% higher than maternal DHA at birth (p<0.0001). Cord DHA 
had a median value of 4.1% TFA and maternal DHA at birth was median 2.4% TFA. 
Cord DHA was also of a significantly higher % TFA than maternal DHA at 15 weeks 
(median 4.1% TFA v^ -. 2.8% TFA, p<0.0001), and at 28 weeks (median 4.2% TFA vs. 
3.4% TFA, p=0.003).
Percentage contributions of palmitoleic acid (16:ln-7, p=0.003), oleic acid (18:ln-9, 
p<0.0001), LA (18:2n-6, p<0.0001), nervonic acid (24:ln-9, p-0.0003), and DPA 
(22:5n-3, p=0.006) were all lower in cord RBC than maternal RBC at birth. Stearic 
acid (18:0, p<0.0001), arachidic acid (20:0, p<0.0001), DHGLA (20:3n-6, p<0.0001), 
AA (20:4n-6, p<0.0001), and adrenic acid (22:4n-6, p<0.0001) were all higher in cord 
RBC than maternal RBC at birth.
192
ôI u§
'H
u
I
ko
13
^  p  c î  
A  t b  ü3
o
spp v m o x  %
i t i
H i
193
9.3.2 RBC Fatty Acids: Concentration (Absolute Levels)
9.3.2(a) Fish Oil Group: Maternal RBC at 15 and 28 weeks gestation (Figure 27)
The concentration of DHA in maternal RBC at 15 weeks (median 178 nmoFml) was 
non-significantly different (p=0.46) from that at 28 weeks (median 195 nmol/ml).
By 28 weeks, the fish oil group had an increased (p=0.0005) concentration of 16: In-7 
(palmitoleic acid) in their RBC, having increased their 15 weeks level by 9 nmoFml, 
or 126%.
9.3.2(b) Fish Oil Group: Maternal RBC at 28 weeks and Birth (Figure 27)
The difference between maternal DHA concentration at 28 weeks (median 195 
nmol/ml) and at birth (median 176 nmol/ml) was not significant (p=0.56). The 
concentration at birth (median 171 nmol/ml) remained similar to that at 15 weeks 
(median 172 nmol/ml) (p=0.57).
The concentration of EPA (20:5n-3) decreased in RBC between 28 weeks and birth 
from a median of 11 nmol/ml to 0.0 nmol/ml (p=0.0003). (Concentrations of 20:5n-3 
at 15 weeks and birth also differed, but only tended to significance at p=0.03).
There were no other significant differences in fatty acid concentrations in the fish oil 
gi'oup between 28 weeks and birth, although 14:0 (myristic acid) was lower (p=0.03) 
and 16:0 (palmitic acid) was higher (p=0.03) at birth.
9.3.2(c) Fish Oil Group: Maternal RBC at Birth and Fetal Umbilical Cord RBC 
(Figure 27)
Cord RBC (median 228 nmol/ml) had a higher concentration of DHA than maternal 
RBC at birth (median 173 nmol/ml) (p=0.0002). The median difference of 68 
nmol/ml between maternal and cord levels corresponded to a maternal level 
equivalent to 76% of the cord level. Although cord DHA concentration was 
significantly different from maternal levels at birth at p<0.01, it was only tending to a 
significant difference from maternal concentrations at 15 weeks (p=0.02, median 221 
nmol/ml vs. 178 nmol/ml) and 28 weeks (p=0.02, median 227 nmol/ml V5. 193 
nmol/ml). Maternal DHA concentration at 28 weeks was equivalent to 85% of that in 
cord RBC.
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Cord RBC also had higher concentrations of DHGLA (20;3n-6, p<0.0001), AA 
(20:4n-6, p<0.0001), adrenic acid (22:4n-6, p<0.0001), but lower concentrations of 
palmitic acid (16:0, p=0.015), oleic acid (18:ln-9, p<0.0001) and LA (18:2n-6,
p<0.0001).
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9.3.2(d) Placebo Group: Maternai RBC at 15 and 28 weeks gestation (Figure 28)
RBC concentrations of DHA did not differ significantly at 15 weeks (median 128 
nmol/mi) and 28 weeks (173 nmol/ml) (p=0.38).
The concentration of 16:ln-7 (palmitoleic acid) increased between 15 and 28 weeks in 
the RBC of the placebo group (p=0.008). The difference (a median of 11.08 nmol/ml) 
was a 543% increase on the 15 weeks level.
Myristic acid (14:0) was higher at 15 weeks, but significance was only 0.04.
9.3.2(e) Placebo Group: Maternal RBC at 28 weeks and Birth (Figure 28)
At the time of delivery, maternal RBC DHA concentration had decreased from its 
level at 28 weeks (median 171 nmol/ml) to a median of 115 nmol/ml, by a median of 
56 nmol/ml (p=0.004). DHA at birth (median 118 nmol/ml) did not, however, differ 
in concentration from 15 weeks (median 128 nmohml) (p=0.85).
The concentration of EPA (20:5n~3) decreased from a median 11 nmol/ml to 0.0 
nmol/ml (p=0.0004). Maternal RBC was also lower in DHGLA (20:3n-6, p=0.0009), 
adrenic acid (22:4n-6, p=0.003), and DPA (22:5n-3, p=0.0009) at birth than 28 weeks. 
However, these decreases did not cause the fatty acids to differ significantly from their 
baseline 15 weeks levels, although the difference between maternal 15 weeks and 
birth adrenic acid (22:4n-6) tended to significance, with p=0.03. Concentrations of 
palmitate (16:0) were higher at birth but with significance of only 0.02, while 
concentrations of AA (20:4n-6) were lower (p=0.04).
9.3.2(f) Placebo Group: Maternal RBC at Birth and Fetal Umbilical Cord RBC 
(Figure 28)
DHA concentrations were significantly higher in cord then maternal RBC at birth 
(p<0.0001). Cord RBC (median 265 nmol/ml) were higher by a median of 149 
nmol/ml than maternal RBC (median 117 nmol/ml); median maternal values were 
thus only 44% of median cord values. Moreover, cord RBC DHA concentration 
(median 264 nmol/ml) was also higher than maternal 28 weeks DHA (median 173 
nmol/ml) (p=0.0001), by a median of 72 nmol/ml. Although maternal DHA was 
maximal at 28 weeks, it was still only 65% of cord levels. The difference (159
197
nmol/ml) between DHA concentrations in maternal 15 weeks RBC (median 128 
nmol/ml) and cord RBC (median 264 nmol/ml) RBC was also significant (p=0.01).
Cord RBC was also higher in concentrations of arachidic acid (20:0, p<0.0001), 
DHGLA (20:3n-6, p<0.0001), AA (20:4n-6, p<0.0001), and adrenic acid (22:4n-6, 
p<0.0001), but lower in LA (18:2n-6, p<0.0001). Oleic acid (18;ln-9) was also lower 
in cord, but not significantly at p<0,01 (p=0.02).
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9.3.3 Plasma Fatty Acids: % Total Fatty Acids (Relative Levels)
9.3.3(a) Fish Oil Group: Maternal Plasma at 15 and 28 weeks gestation (Figure 29) 
There was no change in DHA as a % TFA in plasma of the fish oil group between 15 
and 28 weeks. The difference in 15 weeks DHA (median 1.7% TFA) and 28 weeks 
DHA (median 1.8% TFA) was non-significant (p-0.26).
Palmitoleic acid (16:ln-7, p=0.01) did increase in plasma between 15 weeks and 28 
weeks, while stearic (18:0, p=0.0005) and lignoceric (24:0, p=0.0009) acids both 
decreased.
9.3.3(b) Fish Oil Group: Maternal Plasma at 28 weeks and Birth (Figure 29)
Maternal DHA significantly decreased (p<0.0001) between 28 weeks and birth, from 
a median of 1.8% TFA to 1.4% TFA. This represented a median decline of 28% in its 
level at 28 weeks; despite this, maternal birth plasma DHA (median 1.4% TFA) was 
not significantly different (p=0.06) from that at 15 weeks (median 1.7% TFA).
Myristic acid (14:0, p=0.0003), arachidic acid (20:0, p=0.0001) DHGLA (20:3n-6, 
p=0.002), adrenic acid (22:4n-6, p=0.004), lignoceric acid (24:0, p=0.004) and DPA 
(22:5n-3, p=0.0002) were of lower % TFA at birth than 28 weeks, and had decreased 
to values significantly lower than those observed at baseline 15 weeks (all p<0.01). 
Nervonic acid (24:ln-9) tended to be higher (p=0.02) at 28 weeks than birth, and was 
significantly higher at 15 weeks than birth (p=0.0001). Both ocLA (18:3n-3, p=0.006) 
and EPA (20:5n-3, p=0.0003) also decreased between 28 weeks and birth, but did not 
decrease significantly below baseline levels.
9.3.3(c) Fish Oil Group: Maternal Plasma at Birth and Fetal Umbilical Cord Plasma 
(Figure 29)
DHA was significantly higher in cord plasma than maternal plasma at birth 
(p<0.0001). Maternal plasma DHA was a median of 1.4% TFA while cord DHA was 
a median of 3.0% TFA. Cord DHA was of a significantly higher % TFA than in 
maternal plasma at 15 weeks (median 3.0% V5. 1.7% TFA, p=0.0003), and at 28 
weeks (median 3.0% vs. 1.8% TFA, p<0.0001).
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Palmitoleic acid (16:ln-7, p<0.0001), stearic acid (18:0, p<0.0001), arachidic acid 
(20:0, p<0.0001), DHGLA (20:3n-6, p<0.0001), AA (20:4n-6, p<0.0001), adrenic 
acid (22:4n-6, p<0.0001), lignoceric acid (24:0, p=0.002), and nervonic acid (24:ln-9, 
p=0.009) were all of a higher % TFA in cord plasma than maternal plasma at birth. 
Of these, only cord 24:0 and 24: In-9 were not significantly higher than in maternal 
plasma at 28 weeks, (although the difference between maternal 28 weeks and cord 
plasma in 24:ln-9 tended to significance (p=0.02)).
Oleic acid (18:ln-9, p<0.0001), LA (18:2n-6, p<0.0001), and aLA (18:3n-3, 
p=0.0005) were all lower in cord plasma than maternal plasma at delivery (and also at 
28 weeks, all p<0.01).
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9 . 3 . Placebo Group: Maternal Plasma at 15 and 28 weeks gestation (Figure 30) 
DHA as a % TFA did not change in the plasma of placebo receiving mothers between 
15 weeks (median 1.7% TFA) and 28 weeks (median 1.6% TFA) (p=1.0).
Relative amounts of stearic acid (18:0, p-0.0001) and AA (20:4n-6, p=0.002) were 
lower in plasma from the placebo group at 28 weeks than 15 weeks. Maternal aLA 
(18:3n-3) increased over this time from a median of 0.5% TFA to 0.6% TFA 
(p=0.007), a median increase of 0.2% TFA i.e. 32% of 15 week level.
Although not significant at p<0.01, palmitoleic acid (16:ln-7) was higher at 28 weeks 
than 15 weeks (p=0.02), and nervonic acid (24:ln-9) was lower at 28 weeks (p=0.02).
9.3.3(e) Placebo Group: Maternal Plasma at 28 weeks and Birth (Figure 30)
Plasma DHA decreased from a median of 1.6% TFA at 28 weeks to median 1.2% 
TFA by birth in the placebo group. This (median) 33% decrease in 28 weeks level 
was significant at p<0.0001. Relative levels at 15 weeks (median 1.6% TFA) and 
birth (median 1.2% TFA) also differed significantly (p=0.0003).
AA (20:4n-6) continued to decrease until the time of birth to % TFA lower than at 28 
weeks (p=0.0005) and hence 15 weeks (p<0.0001).
Myristic acid (14:0, p=0,0001), arachidic acid (20:0, p<0.0001), DHGLA (20:3n-6, 
p<0.0001), EPA (20:5n-3, p=0.0001), lignoceric acid (24:0, p=0.003) and DPA 
(22:5n-3, p<0.0001) all decreased from 28 weeks to birth in maternal plasma. The 
decrease in 20:0, 20:3n-6, 24:0 and 22:5n-3 caused these fatty acids to be of lower % 
TFA than at 15 weeks (all p<0.01).
By birth, maternal palmitic (16:0, p=0.009) and oleic (18:ln-9, p=0.009) acids had 
increased from their levels at 28 weeks.
LA (18:2n-6, p=0.03) and adrenic acid (22:4n-6, p=0.02) were also higher at 28 weeks 
than birth, although not significantly at p<0.01.
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9.3.3(f) Placebo Group: Maternai Plasma at Birth and Fetal Umbilical Cord Plasma 
(Figure 30)
DHA was of a significantly higher % TFA (p<0.0001) in cord plasma (median 3,0%) 
than maternal plasma at birth (median 1.2%), with maternal levels a median of 58% 
below that of cord plasma. Cord DHA was also significantly lower than maternal 
DHA at 15 weeks (median 3.0% TFA v .^ 1.6% TFA, p<0.0001), and at 28 weeks 
(median 2.9% TFA v,s. 1.7% TFA, p=0.003).
Cord plasma was also higher than maternal plasma in its % of: palmitoleic acid 
(16:ln-7, p<0.0001); stearic acid (18:0, p<0.0001); arachidic acid (20:0, p<0.0001); 
DHGLA (20:3n-6, p<0.0001); AA (20:4n-6, p<0.0001); adrenic acid (22:4n-6, 
p<0.0001); lignoceric acid (24:0, p=0.004), and nervonic acid (24:ln-9, p=0.006). All 
these fatty acids, except 24:0 and 24:ln-9, were higher in cord than maternal 28 weeks 
plasma.
Cord plasma was lower in oleic acid (18:ln-9, p<0.0001), LA (18:2n-6, p<0.0001), 
and aLA (18:3n-3, p<0.0001) than maternal birth plasma (and also maternal 28 weeks 
plasma).
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9.3.4 Plasma Fatty Acids: Concentration (Absolute Levels)
9.3.4(a) Fish Oil Group: Maternal Plasma at 15 and 28 weeks gestation (Figure 31)
The concentration of DHA in maternal plasma increased significantly (p=0.0005) in 
the fish oil group from a median of 135 nmol/ml at 15 weeks to 216 nmol/ml at 28 
weeks.
Concentrations of myristic acid (14:0, p<0.0001), palmitic acid (16:0, p<0.0001), 
palmitoleic acid (16:ln-7, p<0.0001), stearic acid (18:0, p=0.008), oleic acid (18:ln-9, 
p-0.002), arachidic (20:0, p<0.0001), DHGLA (20:3n-6, p=0.008) and EPA (20:5n-3, 
p=0.002) all increased in the plasma of the fish oil group between 15 and 28 weeks.
9.3.4(b) Fish Oil Group: Maternal Plasma at 28 weeks and Birth (Figure 31)
By birth, maternal DHA concentrations were not significantly different from those at 
28 weeks, although tending to significance at p=0.02, with 28 weeks concentrations 
higher (median 216 nmol/ml ys. 171 nmol/ml). Maternal DHA concentrations at birth 
(median 173 nmol/ml) were higher than at 15 weeks (median 135 nmol/ml), but, 
again, this was not significant with p^0.02.
Myristic (14:0) and arachidic (20:0) acids, which both increased between 15 and 28 
weeks, significantly decreased between 28 weeks and birth (p<0.0001 for both), to 
levels similar to their original 15 weeks levels. DHGLA (20:3n-6, p=0.02), EPA 
(20:5n-3, p=0.02) and adrenic acid (22:4n-6, p=0.04) were also higher at 28 weeks 
than birth, but with a significance level of p<0.01, were not significantly so.
9.3.4(c) Fish Oil Group: Maternal Plasma at Birth and Fetal Umbilical Cord Plasma 
(Figure 31)
The concentration of DHA was not significantly different in maternal plasma at birth 
to that in cord plasma, only tending to significance at p=0.03, with cord concentrations 
higher (median 436 nmol/ml vs. 172 nmol/ml). Cord concentrations were also higher 
than maternal levels at 15 weeks (median 460 nmol/ml 133 nmol/ml), and at 28 
weeks (465 nmol/ml vs. 217 nmol/ml); again, these differences were non-significant 
(p=0.05 and 0.06, respectively).
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Cord plasma was lower in concentrations of myristic acid (14:0), palmitic acid(16:0) 
palmitoleic acid (16:ln-7), stearic acid (18:0), oleic acid (18:ln-9), LA (18:2n-6), 
aLA (18:3n-3), DHGLA (20:3n-6), AA (20:4n-6) (all p<0.0001) and EPA (20:5n-3) 
(p=0.004). All of these cord fatty acids were also lower (all p<0.0001) than maternal 
15 and 28 weeks levels, except for 16:ln-7 which was lower than maternal levels at 28 
weeks but not 15 weeks.
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9.3.4(d) Placebo Group: Maternai Plasma at 15 and 28 weeks gestation (Figure 32) 
Maternai DHA increased in concentration between 15 and 28 weeks, from median 138 
nmol/ml to 179 nmol/ml, a median increase of 59 nmol/ml (p=0.002).
The group also had significant increases in their concentrations of myristic acid (14:0, 
p<0.0001), palmitic acid (16:0, p<0.0001), palmitoleic acid (16:ln-7, p<0.0001), oleic 
acid (18:ln-9, p<0.0001), arachidic acid (20:0, p<0.0001), DHGLA (20:3n-6, 
p=0.0005), and AA (20:4n-6, p=0.0005).
9.3.4(e) Placebo Group : Maternal Plasma at 28 weeks and Birth (Figure 32)
There was no significant difference between DHA concentrations at 28 weeks 
(median 172 nmol/ml) and birth (median 131 nmol/ml) in the placebo group (p=0.56). 
DHA concentrations at birth (median 137 nmol/ml) were similar to those at 15 weeks 
(median 137 nmol/ml) (p=0.34).
Placebo group concentrations of myristic (14:0) and arachidic (20:0) acids increased 
between 15 and 28 weeks, but then decreased between 28 weeks and birth (both 
p=0.009), to levels not significantly different to those as 15 weeks. Indeed, the 
difference in 14:0 between 15 and 28 weeks was 41% of the 28 weeks value, and its 
difference'between 28 weeks and birth was 39% of the 28 weeks value. For 20:6, the 
increment between 15 and 28 weeks was 47% of the 28 weeks value, and the 
corresponding decrease was 38% of the 28 weeks value. Thus it can be seen that the 
magnitude of change for both of these fatty acids between 15 weeks and 28 weeks was 
similar to that between 28 weeks to birth, but of the opposite direction, accounting for 
the significant differences observed between time points.
Oleic acid (18:ln-9) continued to increase (p=0.003) in the placebo group between 28 
weeks and birth, having already increased between 15 and 28 weeks.
9.3.4(f) Placebo Group: Maternal Plasma at Birth and Fetal Umbilical Cord Plasma 
(Figure 32)
The placebo group had no significant difference between DHA concentrations in 
maternal plasma at birth (median 137 nmol/ml) and cord plasma (median 413 
nmol/ml) (p=0.18). Moreover, cord concentrations (median 413 nmol/ml) did not
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differ significantly from maternal 28 weeks (median 172 nmol/ml) concentrations 
(p=0.17). There was, however, a significant difference between concentrations in 
cord plasma (median 374 nmol/ml) and maternal 15 weeks plasma (median 141 
nmol/median) (p=0.01).
Myristic acid (14:0), palmitic acid (16:0), palmitoleic acid (16:ln-7), stearic acid 
(18:0), oleic acid (18:ln-9), LA (18:2n-6), aLA (18:3n-3), DHGLA (20:3n-6), AA 
(20:4n-6) and EPA (20:5n-3) were all of a lower concentration in cord plasma than 
maternal plasma at birth (all p<0.0001). All these cord fatty acids were also 
significantly lower (p<0.01) than maternal concentrations at 15 and 28 weeks, except 
cord 16:ln-7 which was only lower than maternal 28 weeks level.
Placebo group cord plasma had a higher concentration of adrenic acid (22:4n-6) than 
maternal birth plasma (p=0.006).
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9.4 COMPARISON OF THE FATTY ACID PATTERNS OF FISH OIL AND 
PLACEBO GROUPS
This section summarises the inter-group differences, the intra-group patterns of 
change and the relationship between maternal and fetal status. The longitudinal 
maternal changes within each group and their matemo-fetal differences are compared 
in order to explain the differences arising between the supplement and placebo groups.
9.4.1 RBC Fatty Acids: % Total Fatty Acids (Relative Levels)
9.4.1(a) Maternal RBC at 15 and 28 weeks gestation
By 28 weeks, the mothers receiving fish oil supplementation had increased their DHA 
status by (median) 38% of their 15 week status, whereas the placebo group had a 25% 
increase above their 15 weeks % DHA. Thus, although showing the same pattern as 
the fish oil group, i.e. an increase in DHA between 15 and 28 weeks, the magnitude of 
change was smaller in the placebo group, both in relation to the % TFA (0.7% TFA 
vs. 1.1% TFA) and to the original level (25% vs. 38% increase in 15 weeks level). As 
a result the median % TFA of DHA in RBC at 28 weeks in the placebo group was 
80% of that in the fish oil group. Moreover, total n-3 fatty acids in the placebo group 
amounted to 87% of total n-3 levels in the fish oil group.
An increase in both myristic (14:0) and palmitoleic (16:ln-7) acids between 15 and 28 
weeks was observed in the two treatment groups, although the groups differed in the 
patterns of change for other fatty acids. The fish oil group decreased its % TFA of LA 
(18:2n-6), while the placebo group decreased in % of palmitic acid (16:0) and stearic 
acid (18:0). In addition, only the placebo group increased over this time in DHGLA 
(20:3n-6), EPA (20:5n-3) and DP A (22:5n-3). However, at 28 weeks, the groups did 
not differ significantly from each other in any n-3 fatty acids other than DHA, Thus, 
the elevated DHA observed in the fish oil group was sufficient to cause the fish oil 
group to have significantly higher total n-3 fatty acids, and therefore lower n-6/n-3 
ratio, at 28 weeks.
The treatment groups did, however, differ in the amount of AA (20:4n-6) as a % TFA, 
with the placebo group significantly higher at 28 weeks. Since the sum of DHA 
(22:6n-3) and AA (20:4n-6) was approximately equal in both groups (14.8% in the 
fish oil group, 14.5% in the placebo group), it is possible that a compensatory
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mechanism was occurring, with an increase in DHA counterbalancing a decrease in 
AA, and vice versa.
9.4.1(b) Maternal RBC at 28 weeks and Birth
DHA as a % TFA in both groups declined in maternal RBC between 28 weeks and 
birth. Although maternal RBC DHA at birth was not significantly different from that 
at 15 weeks in either fish oil or placebo group, the magnitude of decrease between 28 
weeks and birth was greatest in the placebo group (median decrease in 28 weeks level 
of 41% compared to 19%). At birth, maternal RBC DHA in the fish oil group was 
0,8% TFA lower than at 28 weeks, and was equivalent to 84% of its level at 28 weeks. 
In the placebo group, RBC DHA declined by 1.4% TFA between 28 weeks and birth, 
such that maternal birth DHA was 71% of its 28 week level. Thus in absolute (as % 
TFA) and relative (as % of previous measurement) terms, the placebo group increased 
by less between 15 and 28 weeks (see above), but decreased by more between 28 
weeks and birth, compared to the fish oil group. The median maternal % DHA of the 
placebo group at birth was 77% of that of the fish oil group; the median % of total n-3 
fatty acids in the placebo group was 84% of that in the fish oil group. Thus, the same 
magnitude of difference between the two groups, for DHA and total n-3 fatty acids, 
was observed at birth and at 28 weeks gestation.
There were decreases between 28 weeks and birth in both groups in DHGLA (20:3n-
6), AA (20:4n-6), EPA (20:5n-3), adrenic acid (22:4n-6) and DP A (22:5n-3). 
However, in the placebo group, after an increase between 15 and 28 weeks, DHGLA 
(20:3n-6), EPA (20:5n-3), and DPA (22:5n-3) decreased between 28 weeks and birth 
to levels comparable to those at 15 weeks. This is in contrast to the fish oil group, 
where there were no changes in these fatty acids between 15 and 28 weeks, but 
DHGLA (20:3n-6), EPA (20:5n-3) and DPA (22;5n~3) decreased between 28 weeks 
and birth, such that the levels of 20:5n-3 and 22:5n-3 were lower at birth than at 15 
weeks. Despite the decline in individual n-3 fatty acids as % TFA in the two groups 
prior to birth, the fish oil and placebo groups remained significantly different in % 
DHA and total n-3 at birth, with higher levels and hence a lower n-6/n-3 ratio 
observed in the fish oil group.
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The increases in % of palmitic (16:0) and oleic (18:ln-9) acids between 28 weeks and 
birth were observed in both groups.
9.4.1(c) Maternal RBC at Birth and Fetal Umbilical Cord RBC 
Fish oil group cord RBC DHA was (median) 37% higher than maternal birth RBC, 
with a median of 4.3% TFA compared to 3.1% TFA. Thus, the elevation of DHA in 
cord RBC above that in maternal birth RBC was of the same magnitude as the 
increase in maternal DHA between 15 weeks and 28 weeks. Indeed, the % TFA of 
DHA in cord RBC was not significantly different from that in maternal RBC at 28 
weeks, and maternal RBC at birth was not significantly different from maternal 15 
weeks RBC.
Placebo group cord DHA was 74% higher than maternal plasma % DHA. Moreover 
cord RBC DHA (median 4.2% TFA) was 19% higher (p=0.003) than maternal 28 
weeks DHA (median 3.4% TFA).
The elevation of cord RBC % DHA above baseline maternal RBC levels (15 weeks) 
was similar in both groups. The difference between cord and maternal 15 weeks RBC 
was (median) 1.4% TFA or 48% of 15 weeks levels in the fish oil group, and 1.4% 
TFA or 51 % of 15 weeks levels in the placebo group.
Although cord RBC DHA was not significantly different between treatment groups, 
the difference between cord and maternal birth RBC DHA was greater in the placebo 
group, being 1.2% TFA in the fish oil group, and 1.8% TFA in the placebo group. 
Thus, maternal birth DHA was 72% of cord DHA in the fish oil group, and 58% of 
cord DHA in the placebo group. Cord RBC DHA was significantly higher than 28 
weeks maternal DHA in the placebo group, in contrast to the fish oil group where cord 
DHA was not significantly different from the maximal maternal DHA status observed 
at 28 weeks. The two groups differed further in the differences between cord and 28 
weeks maternal values. In the placebo group, all cord RBC fatty acids significantly 
different to maternal birth RBC were also different to maternal 28 weeks RBC. In the 
fish oil group, DHA was the only fatty acid in cord RBC that was significantly 
different from maternal RBC at birth, which was not significantly different from 
maternal levels at 28 weeks; other cord fatty acids significantly different from
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maternal birth levels also showed the same difference when compared to 28 weeks 
niatemal levels.
In both groups, the relative levels of stearic acid (18:0), arachidic acid (20:0), DHGLA 
(20:3n-6), AA (20:4n-6) and adrenic acid (22:4n-6) were higher in cord than maternal 
RBC at birth. Both groups also had a conversely lower status of oleic acid (18:ln-9), 
LA (18:2n-6), nervonic acid (24:ln-9) and DPA (22:5n-3) in cord compared to 
maternal RBC.
9.4.2 RBC Fatty Acids: Concentration (Absolute Levels)
9.4.2(a) Maternal RBC at 15 and 28 weeks gestation
Despite non-significant increases in DHA concentration between 15 and 28 weeks in 
both treatment groups, the fish oil group had a significantly higher concentration of 
DHA at 28 weeks, compared to the placebo group. At 28 weeks, the median DHA 
concentration in the placebo group had a value of only 88% of that of the fish oil 
group.
The magnitude of the increase in palmitoleic acid (16:ln-7) concentration from 15 to 
28 weeks, in both absolute (nmol/ml) and relative (% of 15 weeks level) terms, was 
larger in the placebo compared to the fish oil group.
9.4.2(b) Maternal RBC at 28 weeks and Birth
Maternal DHA concentration was maximal at 28 weeks in both groups, but in the fish 
oil group, 28 weeks concentration was not significantly different to 15 weeks or birth 
maternal levels. The placebo group also did not differ significantly between 15 and 
28 weeks, but was, however, significantly higher at 28 weeks than at birth.
By birth, the placebo group had a median 32% decline in its 28 weeks concentration 
of DHA. Such a significant decrease in RBC DHA concentration between these times 
was observed only in the placebo group. The fish oil group did not exhibit a 
significant change in RBC DHA concentration between 28 weeks and birth, although 
concentrations at 28 weeks were slightly higher. Thus, when comparing the two 
groups, the significantly higher concentration of DHA observed in the fish oil group at 
birth was mediated by a decline in DHA in the placebo group, rather than an increase
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in the fish oil group. Consequently, the placebo group achieved only 70% of the 
maternal DHA concentration in the fish oil group at birth.
Both groups declined in concentrations of EPA (20:5n-3) between 28 weeks and birth. 
The differences between these time points was similar in the two groups -  a (median) 
reduction of 7 nmol/ml or 60% of 28 weeks level in the fish oil group, and 7 nmol/ml 
or 65% of 28 weeks level in the placebo group. The lower EPA concentration at birth 
tended to a significant difference (p=0.04) from 15 weeks concentration in the fish oil 
group, but not in the placebo group. The placebo group also declined significantly in 
DHGLA (20:3n-6), adrenic acid (22:4n-6) and DPA (22:5n-3) (and non-significantly 
in AA (20;4n-6)). The difference in total n-3 fatty acids between the fish oil and 
placebo groups may therefore be accounted for by the greater decline in DHA, 
coupled with the decrease in both EPA (20:5n-3) and DPA (22:5n-3), observed in the 
placebo group. The overall results were thus significantly higher maternal 
concentrations of DHA and total n-3 fatty acids at the time of birth in the fish oil 
group, compared to the placebo group, accounting for the significantly lower n-6/n-3 
ratio observed in the fish oil group.
Concentrations of palmitic acid (16:0) in both groups were higher at birth but with 
probability greater than 0.01.
9.4.2(c) Maternal RBC at Birth and Fetal Umbilical Cord RBC
Despite a lack of significant difference between treatment groups in cord RBC DHA 
concentrations, the groups differed somewhat in the relationship between maternal 
and cord DHA concentrations.
In the fish oil group, cord DHA concentrations differed significantly from maternal 
birth DHA by (median) 68 nmol/ml, with median maternal concentration equal to 
76% of that in cord RBC. In contrast, placebo group cord DHA concentrations 
differed from corresponding maternal birth concentrations by (median) 149 nmol/ml, 
such that median maternal DHA was only 44% of cord concentration. Fish oil group 
cord DHA was not significantly different to maternal 28 weeks concentrations at a 
significance level of p<0.01, with maternal 28 weeks DHA equivalent to 85% of cord 
DHA (p=0.02), or to maternal 15 weeks DHA concentration (p=0.02). Conversely,
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placebo group cord DHA was higher than maternal 28 weeks concentrations at a 
significance level of p<0.01, with maternal 28 weeks concentrations equal to 65% of 
cord levels (p<0.0001). The higher concentration of DHA in cord RBC was also 
significantly different from maternal 15 weeks concentrations in the placebo group
(p=0.01).
Both groups had higher concentrations in cord than maternal birth plasma for DHGLA 
(20:3n-6), AA (20:4n-6) and adrenic acid (22;4n-6). The placebo group also had 
elevated concentrations of arachidic acid (20:0) in cord RBC; the fish oil group had 
lower cord than maternal palmitic acid (16:0) concentrations. Cord LA (18:2n-6) 
concentrations were lower than corresponding maternal levels in both groups. Cord 
oleic acid (18:ln-9) concentration, significantly lower than maternal birth 
concentration in the fish oil group, was only lower at p=0.02 in the placebo group.
9.4.3 Plasma Fatty Acids: % Total Fatty Acids (Relative Levels)
9.4.3(a) Maternal Plasma at 15 and 28 weeks gestation
Neither treatment group exhibited significant changes in the % TFA accounted for by 
DHA in plasma over the period of 15 to 28 weeks. Thus, the treatment groups had 
similar % DHA in maternal plasma at both 15 and 28 weeks.
Both groups did increase their % palmitoleic acid (16:ln-7), although not significantly 
so in the placebo group. In addition, a decrease in stearic acid (18:0) as % TFA was 
observed in both groups. The fish oil group, however, had a decrease in lignoceric 
acid (24:0), while the placebo group decreased in AA (20:4n-6) and (non- 
significantly) in nervonic acid (24:ln-9). The placebo group also had a significant 
increase in % aLA (18:3n-3).
The elevated DHGLA (20:3n-6) observed in the placebo group at 28 weeks may have 
induced a reciprocal decrease in % total n-3 fatty acids, accounting for the higher total 
n-3 and lower n-6/n-3 ratio of the fish oil group.
9.4.3(b) Maternal Plasma at 28 weeks and Birth
The decline between 28 weeks and birth in maternal plasma DHA as % TFA was 28% 
of the 28 weeks value in the fish oil group, and 33% of the 28 weeks value in the
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placebo group. The similar magnitude of change ensured that the treatment groups 
did not differ significantly from each other in % plasma DHA at birth.
The fatty acids 14:0 (myristic), 20:0 (arachidic), 20:3n-6 (DHGLA), 22:4n-6 
(adrenic), 24:0 (lignoceric) and 22:5n-3 (DPA) all decreased in both groups between 
28 weeks and birth, but in the fish oil group, the values for all of these at birth were 
also lower than those at 15 weeks. In contrast, only 20:0, 20:3n-6, 24:0 and 22:5n-3 
accounted for lower % TFA at birth than 15 weeks in the placebo group.
Nervonic acid (24: In-9) in the fish oil group decreased non-significantly between both 
15 and 28 weeks, and then 28 weeks and birth, such that % 24:ln-9 was significantly 
lower at birth than 15 weeks. Maternal aLA (18:3n-3) and EPA (20:5n-3) also 
decreased between 28 weeks and birth, but remained similar to their % at 15 weeks.
AA (20:4n-6) decreased in the placebo group over the entire period from 15 weeks to 
birth, such that both subsequent levels were lower than at 15 weeks. The placebo 
group also exhibited increased % of palmitate (16:0), oleate (18:ln-9), LA (18:2n-6) 
and adrenic acid (22:4n-6), accounting for the significantly higher % 16:0 observed in 
the placebo compared to fish oil group at birth.
9.4.3(c) Maternal Plasma at Birth and Fetal Umbilical Cord Plasma 
Maternal plasma in the fish oil group had a % DHA level significantly lower than that 
of cord plasma by (median) 49% of the cord level. Maximal maternal DHA, observed 
at 28 weeks, was also significantly lower than cord DHA but to a lesser extent, by a 
median of 30% of the cord level (1.8% TFA V5. 3.0% TFA). Thus, maternal plasma 
DHA at birth was equivalent to 47% of the cord level, while maternal DHA at 28 
weeks was 61% of that of cord plasma.
In the placebo group, the difference between maternal and cord plasma % TFA for 
DHA was a median of 58% of the cord level, with maternal levels significantly below 
that of cord. The difference between 28 weeks and cord levels was also significant 
and equivalent to 31% of the cord level.
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The median differences between maternal birth and cord plasma DHA in the fish oil 
and placebo groups was 1.5% TFA and 1.7% TFA respectively. In relative terms, 
these differences were 49% and 58% of their respective cord levels, such that maternal 
birth levels were 47% of those in the cord in the fish oil group, and 39% of those in 
the cord in the placebo group. At 28 weeks, maternal levels were 61% of those in 
cord for the fish oil group, and 58% of those in cord in the placebo group. Thus 
although the differences are of the same pattern {i.e. higher in cord plasma), the 
magnitude of difference between maternal and cord plasma DHA is smaller in the fish 
oil group. The two groups did not, however, differ significantly from each other in 
their respective % DHA in cord plasma.
Both groups had higher levels in cord than maternal birth plasma for: palmitoleic acid 
(16:ln-9), stearic acid (18:0), arachidic acid (20:0), DHGLA (20:3n-6), AA (20:4n-6), 
adrenic acid (22:4n-6), lignoceric acid (24:0) and nervonic acid (24:ln-9). In both 
groups, only cord 24:0 and 24:ln-9 were not also significantly higher than maternal 28 
weeks values, although the difference in 24: ln-9 tended to significance (p=0.02) in the 
fish oil group.
The magnitude of these changes, for fatty acids other than DHA, were similar in the 
treatment groups in both absolute (% TFA) and relative (as % of maternal levels) 
terms, accounting for the lack of significant differences on comparison of the two 
groups. For example, aLA (18:3n-3) was higher in maternal birth plasma than cord 
plasma by 0.4% TFA, with cord plasma only 20% of the maternal birth value, in the 
fish oil group. In the placebo group, maternal plasma 18:3n-3 was 0.3% TFA higher 
than cord 18:3n-3, with cord 18:3n-3 equivalent to 20% of the maternal level.
9.4.4 Plasma Fatty Acids: Concentration (Absolute Levels)
9.4.4(a) Maternal Plasma at 15 and 28 weeks gestation
The fish oil group had a higher plasma concentration of 18:ln-9 (oleic acid) at 15 
weeks prior to supplementation. This was the only time the two groups differed in 
their levels of oleic acid, despite the expectation that the placebo group would accrue 
higher amounts.
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By increasing a median of 107 nmol/ml between 15 and 28 weeks, fish oil 
supplemented mothers significantly increased their baseline DHA by 79%. The 
placebo group had a significant 42% increase in their baseline DHA concentration by 
28 weeks, increasing by a median 59 nmol/ml. At 28 weeks, maternal DHA 
concentration in the placebo group was only 82% of that in the fish oil group, i.e. 
significantly lower.
The increases in concentrations of myristic acid (14:0), palmitic acid (16:0), 
palmitoleic acid (16: In-7), oleic acid (18: ln-9), arachidic acid (20:0) and DHGLA 
(20:3n-6) were observed in both groups. However, 28 weeks plasma of the fish oil 
group had increased stearic acid (18:0) and EPA (20:5n-3), while that of the placebo 
group had increased AA (20:4n-6).
The larger increase in DHA, coupled with the increase in EPA (20:5n-3), observed in 
the fish oil group account for the significantly higher concentrations of plasma DHA, 
EPA and total n-3 fatty acids present in the fish oil group at 28 weeks, when compared 
to the placebo group.
9.4.4(b) Maternal Plasma at 28 weeks and Birth
There were no significant differences between 28 weeks and birth in DHA 
concentration for either group, although both groups had highest concentrations at 28 
weeks, with the change in the fish oil group tending (p=0.02) to significance. As a 
result, there was no difference in maternal DHA concentration between the two 
groups at birth. However, in the fish oil group at birth, the concentration of DHA in 
maternal plasma tended (p=0.02) to be higher than at baseline (15 weeks), while 
baseline and birth plasma DHA concentrations were almost identical (both median 
137 nmol/ml) in the placebo group.
Also similar in both groups were the patterns of change in the concentrations of 
myristic (14:0) and arachidic (20:0) acids. Having increased between 15 and 28 
weeks, both fatty acids decreased between 28 weeks and birth, to levels not 
significantly different to those as 15 weeks.
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Concentrations of oleic acid (18:ln-9) increased between 15 and 28 weeks in both 
groups, but did not change significantly between 28 weeks and birth in the fish oil 
group. The placebo group, however, continued to increase in 18: ln-9 concentration, 
such that by birth, maternal 18:ln-9 concentration was elevated significantly above 28 
weeks concentration. Nonetheless, there was no significant difference between the 
fish oil and placebo groups in plasma 18:ln-9 concentration at birth.
9.4.4(c) Maternal Plasma at Birth and Fetal Umbilical Cord Plasma 
There were no significant differences between concentrations of DHA in maternal 
birth plasma and cord plasma for either group, although the higher concentration in 
cord plasma was almost significant for the fish oil group (p=0.03). There was no 
significant difference between treatment groups in cord plasma DHA concentrations.
Thus, the two groups followed the same pattern in plasma DHA concentration: 
increase from 15 to 28 weeks, with no significant differences between 28 weeks and 
birth, or mother at birth and cord. However, the fish oil group had a median 107 
nmol/ml or 79% increase in 15 weeks DHA concentration by 28 weeks, while the 
placebo group only had a 59 nmol/ml or 42% increase. Thus, the magnitude of 
increase was greater in the fish oil group.
Concentrations of myristic acid (14:0), palmitic acid (16:0), palmitoleic acid (16: In-
7), stearic acid (18:0), oleic acid (18:ln-9), LA (18:2n-6), aLA (18:3n-3), DHGLA 
(20:3n-6), AA (20:4n-6) and EPA (20:5n~3) were all lower in cord plasma than 
maternal plasma at birth in both treatment groups. These cord fatty acids were also 
significantly lower than maternal 15 and 28 weeks concentrations, except 16:ln-7 
which was only lower than the 28 weeks levels, a characteristic noted in both groups.
In both groups, the concentration of arachidic acid (20:0) decreased in maternal 
plasma between 28 weeks and birth. Although there were no differences between 
cord plasma and maternal plasma at birth, cord plasma was, as therefore expected, 
significantly lower in this fatty acid than maternal 28 weeks plasma in both groups.
Cord plasma of the placebo group had a higher concentration of adrenic acid (22:4n-6) 
than maternal birth plasma.
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9.4.5 Placental Tissue Fatty Acids: % Total Fatty Acids (Relative Levels)
The only placental tissue fatty acid which differed in its % TFA between the two 
groups was myristic acid (14:0), which was lower in the fish oil group.
Although there were no differences in individual or total fatty acids fi*om the n-3 or n- 
6 families when measured as % TFA in placental tissue, the ratio of n-6/n-3 fatty acids 
was lower in the fish oil group.
9.4.6 Placental Tissue Fatty Acids: Concentration (Absolute Levels)
DHA was present in higher concentrations in the placental tissue of the fish oil group, 
although the inter-group difference was not significant. The concentration of myristic 
acid (14:0) was lower in the placental tissue of the fish oil group. The concentrations 
of individual and total n-3 and n-6 fatty acids, as well as the ratio of n-6/n-3 fatty acid 
concentrations, did not differ between the groups.
9.4.7 Umbilical Cord Tissue Fatty Acids: % Total Fatty Acids (Relative Levels)
Umbilical cord tissue did not differ between groups in the relative amounts of any 
fatty acids, although the % TFA accounted for by DHA was slightly higher in the fish 
oil group.
9.4.8 Breast Milk Fatty Acids: % Total Fatty Acids (Relative Levels)
The only significant difference between the fish oil and placebo groups was the % 
palmitic acid (16:0), with the highest relative amount observed in the breast milk of 
the fish oil group.
9.4.9 Breast Milk Fatty Acids: Concentration (Absolute Levels)
Despite higher breast milk % AA (20:4n-6) in the placebo group, the totals and ratio 
of n-6 and n-3 fatty acids were similar in both groups.
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Chapter 10
Discussion
10.1 OVERVIEW
This study was undertaken because of strong evidence that the accumulation of DHA 
in fetal and neonatal tissue is important for optimal infant development, and that the 
DHA status of the fetus/neonate is affected by several factors, including maternal 
diet and nutritional status.
In examining the relationship between diet and maternal and/or fetal fatty acid status, 
previous studies have evaluated either habitual diet (Homstra et al 1992, Lakin et al 
1998, Olsen et al 1991, Reddy et al 1994, Sanjuijo et al 1995) or maternai 
supplementation during the last trimester of pregnancy (Connor et al 1996, van 
Houwelingen et al 1995). Similarly, the fatty acid composition of breast milk has 
been studied in relation to diet (Finley et al 1985, Innis & Kuhnlein 1988, Sanders & 
Reddy 1992) or supplementation (Fidler et al 2000b, Harris et al 1984, Holland et al 
1998, Henderson et al 1992, Makrides et al 1996a) during lactation. While maternai 
supplementation (with LA) from mid-trimester has been undertaken (A1 et al 1995b), 
there is a deficit of studies investigating the effects of earlier maternal 
supplementation with DHA on both mother and fetus.
The dose of DHA provided by supplements during late pregnancy or lactation has 
differed between studies, ranging from 200mg/d (Fidler et al 2000b, Makrides et al 
1996a) to l,3g/d (Makrides et al 1996a) of DHA. Supplementation with 
approximately 200mg/d DHA was effective in modulating maternal and/or infant 
PUFA status in previous studies (Fidler et al 2000b, Makrides et al 1996a, Jensen et 
f l/1999* & 2000).
The effects of neonatal diet and infant formula LCPUFA supplementation on indices 
of infant development have been studied, with no long-term benefits discernible 
(Simmer 2001a & b). Fetal nutrition, and its dependence on maternal nutrition, has 
not been considered in relation to development. The effect of maternal 
supplementation during pregnancy on infant development has not been studied.
This study was therefore designed to provide expectant mothers, from a population 
with habitually low fish consumption, with a dose of DHA (200mg/d) previously 
shown to be beneficial and which could easily be achieved by compliance with
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dietary recommendations, in a palatable and convenient form. The effect of such a 
supplement on the biochemical status of both mother and fetus was subsequently 
assessed in this randomized, placebo controlled trial.
At 15 weeks gestation, 100 mothers were randomly assigned to receive either a fish 
oil supplement rich in DHA (n=50) or a high oleic sunflower oil placebo (n=50) until 
term. Maternal fatty acid status was assessed in RBC and plasma at 15 weeks, 28 
weeks and term. Fetal status was assessed in umbilical cord RBC, umbilical cord 
plasma, placental tissue and umbilical cord tissue. Breast milk fatty acid status was 
assessed in lactating mothers within the first week following delivery. The relative 
(% TFA) and absolute (concentration) values of fatty acids were reported.
The groups were matched in terms of maternal dietary and lifestyle habits, age, 
parity, anthropometry and socio-economic status; their neonates were of comparable 
gestational age and anthropometry.
10.2 DHA IN RELATION TO PARITY AND DIET
The effect of previous pregnancies and fish consumption on matemal/fetal DHA 
status was determined prior to analysis between treatment groups, to ascertain 
whether the distribution of DHA status in the study population varied with these or 
other underlying factors as previously reported.
There have been conflicting reports as to whether maternal plasma and RBC status 
declines with parity and subsequent pregnancies (A1 et al 1997, van Houwelingen et 
al 1999). Within the Glasgow population, no difference in plasma or RBC relative 
(% TFA) fatty acid status was observed between parous and non-parous women 
when not pregnant (Berry et al 2001). “Normalisation” of maternal status apparently 
occurs within one year of parturition (van Houwelingen et al 1999). Neonatal DHA 
status has been reported to be compromised in the successive pregnancies of 
multi gravida mothers (A1 et al 1997). In the current study population, the reports of 
similar maternal fatty acid status regardless of parity and the interval between 
pregnancies (more or less than one year), and the lower umbilical cord plasma in the 
neonates of parous women, thus concur with previous findings.
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The observed elevation of % DHA in baseline RBC and plasma on regular 
consumption of fish, even if only once per week, has been noted previously (Bonaa 
et al 1992). After randomization, the two groups were matched in terms of fish 
consumption; within each dietary group, approximately half received the fish oil 
supplement and half the placebo. Supplementation with 200mg/d DHA, which 
effectively doubled the baseline intake of DHA, would therefore provide those not 
consuming fish but receiving fish oil capsules with the same amount of DHA as 
those consuming dietary fish and placebo capsules. It is therefore unsurprising that 
no effect of fish consumption per se was noted following supplementation. The 
elevation of baseline DHA (% TFA and concentration) in plasma lipids following 
fish consumption in the previous 24 hours is evidence of the suitability of plasma as 
a reliable indicator of dietary intake in the short-term (Bjerve et al 1993, Dougherty 
et al 1987, Pauletto et al 1996). Conversely, the lack of an association between 
recent fish consumption and RBC composition is in keeping with use of RBC as an 
index of longer-term dietary fatty acid intake.
The study population was therefore considered to be a representatively “normal” 
sample, demonstrating typical variation in their fatty acid status.
10.3 EFFECT OF SUPPLEMENTATION ON MATERNAL AND FETAL
STATUS
10.3.1. Summary
Elevated status of DHA and total n-3 fatty acids was observed in the fish oil 
supplemented group, creating a more favourable ratio of n-6 to n-3 PUFA (Table 64). 
However, the most interesting findings were observed when comparing the 
longitudinal maternal changes within each group, which served to explain the 
differences arising between the groups, and when considering the differences 
between mother and fetus. The results illustrate the mobilization of maternal DHA 
in early pregnancy and the subsequent accretion by the fetus at the expense of 
mother, and suggest that this physiological process may be modulated by maternal 
DHA supplementation.
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AA EPA DHA Total n-3 n-6/n-3
RBC; % TFA
15 weeks
28 weeks # * * *
Birth * * *
Cord
RBC: Concentiation
15 weeks
28 weeks * * *
Birth * *
Cord
Plasma: % TFA
15 weeks
28 weeks * *
Birth
Cord
Plasma: Concentration
15 weeks
28 weeks * * * *
Birth
Cord
Placenta: % TFA *
Placenta: Concentration
Cord: % TFA
Breast Milk: %TFA
Breast Milk: Concentration #
Table 64. Summary of indices measured and the statistically significant (p<0.05) 
differences between groups. # Placebo group significantly higher in AA. * Fish oil 
group significantly higher in EPA, DHA or total n-3 fatty acids, or lower in n-6/n-3 
ratio.
10.3.2 RBC Fatty Acids: % Total Fatty Acids (Relative Levels)
DHA, expressed as % TFA, increased in maternal RBC between 15 and 28 weeks 
gestation in both groups, but the greater increase was observed in the fish oil group. 
The fish oil group decreased in % LA while the placebo group increased in other 
LCPUFA (DHGLA, 20:3n-6; EPA, 20:5n-3; DPA 22:5n-3). However, the relative 
levels of these LCPUFA were not significantly different between groups, except for a 
higher % AA (20:4n-6) observed in the placebo group. This suggests that the 
elevation of these LCPUFA in the placebo group between 15 and 28 weeks was in 
part compensatory for the lower maternal accretion of DHA. Despite this, and as a 
result of the enhanced increase in maternal DHA in the fish oil group, the relative 
amounts of DHA and total n-3 fatty acids were significantly higher, and n-6/n-3 ratio 
lower, in the fish oil compared to placebo group at 28 weeks.
RBC % DHA decreased in both groups between 28 weeks and birth but the greater 
decline was observed in the placebo group. The magnitude of the difference in %
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DHA and total n-3 fatty acids observed between groups at 28 weeks was thus 
sustained at birth. Other LCPUFA decreased in both groups; indeed, DHGLA 
(20:3n-6), EPA (20;5n-3) and DPA (22:5n-3) returned to baseline levels in the 
placebo group, suggesting that the compensatory increase in their levels in the 
absence of an adequate DHA source noted between 15 and 28 weeks (see above), 
was transient and unsustainable.
The relative amount of DHA in cord RBC did not differ between groups. In both 
groups, cord RBC had a higher % DHA than maternal RBC at birth, but the matemo- 
fetal difference was smaller in the fish oil group. In addition, cord RBC in the 
placebo group was significantly higher than maternal RBC at 28 weeks; cord RBC in 
the fish oil group was not significantly different from maternal 28 weeks levels. The 
difference between cord and maternal baseline RBC % DHA was however, similar in 
both groups. These findings suggest that fish oil supplementation changed maternal 
status to a greater extent than fetal status.
Both groups also had higher % TFA for stearic acid (18:0), arachidic acid (20:0), 
DHGLA (20:3n-6), AA (20:4n-6) and adrenic acid (22:4n-6) in cord than maternal 
RBC, but lower cord than maternal % oleic acid (18: ln-9), LA (18:2n-6), nervonic 
acid (24:ln-9), and DPA (22:5n-3).
10.3.3 RBC Fatty Acids: Concentration (Absolnte Levels)
Maternal RBC DHA concentration increased between 15 and 28 weeks, then 
decreased between 28 weeks and birth, in both groups. The fish oil group attained a 
higher DHA concentration at 28 weeks than the placebo group, but the former did 
not then significantly decline in DHA between 28 weeks and birth. In contrast, the 
placebo group had a higher DHA concentration at 28 weeks than birth, i.e. the 
placebo group significantly decreased in maternal RBC DHA concentration in the 
last trimester. In addition to the decline in EPA (20:5n-3) observed in both groups, 
the placebo group also showed a decrease in other LCPUFA (DHGLA, 20:3n-6; 
adrenic acid, 22:4n-6; DPA, 22:5n-3). As a result, the maternal concentrations of 
RBC DHA and total n-3 fatty acids were higher, and the n-6/n-3 fatty acid ratio 
lower, at birth in the fish oil compared to placebo group.
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The concentration of DHA in umbilical cord RBC was similar in the supplemented 
and placebo groups. In both groups, cord RBC had a higher concentration of DHA 
than did maternal RBC at birth. The matemo-fetal difference was, however, less in 
the fish oil group. In addition, cord RBC DHA concentrations were not significantly 
different from matemal 15 or 28 weeks concentrations in the fish oil group. DHA 
concentrations in cord RBC of the placebo group were significantly higher than in 
matemal RBC at all time points. Thus, when matemal status is enhanced, the 
elevation of cord DHA above matemal DHA is less pronounced.
Both groups also had higher concentrations of RBC DHGLA (20:3n-6), AA (20:4n- 
6), and adrenic acid (22:4n-6), and lower LA (18:2n-6), in cord compared to 
matemal RBC at birth.
10.3.4 Plasma Fatty Acids: % Total Fatty Acids (Relative Levels)
With neither group varying in their respective % DHA between 15 and 28 weeks, no 
effect of supplementation on plasma % DHA was observed at 28 weeks. The 
increase in aLA (18:3n-3) observed in the placebo group between 15 and 28 weeks 
may have compensated for a lower preformed DHA intake.
Both groups declined in % DHA between 28 weeks and birth, and by comparable 
amounts, thus precluding a difference in % DHA between them. The pattems for 
most fatty acids between 28 weeks and birth were similar in each group. Although 
the fish oil group declined in % aLA (18:3n-3) and EPA (20:5n-3), while the 
placebo group increased in % LA (18:2n-6) and adrenic acid (22:4n-6), EPA and 
LCPUFA levels at birth did not differ from baseline within each group, or between 
groups. The elevation in n-6 acids and the stability of n-3 fatty acids in the placebo 
group may have arisen in response to a lower DHA intake.
DHA contributed a similar % TFA in umbilical cord plasma of the two groups. The 
% of DHA in umbilical cord plasma was significantly higher than in matemal plasma 
at both birth and 28 weeks in each group; the matemo-fetal difference, was however, 
less in the fish oil group. Compared to matemal plasma at birth, cord plasma of both 
groups had higher % of LCPUFA - DHGLA (20:3n-6), AA (20:4n-6) and adrenic
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acid (22:4n-6) - but lower aLA (18:3n-3). Moreover, the magnitude of the 
differences between matemal and cord plasma in these fatty acids were similar in the 
two groups. The similarities between the groups in the % DHA and in other fatty 
acids, suggest that the attenuation of the matemo-fetal difference in plasma DHA 
was indeed a physiological response to matemal fish oil supplementation.
10.3.5 Plasma Fatty Acids: Concentration (Absolute Levels)
In both groups, there was an increase in matemal concentration of DHA between 15 
and 28 weeks, but this was greater in the fish oil group. Similar changes in other 
fatty acids were observed in both groups, but the increase in EPA (20:5n-3) was 
restricted to the fish oil group. Consequently, the fish oil group had a more 
favourable n-3 status at 28 weeks, with significantly higher concentrations of DHA, 
EPA and total n-3 fatty acids compared to the placebo group. The increase in 
matemal AA (20:4n-6) concentration noted in the placebo group between 15 and 28 
weeks suggests compensation for a lower DHA status.
Both groups declined (non-significantly) in the concentration of plasma DHA 
between 28 weeks and birth. The placebo group declined to levels similar to those at 
15 weeks; the fish oil group declined to a lesser extent, such that matemal plasma at 
birth tended to a significantly higher concentration than at 15 weeks. Thus, although 
not significantly different from the matemal concentration at birth in the placebo 
group, plasma DHA in the fish oil group remained elevated above baseline 
concentrations. Other matemal fatty acids exhibited similar pattems of change in 
both groups.
There was no difference in the concentration of DHA in umbilical cord plasma 
between the two groups. In each group, the DHA concentration of cord plasma was 
not significantly higher than in matemal plasma at birth. Both groups had lower 
concentrations of LA (18:2n-6), aLA (18;3n-6), DHGLA (20:3n-6), AA (20:4n-6) 
and EPA (20:5n-3) in cord compared to matemal plasma at birth.
10.3.6 Placental Tissue
The fatty acid composition of placental tissue was similar in the fish oil and placebo 
groups, with the fish oil group exhibiting a lower n-6/n-3 ratio of fatty acids
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measured as relative values. Since circulating levels of DHA were higher in the fish 
oil supplemented mothers, matemal differences obviously arose prior to uptake by 
the placenta. Fatty acids can be metabolised via oxidation and/or de novo synthesis 
by placental cells. It is therefore possible that the placenta regulates the fatty acid 
supply to the fetus. When the circulating matemal DHA status is low, such as in the 
placebo group, the placenta could putatively modulate the composition of matemal 
blood to ensure appropriate supply to and accretion by the fetus. Such compensation 
would explain the difference in matemal status and similarity in placental and fetal 
status of the treatment groups.
Few studies have included placental tissue analyses. Placental tissue fatty acid status 
did not reflect the differences observed in either matemal and umbilical cord blood 
between pregnancies delivered preterm and at term (Reece et al 1997). Relatively 
consistent differences between omnivorous, vegetarian and diabetic mothers have 
been observed in the fatty acid composition of matemal RBC, cord tissue and 
placenta (Lakin et al 1998). Thus, with so few reports of placental tissue 
composition, it is not possible to determine whether its fatty acid composition varies 
with matemal circulating status or remains constant, and whether this putative 
constancy is physiological or related to its regulation of the supply to the fetus.
10.3.7 Umbilical Cord Tissue
Analyses of whole cord tissue (Lakin et al 1998) and of the separate vessels (A1 et al 
1990, Hornstra et al 1989) have been reported to reflect the differential status of the 
fetus. As with cord blood and placental tissue, no differences in the current study 
population were detected in whole cord tissue following supplementation with fish 
oil. Given that umbilical veins reflect the blood supply from the placenta to the fetus 
and that the arteries reflect the returning blood, it is not surprising that cord tissue 
composition was similar between groups.
10.3.8 Breast Milk
The relative levels of individual fatty acids observed in the breast milk of study 
participants were similar to those published previously (Koletzko et al 1992). 
Although previous studies have shown an elevation in breast milk DHA following 
matemal supplementation with 120-25 Omg/d DHA (Fidler et al 2000b, Holland et al
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1998, Henderson et al 1992, Makrides et al 1996a), supplementation did not begin 
until lactation was established. The current study provided mothers with a similar 
dose, but supplementation began at 15 weeks and continued until term. No 
difference in breast milk DHA was observed between groups, although the range of 
DHA as both % TFA and a concentration was greater in the fish oil group.
A proportion of breast milk LCPUFA are derived from matemal diet (Demmelmair 
et al 1989, Hachey et al 1987), to which breast milk composition responds rapidly 
(Emken et al 1989, Fidler et al 2000b, Holland et al 1998). The supplemented 
mothers consumed their final dose of DHA prior to labour and did not express the 
milk samples subsequently collected until at least 48 hours after their last capsules. 
It is therefore possible that this time delay accounts for a lack of an effect of 
supplementation on breast milk fatty acid composition from being detected. 
However, supplemented mothers presumably accumulated more DHA in their 
adipose tissue, which could have been mobilized and incorporated into breast milk. 
It is therefore possible that supplementation at this dose prior to lactation had no 
effect on breast milk. Altematively, since breast milk DHA levels are relatively well 
conserved (Innis 1992, Jensen 1989a & b & 1999, Koletzko et al 1992) 
compensatory mechanisms may have ensured that the placebo group had adequate 
breast milk DHA.
For whatever reason a difference in breast milk composition between groups was not 
seen, it is reassuring that the median % DHA was 0.2-0.3% TFA in both groups. 
This is a “normal” % of DHA in breast milk (Innis 1992, Jensen 1989a & b & 1999, 
Koletzko et al 1992); it is thought to be adequate for postnatal tissue accretion and 
has been suggested as the level to which infant formulae should be supplemented 
(Cunnane 1999, Cunnane et al 1999, Cunnane et al 2000a & b, Farquharson et al 
1993).
10.4 STUDY LIMITATIONS AND FUTURE STUDIES
10.4.1 Adipose Tissue
The enhanced matemal status observed in the fish oil group could be accounted for 
by either/both short- and long-term adaptations. Elevation of DHA in the matemal 
circulation probably arose, at least in part, as a result of a greater DHA intake. In
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addition, supplemented mothers may also have accumulated more DHA in their 
adipose tissue, sustaining their superior DHA status. In the present study, it was not 
possible to differentiate between these two mechanisms, or to evaluate their relative 
contribution.
Analysis of adipose tissue would have helped to determine whether a greater quantity 
of DHA accumulated in the adipose stores of fish oil supplemented mothers. 
Collection and analysis of adipose tissue was planned for those participants 
undergoing a caesarean section at delivery. Several participants (13% in total) 
intending an elective caesarean section were identified at enrolment; the number 
undergoing elective or emergency caesareans at delivery (26%) was similar to that 
originally calculated as sufficient to perform an appropriate statistical analyses 
(25%). However, adipose tissue was obtained from only 31% of those participants 
undergoing a caesarean section, amounting to only 8% of the whole study 
population. Because this rate was both poor in itself and relative to the collection of 
other samples obtained at birth, specific factors may have been responsible.
All participants were aware of and agreed to adipose tissue sampling both at 
enrolment and prior to birth; only one mother undergoing an elective caesarean 
declined the removal of adipose while allowing placenta and cord tissue to be 
obtained, as adipose sampling was considered invasive at a sensitive time. At some 
planned procedures, the reluctance of medical staff to obtain adipose, despite ethical 
approval and general awareness of the study, was a contributing factor. In the case 
of emergency caesarean sections, the event was often sudden and medical care and 
attention were understandably a priority. As a result, notification of the delivery did 
not occur until slightly later, at which time placenta and cord tissue could be obtained 
but adipose tissue could not. The requirement for a caesarean section thus limited 
the success of adipose tissue sampling.
Since the analysis of adipose tissue could be used to determine the composition of 
matemal stores, and therefore help to evaluate whether the observed differences in 
matemal blood and similarities in breast milk were in part attributable to matemal 
fatty acid accretion and mobilization, future studies should consider the sampling of 
adipose tissue. The practical difficulties encountered in the current study may be
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eliminated by the use of aspiration to obtain a buttock adipose tissue biopsy. This 
technique has been established, without discomfort and complications (Berry et al 
1986, Beynen & Katan 1985) and has been performed on lactating mothers (Pugo- 
Gunsam et al 1999). Such a procedure would enable a whole study population to be 
sampled, including expectant mothers regardless of delivery mode. In addition, it 
could be performed at various times and prevent reliance on staff external to the 
study. Indeed, the need for tissue analysis has been highlighted (Cunnane & 
Francescutti 1999) and future studies should aim to incorporate such analyses in the 
overall study design.
10.4.2 Analysis of Total Lipids
This study reports the fatty acid composition of total lipids and therefore does not 
differentiate between the various lipid fractions of triacylglycerols, phospholipids 
and cholesterol esters. Previous studies also differ in the lipid ffaction(s) analysed, 
which may account for some of the apparent discrepancies reported in the literature. 
Analysis of total lipids determines overall fatty acid status but does not identify any 
changes or differences in a class specific manner. It is therefore possible that the 
analysis of total lipids in this study obscured differences between supplemented and 
placebo groups, which may have been more evident on analysis of the distinct lipid 
fractions. Practical considerations, however, necessitated the analysis of total lipids. 
In RBC, phospholipids are the main lipid species, while triacylglycerols - are 
dominant in breast milk (and adipose tissue). Thus, if only the major class of lipid 
was analysed in each sample type, the various samples would have differed in the 
fraction analysed, which would have limited comparison between sample types. 
Altematively, the analysis of each lipid fraction in all samples would not have been 
feasible in the time permitted and would have incurred serious statistical concern 
regarding multiple testing. On considering the results of total lipid analyses, 
analyses of the lipid fractions may be of further interest and could be performed on 
the remaining samples in storage. Total lipid analysis remains, in a study with 
several sample types and time points, an appropriate index of overall fatty acid status 
with which to detect gross differences between treatment groups.
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10.5 CONCLUSION
In all measures of circulating DHA status (relative and absolute levels in both RBC 
and plasma), the same pattern for DHA was noted: an increase in matemal status 
between 15 and 28 weeks, followed by a decline between 28 weeks and birth, and a 
subsequently higher cord than matemal DHA status. Although these changes and 
differences did not always attain statistical significance either within or between 
groups, differences were noted in the magnitude of change and in the matemo-fetal 
difference between the groups. The fish oil group exhibited either an enhanced 
matemal DHA status relative to baseline, a less pronounced decline in matemal 
status during the last trimester, and/or a less compromised matemal status relative to 
fetal status.
Fluctuations in matemal DHA and other PUFA during pregnancy have been noted 
previously and shown to be consistent (Otto et al 1997). In particular, the elevation 
of DHA and LCPUFA in the early and mid trimesters (A1 et al 1995c, Ashby et al 
1997, Otto et al 2001), and subsequent decrease in the last trimester (A1 et al 1995a) 
reported previously accord with the longitudinal matemal changes observed in both 
supplement and placebo groups of this study. The early increase in matemal DHA 
has been suggested as indicative of mobilization of matemal stores to facilitate 
preferential transfer to and accumulation by the fetus (A1 et al 1995c).
The increase in matemal DHA observed between 15 and 28 weeks suggests that 
matemal mobilization of DHA inevitably occurs to ensure adequate accretion by the 
fetus, resulting in an elevation of fetal relative to matemal DHA status. The larger 
increase noted in the fish oil group may be attributable to both a greater circulating 
status and a larger store in adipose tissue, from which to mobilize DHA. The 
subsequent decline from 28 weeks to birth indicates that elevated matemal levels 
cannot be sustained and that accretion by the fetus probably occurs at the expense of 
matemal status. Matemal fish oil supplementation, however, reduces the inevitable 
last trimester decline in matemal DHA status, and attenuates the difference between 
matemal and fetal status. Matemal DHA supplementation, therefore, may not 
increase fetal RBC status per se, but by increasing the overall matemal RBC status 
during pregnancy, it makes available to the fetus a greater “pool” of DHA from 
which it can be supplied.
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The fish oil supplemented mothers had concentrations of DHA that were 22% higher 
in plasma (p=0.02) and 13% higher in RBC (p=0.02) at 28 weeks, and 42% higher in 
RBC at term (p=0.02) compared to the placebo group. DHA accounted for a 
similarly higher % TFA in RBC of fish oil supplemented mothers at 28 weeks 
(p=0.003) and at term (p=0.01).
A differential elevation of circulating DHA and total n-3 fatty acids, with 
concomitant lowering of the n-6/n-3 ratio, was observed in mothers receiving fish oil 
compared to placebo supplements. The enrichment of maternal n-3 PUFA status has 
been noted previously in mothers with a habitually higher amount of fish in their diet 
throughout pregnancy (Olsen et al 1991, Sanjurjo et al 1995), and in mothers 
supplemented during the last trimester of pregnancy (Connor et al 1996, van 
Houwelingen et al 1995).
It is perhaps surprising that no differences were observed between groups in the 
circulating fatty acids of umbilical cord blood, as other studies have reported 
variations in cord plasma and RBC consistent with maternal diet (A1 et al 1995b 
Connor et al 1996, Reddy et al 1994, Sanjurjo et al 1995, van Houwelingen et al 
1995). However, habitually high intakes of marine foods in the maternal diet are not 
consistently associated with elevated n-3 PUFA in cord blood (Homstra et al 1992), 
suggesting that other factors may be involved when the matemal-to-fetal supply is 
adequate over prolonged periods.
The relative and absolute amount of DHA in cord RBC and plasma was consistently 
higher than in the corresponding maternal sample at birth. Moreover, the matemo- 
fetal difference was generally characterised by lower EFA and higher LCPUFA, 
including AA, in cord than maternal blood samples. These findings are in agreement 
with previous comparisons of maternal and fetal fatty acids (A1 et al 1990, Al et al 
1995c, Berghaus et al 2000, Crawford et al 1989, Hoving et al 1994, Otto et al 1997, 
Reece et al 1997, van der Schouw et al 1991).
Conservation of the differences between mother and fetus (in both the current and 
previous studies) suggests a physiological requirement by the fetus to accrue greater
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amounts of and to attain a higher status of DHA and LCPUFA, relative to mother. 
Moreover, the requirement appears specific for preformed LCPUFA as the fetus 
accumulates less EFA compared to mother. Indeed, the lack of difference in cord 
blood samples between the supplemented and placebo groups suggests that the 
differential EFA and LPCUFA status of mother and infant is a natural physiological 
response. That manipulation of the maternal diet and DHA status did not influence 
fetal DHA status is further evidence that DHA accretion by the fetus is a pre­
requisite. Moreover, there may be a threshold level (relative or absolute amount) 
which the fetus must attain; this would explain the current and previous (Otto et al 
1997) observation that the matemo-fetal difference is greater when maternal status is 
lower. Fetal requirements appear to be met at the expense of maternal status, which 
becomes relatively depleted by term. Maternal DHA supplementation apparently 
limits the extent to which maternal status is compromised by fetal accretion. This 
may have implications for the maternal and fetal status in subsequent pregnancies 
(A1 et al 1997).
In conclusion, DHA supplementation enhances maternal plasma and RBC status (% 
TFA and concentration) during pregnancy. Supplementation may not directly 
increase fetal DHA status. The biomagnification (Crawford et al 1976) of DHA 
from mother to fetus appears to be physiologically pre-determined. The gradient 
between mother and fetus may however be enhanced on the maternal side by fatty 
acid supplementation.
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